e424b3
Filed
pursuant to Rule No. 424(b)(3)
Registration No. 333-145803
PROSPECTUS
$150,000,000
Sterling Chemicals,
Inc.
101/4% Senior
Secured Notes due 2015
This prospectus relates to our proposed exchange offer. We are
offering to exchange up to $150,000,000 aggregate principal
amount of new and freely transferable
101/4% Senior
Secured Notes due 2015, which we refer to as the registered
notes, for any and all outstanding
101/4% Senior
Secured Notes due 2015 issued in a private offering on
March 29, 2007, which we refer to as the unregistered notes
and which are subject to transfer restrictions. In this
prospectus we sometimes refer to the unregistered notes and the
registered notes collectively as the notes.
The terms of the registered notes are identical to the terms of
the unregistered notes in all material respects, except for the
elimination of some transfer restrictions, registration rights
and additional interest provisions relating to the unregistered
notes. The registered notes will be issued under the same
indenture as the unregistered notes. All of our
101/4% Senior
Secured Notes due 2015 outstanding from time to time under the
indenture are referred to as our senior secured notes. The
registered notes and the guarantees, if any, will rank senior in
right of payment to all existing and future subordinated
indebtedness of us and any guarantors, as applicable, and equal
in right of payment with all existing and future senior
indebtedness of us and of such guarantors. Holders of
unregistered notes do not have any appraisal or dissenters
rights in connection with the exchange offer. The exchange of
unregistered notes for registered notes will not be a taxable
event for United States federal income tax purposes.
We will exchange any and all unregistered notes that are validly
tendered and not validly withdrawn prior to 5:00 p.m. (New
York City time) on, September 12, 2008, unless extended.
We will not receive any cash proceeds from the exchange offer.
You will be required to make the representations described on
page 23. We have not applied, and do not intend to apply,
for listing the notes on any national securities exchange or
automated quotation system.
Unregistered notes not exchanged in the exchange offer will
remain outstanding and will be entitled to the benefits of the
indenture but, except under certain circumstances, will have no
further exchange or registration rights under the registration
rights agreement discussed in this prospectus.
Each broker-dealer that receives registered notes for its own
account pursuant to the exchange offer must acknowledge that it
will deliver a prospectus in connection with any resale of such
registered notes. The letter of transmittal states that by so
acknowledging and by delivering a prospectus, a broker-dealer
will not be deemed to admit that it is an
underwriter within the meaning of the Securities Act
of 1933, as amended, or the Securities Act. This prospectus, as
it may be amended or supplemented from time to time, may be used
by a broker-dealer in connection with resales of registered
notes received in exchange for unregistered notes where such
unregistered notes were acquired by such broker-dealer as a
result of market-making activities or other trading activities.
We have agreed that, for such period of time as may be required
under the Securities Act to permit resales of registered notes,
we will make this prospectus available to any broker-dealer for
use in connection with any such resale. See Plan of
Distribution.
Neither the Securities and Exchange Commission nor any state
securities commission has approved or disapproved of the notes
or determined if this prospectus is truthful or complete. Any
representation to the contrary is a criminal offense.
See Risk Factors beginning on page 16 of
this prospectus for a discussion of risks that you should
consider before participating in this exchange offer.
The date of this prospectus is August 13, 2008
TABLE OF
CONTENTS
|
|
|
|
|
|
|
|
i
|
|
|
|
|
i
|
|
|
|
|
ii
|
|
|
|
|
iv
|
|
|
|
|
iv
|
|
|
|
|
iv
|
|
|
|
|
1
|
|
|
|
|
14
|
|
|
|
|
16
|
|
|
|
|
23
|
|
|
|
|
33
|
|
|
|
|
34
|
|
|
|
|
35
|
|
|
|
|
36
|
|
|
|
|
52
|
|
|
|
|
65
|
|
|
|
|
71
|
|
|
|
|
90
|
|
|
|
|
93
|
|
|
|
|
95
|
|
|
|
|
96
|
|
|
|
|
149
|
|
|
|
|
150
|
|
|
|
|
151
|
|
|
|
|
151
|
|
|
|
|
151
|
|
ABOUT
THIS PROSPECTUS
This prospectus is part of a registration statement on
Form S-4
under the Securities Act that we filed with the Securities and
Exchange Commission, or the SEC. In making your decision whether
to participate in the exchange offer, you should rely only on
the information contained in this prospectus and in the
accompanying letter of transmittal. We have not authorized any
person to provide you with different information. If anyone
provides you with different or inconsistent information, you
should not rely on it. You should not assume that the
information appearing in this prospectus is accurate as of any
date other than the date on the front cover of this prospectus.
Moreover, this prospectus does not contain all of the
information set forth in the registration statement and the
exhibits thereto. You may refer to the registration statement
and the exhibits thereto for more information. Statements made
in this prospectus regarding the contents of any contract or
document filed as an exhibit to the registration statement are
not necessarily complete and, in each instance, reference is
hereby made to the copy of such contract or document so filed.
Each such statement is qualified in its entirety by such
reference.
WHERE YOU
CAN FIND MORE INFORMATION
We file annual, quarterly and special reports, proxy statements
and other information with the SEC. You may read and copy any
reports, statements or other information we file at the
SECs public reference room at 100 F. Street
N.E., NW, Washington, DC 20549. Please call the SEC at
1-800-SEC-0330
for further information on the public
i
reference room. Our SEC filings are also available to the public
from commercial document retrieval services and at the web site
maintained by the SEC at
http://www.sec.gov.
You can also find more information about us at our Internet
website located at
http://www.sterlingchemicals.com.
Our annual report on
Form 10-K,
our quarterly reports on
Form 10-Q,
our current reports on
Form 8-K,
and any amendments to those reports are available free of charge
through our website. Our website provides a hyperlink to a
third-party website where these reports may be viewed and
printed at no cost as soon as reasonably practicable after we
have electronically filed such material with the SEC. Except for
such reports that may be specifically incorporated by reference
in this prospectus, information that has been filed with the SEC
or that is contained on our website does not constitute part of
this prospectus.
This prospectus contains summaries of certain agreements, such
as the indenture and the agreements described under
Summary Registered Notes,
Description of Notes, and Managements
Discussion and Analysis of Financial Condition and Results of
Operations. The descriptions contained in this prospectus
of these agreements do not purport to be complete and are
subject to, or qualified in their entirety by reference to, the
definitive agreements. Copies of the definitive agreements will
be made available without charge to you by making a written or
oral request to us at the following address:
Sterling Chemicals, Inc.
333 Clay Street, Suite 3600
Houston, Texas 77002
Attention: Corporate Secretary
FORWARD-LOOKING
STATEMENTS
This prospectus contains forward-looking statements
within the meaning of Section 27A of the Securities Act and
Section 21E of the United States Securities Exchange Act of
1934, as amended, or the Exchange Act. Forward-looking
statements give our current expectations or forecasts of future
events. All statements other than statements of historical fact
are, or may be deemed to be, forward-looking statements. Such
statements include, without limitation, any statement that may
project, indicate or imply future results, events, performance
or achievements, and may contain or be identified by the words
expect, intend, plan,
predict, anticipate,
estimate, believe, should,
could, may, might,
will, will be, will
continue, will likely result,
project, forecast, budget
and similar expressions. Statements in this prospectus that
contain forward-looking statements include, but are not limited
to, information concerning our possible or assumed future
results of operations. While our management considers these
expectations and assumptions to be reasonable, they are
inherently subject to significant business, economic,
competitive, regulatory and other risks, contingencies and
uncertainties, most of which are difficult to predict and many
of which are beyond our control. We disclose important factors
that could cause our actual results to differ materially from
our expectations under Risk Factors,
Managements Discussion and Analysis of Financial
Condition and Results of Operations and elsewhere in this
prospectus. These risks, contingencies and uncertainties relate
to, among other matters, the following:
|
|
|
|
|
the cyclicality of the petrochemicals industry;
|
|
|
|
current and future industry conditions and their effect on our
results of operations or financial position;
|
|
|
|
the extent, timing and impact of expansions of production
capacity of our products, by us or by our competitors;
|
|
|
|
the potential effects of market and industry conditions and
cyclicality on our competitiveness, business strategy, results
of operations or financial position;
|
|
|
|
the adequacy of our liquidity;
|
|
|
|
our environmental management programs and safety initiatives;
|
|
|
|
our market sensitive financial instruments;
|
|
|
|
future uses of, and requirements for, financial resources;
|
|
|
|
future contractual obligations;
|
ii
|
|
|
|
|
future amendments, renewals or terminations of existing
contractual relationships;
|
|
|
|
business strategies;
|
|
|
|
growth opportunities;
|
|
|
|
competitive position;
|
|
|
|
expected financial position;
|
|
|
|
future cash flows or dividends;
|
|
|
|
budgets for capital and other expenditures;
|
|
|
|
plans and objectives of management;
|
|
|
|
outcomes of legal proceedings;
|
|
|
|
compliance with applicable laws;
|
|
|
|
our reliance on marketing partners;
|
|
|
|
adequacy of insurance coverage or indemnification rights;
|
|
|
|
the timing and extent of changes in commodity prices for our
products or raw materials;
|
|
|
|
petrochemicals industry production capacity or operating rates;
|
|
|
|
costs associated with the shut down and decommissioning of our
styrene facility;
|
|
|
|
increases in the cost of, or our ability to obtain, raw
materials or energy;
|
|
|
|
regulatory initiatives and compliance with governmental laws or
regulations, including environmental laws or regulations;
|
|
|
|
customer preferences;
|
|
|
|
our ability to attract or retain high quality employees;
|
|
|
|
operating hazards attendant to the petrochemicals industry;
|
|
|
|
casualty losses, including those resulting from weather related
events;
|
|
|
|
changes in foreign, political, social or economic conditions;
|
|
|
|
risks of war, military operations, other armed hostilities,
terrorist acts or embargoes;
|
|
|
|
changes in technology, which could require significant capital
expenditures in order to maintain competitiveness or could cause
existing manufacturing processes to become obsolete;
|
|
|
|
effects of litigation;
|
|
|
|
cost, availability or adequacy of insurance; and
|
|
|
|
various other matters, many of which are beyond our control.
|
The risks included here are not exhaustive. Other sections of
this prospectus, and our filings with the SEC, include
additional factors that could adversely affect our business,
results of operations or financial performance. See Risk
Factors. Given these risks and uncertainties, investors
should not place undue reliance on forward-looking statements.
Forward-looking statements included in this prospectus are made
only as of the date of this prospectus and are not guarantees of
future performance. Although we believe that the expectations
reflected in these forward-looking statements are reasonable,
such expectations may prove to have been incorrect. All written
or oral forward-looking statements attributable to us, or
persons acting on our behalf, are expressly qualified in their
entirety by these cautionary statements.
iii
NOTICE TO
NEW HAMPSHIRE RESIDENTS
NEITHER THE FACT THAT A REGISTRATION STATEMENT OR AN
APPLICATION FOR A LICENSE HAS BEEN FILED UNDER
CHAPTER 421-B
OF THE NEW HAMPSHIRE REVISED STATUTES WITH THE STATE OF NEW
HAMPSHIRE NOR THE FACT THAT A SECURITY IS EFFECTIVELY REGISTERED
OR A PERSON IS LICENSED IN THE STATE OF NEW HAMPSHIRE
CONSTITUTES A FINDING BY THE SECRETARY OF STATE OF NEW HAMPSHIRE
THAT ANY DOCUMENT FILED UNDER
RSA 421-B
IS TRUE, COMPLETE AND NOT MISLEADING. NEITHER ANY SUCH FACT NOR
THE FACT THAT AN EXEMPTION OR EXCEPTION IS AVAILABLE FOR A
SECURITY OR A TRANSACTION MEANS THAT THE SECRETARY OF STATE HAS
PASSED IN ANY WAY UPON THE MERITS OR QUALIFICATIONS OF, OR
RECOMMENDED OR GIVEN APPROVAL TO, ANY PERSON, SECURITY OR
TRANSACTION. IT IS UNLAWFUL TO MAKE, OR CAUSE TO BE MADE, TO ANY
PROSPECTIVE PURCHASER, CUSTOMER OR CLIENT ANY REPRESENTATION
INCONSISTENT WITH THE PROVISIONS OF THIS PARAGRAPH.
INDUSTRY
AND MARKET DATA
Industry and market data used throughout this prospectus were
obtained through internal company research, surveys and studies
conducted by third parties and industry and general
publications, including information from Chemical Market
Associates, Inc., or CMAI, and Tecnon OrbiChem, or Tecnon. We
have not independently verified market and industry data from
third-party sources. Furthermore, the research, surveys and
studies provided by such third party sources have been based in
part on market and industry data that has not in turn been
independently verified by those third party sources. While we
believe internal company estimates are reliable, such estimates
have not been verified by any independent sources, and we do not
make any representations as to the accuracy of such estimates.
Changes in factors upon which our estimates or the analyses or
forecasts contained in such third party reports, surveys or
studies referred to herein are based could effect the results of
such estimates, analyses and forecasts, and are inherently
uncertain because of events or combinations of events that
cannot reasonably be foreseen, including the actions of
government, individuals, third parties and competitors.
PRODUCTION
CAPACITY
Unless we state otherwise, annual production capacity used
throughout this prospectus represents rated capacity at
December 31, 2007. We calculated rated capacity by
estimating the number of days in a typical year that a
production unit of a plant is expected to operate, after
allowing for downtime for regular maintenance, and multiplying
that number by the units optimal daily output based on the
design feedstock mix. Because the rated capacity of a production
unit is an estimated amount, actual production volumes may be
more or less than the rated capacity.
iv
This summary is not complete and does not contain all of the
information that you should consider before investing in our
notes. You should read the entire prospectus carefully,
including Risk Factors and our consolidated
financial statements and the related notes and other financial
information appearing elsewhere in this prospectus before you
decide to invest in our notes. Generally, references to
Sterling Chemicals, we, us
and our mean Sterling Chemicals, Inc. and its
consolidated subsidiaries. In addition, in this prospectus our
fiscal years ended December 31, 2005, December 31,
2006, and December 31, 2007 are referred to as 2005, 2006
and 2007, respectively.
The
Company
We are a North American producer of selected petrochemicals used
to manufacture a wide array of consumer goods and industrial
products. Our primary products are acetic acid and plasticizers.
Our acetic acid is used primarily to manufacture vinyl acetate
monomer, which is used in a variety of products, including
adhesives and surface coatings. Pursuant to a long-term
contract, or Production Agreement, that began in 1986 and
extends to 2016, all of our acetic acid production is sold to BP
Amoco Chemical Company, or BP Chemicals, and we are BP
Chemicals sole source of acetic acid production in the
Americas. BP Chemicals markets all of the acetic acid that we
produce and pays us, among other amounts, a portion of the
profits derived from its sales of the acetic acid we produce. In
addition, BP Chemicals reimburses us for 100% of our fixed and
variable costs of production. Prior to August 2006, BP Chemicals
also paid us a set monthly amount. However, under the terms of
this Production Agreement, beginning in August 2006, the portion
of the profits we receive from the sales of acetic acid produced
at our plant increased and BP Chemicals was no longer required
to pay us the set monthly amount. This change in payment
structure did not affect BP Chemicals obligation to
reimburse us for all of our fixed and variable costs of
production.
We believe that we have one of the lowest cost acetic acid
facilities in the world. Our acetic acid facility utilizes
BP Chemicals proprietary carbonylation technology, or
Cativa Technology, which we believe offers several advantages
over competing production methods, including lower energy
requirements and lower fixed and variable costs. We also jointly
invest with BP Chemicals in capital expenditures related to our
acetic acid facility. Acetic acid production has two major raw
material requirements methanol and carbon monoxide.
BP Chemicals, a producer of methanol, supplies 100% of our
methanol requirements related to our production of acetic acid.
All of the required carbon monoxide is supplied by Praxair
Hydrogen Supply, Inc., or Praxair, from a partial oxidation unit
constructed by Praxair on land leased from us at our site in
Texas City, Texas.
All of our plasticizers, which are used to make flexible
plastics, such as shower curtains, floor coverings, automotive
parts and construction materials, are sold to BASF Corporation,
or BASF, pursuant to a long-term production agreement that
extends until 2013, subject to some early termination rights
held by BASF that begin in 2010. Under our agreement with BASF,
BASF provides us with most of the required raw materials,
markets the plasticizers we produce, and is obligated to make
certain fixed quarterly payments to us and to reimburse us
monthly for our actual production costs and capital expenditures
related to our plasticizers facility. In May 2008, we entered
into an amended production agreement with BASF (sometimes
referred to in this prospectus as our Amended Plasticizers
Production Agreement). This amended agreement was entered into
in connection with BASFs nomination of zero pounds of
phthalic anhydride, or PA, under the existing production
agreement (sometimes referred to in this prospectus as the Old
Plasticizers Production Agreement) due to deteriorating market
conditions which were not expected to improve over the next few
years, which resulted in the shutdown of our PA unit. See
Managements Discussion and Analysis of Financial
Condition and Results of Operations Recent
Developments and Business
Contracts.
Prior to December 3, 2007, we manufactured styrene.
However, on September 17, 2007, we entered into a long-term
exclusive styrene supply agreement and a related railcar
purchase and sale agreement with NOVA Chemicals Inc., or NOVA.
Under this supply agreement, NOVA had the exclusive right to
purchase 100% of our styrene production (subject to existing
contractual commitments), the amount of styrene supplied in any
particular period being at NOVAs option, based on a
full-cost formula. In November 2007, the styrene supply
agreement with
1
NOVA, which was subsequently assigned by NOVA to INEOS NOVA
LLC, or INEOS NOVA, obtained clearance under the
Hart-Scott-Rodino
Act. This clearance caused the supply agreement and the railcar
agreement to become effective and triggered a $60 million
payment to us in November 2007. In addition, in accordance with
the terms of the supply agreement, INEOS NOVA assumed
substantially all of our contractual obligations for future
styrene deliveries. After the supply agreement became effective,
INEOS NOVA nominated zero pounds of styrene under the supply
agreement for the balance of 2007 and, in response, we exercised
our right to terminate the supply agreement and permanently shut
down our styrene plant. Under the supply agreement, we are
responsible for the closure costs of our styrene facility and
are also subject to a long-term commitment to not reenter the
styrene business until December of 2012. We operated our styrene
facility through early December 2007, as we completed our
production of inventory and exhausted our raw materials and
purchase requirements, and sold substantially all our inventory
during the first quarter of 2008. During 2007 and the first
quarter of 2008, we incurred closure costs to decommission our
styrene facility of approximately $1 million and
$9 million, respectively. We expect to incur up to
$4 million in additional decommissioning costs related to
the closure of our styrene facility. In mid-July, with the
decontamination process for the styrene facility nearing
completion, we announced a reduction in work force in order to
reduce our staffing to a level appropriate for our existing
operations and site development projects. As a result, seven
members of our salaried work force were immediately laid off. In
addition, we made offers for early retirement to several members
of our hourly work force and our salaried administrative and
process supervisors. Upon completion of the down-sizing of our
hourly work force and our administrative and process supervisor
positions, which will occur after the period for accepting
offers of early retirement has closed in September, total staff
reductions are expected to be approximately 40 employees,
and we expect to recognize approximately $2.2 million in
severance costs in the third and fourth quarters of 2008, in
accordance with SFAS No. 146, Accounting for
Costs Associated with Exit of Disposal Activities.
We manufacture all of our petrochemicals products at our Texas
City facility. In terms of production capacity, our Texas City
site has the sixth largest acetic acid facility in the world.
The Texas City site covers an area of 290 acres, is
strategically located on Galveston Bay and benefits from a
deep-water dock capable of handling ships with up to a 40-foot
draft, as well as four barge docks and direct access to Union
Pacific and Burlington Northern Santa Fe railways with in-motion
rail scales on site. Our Texas City site also has truck loading
racks, weigh scales, stainless and mild steel storage tanks,
three waste deepwells, 160 acres of available land zoned
for heavy industrial use and additional land zoned for light
industrial use and a supportive political environment for
growth. In addition, we are in the heart of one of the largest
petrochemical complexes on the Gulf Coast and, as a result, have
on-site
access to a number of key raw material pipelines, as well as
close proximity to a number of large refinery complexes.
We own the acetic acid and plasticizers manufacturing units
located at our Texas City site. We also lease a portion of our
Texas City site to Praxair, who constructed a partial oxidation
unit on that land, and we lease a portion of our Texas City site
to S&L Cogeneration Company, a 50/50 joint venture between
us and Praxair Energy Resources, Inc., who constructed a
cogeneration facility on that land. We lease space for our
principal offices located in Houston, Texas.
We intend to further expand the capacity of our acetic acid
facility and we are presently undertaking numerous initiatives
to attract new manufacturing and/or storage related businesses
to our Texas City site. Given our significant under-utilized
infrastructure, land, materials handling, utilities and storage,
our Texas City site should be a favorable location for companies
looking to construct new manufacturing facilities on the Gulf
Coast of the United States. We believe that the construction of
a new facility at our site by another company would lower the
amount of overall fixed costs allocated to each of our operating
units and provide us with additional profit. Accordingly, we are
seeking long-term contractual business arrangements or
partnerships that will provide us with an ability to realize the
value of our under-utilized assets through profit sharing or
other cash generating arrangements. For development projects
that may have significant capital expenditure requirements, we
are considering joint ventures or other arrangements where we
would contribute certain of our assets and management expertise
to minimize our share of the capital costs.
2
Current
Industry Conditions
Acetic Acid. The North American acetic acid
industry has enjoyed a period of sustained domestic demand
growth, as well as substantial export demand. This has led to
current North American industry utilization rates of 86% and
Tecnon projects utilization rates to increase to over 98% by
2013, although the recent difficulties in the housing and
automotive sectors will likely cause reduced demand for vinyl
acetate monomer, and consequently acetic acid, in North America
in the short term. The North American acetic acid industry is
inherently less cyclical than many other petrochemical products
due to a number of important factors.
There are only four large producers of acetic acid in North
America and historically these producers have made capacity
additions in a disciplined and incremental manner, primarily
using small expansion projects or exploiting debottlenecking
opportunities. In addition, the leading technology required to
manufacture acetic acid is controlled by two global companies,
which permits these companies to control the pace of new
capacity additions through the licensing or development of such
additional capacity. The limited availability of this technology
also creates a significant barrier to entry into the acetic acid
industry by potential competitors.
Global production capacity of acetic acid, as of
December 31, 2007, was approximately 24 billion pounds
per year, with current North American production capacity at
approximately 7 billion pounds per year. The
North American acetic acid market is mature and well
developed and is dominated by four major producers that account
for over 94% of the production capacity of acetic acid in North
America. Demand for acetic acid is linked to the demand for
vinyl acetate monomer, a key intermediate in the production of a
wide array of polymers. Vinyl acetate monomer is the largest
derivative of acetic acid, representing over 40% of total
demand. Annual global production of vinyl acetate monomer is
expected to increase from 10.4 billion pounds in 2005 to
12.2 billion pounds in 2010, although the recent
difficulties in the housing and automotive sectors will likely
cause reduced demand for vinyl acetate monomer in North America
in the short term. The North American acetic acid industry tends
to sell most of its products through long-term sales agreements
having cost plus pricing mechanisms, eliminating
much of the volatility seen in other petrochemicals products and
resulting in more stable and predictable earnings and profit
margins.
Styrene. The North American styrene industry
is currently in a protracted down cycle, primarily as a result
of over-supply. This extended down cycle resulted from two major
developments. Initially, export demand, which historically has
represented over 20% of North American production capacity, has
significantly diminished. In recent months, U.S. styrene
producers have seen an increase in styrene exports, largely due
to delays in the start up of announced new capacity in the
Middle East. However, this increase is expected to reverse
itself after the new styrene plant being constructed in Al
Jubail, Saudi Arabia is completed, which is currently expected
to occur later in 2008. Regional cost pressures, in addition to
new production capacity being added in Asia and the Middle East,
have made it difficult for North American producers to compete
in these export markets on a continuous basis. In addition, a
significant amount of styrene capacity has been added globally
over the past five to ten years by producers of propylene oxide
using so-called PO-SM technology, which produces styrene as a
co-product. Propylene oxide is a key intermediate in the
production of polyurethane, and polyurethane demand growth has
been significantly greater than demand growth for styrene,
exacerbating the over-supply of styrene. During periods of
over-supply, production rates for styrene producers decrease
significantly. When production rates are low, unit production
costs increase due to the allocation of fixed costs over a lower
production volume and a reduction in the efficiency of the
manufacturing unit, both in energy usage and in the conversion
rates for raw materials. Compounding these cost impacts, prices
for the principal styrene raw materials, benzene and ethylene,
are currently near historical highs, putting pressure on margins
on styrene sales even though styrene contract prices are at near
historic highs.
Over the last five years, China has been the driver for growth
in styrene demand, representing approximately 75% of the
worlds styrene demand growth in that period. Historically,
we positioned ourselves to take advantage of peaks in the Asian
styrene markets, with a large portion of our styrene capacity
not being committed under long-term arrangements. However, over
the last several years, relatively high benzene and domestic
natural gas prices significantly limited our ability to sell
styrene into the Asian markets, and high styrene prices have
reduced styrene global demand growth rates. In addition, several
of our competitors announced their intention to build new
styrene production units outside the United States, further
complicating our ability to sell styrene into the Asian markets.
In
3
2006, our competitors added 2.6 billion pounds of new
styrene capacity in Asia and an additional 1.6 billion
pounds in 2007. The remaining announced construction projects
are scheduled to start up in 2008 and beyond. If and when these
new units are completed, we anticipate more difficult market
conditions, especially in the export markets, until the
additional supply is absorbed by growth in styrene demand or
significant capacity rationalization occurs.
CMAI currently projecting no additional capacity increases in
North America through 2010, with operating rates reaching a
trough of 75% in 2007, and less than 80% operating rates
projected through 2010, without any further industry
restructuring. Although we believe an improved North American
industry outlook is possible, this largely depends on a
significant industry restructuring. Previously, styrene and
polystyrene industry participants, including The DOW Chemical
Company and NOVA Chemicals Corporation, or NOVA Chemicals, have
announced a desire to seek transactions which would restructure
the North American styrene and polystyrene industries, thereby
improving the balance of supply and demand in North America.
More recently, on October 1, 2007, NOVA Chemicals expanded
its European joint venture with INEOS to include North American
styrene and solid polystyrene assets, and, in May of 2008,
Americas Styrenics LLC, a joint venture between The Dow Chemical
Company and Chevron Phillips Chemical Company, which includes
selected styrene and polystyrene assets of the two companies in
North America and South America, began operations.
Competitive
Strengths
World Class Acetic Acid Facility. Our
acetic acid facility, one of the largest in terms of production
capacity in the world, enjoys high reliability and we believe it
is the second most efficient facility in the world. With a rated
annual production capacity of 1.1 billion pounds, our
acetic acid facility produces approximately 17% of total
North American capacity and approximately 5% of worldwide
capacity. In terms of production capacity, our acetic acid
facility is the third largest acetic acid facility in North
America and the sixth largest in the world. Our acetic acid
facility produces acetic acid using BP Chemicals Cativa
Technology, which offers several advantages over competing
production methods, including lower energy requirements and
lower fixed and variable costs.
Well-Positioned for Further Growth. Since
1986, we and BP Chemicals have increased the annual rated
production capacity of our acetic acid facility by 126%, from
490 million pounds of annual production capacity in 1986 to
1.1 billion pounds of annual production capacity today. In
2007, our acetic acid facility operated at 99% of capacity, in
part as a result of its relatively low production costs and the
efforts of BP Chemicals global sales organization. We also
have undertaken projects with BP Chemicals to ensure that we
would be positioned to expand production capacity in the future.
For example, in 2003, we and BP Chemicals installed a larger
reactor at our acetic acid facility, which will continue to
permit additional cost-effective expansions of this facility. We
expect a further expansion of the production capacity of our
facility to 1.2 billion pounds by 2009. Following this
expansion, we expect the facility to continue to operate at or
near maximum utilization rates.
Highly Contracted Sources of Cash Flows for Our Acetic Acid
and Plasticizers Products. Our business benefits
from long-term requirements contracts with BP Chemicals and
BASF. We sell 100% of our acetic acid production to BP Chemicals
pursuant to the Production Agreement. Under the Production
Agreement, which runs through July 31, 2016, BP Chemicals
markets all of the acetic acid that we produce and pays us,
among other amounts, a portion of the profits earned from sales
of the product. The Production Agreement has allowed us to
operate our acetic acid facility consistently at or near full
capacity and generate steadily growing cash flows. BP
Chemicals largest customer for acetic acid produced at our
acetic acid facility is American Acetyls, a joint venture
between BP Chemicals and The DOW Chemical Company, which
currently accounts for approximately 50% of the acetic acid we
produce. Sales to American Acetyls are made under a cost-plus
contract that extends until 2016. Much of the remaining sales of
the acetic acid we produce are made by BP Chemicals under
multiple year contracts. This high percentage of contractually
committed volume has provided us with secure demand for our
acetic acid and steadily increasing cash flows.
Our long-term plasticizers business relationship with BASF,
established in 1986, was extended in 2006 until the end of 2013
subject to some termination rights held by BASF beginning 2010.
In December 2007, BASF caused the shutdown of our PA unit by
nominating zero pounds of PA in response to deteriorating market
conditions which are not expected to improve in the foreseeable
future. As a result of this shutdown, in May 2008, we entered
into an
4
amended production agreement with BASF, effective as of
April 1, 2008. The amended agreement relieves BASF of most
of its obligations related to our PA manufacturing unit,
requires that BASF pay approximately $3.7 million to us for
reimbursement of certain direct fixed and variable costs
associated with the shutdown and decontamination of our PA
manufacturing unit. The amended agreement also requires that
BASF pay to us an aggregate amount of approximately
$3.2 million (the remaining $0.2 million of which is
required to be paid on or before August 15, 2008), subject
to a 25%-75% refund right in BASFs favor if we restart our
PA unit before the end of 2010, depending on the year in which
we restart the unit. Under the amended agreement, BASF is still
required to make the same quarterly fixed periodic payments as
previously required. In addition, under the amended production
agreement, the methods for calculating (i) payments
required to be made by BASF to us for achieving reductions in
direct fixed and variable costs and (ii) BASFs right
to terminate the agreement in the event that direct fixed and
variable costs exceed a specified threshold (unless we elect to
cap BASFs reimbursement obligations), have both been
modified to exclude costs savings and direct fixed and variable
costs pertaining to our PA manufacturing unit. The amended
agreement also removed all restrictions or rights BASF formerly
had with respect to our use or disposition of the PA
manufacturing unit, including a limited purchase right, the
right to request capacity increases and consultation rights
regarding future capital expenditures with respect to our PA
unit.
Additionally, in both contracts, principal raw materials are
provided by BP Chemicals and BASF, respectively, allow us to
operate our business with relatively low working capital
requirements, including finished product inventory requirements.
Well-Invested Production Assets. Over the past
five years, we and BP Chemicals invested $19 million in
capital in our acetic acid facility. A new and larger reactor
was installed in 2003, which was sized for an ultimate capacity
in excess of 1.7 billion pounds of annual production. A new
and larger product column is expected to be installed during the
facility turnaround scheduled for 2009. All new capital
investments for our acetic acid facility are being made with a
view to ultimately achieving 1.7 billion pound annual
production capacity in a cost efficient manner. We believe that
the capital cost to expand our acetic acid facility to maximum
capacity would be significantly less than the cost for new
capacity at a greenfield location. In 2006, BASF invested
approximately $4 million to convert our plasticizers
production unit over to a new range of esters as part of the
extension of its production agreement with us which runs until
2013. BASF is responsible for all capital investment in the
plasticizers, esters and phthalic anhydride production
facilities through the length of the agreement.
We and third parties subject to agreements with us invested a
further $22 million in site infrastructure capital over the
past five years, including the rebuilding of a ship dock and two
barge docks. Given the condition of our Texas City site and
infrastructure, we anticipate spending only approximately
$2 million annually on utilities and services maintenance
over the next five years.
Attractive Logistics Assets and
Infrastructure. Our logistics assets include
strategic access to the intercoastal waterway and the Gulf of
Mexico, a deep water dock capable of handling ships with up to a
40-foot draft, as well as four barge docks, direct access to
Union Pacific and Burlington Northern Santa Fe railways with
in-motion rail scales on site, truck loading racks, weigh
scales, stainless and mild steel storage tanks, three waste
deepwells, 160 acres of available land zoned for heavy
industrial use and additional land zoned for light industrial
use and a supportive political environment for growth. We are in
the heart of one of the largest petrochemical complexes on the
Gulf Coast, in close proximity to a number of large refinery
complexes. As a result, we have
on-site
access to a number of key raw material pipelines and convenient
access to several of our suppliers and customers. Currently, our
dock facilities can accommodate new uses and we have 31 tanks
available for third party use. These assets present a
substantial opportunity to grow our business by attracting new
businesses to our Texas City site and significant opportunities
for further development.
Leading Market Position in Acetic Acid
Production. We have a leading market position in
acetic acid. Our rated annual production capacity for acetic
acid of 1.1 billion pounds represents 17% of the total
North American production capacity and 5% of the global
production capacity. In acetic acid, we are the third largest
producer in North America with a low cost position derived from
our use of BP Chemicals Cativa Technology, global sales
and marketing network and acetyls know-how.
5
Experienced Management Team. Our senior
management team consists of five executives with an average of
over 20 years of experience in the chemicals industry,
11 years of which have been with us. Our management team
has demonstrated expertise in capturing cost efficiencies,
project development, improving profitability and expanding
profitable production capacity, while exiting unprofitable
businesses through various economic cycles.
Business
Strategy
Grow Our Business. We believe that our acetic
acid facility is positioned for cost-effective future capacity
expansions at lower incremental cost due to previous investments
made by us and BP Chemicals, including the installation of a new
reactor in 2003 that is capable of producing up to
1.7 billion pounds of acetic acid annually. We intend to
grow our acetic acid business through capacity expansions that
take advantage of this positioning. Currently, we have low-cost
debottlenecking opportunities which could increase annual
capacity of our acetic acid facility to approximately
1.2 billion pounds, an increase of approximately 7%.
Our Texas City site offers approximately 160 acres for
future expansion by us or by other companies that can benefit
from our existing infrastructure and facilities, and includes a
greenbelt around the northern edge of the plant site. Our Texas
City site is strategically located on Galveston Bay and we
benefit from a deep water dock capable of handling ships with up
to a 40-foot draft, as well as four barge docks and direct
access to Union Pacific and Burlington Northern Santa Fe
railways with in-motion rail scales on site. Our Texas City site
also has truck loading racks, weigh scales, stainless and mild
steel storage tanks, three waste deepwells, 160 acres of
available land zoned for heavy industrial use and additional
land zoned for light industrial use, and a supportive political
environment for growth. In addition, we are in the heart of one
of the largest petrochemical complexes on the Gulf Coast and, as
a result, have
on-site
access to a number of key raw material pipelines and are in
close proximity to a number of the larger refinery complexes.
Given our under-utilized infrastructure, our management and
engineering expertise, as well as ample unoccupied land, we
believe that there are significant opportunities for further
development of our Texas City site. We are currently pursuing
numerous initiatives to attract new manufacturing and/or storage
related businesses to our Texas City site, including
opportunities involving renewable fuels projects, gasification,
energy projects and chemicals terminalling. Specifically, we are
seeking long-term contractual business arrangements or
partnerships that will provide us with an ability to realize the
value of our under-utilized assets through profit sharing or
other cash generating arrangements. For development projects
that may have significant capital expenditure requirements, we
are considering joint ventures or other arrangements where we
would contribute certain of our assets and management expertise
to minimize our share of the capital costs. In any case, we
expect any new facility constructed at our Texas City site to
lower the amount of overall fixed costs allocated to each of our
operating units and provide us with additional profit.
We plan to evaluate strategic acquisitions, focusing on chemical
businesses and assets which would allow us to increase our
market share of products we currently produce or those that
would provide upstream or downstream integration within our
existing businesses.
Improve Organization Efficiency and Cost
Structure. We continually seek to improve our
cost competitiveness through organizational efficiencies,
productivity enhancements, operating controls and general cost
reductions. We believe that the expansion of our acetic acid
business, the further development of our Texas City site and
acquisitions will lead to further cost efficiencies.
6
Recent
Developments
In May 2008, we entered into an amended production agreement
with BASF, effective as April 1, 2008. This amended
agreement was entered into in connection with BASFs
nomination of zero pounds of PA under the existing production
agreement due to deteriorating market conditions which were not
expected to improve over the next few years, which resulted in
the shutdown of our PA unit. See Managements
Discussion and Analysis of Financial Condition and Results of
Operations Recent Developments and
Business Contracts.
Effective as of May 27, 2008, John V. Genova was appointed
as our President and Chief Executive Officer and was elected as
a member of our Board of Directors. Mr Genova succeeded Richard
K. Crump, who retired as President and Chief Executive Officer
as of May 27, 2008. Mr. Crump will remain a member of
our Board of Directors.
Principal
Executive Offices
Our principal executive offices are located at 333 Clay Street,
Suite 3600, Houston, Texas
77002-4109
and our telephone number is
(713) 650-3700.
Our corporate website address is www.sterlingchemicals.com. The
information contained on our corporate website is not part of
this prospectus.
7
THE
EXCHANGE OFFER
You are entitled to exchange in the exchange offer your
outstanding unregistered notes for registered notes with
substantially identical terms. The summary below describes the
principal terms of the exchange offer. Certain of the terms and
conditions described below are subject to important limitations
and exceptions. You should read the discussion under the heading
Description of Notes for further information
regarding the registered notes.
|
|
|
The Exchange Offer |
|
We are offering to exchange up to $150,000,000 aggregate
principal amount of our registered
101/4% Senior
Secured Notes due 2015, for a like principal amount of our
unregistered
101/4% Senior
Secured Notes due 2015, which were issued on March 29, 2007. |
|
Registration Rights |
|
Under the registration rights agreement executed as part of the
offering of the unregistered notes, we agreed to use our
commercially reasonable efforts to: |
|
|
|
file a registration statement within 180 days
after the issue date of the unregistered notes, or by
September 25, 2007, enabling holders of unregistered notes
to exchange the unregistered notes for registered notes with
substantially identical terms;
|
|
|
|
cause the registration statement to become effective
within 270 days after the issue date of the unregistered
notes, or by December 24, 2007, and to complete the
exchange offer within 50 days after the effective date of
our registration statement; and
|
|
|
|
file a shelf registration statement for the resale
of the notes if we cannot effect an exchange offer within the
time periods listed above and in other circumstances.
|
|
|
|
The interest rate on the unregistered notes has increased as we
have not complied with our obligations under the registration
rights agreement and will continue at such increased rate until
the registration statement of which this prospectus forms a part
is declared effective. |
|
Resales |
|
Based on an interpretation by the staff of the SEC set forth in
no-action letters issued to third parties, we believe that the
registered notes issued pursuant to the exchange offer in
exchange for unregistered notes may be offered for resale,
resold and otherwise transferred by you (unless you are our
affiliate within the meaning of Rule 405 of the
Securities Act) without compliance with the registration and
prospectus delivery provisions of the Securities Act, provided
that you: |
|
|
|
are acquiring the registered notes in the ordinary
course of business; and
|
|
|
|
have not engaged in, do not intend to engage in and
have no arrangement or understanding with any person or entity,
including any of our affiliates, to participate in, a
distribution of the registered notes.
|
|
|
|
In addition, each participating broker-dealer that receives
registered notes for its own account pursuant to the exchange
offer in exchange for unregistered notes that were acquired as a
result of market-making or other trading activity must also
acknowledge that it will deliver a prospectus in connection with
any resale of the exchange notes. For more information, see
Plan of Distribution. |
8
|
|
|
|
|
Any holder of unregistered notes, including any broker-dealer,
who |
|
|
|
is our affiliate,
|
|
|
|
does not acquire the registered notes in the
ordinary course of its business, or
|
|
|
|
tenders in the exchange offer with the intention to
participate, or for the purpose of participating, in a
distribution of registered notes,
|
|
|
|
cannot rely on the position of the staff of the SEC expressed in
Exxon Capital Holdings Corporation, Morgan Stanley &
Co., Incorporated or similar no-action letters and, in the
absence of an exemption, must comply with the registration and
prospectus delivery requirements of the Securities Act in
connection with the resale of the registered notes. |
|
Expiration Time |
|
The exchange offer will expire at 5:00 p.m., New York City
time, on September 12, 2008, unless we extend the exchange
offer in our sole discretion, in which case the term
expiration time means the latest date and time to
which the exchange offer is extended. We do not currently intend
to extend the expiration date. |
|
Conditions to the Exchange Offer |
|
The exchange offer is subject to customary conditions, some of
which we may waive. For more information, see The Exchange
Offer Certain Conditions to the Exchange Offer. |
|
Procedures for Tendering Unregistered Notes |
|
If you wish to exchange your unregistered notes in the exchange
offer, you must complete, sign and date the accompanying letter
of transmittal, or a copy of the letter of transmittal,
according to the instructions contained in this prospectus and
the letter of transmittal. You must also mail or otherwise
deliver the letter of transmittal, or the copy, together with
the unregistered notes and any other required documents, to the
exchange agent at the address set forth on the cover of the
letter of transmittal. If you hold unregistered notes through
The Depository Trust Company, or DTC, and wish to
participate in the exchange offer, you must comply with the
Automated Tender Offer Program procedures of DTC, by which you
will agree to be bound by the letter of transmittal. |
|
|
|
By signing or agreeing to be bound by the letter of transmittal,
you will represent to us that, among other things: |
|
|
|
any registered notes that you receive will be
acquired in the ordinary course of your business;
|
|
|
|
you have no arrangement or understanding with any
person or entity, including any of our affiliates, to
participate in the distribution of the registered notes;
|
|
|
|
you are not our affiliate as defined in
Rule 405 of the Securities Act, or, if you are an
affiliate, you will comply with any applicable registration and
prospectus delivery requirements of the Securities Act; and
|
|
|
|
if you are a broker-dealer that will receive
registered notes for your own account in exchange for
unregistered notes that were acquired as a result of
market-making activities, you will deliver a
|
9
|
|
|
|
|
prospectus, as required by law, in connection with any resale of
the registered notes. |
|
Withdrawal of Tenders |
|
A tender of unregistered notes pursuant to this exchange offer
may be withdrawn at any time prior to the expiration date. Any
unregistered notes not accepted for exchange for any reason will
be returned without expense to the tendering holder promptly
after the expiration or termination of this exchange offer. |
|
Guaranteed Delivery Procedures |
|
If you wish to tender your unregistered notes and your
unregistered notes are not immediately available or you cannot
deliver your unregistered notes, the letter of transmittal or
any other documents required by the letter of transmittal or
comply with the applicable procedures under DTCs Automated
Tender Offer Program prior to the expiration date, you must
tender your unregistered notes according to the guaranteed
delivery procedures set forth in this prospectus under The
Exchange Offer Guaranteed Delivery. |
|
Delivery of the Registered Notes |
|
The registered notes issued pursuant to this exchange offer will
be delivered to holders who tender unregistered notes promptly
following the expiration time. |
|
Effect on Holders of Unregistered Notes |
|
As a result of the making of, and upon acceptance for exchange
of all validly tendered unregistered notes pursuant to the terms
of the exchange offer, we will have fulfilled a covenant
contained in the registration rights agreement and, accordingly,
we will not be obligated to pay additional interest as described
in the registration rights agreement. If you are a holder of
unregistered notes and do not tender your unregistered notes in
the exchange offer, you will continue to hold such unregistered
notes and you will be entitled to all the rights and limitations
applicable to the unregistered notes in the indenture, except
for any rights under the registration rights agreement that by
their terms terminate upon the consummation of the exchange
offer. |
|
Consequences of Failure to Exchange |
|
All untendered unregistered notes will continue to be subject to
the restrictions on transfer provided for in the unregistered
notes and in the indenture. In general, the unregistered notes
may not be offered or sold unless registered under the
Securities Act, except pursuant to an exemption from, or in a
transaction not subject to, the Securities Act and applicable
state securities laws. Other than in connection with this
exchange offer, we do not anticipate that we will register the
unregistered notes under the Securities Act. |
|
Material United States Federal Income Tax Consequences |
|
The exchange of unregistered notes for registered notes in the
exchange offer should not be a taxable event for U.S. federal
income tax purposes. For more information, see Material
U.S. Federal Income Tax Consequences. |
|
Use of Proceeds |
|
We will not receive any cash proceeds from the issuance of the
registered notes. |
|
Exchange Agent |
|
U. S. Bank National Association is the exchange agent for this
exchange offer. The address and telephone number of the exchange
agent are set forth in the section captioned The Exchange
Offer Exchange Agent. |
10
THE
REGISTERED NOTES
The summary below describes the principal terms of the
registered notes. Some of the terms and conditions described
below are subject to important limitations and exceptions. The
Description of Notes section of this prospectus
contains a more detailed description of the terms and conditions
of the registered notes.
|
|
|
Issuer |
|
Sterling Chemicals, Inc. |
|
Securities Offered |
|
$150.0 million aggregate principal amount of
101/4% senior
secured notes. |
|
Maturity Date |
|
April 1, 2015. |
|
Interest |
|
We will pay interest in cash on the principal amount of the
registered notes at an annual rate of
101/4%.
Interest will be payable in cash semi-annually in arrears on
April 1 and October 1 of each year. |
|
Guarantees |
|
The registered notes will be unconditionally guaranteed by all
of our domestic restricted subsidiaries on a senior secured
basis. Currently, we do not have any domestic restricted
subsidiaries. |
|
Collateral |
|
The registered notes and the guarantees, if any, will be
secured, subject to specified permitted liens, by a first
priority lien on substantially all of our and any
guarantors fixed assets and certain related assets,
including, without limitation, all property, plant and
equipment. The first priority lien will not extend to assets
securing our revolving credit facility. The registered notes and
any guarantees will be secured, subject to specified permitted
liens, by a second priority lien on our and the guarantors
other assets including, without limitation, accounts receivable,
inventory, capital stock of our and their respective direct
subsidiaries, certain intellectual property, deposit accounts
and investment property securing on a first priority basis the
obligations under our revolving credit facility. Consequently,
the registered notes and any guarantees will be effectively
subordinated to the revolving credit facility to the extent of
the value of the assets securing our revolving credit facility.
See Description of Notes Collateral. |
|
Ranking |
|
The registered notes will be: |
|
|
|
senior secured obligations of the Issuer;
|
|
|
|
equal in right of payment with all existing and
future senior indebtedness of the Issuer;
|
|
|
|
effectively senior to all existing and future senior
unsecured indebtedness of the Issuer to the extent of the value
of the assets securing the registered notes; and
|
|
|
|
senior in right of payment to all existing and
future subordinated indebtedness of the Issuer.
|
|
|
|
The guarantee of any guarantor will be: |
|
|
|
senior secured obligations of that guarantor;
|
|
|
|
equal in right of payment with all of that
guarantors existing and future senior indebtedness,
including guarantees;
|
11
|
|
|
|
|
effectively senior to all of that guarantors
existing and future senior unsecured indebtedness to the extent
of the value of the assets securing the registered notes; and
|
|
|
|
senior in right of payment to all of that
guarantors existing and future subordinated indebtedness.
|
|
|
|
As of March 31, 2008, we had $150 million of senior
indebtedness, all of which would have represented outstanding
principal under the unregistered notes. The indenture governing
the registered notes permits us, subject to specified
limitations, to incur additional debt, some or all of which may
be senior indebtedness. |
|
Optional Redemption |
|
We may redeem some or all of the senior secured notes at any
time prior to April 1, 2011 at the make-whole redemption
price set forth in Description of Notes. We may
redeem the senior secured notes, in whole or in part, at any
time on and after April 1, 2011 at the redemption prices
described in the section Description of Notes
Optional Redemption Optional Redemption on or after
April 1, 2011, plus accrued and unpaid interest to
the date of redemption. |
|
|
|
In addition, prior to April 1, 2010, we may redeem up to
35% of our senior secured notes with the net cash proceeds from
specified equity offerings at a redemption price equal to
110.25% of the aggregate principal amount, plus accrued and
unpaid interest to the date of redemption, so long as at least
65% of the aggregate principal amount of the senior secured
notes issued under the indenture remain outstanding immediately
after the redemption. See Description of Notes
Optional Redemption Optional Redemption Upon
Equity Offerings. |
|
Change of Control Offer |
|
If we undergo a change of control, we must offer to repurchase
the senior secured notes at a purchase price equal to 101% of
the aggregate principal amount, plus accrued and unpaid interest
to the date of repurchase. See Description of
Notes Repurchase upon Change of Control. |
|
Asset Sale or Event of Loss Offer |
|
If we engage in certain sales or suffer a loss of material
plant, property or equipment that constitutes collateral
securing the senior secured notes, we generally must invest the
net cash proceeds from such sales and losses in our business
within 360 days or make an offer to repurchase a principal
amount of senior secured notes equal to the net cash proceeds,
in which case the purchase price of the senior secured notes
will be 100% of their aggregate principal amount, plus accrued
and unpaid interest to the date of such repurchase. See
Description of Notes Certain
Covenants Asset Sales and Description of
Notes Event of Loss. |
|
Certain Indenture Covenants |
|
The registered notes will be issued under the same indenture
that governs our unregistered notes, which agreement restricts
our and any guarantors ability to, among other things: |
|
|
|
pay dividends, redeem stock, prepay subordinated
indebtedness or make other restricted payments;
|
|
|
|
incur indebtedness or issue disqualified capital
stock;
|
|
|
|
make certain investments;
|
12
|
|
|
|
|
create liens on assets;
|
|
|
|
restrict dividend payments or other payments from
subsidiaries to us;
|
|
|
|
consolidate or merge;
|
|
|
|
sell or otherwise transfer or dispose of assets,
including equity interests of restricted subsidiaries;
|
|
|
|
enter into transactions with affiliates;
|
|
|
|
designate subsidiaries as unrestricted subsidiaries;
|
|
|
|
use the proceeds of permitted sales of assets; and
|
|
|
|
change our line of business.
|
|
|
|
These covenants are subject to a number of important exceptions.
For more details, see Description of Notes
Certain Covenants. |
13
SUMMARY
HISTORICAL CONSOLIDATED FINANCIAL DATA
The following table sets forth our summary historical
consolidated financial data as of the dates and for the periods
indicated. The historical consolidated statement of operations
data for each of the three fiscal years ended December 31,
2005, December 31, 2006 and December 31, 2007 and the
three months ended March 31, 2007 and 2008 and the
historical consolidated balance sheet data as of March 31,
2008 are derived from, and are qualified in their entirety by,
our historical consolidated financial statements included
elsewhere in this prospectus. The results of any interim period
are not necessarily indicative of the results that may be
expected for any other interim period or for the full fiscal
year, and the historical results set forth below do not
necessarily indicate results expected for any future period.
You should read the following summary and financial data
together with Business, Selected Historical
Consolidated Financial and Operating Data,
Managements Discussion and Analysis of Financial
Condition and Results of Operations and our consolidated
financial statements and related notes appearing elsewhere in
this prospectus.
On September 17, 2007, we entered into a long-term
exclusive styrene supply agreement and a related railcar
purchase and sale agreement with NOVA. On November 13,
2007, we announced that we will exit the styrene business to
pursue other strategic initiatives. Due to the shut down of our
styrene plant, we have reported the operating results of the
styrene business as discontinued operations in our consolidated
financial statements beginning in the first quarter of 2008. All
prior periods have been reclassified. The selected financial
data presented below includes our styrene business in
discontinued operations. In the following tables (including the
footnotes thereto), dollars are in thousands, except as
otherwise indicated.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Three Months Ended
|
|
|
|
Year Ended December 31,
|
|
|
March 31,
|
|
|
|
2005(1)
|
|
|
2006(1)
|
|
|
2007
|
|
|
2007(1)
|
|
|
2008
|
|
|
|
(Dollars in thousands)
|
|
|
Statement of Operations Data:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Revenues
|
|
$
|
128,098
|
|
|
$
|
141,259
|
|
|
$
|
129,813
|
|
|
$
|
32,715
|
|
|
$
|
38,199
|
|
Cost of goods sold
|
|
|
120,254
|
|
|
|
127,413
|
|
|
|
116,431
|
|
|
|
27,088
|
|
|
|
33,799
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Gross profit
|
|
|
7,844
|
|
|
|
13,846
|
|
|
|
13,382
|
|
|
|
5,627
|
|
|
|
4,400
|
|
Selling, general and administrative expenses
|
|
|
6,548
|
|
|
|
7,073
|
|
|
|
8,679
|
|
|
|
2,298
|
|
|
|
2,418
|
|
Other expense (income)
|
|
|
|
|
|
|
(724
|
)
|
|
|
839
|
|
|
|
|
|
|
|
|
|
Interest and debt related expenses, net of interest income
|
|
|
10,090
|
|
|
|
10,079
|
|
|
|
15,706
|
|
|
|
3,385
|
|
|
|
2,887
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Loss from continuing operations before income tax
|
|
$
|
(8,794
|
)
|
|
$
|
(2,582
|
)
|
|
$
|
(11,842
|
)
|
|
$
|
(56
|
)
|
|
$
|
(905
|
)
|
Benefit for income taxes
|
|
|
(2,938
|
)
|
|
|
(388
|
)
|
|
|
(4,129
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Loss from continuing operations
|
|
$
|
(5,856
|
)
|
|
$
|
(2,194
|
)
|
|
$
|
(7,713
|
)
|
|
$
|
(56
|
)
|
|
$
|
(905
|
)
|
Income (loss) from discontinued operations, net of tax
|
|
|
(23,712
|
)
|
|
|
(103,465
|
)
|
|
|
(11,215
|
)
|
|
|
2,725
|
|
|
|
(6,224
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net income (loss)
|
|
$
|
(29,568
|
)
|
|
$
|
(105,659
|
)
|
|
$
|
(18,928
|
)
|
|
$
|
2,669
|
|
|
$
|
(7,129
|
)
|
Other Financial Data:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Depreciation and
amortization(2)
|
|
|
33,342
|
|
|
|
30,476
|
|
|
|
10,908
|
|
|
|
2,729
|
|
|
|
2,635
|
|
Capital
expenditures(3)
|
|
|
9,460
|
|
|
|
11,547
|
|
|
|
6,411
|
|
|
|
2,248
|
|
|
|
2,037
|
|
Ratio of earnings to fixed
charges(4)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(1) |
|
We have restated our consolidated
financial statements and selected financial data for the fiscal
years ended December 31, 2006 and 2005 and three months
ended March 31, 2007. For further information, see
Note 16 to the consolidated financial statements for the
year ended December 31, 2006 and 2005, and Note 15 to the
consolidated financial statements for the quarter ended
March 31, 2007, found elsewhere in this prospectus.
|
|
(2) |
|
Includes depreciation and
amortization for discontinued operations for the years ended
December 31, 2005, 2006 and 2007, and for the three months ended
March 31, 2007 and 2008 of $23.8 million, $18.1 million, $1.0
million, $0.6 million and $0.1 million, respectively.
|
14
|
|
|
(3) |
|
Includes capital expenditures for
discontinued operations for the years ended December 31, 2005,
2006 and 2007 and for the three months ended March 31, 2007
and 2008 of $4.6 million, $6.6 million, $2.6 million, $1.5
million and zero, respectively.
|
|
(4) |
|
Additional pre-tax earnings needed
to achieve a 1:1 ratio for the years ended December 31,
2005, 2006 and 2007 and for the three months ended
March 31, 2007 and 2008 were $8.8 million,
$2.6 million, $11.8 million, less than
$0.1 million, and $0.9 million, respectively.
|
|
|
|
|
|
|
|
As of March 31,
|
|
|
|
2008
|
|
|
Summary Balance Sheet Data:
|
|
|
|
|
Cash and cash equivalents
|
|
$
|
170,459
|
|
Accounts receivable, net
|
|
|
11,713
|
|
Inventories, net
|
|
|
5,211
|
|
Property, plant and equipment, net
|
|
|
76,678
|
|
Total assets
|
|
|
287,225
|
|
Total liabilities
|
|
|
268,575
|
|
Redeemable preferred stock
|
|
|
104,137
|
|
Stockholders deficiency in assets
|
|
|
(85,487
|
)
|
15
RISK
FACTORS
An investment in the notes involves certain risks. You should
consider carefully these risks together with all of the other
information included in this prospectus before deciding whether
this investment is suitable for you.
Risks
Related to Our Business
Substantially
all of our products are sold to only one customer.
In 2007, a single customer, BP Chemicals, accounted for 100% of
our acetic acid revenues while another customer, BASF, accounted
for 100% of our plasticizers revenues. The termination of one or
more of the long-term contracts for the purchase of these
products, or a material reduction in the amount of product
purchased under either of these contracts, could materially
adversely affect our overall business, financial condition,
results of operations or cash flows.
Our
ability to realize increases in our acetic acid production
capacity made possible through capacity expansions is limited by
our current inability to obtain sufficient quantities of carbon
monoxide.
Carbon monoxide is one of the principal raw materials required
for acetic acid production. Currently, all of the carbon
monoxide we use in the production of acetic acid is supplied by
Praxair from a partial oxidation unit constructed by Praxair on
land leased from us at our Texas City site. Although our new
acetic acid reactor installed in 2003 is capable of producing up
to 1.7 billion pounds annually, Praxairs partial
oxidation unit is not capable of supplying carbon monoxide in
quantities sufficient for more than approximately
1.2 billion pounds of annual acetic acid production.
Moreover, the supply of sufficient quantities of carbon monoxide
will likely require the construction of a new supply pipeline,
which will require numerous third party and regulatory consents,
or a substantial expansion of the Praxair oxidation unit. The
expansion of the Praxair oxidation unit may not be cost
effective and we may not be able to contract for the supply of
carbon monoxide in quantities sufficient to increase our annual
acetic acid production to 1.7 billion pounds. Furthermore,
the construction of a supply pipeline may require a substantial
period of time.
We
depend upon the continued operation of a single site for all of
our production.
All of our products are produced at our Texas City site.
Significant unscheduled downtime at our Texas City site could
have a material adverse effect on our business, financial
condition, results of operations or cash flows. Unanticipated
downtime can occur for a variety of reasons, including equipment
breakdowns, interruptions in the supply of raw materials, power
failures, sabotage, natural forces or other hazards associated
with the production of petrochemicals. Although we maintain
business interruption insurance, this insurance does not provide
coverage for business interruptions of less than 45 days
and is limited in its overall coverage.
Our
operations involve risks that may increase our operating costs,
which could reduce our profitability.
Although we take precautions to enhance the safety of our
operations and minimize the risk of disruptions, our operations
are subject to hazards inherent in the manufacturing and
marketing of chemical products. These hazards include:
|
|
|
|
|
pipeline or storage tank leaks and ruptures, explosions and
fires;
|
|
|
|
severe weather and natural disasters;
|
|
|
|
mechanical failures, unscheduled downtimes, labor difficulties
and transportation interruptions;
|
|
|
|
environmental remediation complications; and
|
|
|
|
chemical spills and discharges or releases of toxic or hazardous
substances or gases.
|
Many of these hazards can cause bodily injury or loss of life,
severe damage to or destruction of property or equipment or
environmental damage, and may result in suspension of operations
or the imposition of civil or criminal penalties and
liabilities. Furthermore, we are subject to present and future
claims with respect to workplace exposure of our employees or
contractors on our premises or other persons located nearby,
workers compensation and other matters.
16
Our
operations are subject to operating hazards and unforeseen
interruptions for which we may not be adequately
insured.
We maintain insurance coverage at levels that we believe are
reasonable and typical for our industry, portions of which are
provided by a captive insurance company maintained by us and a
few other chemical companies. However, we are not fully insured
against all potential hazards incident to our business.
Accordingly, our insurance coverage may be inadequate for any
given risk or liability, such as property damage suffered in
hurricanes or from terrorist acts or business interruption
incurred from a loss of our supply of electricity or carbon
monoxide. In addition, our insurance companies may be incapable
of honoring their commitments if an unusually high number of
claims are concurrently made against their policies. As a result
of market conditions, premiums and deductibles for certain
insurance policies can increase substantially and, in some
instances, certain insurance may become unavailable or available
only for reduced amounts of coverage. If we were to incur a
significant liability for which we were not fully insured, it
could have a material adverse effect on our business, financial
condition, results of operations or cash flows. We can make no
assurances that we can renew our existing insurance coverages at
commercially reasonable rates or that such coverage will be
adequate to cover future claims that may arise.
In addition, concerns about terrorist attacks, as well as other
factors, have caused significant increases in the cost of our
insurance coverage. We have determined that it is not
economically prudent to obtain terrorism insurance and we do not
carry terrorism insurance on our property at this time. In the
event of a terrorist attack impacting one or more of our
production units, we could lose the production and sales from
one or more of these facilities, and the facilities themselves,
and could become liable for contamination or personal or
property damage from exposure to hazardous materials caused by a
terrorist attack. Such loss of production, sales, or facilities
or incurrence of liabilities could materially adversely affect
our business, financial condition, results of operations or cash
flows.
Terrorist
attacks, the current military action in Iraq, general
instability in various OPEC member nations and other attacks or
acts of war in the United States and abroad may adversely affect
the markets in which we operate.
The attacks of September 11, 2001 and subsequent events,
including the current military action in Iraq, have caused
instability in the United States and other financial markets and
have led, and may continue to lead, to further armed
hostilities, prolonged military action in Iraq or further acts
of terrorism in the United States or abroad, which could cause
further instability in the financial markets and in the markets
for our products. Current regional tensions and conflicts in
various OPEC member nations, including the current military
action in Iraq, have caused, and may continue to cause,
increased raw materials costs, specifically raising the prices
of oil and gas, which are used in our operations or affect the
prices of our raw materials. Furthermore, the terrorist attacks,
subsequent events or future developments in any of these areas
may result in reduced demand from our customers for our
products. These developments could subject our operations to
increased risks and, depending on their magnitude, could have a
material adverse effect on our business, financial condition,
results of operations or cash flows.
New
regulations concerning the transportation of hazardous chemicals
and the security of chemical manufacturing facilities could
result in higher operating costs.
Chemical manufacturing facilities may be at greater risk of
future terrorist attacks than other potential targets in the
United States. As a result, the chemical industry has responded
to the issues surrounding the terrorist attacks of
September 11, 2001 by starting new initiatives relating to
the security of chemicals industry facilities and the
transportation of hazardous chemicals in the United States.
Simultaneously, local, state and federal governments have begun
a regulatory process that could lead to new regulations
impacting the security of chemical plant locations and the
transportation of hazardous chemicals. Our business or our
customers businesses could be adversely affected because
of the cost of complying with new security regulations.
We are
subject to many environmental and safety regulations that may
result in significant unanticipated costs or liabilities or
cause interruptions in our operations.
Our operations involve the handling, production, transportation,
treatment and disposal of materials that are classified as
hazardous or toxic and that are extensively regulated by
environmental and health and safety laws,
17
regulations and permit requirements. We may incur substantial
costs, including fines, damages and criminal or civil sanctions,
or experience interruptions in our operations for actual or
alleged violations or compliance requirements arising under
environmental laws, any of which could have a material adverse
effect on our business, financial condition, results of
operations or cash flows. Our operations could result in
violations of environmental laws, including spills or other
releases of hazardous substances to the environment. In the
event of a catastrophic incident, we could incur material costs.
Furthermore, we may be liable for the costs of investigating and
cleaning up environmental contamination on or from our
properties or at off-site locations where we disposed of or
arranged for the disposal or treatment of hazardous materials.
Based on available information, we believe that the costs to
investigate and remediate known contamination will not have a
material adverse effect on our business, financial condition,
results of operations or cash flows. However, if significant
previously unknown contamination is discovered, or if existing
laws or their enforcement change, then the resulting
expenditures could have a material adverse effect on our
business, financial condition, results of operations or cash
flows.
Environmental, health and safety laws, regulations and permit
requirements, and the potential for further expanded laws,
regulations and permit requirements may increase our costs or
reduce demand for our products and thereby negatively affect our
business. Environmental permits required for our operations are
subject to periodic renewal and may be revoked or modified for
cause or when new or revised environmental requirements are
implemented. Changing and increasingly strict environmental
requirements and the potential for further expanded regulation
may increase our costs and can affect the manufacturing,
handling, processing, distribution and use of our products. If
so affected, our business and operations may be materially and
adversely affected. In addition, changes in these requirements
may cause us to incur substantial costs in upgrading or
redesigning our facilities and processes, including our waste
treatment, storage, disposal and other waste handling practices
and equipment. For these reasons, we may need to make capital
expenditures beyond those currently anticipated to comply with
existing or future environmental or safety laws.
Approximately
39% of our employees are covered by a collective bargaining
agreement that expires on May 1, 2012. Disputes with the
union representing these employees or other labor relations
issues may negatively affect our business.
As of March 31, 2008, we had 236 employees, of whom
approximately 39% (all of our hourly employees at our Texas City
site) were represented by the Texas City, Texas Metal Trades
Council, AFL-CIO, or the Union, and are covered by a collective
bargaining agreement which expires on May 1, 2012. Although
we believe our relationship with our hourly employees is
generally good, we locked out these employees for 16 weeks
in 2002 and our hourly employees engaged in a one-week strike in
2004, in both cases in connection with efforts to reach new
collective bargaining agreements. Future strikes or other labor
disturbances could have a material adverse effect on our
business, financial condition, results of operations or cash
flows.
A
failure to retain our key employees could adversely affect our
business.
We are dependent on the services of the members of our senior
management team to remain competitive in our industry. There is
a risk that we will not be able to retain or replace these key
employees. Our current key employees are subject to employment
conditions or arrangements that permit the employees to
terminate their employment without notice. The loss of any
member of our senior management team could materially adversely
affect our business, financial condition, results of operations
or cash flows.
Transactions
consummated pursuant to our plan of reorganization could result
in the imposition of material tax liabilities.
Prior to our emergence from bankruptcy in 2002, we eliminated
our holding company structure by merging Sterling Chemicals
Holdings, Inc. with and into us. We believe that this merger
qualifies as a tax-free reorganization pursuant to
Section 368(a)(1)(G) of the Internal Revenue Code (commonly
referred to as a G Reorganization) for United States
federal income tax purposes. However, a judicial determination
that this merger did not qualify as a G Reorganization would
result in additional federal income tax liability which could
materially adversely affect our business, financial condition,
results of operations and cash flows.
18
We may
not successfully implement our acquisition strategy, and
acquisitions that we pursue may present unforeseen integration
obstacles or costs, increase our leverage or negatively impact
our performance.
We may not be able to identify suitable acquisition candidates,
and the expense incurred in consummating acquisitions of related
businesses, or our failure to integrate such businesses
successfully into our existing businesses, could affect our
growth or result in our incurring unanticipated expenses and
losses. Furthermore, we may not be able to realize any
anticipated benefits from acquisitions. From time to time we
evaluate potential acquisitions and may complete one or more
significant acquisitions in the future. To finance an
acquisition we may need to incur debt or issue equity. However,
we may not be able to obtain favorable debt or equity financing
to complete an acquisition, or at all. In particular, the lack
of an active trading market in our common stock, as well as the
dilutive terms of our outstanding Series A Convertible
Preferred Stock, or Series A Preferred Stock, may make our
common stock unattractive as consideration for an acquisition.
The process of integrating acquired operations into our existing
operations may result in unforeseen operating difficulties and
may require significant financial resources that would otherwise
be available for the ongoing development or expansion of
existing operations. Some of the risks associated with our
acquisition strategy, which could materially adversely affect
our business, financial condition, results of operations or cash
flows, include:
|
|
|
|
|
potential disruption of our ongoing business and distraction of
management;
|
|
|
|
unexpected loss of key employees or customers of an acquired
business;
|
|
|
|
conforming an acquired business standards, processes,
procedures or controls with our operations;
|
|
|
|
coordinating new product and process development;
|
|
|
|
hiring additional management or other critical personnel;
|
|
|
|
encountering unknown contingent liabilities which could be
material; and
|
|
|
|
increasing the scope, geographic diversity and complexity of our
operations.
|
Our acquisition strategy may not be favorably received by
customers, and we may not realize any anticipated benefits from
acquisitions.
Risks
Relating to the Notes
Our
leverage and debt service obligations may adversely affect our
cash flow and our ability to make payments on the
notes.
As of March 31, 2008, we had total long-term debt of
$150.0 million (consisting of outstanding principal on the
unregistered notes). The terms and conditions governing our
indebtedness, including our notes and our revolving credit
facility:
|
|
|
|
|
require us to dedicate a substantial portion of our cash flow
from operations to service our existing debt service
obligations, thereby reducing the availability of our cash flow
to fund working capital, capital expenditures and other general
corporate expenditures;
|
|
|
|
increase our vulnerability to adverse general economic or
industry conditions and limit our flexibility in planning for,
or reacting to, competition or changes in our business or our
industry;
|
|
|
|
limit our ability to obtain additional financing;
|
|
|
|
place restrictions on our ability to make certain payments or
investments, sell assets, make strategic acquisitions, engage in
mergers or other fundamental changes and exploit business
opportunities; and
|
|
|
|
place us at a competitive disadvantage relative to competitors
with lower levels of indebtedness in relation to their overall
size or less restrictive terms governing their indebtedness.
|
Our ability to meet our expenses and debt obligations will
depend on our future performance, which will be affected by
financial, business, economic, regulatory and other factors. We
will not be able to control many of these factors, such as
economic conditions and governmental regulation. We cannot be
certain that our earnings will be
19
sufficient to allow us to pay the principal and interest on our
debt, including the notes, and meet our other obligations. If we
do not have enough money, we may be required to refinance all or
part of our existing debt, including the notes, sell assets,
borrow more money or raise equity. We may not be able to
refinance our debt, sell assets, borrow more money or raise
equity on terms acceptable to us, if at all. Further, failing to
comply with the financial and other restrictive covenants in our
indebtedness could result in an event of default under such
indebtedness, which could adversely affect our business,
financial condition, results of operations or cash flows.
Any
failure to meet our debt obligations could harm our business,
financial condition, results of operations or cash
flows.
If our cash flow and capital resources are insufficient to fund
our debt obligations, we may be forced to sell assets, seek
additional equity or debt capital or restructure our debt. In
addition, any failure to make scheduled payments of interest and
principal on our outstanding indebtedness would likely result in
a reduction of our credit rating, which could harm our ability
to incur additional indebtedness on acceptable terms. Our cash
flow and capital resources may be insufficient for payment of
interest on and principal of our debt in the future, including
payments on the notes, and any such alternative measures may be
unsuccessful or may not permit us to meet scheduled debt service
obligations, which could cause us to default on our obligations
and impair our liquidity.
There
may not be sufficient collateral to pay all or any of the
notes.
The notes and the related guarantees, if any, are secured,
subject to certain permitted liens, by a first priority lien on
substantially all of our and any guarantors fixed assets
and certain related assets, or the primary collateral,
including, without limitation, all property, plant and
equipment. See Description of Notes
Collateral. Concurrently with the closing of the offering
of our unregistered notes, we amended and restated our revolving
credit facility. Our revolving credit facility has a first
priority lien on all assets that do not constitute primary
collateral, or the secondary collateral, including without
limitation, accounts receivable, inventory, capital stock of
certain of our subsidiaries, intellectual property, deposit
accounts and investment property. The notes and any related
guarantees are secured by a second priority lien on the
secondary collateral.
Although the noteholders may share in the proceeds of the
secondary collateral, the lenders under our revolving credit
facility are entitled to receive proceeds from any realization
of their first priority collateral to repay their obligations in
full before the noteholders will receive any repayment.
Therefore, your security interest in the secondary collateral
ranks behind that of the lenders under our revolving credit
facility. In addition, the noteholders will not generally have
any control over the secondary collateral even if the notes are
in default.
We cannot assure you of the value of the primary collateral and
secondary collateral, or the collateral. We further cannot
assure you that the net proceeds of a sale of the collateral
would be sufficient to repay all of the notes following a
foreclosure upon the collateral (and any payments in respect of
prior liens) or a liquidation of our assets or the assets of any
guarantors that may grant these security interests. As of
March 31, 2008, the book value of the primary collateral
was $76.7 million. The value of the collateral at any time
will depend upon market and other economic conditions, including
the availability of suitable buyers for the collateral. By their
nature, some of the pledged assets may be illiquid and may have
no readily ascertainable market value. The value of the assets
constituting the collateral could be impaired in the future as a
result of changing economic conditions and other factors beyond
our control. In the event of a foreclosure, liquidation,
bankruptcy or similar proceeding, the proceeds from any sale or
liquidation of the collateral may be insufficient to pay our
obligations under the notes in full.
If the net proceeds received from the sale of the collateral,
after payment of our creditors having first priority security
interests in the collateral for which the noteholders hold a
second priority lien, are not sufficient to repay all amounts
due with respect to the notes, you would, to the extent of the
insufficiency, have only an unsecured claim against any
guarantors remaining assets, if any. Moreover, the ability
of the trustee for the notes to foreclose upon the collateral
securing the notes would be delayed if we, or any future
guarantors, were subject to proceedings under applicable
bankruptcy law.
The
security documents allow us to remain in possession of the
collateral.
The security documents allow us and our subsidiaries to remain
in possession of, retain exclusive control over, freely operate,
and collect, invest and dispose of any income from the
collateral securing the notes. In addition, to
20
the extent we sell any assets that constitute collateral, the
proceeds from such sale will be subject to the liens securing
the notes only to the extent such proceeds would otherwise
constitute collateral securing the notes under the
security documents. To the extent the proceeds from any such
sale of collateral do not constitute collateral
under the security documents, the pool of assets securing the
notes would be reduced and the notes would not be secured by
such proceeds.
In the
event of a bankruptcy, the ability of the noteholders to realize
upon the collateral will be subject to certain bankruptcy law
limitations.
The ability of noteholders to realize upon the collateral will
be subject to certain bankruptcy law limitations in the event of
our bankruptcy or the bankruptcy of any guarantors. Under
applicable federal bankruptcy laws, secured creditors are
prohibited from repossessing their security from a debtor in a
bankruptcy case, or from disposing of security repossessed from
such a debtor, without bankruptcy court approval. Moreover,
applicable federal bankruptcy laws generally permit the debtor
to continue to retain collateral even though the debtor is in
default under the applicable debt instruments, provided
generally that the secured creditor is given adequate
protection. The meaning of the term adequate
protection may vary according to the circumstances, but is
intended in general to protect the value of the secured
creditors interest in the collateral at the commencement
of the bankruptcy case and may include cash payments or the
granting of additional security, if and at such times as the
court in its discretion determines, for any diminution in the
value of the collateral as a result of the stay of repossession
or disposition of the collateral by the debtor during the
pendency of the bankruptcy case. In view of the lack of a
precise definition of the term adequate protection
and the broad discretionary powers of a bankruptcy court, we
cannot predict whether payments under the notes would be made
following commencement of and during a bankruptcy case, whether
or when the collateral agent, on behalf of the trustee and the
noteholders, could foreclose upon or sell the collateral or
whether or to what extent noteholders would be compensated for
any delay in payment or loss of value of the collateral through
the requirement of adequate protection. Furthermore,
in the event the bankruptcy court determines that the value of
the collateral is not sufficient to repay all amounts due on the
notes, noteholders would hold undersecured claims.
Applicable federal bankruptcy laws do not permit the payment or
accrual of interest, costs and attorneys fees for
undersecured claims during a debtors
bankruptcy case.
The
intercreditor agreement limits the ability of the noteholders to
realize upon the collateral.
Concurrently with the closing of the offering of our
unregistered notes on March 29, 2007, U. S. Bank
National Association, in its capacity as the collateral agent,
entered into an intercreditor agreement with the credit facility
agent under our revolving credit facility. Under the terms of
the intercreditor agreement, your security interest in the
secondary collateral is subordinated to the security interest
held by the lenders under our revolving credit facility.
If we incur any other secondary collateral loans, the applicable
lender will enter into a counterpart to the intercreditor
agreement, or agreement similar to the existing intercreditor
agreement, with the collateral agent. The terms of the
intercreditor agreement provide that you will generally have no
rights in the secondary collateral (including any rights in the
manner of disposing the secondary collateral) until all of our
obligations owing to the lenders under our revolving credit
facility have been paid in full. See Description of
Notes Collateral Intercreditor
Agreement. The lenders who are secured by the first
priority security interests in the secondary collateral will
generally have control over releasing those assets subject to
the terms of the intercreditor agreement with the collateral
agent. These lenders may have significantly different interests
than the noteholders and may have very little indebtedness
outstanding. The credit facility agent and the lenders under our
revolving credit facility are under no obligation to take the
interests of the noteholders into account in determining whether
to exercise their rights in respect of the secondary collateral,
subject to the intercreditor agreement, and their interests may
differ or be adverse from yours. See Description of
Notes Collateral Intercreditor
Agreement.
Rights
of noteholders in the collateral may be adversely affected by
the failure to perfect security interests in certain collateral
existing or acquired in the future.
The security interest in the collateral securing the notes
includes domestic assets, both tangible and intangible, whether
now owned or acquired or arising in the future. There can be no
assurance that the trustee or the collateral agent will monitor,
or that we will inform the trustee or the collateral agent of,
the future acquisition of property and
21
rights that constitute collateral, and that the necessary action
will be taken to properly perfect the security interest in such
after acquired collateral. The failure to perfect a security
interest in respect of such acquired collateral may result in
the loss of the security interest therein or the priority of the
security interest in favor of the notes against third parties.
If we or any guarantor were to become subject to a bankruptcy
proceeding after the issue date of the notes, any liens recorded
or perfected after the issue date of the notes would face a
greater risk of being invalidated than if they had been recorded
or perfected on the issue date. If a lien is recorded or
perfected after the issue date, it may be treated under
bankruptcy law as if it were delivered to secure previously
existing debt. In bankruptcy proceedings commenced within
90 days of lien perfection, a lien given to secure
previously existing debt is materially more likely to be avoided
as a preference by the bankruptcy court than if delivered and
promptly recorded on the issue date of the notes. Accordingly,
if we or any guarantor were to file for bankruptcy after the
issue date of the notes and the liens had been perfected less
than 90 days before commencement of such bankruptcy
proceeding, the liens securing the notes may be especially
subject to challenge as a result of having been delivered after
the issue date of the notes. To the extent that such challenge
succeeded, you would lose the benefit of the security that the
collateral was intended to provide.
Federal
and state statutes allow courts, under specific circumstances,
to void guarantees and require noteholders to return payments
received from guarantors.
Under the federal bankruptcy law and comparable provisions of
state fraudulent transfer laws, a guarantee could be voided, or
claims in respect of a guarantee could be subordinated to all
other debts of that guarantor if, among other things, the
guarantor, at the time it incurred the indebtedness evidenced by
its guarantee:
|
|
|
|
|
received less than reasonably equivalent value or fair
consideration for the incurrence of such guarantee;
|
|
|
|
was insolvent or rendered insolvent by reason of such incurrence;
|
|
|
|
was engaged in a business or transaction for which the
guarantors remaining assets constituted unreasonably small
capital; or
|
|
|
|
intended to incur, or believed that it would incur, debts beyond
its ability to pay such debts as they mature.
|
In addition, any payment by that guarantor pursuant to its
guarantee could be voided and required to be returned to the
guarantor, or to a fund for the benefit of the creditors of the
guarantor.
The measures of insolvency for purposes of these fraudulent
transfer laws will vary depending upon the law applied in any
proceeding to determine whether a fraudulent transfer has
occurred. Generally, however, a guarantor would be considered
insolvent if:
|
|
|
|
|
the sum of its debts, including contingent liabilities, was
greater than the fair saleable value of all of its assets;
|
|
|
|
if the present fair saleable value of its assets was less than
the amount that would be required to pay its probable liability
on its existing debts, including contingent liabilities, as they
become absolute and mature; or
|
|
|
|
it could not pay its debts as they become due.
|
We may
not have the ability to raise the funds necessary to finance any
change of control offer required by the indenture.
Upon the occurrence of certain specific kinds of change of
control events, we are required to offer to repurchase all of
our outstanding senior secured notes at 101% of the aggregate
principal amount thereof plus accrued and unpaid interest to the
date of repurchase. We cannot assure you that we will have
sufficient funds at the time of the change of control to make
the required repurchase of all the senior secured notes. Any
such failure to comply with this offer and repurchase obligation
would constitute an event of default under the indenture. See
Description of Notes Repurchase upon Change of
Control.
22
THE
EXCHANGE OFFER
Purpose
and Effect of the Exchange Offer
We entered into a registration rights agreement with the initial
purchasers of the unregistered notes, in which we agreed to file
a registration statement relating to an offer to exchange the
unregistered notes for the registered notes. The registration
statement of which this prospectus forms a part was filed in
compliance with this obligation. We also agreed to use our
commercially reasonable efforts to cause the registration
statement to become effective under the Securities Act. The
registered notes will have terms substantially identical to the
unregistered notes except that the registered notes will not
contain terms with respect to transfer restrictions,
registration rights and additional interest payable for the
failure to comply with our obligations under the registration
rights agreement. Unregistered notes in an aggregate principal
amount of $150.0 million were issued on March 29, 2007.
Each holder of unregistered notes that wishes to exchange such
unregistered notes for transferable registered notes in the
exchange offer will be required to make the following
representations:
|
|
|
|
|
that any registered notes to be received by it will be acquired
in the ordinary course of its business;
|
|
|
|
that at the time of the commencement of the exchange offer it
has no arrangement or understanding with any person to
participate in the distribution (within the meaning of
Securities Act) of the registered notes in violation of the
Securities Act;
|
|
|
|
that it is not our affiliate (as defined in
Rule 405 promulgated under the Securities Act), or, if it
is an affiliate, that it will comply with any applicable
registration and prospectus delivery requirements of the
Securities Act;
|
|
|
|
if such holder is not a broker-dealer, that it is not engaged
in, and does not intend to engage in, the distribution of
registered notes; and
|
|
|
|
if such holder is a broker-dealer that will receive registered
notes for its own account in exchange for notes that were
acquired as a result of market-making or other trading
activities, that it will deliver a prospectus in connection with
any resale of such registered notes.
|
In addition, the SEC has taken the position that each
broker-dealer that receives registered notes for its own account
in exchange for unregistered notes, where such unregistered
notes were acquired by such broker-dealer as a result of
market-making activities or other trading activities, may
fulfill their prospectus delivery requirements with respect to
the registered notes (other than a resale of an unsold allotment
from the original sale of the registered notes) by delivering a
prospectus in connection with any resale of such registered
notes. See Plan of Distribution.
Resale of
Registered Notes
Based on interpretations of the SEC staff set forth in no-action
letters issued to unrelated third parties, we believe that
registered notes issued in the exchange offer in exchange for
unregistered notes may be offered for resale, resold and
otherwise transferred by any exchange note holder without
compliance with the registration and prospectus delivery
provisions of the Securities Act, if:
|
|
|
|
|
such holder is not an affiliate of ours within the
meaning of Rule 405 under the Securities Act;
|
|
|
|
such registered notes are acquired in the ordinary course of the
holders business; and
|
|
|
|
the holder does not intend to participate in the distribution of
such registered notes.
|
Any holder who tenders in the exchange offer with the intention
of participating in any manner in a distribution of the
registered notes:
|
|
|
|
|
cannot rely on the position of the staff of the SEC set forth in
Exxon Capital Holdings Corporation or similar
interpretive letters: and
|
|
|
|
must comply with the registration and prospectus delivery
requirements of the Securities Act in connection with a
secondary resale transaction.
|
23
If, as stated above, a holder cannot rely on the position of the
staff of the SEC set forth in Exxon Capital Holdings
Corporation or similar interpretive letters, any effective
registration statement used in connection with a secondary
resale transaction must contain the selling security holder
information required by Item 507 of
Regulation S-K
under the Securities Act.
This prospectus may be used for an offer to resell, for the
resale or for other retransfer of registered notes only as
specifically set forth in this prospectus. With regard to
broker-dealers, only broker-dealers that acquired the
unregistered notes as a result of market-making activities or
other trading activities may participate in the exchange offer.
Each broker-dealer that receives registered notes for its own
account in exchange for unregistered notes, where such
unregistered notes were acquired by such broker-dealer as a
result of market-making activities or other trading activities,
must acknowledge that it will deliver a prospectus in connection
with any resale of the registered notes. Please read the section
captioned Plan of Distribution for more details
regarding these procedures for the transfer of registered notes.
We have agreed that, for the period required by the Securities
Act after the exchange offer is consummated, we will make this
prospectus available to any broker-dealer for use in connection
with any resale of the registered notes.
Terms of
the Exchange Offer
Upon the terms and subject to the conditions set forth in this
prospectus and in the letter of transmittal, we will accept for
exchange any unregistered notes properly tendered and not
withdrawn prior to the expiration date. We will issue up to
$150,000,000 in principal amount of registered notes, in the
aggregate, in exchange for an equal principal amount of the
unregistered notes surrendered under the exchange offer.
Unregistered notes may be tendered for the registered notes only
in integral multiples of $1,000.
The form and terms of the registered notes will be substantially
identical to the form and terms of the unregistered notes except
that the registered notes will be registered under the
Securities Act, will not bear legends restricting their transfer
and will not provide for any Additional Interest upon our
failure to fulfill our obligations under the registration rights
agreement to file, and cause to become effective, a registration
statement. The registered notes will evidence the same debt as
the unregistered notes. The registered notes will be issued
under and entitled to the benefits of the same indenture that
authorized the issuance of the unregistered notes. Consequently,
each series of notes will be treated as a single class of debt
securities under the applicable indenture.
The exchange offer is not conditioned upon any minimum aggregate
principal amount of unregistered notes being tendered for
exchange.
As of the date of this prospectus, $150.0 million aggregate
principal amount of the unregistered notes are outstanding. This
prospectus and the letter of transmittal are being sent to all
registered holders of unregistered notes. There will be no fixed
record date for determining registered holders of unregistered
notes entitled to participate in the exchange offer.
We intend to conduct the exchange offer in accordance with the
provisions of the registration rights agreement, the applicable
requirements of the Securities Act and the Exchange Act, and the
rules and regulations of the SEC. Unregistered notes that are
not tendered for exchange in the exchange offer will remain
outstanding and continue to accrue interest and will be entitled
to the rights and benefits such holders have under the indenture
relating to the unregistered notes.
We will be deemed to have accepted for exchange properly
tendered unregistered notes when we have given oral or written
notice of the acceptance to the exchange agent. The exchange
agent will act as agent for the tendering holders for the
purposes of receiving the registered notes from us and
delivering registered notes to such holders. Subject to the
terms of the registration rights agreement, we expressly reserve
the right to amend or terminate the exchange offer, and not to
accept for exchange any unregistered notes not previously
accepted for exchange, upon the occurrence of any of the
conditions specified below under the caption
Certain Conditions to the Exchange Offer.
Holders who tender unregistered notes in the exchange offer will
not be required to pay brokerage commissions or fees, or,
subject to the instructions in the letter of transmittal,
transfer taxes with respect to the exchange of unregistered
notes. We will pay all charges and expenses, other than those
transfer taxes described below, in
24
connection with the exchange offer. It is important that you
read the section labeled Fees and
Expenses below for more details regarding fees and
expenses incurred in the exchange offer.
Expiration
Date; Extensions; Amendments
The exchange offer will expire 5:00 p.m. (New York City
time) on September 12, 2008, unless we extend it in our
sole discretion. However, we will not extend the exchange offer
for more than 50 days after the date of this prospectus.
In order to extend the exchange offer, we will notify the
exchange agent orally or in writing. In addition, we will notify
the registered holders of unregistered notes, in writing, by
public announcement or both, of the extension no later than
9:00 a.m. (New York City time) on the business day after
the previously scheduled expiration date.
We reserve the right, in our sole discretion:
|
|
|
|
|
to delay accepting for exchange any unregistered notes before
expiration or termination of the exchange offer, including any
extensions;
|
|
|
|
to extend the exchange offer or to terminate the exchange offer
and to refuse to accept unregistered notes not previously
accepted if any of the conditions set forth below under
Certain Conditions to the Exchange Offer
have not been satisfied, by giving oral or written notice of
such delay, extension or termination to the exchange
agent; or
|
|
|
|
subject to the terms of the registration rights agreement, to
amend the terms of the exchange offer in any manner.
|
Any such delay in acceptance, extension, termination or
amendment will be followed as promptly as practicable by giving
notice or public announcement thereof to the registered holders
of unregistered notes. Holders of unregistered notes that tender
before or after the offer is extended will have until the new
expiration date to withdraw their notes. If we amend the
exchange offer in a manner that we determine to constitute a
material change, including a waiver of what we determine to be a
material condition, we will promptly disclose such amendment in
a manner reasonably calculated to inform the holders of
unregistered notes of such amendment and extend the exchange
offer for a period deemed adequate by us to permit holders to
withdraw their unregistered notes. In any event, the extension
will be at least five business days. If we amend the exchange
offer to condition our offer on valid tenders from a specified
percentage of unregistered notes or increase or decrease this
percentage we will extend the exchange offer by at least
10 days. If we terminate this exchange offer as provided in
this prospectus before accepting any unregistered notes for
exchange or if we amend the terms of this exchange offer in a
manner that constitutes a material change in the information set
forth in the registration statement of which this prospectus
forms a part, we will promptly file a post-effective amendment
to the registration statement of which this prospectus forms a
part and, if necessary, recirculate a revised prospectus. In
addition, we will in all events comply with our obligation to
promptly issue registered notes for all unregistered notes
properly tendered and accepted for exchange in the exchange
offer upon expiration of the exchange offer and will return
unregistered notes not accepted for exchange promptly upon
termination or expiration of the exchange offer.
Without limiting the manner in which we may choose to make
public announcements of any delay in acceptance, extension,
termination or amendment of the exchange offer, we shall not
have any obligation to publish, advertise or otherwise
communicate any such public announcement, other than by filing a
Current Report on
Form 8-K
with the SEC or issuing a timely press release to a financial
news service.
Certain
Conditions to the Exchange Offer
Despite any other terms of the exchange offer, we will not be
required to accept for exchange, or exchange any registered
notes for, any unregistered notes, and we may terminate the
exchange offer as provided in this prospectus before accepting
any unregistered notes for exchange if:
|
|
|
|
|
the exchange offer, or the making of any exchange by a holder of
unregistered notes, would violate applicable law or any
applicable interpretation of the staff of the SEC;
|
25
|
|
|
|
|
any action or proceeding is instituted or threatened in any
court or by or before any governmental agency with respect to
the exchange offer which, in our sole judgment, might materially
impair our ability to proceed with the exchange offer;
|
|
|
|
any material adverse development has occurred in any existing
action or proceeding with respect to us; or
|
|
|
|
any governmental approval has not been obtained, which approval
we, in our sole discretion, deem necessary for the consummation
of the exchange offer as contemplated by this prospectus.
|
In addition, we will not be obligated to accept for exchange the
unregistered notes of any holder that has not made:
|
|
|
|
|
the representations described under Purpose
and Effect of the Exchange Offer,
Procedures for Tendering and Plan
of Distribution; and
|
|
|
|
such other representations as may be reasonably necessary under
applicable SEC rules, regulations or interpretations to make
available to us an appropriate form for registration of the
registered notes under the Securities Act.
|
We expressly reserve the right, at any time or at various times
on or prior to the scheduled expiration date of the exchange
offer, to extend the period of time during which the exchange
offer is open. Consequently, we may delay acceptance of any
unregistered notes by giving oral or written notice of such
extension to the registered holders of the unregistered notes.
During any such extensions, all unregistered notes previously
tendered will remain subject to the exchange offer, and we may
accept them for exchange unless they have been previously
withdrawn. We will return any unregistered notes that we do not
accept for exchange for any reason without expense to their
tendering holder promptly after the expiration or termination of
the exchange offer.
We expressly reserve the right to amend or terminate the
exchange offer on or prior to the scheduled expiration date of
the exchange offer, and to reject for exchange any unregistered
notes not previously accepted for exchange, upon the occurrence
of any of the conditions of the exchange offer specified above.
We will give notice of or publicly announce any extension,
amendment, non-acceptance or termination to the registered
holders of the unregistered notes as promptly as practicable. In
the case of any extension, such notice will be issued no later
than 9:00 a.m. (New York City time) on the business day
after the previously scheduled expiration date. We will in all
events comply with our obligation to promptly issue registered
notes for all unregistered notes properly tendered and accepted
for exchange in the exchange offer upon expiration of the
exchange offer or to promptly return unregistered notes not
accepted for exchange upon termination or expiration of the
exchange offer.
These conditions are for our sole benefit and we may, in our
sole discretion, assert them regardless of the circumstances
that may give rise to them or waive them in whole or in part at
any or at various times (provided that, if we waive a condition
for one participant in the exchange offer, we must waive that
condition for all participants). All conditions to the exchange
offer, however, must be satisfied or waived by us prior to the
expiration of the exchange offer.
In addition, we will not accept for exchange any unregistered
notes tendered, and will not issue registered notes in exchange
for any such unregistered notes, if at such time any stop order
is threatened or in effect with respect to the registration
statement of which this prospectus constitutes a part or the
qualification of the indenture under the Trust Indenture
Act of 1939, as amended.
Procedures
for Tendering
Only a holder of unregistered notes may tender such unregistered
notes in the exchange offer. To tender in the exchange offer, a
holder must:
|
|
|
|
|
complete, sign and date the letter of transmittal, or a
facsimile of the letter of transmittal, have the signature on
the letter of transmittal guaranteed if the letter of
transmittal so requires and mail or deliver such letter of
transmittal or facsimile to the exchange agent prior to the
expiration date; or
|
|
|
|
comply with DTCs Automated Tender Offer Program procedures
described below.
|
26
In addition, either:
|
|
|
|
|
the exchange agent must receive unregistered notes along with
the letter of transmittal;
|
|
|
|
the exchange agent must receive, prior to the expiration date, a
timely confirmation of book-entry transfer of such unregistered
notes into the exchange agents account at DTC according to
the procedures for book-entry transfer described below or a
properly transmitted agents message; or
|
|
|
|
the holder must comply with the guaranteed delivery procedures
described below.
|
To be tendered effectively, the exchange agent must receive any
physical delivery of the letter of transmittal and other
required documents at the address set forth below under
Exchange Agent prior to the expiration date.
The tender by a holder that is not withdrawn prior to the
expiration date will constitute an agreement between such holder
and us in accordance with the terms and subject to the
conditions set forth in this prospectus and in the letter of
transmittal.
The method of delivery of unregistered notes, the letter of
transmittal and all other required documents to the exchange
agent is at the holders election and risk. Rather than
mail these items, we recommend that holders use an overnight or
hand delivery service. In all cases, holders should allow
sufficient time to assure delivery to the exchange agent before
the expiration date. Holders should not send us the letter of
transmittal or unregistered notes. Holders may request their
respective brokers, dealers, commercial banks, trust companies
or other nominees to effect the above transactions for them.
Any beneficial owner whose unregistered notes are registered in
the name of a broker, dealer, commercial bank, trust company or
other nominee and who wishes to tender should contact the
registered holder promptly and instruct it to tender on the
owners behalf. If such beneficial owner wishes to tender
on its own behalf, it must, prior to completing and executing
the letter of transmittal and delivering its unregistered notes,
either:
|
|
|
|
|
make appropriate arrangements to register ownership of the
unregistered notes in such owners name; or
|
|
|
|
obtain a properly completed bond power from the registered
holder of unregistered notes.
|
Depending on the facts and circumstances applicable to a
particular beneficial owner, including the nominee in whose name
the notes are registered and applicable state laws, the transfer
of registered ownership may take an indeterminable amount of
time and may not be completed prior to the expiration date.
Signatures on a letter of transmittal or a notice of withdrawal
described below must be guaranteed by a member of the Medallion
Signature Guarantee Program or by any other eligible
guarantor institution within the meaning of
Rule 17Ad-15
under the Exchange Act (each are referred to as an
eligible institution) unless the unregistered notes
tendered pursuant thereto are tendered:
|
|
|
|
|
by a registered holder who has not completed the box entitled
Special Issuance Instructions or Special
Delivery Instructions on the letter of transmittal; or
|
|
|
|
for the account of an eligible institution.
|
If the unregistered notes are registered in the name of a person
other than the signer of the letter of transmittal or if
unregistered notes not accepted for exchange or not tendered are
to be returned to a person other than the registered holder,
then the signatures on the letter of transmittal accompanying
the tendered unregistered notes must be guaranteed by an
eligible institution as described above. See Instructions 1
and 5 of the letter of transmittal.
If the letter of transmittal or any unregistered notes or bond
powers are signed by trustees, executors, administrators,
guardians, attorneys-in-fact, officers of corporations or others
acting in a fiduciary or representative capacity, such persons
should so indicate when signing. Unless waived by us, they
should also submit evidence satisfactory to us of their
authority to deliver the letter of transmittal.
The exchange agent and DTC have confirmed that any financial
institution that is a participant in DTCs system may use
DTCs Automated Tender Offer Program to tender.
Participants in the program may, instead of physically
completing and signing the letter of transmittal and delivering
it to the exchange agent, transmit their acceptance of the
exchange offer electronically. They may do so by causing DTC to
transfer the unregistered notes
27
to the exchange agent in accordance with its procedures for
transfer. DTC will then send an agents message to the
exchange agent. The term agents message means
a message transmitted by DTC, received by the exchange agent and
forming part of the book-entry confirmation, to the effect that:
|
|
|
|
|
DTC has received an express acknowledgment from a participant in
its Automated Tender Offer Program that is tendering
unregistered notes that are the subject of such book-entry
confirmation;
|
|
|
|
such participant has received and agrees to be bound by the
terms of the letter of transmittal (or, in the case of an
agents message relating to guaranteed delivery, that such
participant has received and agrees to be bound by the
applicable notice of guaranteed delivery); and
|
|
|
|
the agreement may be enforced against such participant.
|
We will determine in our sole discretion all questions as to the
validity, form, eligibility (including time of receipt),
acceptance of tendered unregistered notes and withdrawal of
tendered unregistered notes. Our determination will be final and
binding. We reserve the absolute right to reject any
unregistered notes not properly tendered or any unregistered
notes the acceptance of which would, in the opinion of our
counsel, be unlawful. We also reserve the right to waive any
defects, irregularities or conditions of tenders as to
particular unregistered notes. Our interpretation of the terms
and conditions of the exchange offer (including the instructions
in the letter of transmittal) will be final and binding on all
parties. Unless waived, any defects or irregularities in
connection with tenders of unregistered notes must be cured
within such time as we shall determine. Although we intend to
notify holders of defects or irregularities with respect to
tenders of unregistered notes, neither we, the exchange agent
nor any other person will incur any liability for failure to
give such notification. Tenders of unregistered notes will not
be deemed made until such defects or irregularities have been
cured or waived. Any unregistered notes received by the exchange
agent that are not properly tendered and as to which the defects
or irregularities have not been cured or waived will be returned
without cost to the tendering holder, unless otherwise provided
in the letter of transmittal, promptly following the expiration
or termination date.
In all cases, we will issue registered notes for unregistered
notes that we have accepted for exchange under the exchange
offer only after the exchange agent timely receives:
|
|
|
|
|
unregistered notes or a timely book-entry confirmation of such
unregistered notes into the exchange agents account at
DTC; and
|
|
|
|
a properly completed and duly executed letter of transmittal and
all other required documents or a properly transmitted
agents message.
|
By signing the letter of transmittal, each tendering holder of
unregistered notes will represent that, among other things:
|
|
|
|
|
that any registered notes to be received by it will be acquired
in the ordinary course of its business;
|
|
|
|
that at the time of the commencement of the exchange offer it
has no arrangement or understanding with any person to
participate in the distribution (within the meaning of
Securities Act) of the registered notes in violation of the
Securities Act;
|
|
|
|
that it is not our affiliate (as defined in
Rule 405 promulgated under the Securities Act), or, if it
is an affiliate, that it will comply with any applicable
registration and prospectus delivery requirements of the
Securities Act;
|
|
|
|
if such holder is not a broker-dealer, that it is not engaged
in, and does not intend to engage in, the distribution of
registered notes; and
|
|
|
|
if such holder is a broker-dealer that will receive registered
notes for its own account in exchange for notes that were
acquired as a result of market-making or other trading
activities, that it will deliver a prospectus in connection with
any resale of such registered notes.
|
In addition, the SEC has taken the position that each
broker-dealer that receives registered notes for its own account
in exchange for unregistered notes, where such unregistered
notes were acquired by such broker-dealer as a result of
market-making activities or other trading activities, may
fulfill their prospectus delivery requirements with
28
respect to the registered notes (other than a resale of an
unsold allotment from the original sale of the registered notes)
by delivering a prospectus in connection with any resale of such
registered notes. See Plan of Distribution.
Book-Entry
Transfer
The exchange agent will make a request to establish an account
with respect to the unregistered notes at DTC for purposes of
the exchange offer promptly after the date of this prospectus
and any financial institution participating in DTCs system
may make book-entry delivery of unregistered notes by causing
DTC to transfer such unregistered notes into the exchange
agents account at DTC in accordance with DTCs
procedures for transfer. Holders of unregistered notes who are
unable to deliver confirmation of the book-entry tender of their
unregistered notes into the exchange agents account at DTC
or all other documents of transmittal to the exchange agent on
or prior to the expiration date must tender their unregistered
notes according to the guaranteed delivery procedures described
below.
Guaranteed
Delivery Procedures
Holders wishing to tender their unregistered notes but whose
unregistered notes are not immediately available or who cannot
deliver their unregistered notes, the letter of transmittal or
any other required documents to the exchange agent or comply
with the applicable procedures under DTCs Automated Tender
Offer Program prior to the expiration date may tender if:
|
|
|
|
|
the tender is made through an eligible institution;
|
|
|
|
prior to the expiration date, the exchange agent receives from
such eligible institution either a properly completed and duly
executed notice of guaranteed delivery by facsimile
transmission, mail or hand delivery or a properly transmitted
agents message and notice of guaranteed delivery:
|
|
|
|
|
|
stating that the tender is being made thereby;
|
|
|
|
guaranteeing that, within three New York Stock Exchange trading
days after the expiration date, the letter of transmittal or
facsimile thereof together with the unregistered notes or a
book-entry confirmation, and any other documents required by the
letter of transmittal will be deposited by the eligible
institution with the exchange agent; and
|
|
|
|
setting forth the name and address of the holder, the registered
number(s) of such unregistered notes and the principal amount of
unregistered notes tendered; and
|
|
|
|
|
|
the exchange agent receives such properly completed and executed
letter of transmittal or facsimile thereof, as well as all
tendered unregistered notes in proper form for transfer or a
book-entry confirmation, and all other documents required by the
letter of transmittal, within three New York Stock Exchange
trading days after the expiration date.
|
Upon request to the exchange agent, a notice of guaranteed
delivery will be sent to holders who wish to tender their
unregistered notes according to the guaranteed delivery
procedures set forth above.
Withdrawal
of Tenders
Except as otherwise provided in this prospectus, holders of
unregistered notes may withdraw their tenders at any time prior
to the expiration date.
For a withdrawal to be effective:
|
|
|
|
|
the exchange agent must receive a written notice of withdrawal,
which notice may be by facsimile transmission or letter, at one
of the addresses set forth below under
Exchange Agent; or
|
|
|
|
holders must comply with the appropriate procedures of
DTCs Automated Tender Offer Program system.
|
Any such notice of withdrawal must:
|
|
|
|
|
specify the name of the person who tendered the unregistered
notes to be withdrawn;
|
29
|
|
|
|
|
identify the unregistered notes to be withdrawn, including the
principal amount of such unregistered notes; and
|
|
|
|
where certificates for unregistered notes have been transmitted,
specify the name in which such unregistered notes were
registered, if different from that of the withdrawing holder.
|
If certificates for unregistered notes have been delivered or
otherwise identified to the exchange agent, then, prior to the
release of such certificates, the withdrawing holder must also
submit:
|
|
|
|
|
the serial numbers of the particular certificates to be
withdrawn; and
|
|
|
|
a signed notice of withdrawal with signatures guaranteed by an
eligible institution unless such holder is an eligible
institution.
|
If unregistered notes have been tendered pursuant to the
procedure for book-entry transfer described above, any notice of
withdrawal must specify the name and number of the account at
DTC to be credited with the withdrawn unregistered notes and
otherwise comply with the procedures of such facility. We will
determine all questions as to the validity, form and
eligibility, including time of receipt of such notices, and our
determination shall be final and binding on all parties. We will
deem any unregistered notes so withdrawn not to have been
validly tendered for exchange for purposes of the exchange
offer. Any unregistered notes that have been tendered for
exchange but which are not exchanged for any reason will be
returned to the holder thereof without cost to such holder (or,
in the case of unregistered notes tendered by book-entry
transfer into the exchange agents account at DTC according
to the procedures described above, such unregistered notes will
be credited to an account maintained with DTC for unregistered
notes) promptly after withdrawal, rejection of tender or
termination of the exchange offer. Properly withdrawn
unregistered notes may be retendered by following one of the
procedures described under Procedures for
Tendering above at any time prior to the expiration date.
Exchange
Agent
U. S. Bank National Association has been appointed as
exchange agent for the exchange offer. You should direct
questions and requests for assistance, requests for additional
copies of this prospectus or of the letter of transmittal and
requests for the notice of guaranteed delivery to the exchange
agent addressed as follows:
U. S. Bank National Association
Westside Operations Center
60 Livingston Avenue
St. Paul, MN 55107
Attention: Specialized Finance
DELIVERY OF THE LETTER OF TRANSMITTAL TO AN ADDRESS OTHER THAN
AS SET FORTH ABOVE OR TRANSMISSION VIA FACSIMILE OTHER THAN AS
SET FORTH ABOVE DOES NOT CONSTITUTE A VALID DELIVERY OF SUCH
LETTER OF TRANSMITTAL.
Fees and
Expenses
We will bear the expenses of soliciting tenders. The principal
solicitation is being made by mail; however, we may make
additional solicitations by telephone or in person by our
officers and regular employees and those of our affiliates.
We have not retained any dealer-manager in connection with the
exchange offer and will not make any payments to broker-dealers
or others soliciting acceptances of the exchange offer. We will,
however, pay the exchange agent reasonable and customary fees
for its services and reimburse it for its related reasonable
out-of-pocket expenses.
Our expenses in connection with the exchange offer include:
|
|
|
|
|
SEC registration fees;
|
|
|
|
fees and expenses of the exchange agent and trustee;
|
30
|
|
|
|
|
accounting and legal fees and printing costs; and
|
|
|
|
related fees and expenses.
|
Transfer
Taxes
In general, we will pay all transfer taxes, if any, applicable
to the exchange of unregistered notes under the exchange offer.
The tendering holder, however, will be required to pay any
transfer taxes, whether imposed on the registered holder or any
other person, if:
|
|
|
|
|
certificates representing unregistered notes for principal
amounts not tendered or accepted for exchange are to be
delivered to, or are to be issued in the name of, any person
other than the registered holder of unregistered notes tendered;
|
|
|
|
tendered unregistered notes are registered in the name of any
person other than the person signing the letter of
transmittal; or
|
|
|
|
a transfer tax is imposed for any reason other than the exchange
of unregistered notes under the exchange offer.
|
If satisfactory evidence of payment of such taxes is not
submitted with the letter of transmittal, the amount of such
transfer taxes will be billed to that tendering holder.
In addition, holders who instruct us to register registered
notes in the name of, or request that unregistered notes not
tendered or not accepted in the exchange offer be returned to, a
person other than the registered tendering holder will be
required to pay any applicable transfer taxes.
Consequences
of Failure to Exchange
Holders of unregistered notes who do not exchange their
unregistered notes for registered notes under the exchange
offer, including as a result of failing to timely deliver
unregistered notes to the exchange agent, together with all
required documentation, including a properly completed and
signed letter of transmittal, will remain subject to the
restrictions on transfer of such unregistered notes:
|
|
|
|
|
as set forth in the legend printed on the unregistered notes as
a consequence of the issuance of the unregistered notes pursuant
to the exemptions from, or in transactions not subject to, the
registration requirements of the Securities Act and applicable
state securities laws; and
|
|
|
|
otherwise as set forth in the offering circular distributed in
connection with the private offering of the unregistered notes.
|
In addition, you will no longer have any registration rights or
be entitled to Additional Interest with respect to the
unregistered notes. Therefore, you should allow sufficient time
to ensure timely delivery of the unregistered notes and you
should carefully follow the instructions on how to tender your
unregistered notes.
In general, you may not offer or sell the unregistered notes
unless they are registered under the Securities Act, or if the
offer or sale is exempt from registration under the Securities
Act and applicable state securities laws. Except as required by
the registration rights agreement, we do not intend to register
resales of the unregistered notes under the Securities Act.
Based on interpretations of the SEC staff, registered notes
issued pursuant to the exchange offer may be offered for resale,
resold or otherwise transferred by their holders, other than any
such holder that is our affiliate within the meaning
of Rule 405 under the Securities Act, without compliance
with the registration and prospectus delivery provisions of the
Securities Act, provided that the holders acquired the
registered notes in the ordinary course of the holders
business and the holders have no arrangement or understanding
with respect to the distribution of the registered notes to be
acquired in the exchange offer. Any holder who tenders in the
exchange offer for the purpose of participating in a
distribution of the registered notes:
|
|
|
|
|
cannot rely on the applicable interpretations of the
SEC; and
|
|
|
|
must comply with the registration and prospectus delivery
requirements of the Securities Act in connection with a
secondary resale transaction.
|
31
After the exchange offer is consummated, if you continue to hold
any unregistered notes, you may have difficulty selling them.
Accounting
Treatment
We will record the registered notes in our accounting records at
the same carrying value as the unregistered notes, as reflected
in our accounting records on the date of exchange. Accordingly,
we will not recognize any gain or loss for accounting purposes
in connection with the exchange offer. We will expense the costs
of this exchange offer as incurred.
Other
Participation in the exchange offer is voluntary, and you should
carefully consider whether to accept. You are urged to consult
your financial and tax advisors in making your own decision on
what action to take.
We may in the future seek to acquire untendered unregistered
notes in the open market or privately negotiated transactions,
through subsequent exchange offers or otherwise. We have no
present plans to acquire any unregistered notes that are not
tendered in the exchange offer or to file a registration
statement to permit resales of any untendered unregistered notes.
32
USE OF
PROCEEDS
This exchange offer is intended to satisfy some of our
obligations under the registration rights agreement. We will not
receive any cash proceeds from the issuance of the registered
notes in the exchange offer. In consideration for issuing the
registered notes contemplated in this prospectus, we will
receive unregistered notes in like principal amount, the form
and terms of which are the same as the form and terms of the
registered notes, except that the registered notes will not
contain transfer restrictions or registration rights.
Unregistered notes surrendered in exchange for registered notes
will be retired and cancelled and will not be reissued.
Accordingly, the issuance of the registered notes will not
result in any change in our outstanding indebtedness.
The net proceeds from the offering of the unregistered notes,
after deducting fees and expenses, was $142.0 million. We
used those proceeds to purchase and redeem all of our
outstanding 10% Senior Secured Notes due 2007, or our 2007
secured notes, and for general corporate purposes.
The following table sets forth the sources and uses of funds in
connection with the offering of the unregistered notes:
|
|
|
|
|
|
|
|
|
|
|
Sources of Funds
|
|
|
|
|
Uses of Funds
|
|
|
|
|
Unregistered notes offered
|
|
$
|
150,000
|
|
|
2007 secured
notes(1)
|
|
$
|
103,961
|
|
|
|
|
|
|
|
General corporate purposes
|
|
|
38,013
|
|
|
|
|
|
|
|
Fees and expenses
|
|
|
8,026
|
|
|
|
|
|
|
|
|
|
|
|
|
Total sources of funds
|
|
$
|
150,000
|
|
|
Total uses of funds
|
|
$
|
150,000
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(1) |
|
Includes the repurchase and
redemption of all of our 2007 secured notes at par plus accrued
interest thereon.
|
33
CAPITALIZATION
The following table sets forth our cash and cash equivalents and
capitalization at March 31, 2008, and should be read in
conjunction with our historical consolidated financial
statements and related notes, Managements Discussion
and Analysis of Financial Conditions and Results of
Operations and other financial information included
elsewhere in this prospectus.
|
|
|
|
|
|
|
At March 31, 2008
|
|
|
|
(Dollars in thousands)
|
|
|
Cash and cash equivalents
|
|
$
|
170,459
|
|
|
|
|
|
|
Long-term debt, including current maturities:
|
|
|
|
|
Revolving credit facility
|
|
|
|
|
Senior secured notes due 2015
|
|
|
150,000
|
|
|
|
|
|
|
Total long-term debt
|
|
|
150,000
|
|
Redeemable preferred stock
|
|
|
104,137
|
|
Stockholders equity (deficiency in assets)
|
|
|
(85,487
|
)
|
|
|
|
|
|
Total capitalization
|
|
$
|
168,650
|
|
|
|
|
|
|
34
SELECTED
CONSOLIDATED FINANCIAL AND OPERATING DATA
The following table sets forth selected financial data with
respect to our consolidated financial condition and consolidated
results of operations and should be read in conjunction with our
historical consolidated financial statements and related notes,
Managements Discussion and Analysis of Financial
Condition and Results of Operations and other financial
information included elsewhere in this prospectus.
On September 17, 2007, we entered into a long-term
exclusive styrene supply agreement and a related railcar
purchase and sale agreement with NOVA. On November 13,
2007, we announced that we will exit the styrene business to
pursue other strategic initiatives. Due to the shut down of our
styrene plant, we have reported the operating results of the
styrene business as discontinued operations in our consolidated
financial statements beginning in the first quarter of 2008. All
prior periods have been reclassified. The selected financial
data presented below includes our styrene business in
discontinued operations.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Three Months
|
|
|
Three Months
|
|
|
Year Ended
|
|
|
Year Ended
|
|
|
Year Ended
|
|
|
Year Ended
|
|
|
Year Ended
|
|
|
|
Ended March 31,
|
|
|
Ended March 31,
|
|
|
December 31,
|
|
|
December 31,
|
|
|
December 31,
|
|
|
December 31,
|
|
|
December 31,
|
|
|
|
2008
|
|
|
2007(1)
|
|
|
2007
|
|
|
2006(1)
|
|
|
2005(1)
|
|
|
2004(1)
|
|
|
2003(1)
|
|
|
|
(In thousands, except per share data)
|
|
|
|
|
|
|
|
|
Operating Data:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Revenues
|
|
$
|
38,199
|
|
|
$
|
32,715
|
|
|
$
|
129,813
|
|
|
$
|
141,259
|
|
|
$
|
128,098
|
|
|
$
|
125,624
|
|
|
$
|
109,949
|
|
Gross profit
|
|
|
4,400
|
|
|
|
5,627
|
|
|
|
13,382
|
|
|
|
13,846
|
|
|
|
7,844
|
|
|
|
10,886
|
|
|
|
4,522
|
|
Loss from continuing
operations(2)
|
|
|
(905
|
)
|
|
|
(56
|
)
|
|
|
(7,713
|
)
|
|
|
(2,194
|
)
|
|
|
(5,856
|
)
|
|
|
(42,212
|
)
|
|
|
(9,761
|
)
|
Income (loss) from discontinued
operations(3)
|
|
|
(6,224
|
)
|
|
|
2,725
|
|
|
|
(11,215
|
)
|
|
|
(103,465
|
)
|
|
|
(23,712
|
)
|
|
|
(20,432
|
)
|
|
|
(4,438
|
)
|
Per Share Data:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net loss attributable to common stockholders
|
|
$
|
(4.03
|
)
|
|
$
|
(0.14
|
)
|
|
$
|
(12.90
|
)
|
|
$
|
(41.52
|
)
|
|
$
|
(16.46
|
)
|
|
$
|
(27.08
|
)
|
|
$
|
(8.38
|
)
|
Net loss from continuing operations attributable to common
stockholders
|
|
|
(1.83
|
)
|
|
|
(1.10
|
)
|
|
|
(8.93
|
)
|
|
|
(4.94
|
)
|
|
|
(8.08
|
)
|
|
|
(19.85
|
)
|
|
|
(6.80
|
)
|
Cash dividends
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Ratio of earnings to fixed
charges(4)
|
|
$
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Balance Sheet Data:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Working
capital(5)
|
|
$
|
157,917
|
|
|
$
|
131,902
|
|
|
$
|
166,264
|
|
|
$
|
99,110
|
|
|
$
|
208,179
|
|
|
$
|
248,166
|
|
|
$
|
289,491
|
|
Total assets
|
|
|
287,225
|
|
|
|
321,224
|
|
|
|
306,444
|
|
|
|
245,823
|
|
|
|
386,594
|
|
|
|
473,553
|
|
|
|
550,503
|
|
Long-term debt
|
|
|
150,000
|
|
|
|
150,000
|
|
|
|
150,000
|
|
|
|
100,579
|
|
|
|
100,579
|
|
|
|
100,579
|
|
|
|
100,579
|
|
Redeemable preferred
stock(6)
|
|
|
104,137
|
|
|
|
58,767
|
|
|
|
99,866
|
|
|
|
82,316
|
|
|
|
70,542
|
|
|
|
53,559
|
|
|
|
39,701
|
|
Stockholders equity (deficiency in
assets)(7)
|
|
|
(85,487
|
)
|
|
|
(22,347
|
)
|
|
|
(74,087
|
)
|
|
|
(48,575
|
)
|
|
|
58,045
|
|
|
|
107,813
|
|
|
|
185,029
|
|
|
|
|
(1) |
|
We have restated our consolidated
financial statements and selected financial data for the fiscal
years ended December 31, 2006, 2005, 2004 and 2003 and the
three months ended March 31, 2007. For further information,
see Note 16 to the consolidated financial statements for
the years ended December 31, 2006 and 2005, and
Note 15 to the consolidated financial statements for the
quarter ended March 31, 2007, found elsewhere in this
prospectus.
|
(2) |
|
During 2004, we recorded a
$48.5 million goodwill impairment charge. Also during 2004,
we recorded a pension curtailment gain of $13 million.
|
(3) |
|
During 2006, we recorded a
$127.7 million impairment charge to our styrene assets and
a related deferred tax benefit of $45 million. This tax
benefit was offset by deferred tax expense of $28 million
in connection with the recording of a valuation allowance
against our deferred tax assets. During 2005, we announced that
we were exiting the acrylonitrile business and related
derivatives operations. During 2004, we recorded a
$22 million pre-tax impairment charge related to our
acrylonitrile long-lived assets. Loss from discontinued
operations during 2007 and 2006 reflects costs associated with
the dismantling of our acrylonitrile unit.
|
(4) |
|
Additional pre-tax earnings needed
to achieve a 1:1 ratio for the three months ended March 31,
2008 and 2007 and the years ended December 31, 2007, 2006,
2005, 2004 and 2003 were $0.9 million, less than
$0.1 million, $11.8 million, $2.6 million,
$8.8 million, $42.3 million and $15.6 million,
respectively.
|
(5) |
|
Working capital as of
March 31, 2008 and 2007, December 31, 2007, 2006,
2005, 2004 and 2003 includes net assets (liabilities) of
discontinued operations of $(5.7) million,
$85.5 million $60.2 million, $88.3 million,
$181.6 million, $290.1 million and
$266.2 million, respectively.
|
(6) |
|
Our Series A Preferred Stock
is not currently redeemable or probable of redemption. If our
Series A Preferred Stock had been redeemed as of
March 31, 2008, the redemption amount would have been
approximately $79.7 million. The liquidation value of our
Series A Preferred Stock as of March 31, 2008 is
$68.7 million.
|
(7) |
|
The balance as of December 31,
2006 includes a change in stockholders equity (deficiency
in assets) of $6.8 million (net of tax) due to the adoption
of SFAS No. 158, Employers Accounting for Defined
Benefit Pension and Other Postretirement Plans.
|
35
MANAGEMENTS
DISCUSSION AND ANALYSIS OF
FINANCIAL CONDITION AND RESULTS OF OPERATIONS
Restatement
We have restated our previously issued consolidated financial
statements for the years ended December 31, 2006 and 2005
and the three months ended March 31, 2007 for the matters
discussed more fully in Note 15 to the consolidated
financial statements for the quarter ended March 31, 2007,
and Note 16 to the consolidated financial statements for
the years ended December 31, 2006 and 2005, included
elsewhere in this prospectus.
The following information should be read in conjunction with our
historical consolidated financial statements and related notes
and other financial information included elsewhere in this
prospectus.
Overview
Business
We are a North American producer of selected petrochemicals used
to manufacture a wide array of consumer goods and industrial
products. We currently operate in two segments: acetic acid and
plasticizers.
Our acetic acid is used primarily to manufacture vinyl acetate
monomer, which is used in a variety of products, including
adhesives and surface coatings. Pursuant to the Production
Agreement that began in 1986 and extends to 2016, all of our
acetic acid production is sold to BP Chemicals and we are BP
Chemicals sole source of acetic acid production in the
Americas. BP Chemicals markets all of the acetic acid that we
produce and pays us, among other amounts, a portion of the
profits derived from its sales of the acetic acid we produce. In
addition, BP Chemicals reimburses us for 100% of our fixed and
variable costs of production. Prior to August 2006, BP Chemicals
also paid us a set monthly amount. However, under the terms of
this Production Agreement, beginning in August 2006, the portion
of the profits we receive from the sales of acetic acid produced
at our plant increased and BP Chemicals was no longer required
to pay us the set monthly amount. This change in payment
structure did not affect BP Chemicals obligation to
reimburse us for all of our fixed and variable costs of
production. We believe that we have one of the lowest cost
acetic acid facilities in the world. Our acetic acid facility
utilizes BP Chemicals Cativa Technology, which we believe
offers several advantages over competing production methods,
including lower energy requirements and lower fixed and variable
costs. We also jointly invest with BP Chemicals in capital
expenditures related to our acetic acid facility in the same
percentage as the profits from the business are divided. We
initially pay for 100% of the capital expenditures related to
our acetic acid business and then invoice BP Chemicals for its
portion. The net amount that is not reimbursed by BP Chemicals
represents our basis in the property, plant and equipment
related to our acetic acid business, which is capitalized and
depreciated over its useful life. Acetic acid production has two
major raw material requirements methanol and carbon
monoxide. BP Chemicals, a producer of methanol, supplies 100% of
our methanol requirements related to our production of acetic
acid. All of the required carbon monoxide is supplied by Praxair
from a partial oxidation unit constructed by Praxair on land
leased from us at our site in Texas City, Texas.
All of our plasticizers, which are used to make flexible
plastics, such as shower curtains, floor coverings, automotive
parts and construction materials, are sold to BASF pursuant to a
long-term production agreement that extends until 2013, subject
to some early termination rights held by BASF that begin in
2010. Under our agreement with BASF, BASF provides us with most
of the required raw materials, markets the plasticizers we
produce and is obligated to make certain fixed quarterly
payments to us and to reimburse us monthly for our actual
production costs and capital expenditures related to our
plasticizers facility. In May 2008, we entered into an amended
production agreement with BASF, effective as of April 1,
2008. This amended agreement was entered into in connection with
BASFs nomination of zero pounds of PA under the existing
production agreement due to deteriorating market conditions
which were not expected to improve over the next few years,
which resulted in the shutdown of our PA unit. For further
discussion of the amended agreement with BASF, see
Recent Developments.
Prior to December 3, 2007, we manufactured styrene.
However, on September 17, 2007, we entered into a long-term
exclusive styrene supply agreement and a related railcar
purchase and sale agreement with NOVA. Under this supply
agreement, NOVA had the exclusive right to purchase 100% of our
styrene production (subject to existing contractual
commitments), the amount of styrene supplied in any particular
period being at NOVAs option,
36
based on a
full-cost
formula. In November 2007, the styrene supply agreement
with NOVA, which was subsequently assigned by NOVA to INEOS
NOVA, obtained clearance under the Hart-Scott-Rodino Act. This
clearance caused the supply agreement and the railcar agreement
to become effective and triggered a $60 million payment to
us in November 2007. In addition, in accordance with the
terms of the supply agreement, INEOS NOVA assumed substantially
all of our contractual obligations for future styrene
deliveries. After the supply agreement became effective, INEOS
NOVA nominated zero pounds of styrene under the supply agreement
for the balance of 2007 and, in response, we exercised our right
to terminate the supply agreement and permanently shut down our
styrene facility. Under the supply agreement, we are responsible
for the closure costs of our styrene facility and are also
subject to a long-term commitment to not reenter the styrene
business until December of 2012. We operated our styrene
facility through early December 2007, as we completed our
production of inventory and exhausted our raw materials and
purchase requirements, and sold substantially all our inventory
during the first quarter of 2008. During 2007 and the first
quarter of 2008, we incurred closure costs to decommission our
styrene facility of approximately $1 million and
$9 million, respectively. We expect to incur up to
$4 million in additional decommissioning costs related to
the closure of our styrene facility. In mid-July, with the
decontamination process for the styrene facility nearing
completion, we announced a reduction in work force in order to
reduce our staffing to a level appropriate for our existing
operations and site development projects. As a result, seven
members of our salaried work force were immediately laid off. In
addition, we made offers for early retirement to several members
of our hourly work force and our salaried administrative and
process supervisors. Upon completion of the down-sizing of our
hourly work force and our administrative and process supervisor
positions, which will occur after the period for accepting
offers of early retirement has closed in September, total staff
reductions are expected to be approximately 40 employees,
and we expect to recognize approximately $2.2 million in
severance costs in the third and fourth quarters of 2008, in
accordance with SFAS No. 146, Accounting for
Costs Associated with Exit of Disposal Activities.
We manufacture all of our petrochemicals products at our Texas
City facility. In terms of production capacity, our Texas City
site has the sixth largest acetic acid facility in the world.
Our Texas City site covers an area of 290 acres, is
strategically located on Galveston Bay and benefits from a
deep-water dock capable of handling ships with up to a 40-foot
draft, as well as four barge docks and direct access to Union
Pacific and Burlington Northern Santa Fe railways with in-motion
rail scales on site. Our Texas City site also has truck loading
racks, weigh scales, stainless and mild steel storage tanks,
three waste deepwells, 160 acres of available land zoned
for heavy industrial use and additional land zoned for light
industrial use and a supportive political environment for
growth. In addition, we are in the heart of one of the largest
petrochemical complexes on the Gulf Coast and, as a result, have
on-site
access to a number of raw material pipelines, as well as close
proximity to a number of large refinery complexes.
Given our under-utilized infrastructure, our management and
engineering expertise, as well as ample unoccupied land, we
believe that there are significant opportunities for further
development of our Texas City site. We are currently pursuing
numerous initiatives to attract new manufacturing and/or storage
related businesses to our Texas City site, including
opportunities involving renewable fuels projects, gasification,
energy projects and chemicals terminalling. Specifically, we are
seeking long-term contractual business arrangements or
partnerships that will provide us with an ability to realize the
value of our under-utilized assets through profit sharing or
other cash generating arrangements. For development projects
that may have significant capital expenditure requirements, we
are considering joint ventures or other arrangements where we
would contribute certain of our assets and management expertise
to minimize our share of the capital costs. In any case, we
expect any new facility constructed at our Texas City site to
lower the amount of overall fixed costs allocated to each of our
operating units and provide us with additional profit.
We plan to evaluate strategic acquisitions, focusing on chemical
businesses and assets which would allow us to increase our
market share of products we currently produce or those that
would provide upstream or downstream integration within our
existing businesses.
Our petrochemicals products are generally sold to customers for
use in the manufacture of other chemicals and products which, in
turn, are used in the production of a wide array of consumer
goods and industrial products throughout the world.
37
Acetic Acid. The North American acetic acid
industry has enjoyed a period of sustained domestic demand
growth, as well as substantial export demand. This has led to
current North American industry utilization rates of 86% and
Tecnon projects utilization rates to increase to over 98% by
2013, although the recent difficulties in the housing and
automotive sectors will likely cause reduced demand for vinyl
acetate monomer, and consequently acetic acid, in North America
in the short term. The North American acetic acid industry is
inherently less cyclical than many other petrochemical products
due to a number of important factors.
There are only four large producers of acetic acid in North
America and historically these producers have made capacity
additions in a disciplined and incremental manner, primarily
using small expansion projects or exploiting debottlenecking
opportunities. In addition, the leading technology required to
manufacture acetic acid is controlled by two global companies,
which permits these companies to control the pace of new
capacity additions through the licensing or development of such
additional capacity. The limited availability of this technology
also creates a significant barrier to entry into the acetic acid
industry by potential competitors.
Global production capacity of acetic acid, as of
December 31, 2007, was approximately 24 billion pounds
per year, with current North American production capacity at
approximately 7 billion pounds per year. The North American
acetic acid market is mature and well developed and is dominated
by four major producers that account for over 94% of the
production capacity of acetic acid in North America. Demand for
acetic acid is linked to the demand for vinyl acetate monomer, a
key intermediate in the production of a wide array of polymers.
Vinyl acetate monomer is the largest derivative of acetic acid,
representing over 40% of total demand. Annual global production
of vinyl acetate monomer is expected to increase from
10.4 billion pounds in 2005 to 12.2 billion pounds in
2010, although the recent difficulties in the housing and
automotive sectors will likely cause reduced demand for vinyl
acetate monomer in North America in the short term.
The North American acetic acid industry tends to sell most of
its products through long-term sales agreements having
cost plus pricing mechanisms, eliminating much of
the volatility seen in other petrochemicals products and
resulting in more stable and predictable earnings and profit
margins.
Several acetic acid capacity additions have occurred since 1998,
including an expansion of our acetic acid unit from
800 million pounds of rated annual production capacity to
1.1 billion pounds during 2005. These capacity additions
were somewhat offset by reductions of approximately
1.6 billion pounds in annual global capacity from the
shutdown of various outdated acetic acid plants from 1999
through 2001. In 2006, BP Chemicals closed two of its outdated
acetic acid production units in Hull, England that had a
combined annual capacity of approximately 500 million
pounds (which had been sold primarily in Europe and South
America). We and BP Chemicals are reviewing further expansion of
our acetic acid plant in 2008 or 2009.
Plasticizers. Historically, we produced
ethylene-based linear plasticizers, which typically receive a
premium over competing branched propylene-based products for
customers that require enhanced performance properties. However,
the markets for competing plasticizers can be affected by the
cost of the underlying raw materials, especially when the cost
of one olefin rises faster than the other, or by the
introduction of new products. One of the raw materials for
linear plasticizers is a product known as linear alpha-olefins.
Over the last few years, the price of linear alpha-olefins has
increased sharply as supply has declined, which has caused many
consumers to switch to lower cost branched products, despite the
loss of some performance properties. Ultimately, we expect
branched plasticizers to replace linear plasticizers for most
applications over the long-term. As a result, we modified our
plasticizers facilities during the third quarter of 2006 to
produce lower cost branched plasticizers products.
In 2005, BP Chemicals announced the permanent closure of its
linear alpha-olefins production facility in Pasadena, Texas, the
primary source of supply of this feedstock to the oxo-alcohols
production unit at our plasticizers facility. After pursuing
various alternative uses for our oxo-alcohols unit, we were
unable to secure an alternative use for this facility. As a
result, we permanently shut down our oxo-alcohols production
unit on July 31, 2006. Due to the closure of our
oxo-alcohols unit and our conversion to the production of
branched plasticizers, the phthalate esters production unit at
our plasticizers facility now uses oxo-alcohols supplied by BASF
that have a different chemical composition. In December 2007,
BASF caused the shutdown of our PA, unit by nominating zero
pounds of PA in response to deteriorating market conditions
which are not expected to improve in the foreseeable future. As
a result of this shutdown, in May 2008, we entered into an
amended production agreement with BASF, effective April 1,
2008. The amended agreement relieves BASF of most of its
obligations related to our PA
38
manufacturing unit, requires that BASF pay approximately
$3.7 million to us for reimbursement of certain direct
fixed and variable costs associated with the shutdown and
decontamination of our PA manufacturing unit. The amended
agreement also requires that BASF pay to us an aggregate amount
of approximately $3.2 million (the remaining
$0.2 million of which is required to be paid on or before
August 15, 2008), subject to a 25%-75% refund right in
BASFs favor if we restart our PA unit before the end of
2010, depending on the year in which we restart the unit. Under
the amended agreement, BASF is still required to make the same
quarterly fixed periodic payments as previously required. In
addition, under the amended production agreement, the methods
for calculating (i) payments required to be made by BASF to use
for achieving reductions in direct fixed and variable costs and
(ii) BASFs right to terminate the agreement in the event
that direct fixed and variable costs exceed a specified
threshold (unless we elect to cap BASFs reimbursement
obligations), have both been modified to exclude costs savings
and direct fixed and variable costs pertaining to our PA
manufacturing unit. The amended agreement also removed all
restrictions of rights BASF formerly had with respect to our use
or disposition of the PA manufacturing unit, including a
purchase right, the right to request capacity increases and
consultation rights regarding future capital expenditures with
respect to our PA unit. For further discussion of the amended
agreement with BASF, see Recent
Developments.
Styrene. The North American styrene industry
is currently in a protracted down cycle, primarily as a result
of over-supply. This extended down cycle resulted from two major
developments. Initially, export demand, which historically has
represented over 20% of North American production capacity, has
significantly diminished. In recent months, U.S. styrene
producers have seen an increase in styrene exports, largely due
to delays in the start up of announced new capacity in the
Middle East. However, this increase is expected to reverse
itself after the new styrene plant being constructed in Al
Jubail, Saudi Arabia is completed, which is currently expected
to occur later in 2008. Regional cost pressures, in addition to
new production capacity being added in Asia and the Middle East,
have made it difficult for North American producers to compete
in these export markets on a continuous basis. In addition, a
significant amount of styrene capacity has been added globally
over the past five to ten years by producers of propylene oxide
using so-called PO-SM technology, which produces styrene as a
co-product. Propylene oxide is a key intermediate in the
production of polyurethane, and polyurethane demand growth has
been significantly greater than demand growth for styrene,
exacerbating the over-supply of styrene. During periods of
over-supply, production rates for styrene producers decrease
significantly. When production rates are low, unit production
costs increase due to the allocation of fixed costs over a lower
production volume and a reduction in the efficiency of the
manufacturing unit, both in energy usage and in the conversion
rates for raw materials. Compounding these cost impacts, prices
for the principal styrene raw materials, benzene and ethylene,
are currently near historical highs, putting pressure on margins
on styrene sales even though styrene contract prices are at near
historic highs.
Over the last five years, China has been the driver for growth
in styrene demand, representing approximately 75% of the
worlds styrene demand growth in that period. Historically,
we positioned ourselves to take advantage of peaks in the Asian
styrene markets, with a large portion of our styrene capacity
not being committed under long-term arrangements. However, over
the last several years, relatively high benzene and domestic
natural gas prices significantly limited our ability to sell
styrene into the Asian markets, and high styrene prices have
reduced styrene global demand growth rates. In addition, several
of our competitors announced their intention to build new
styrene production units outside the United States, further
complicating our ability to sell styrene into the Asian markets.
In 2006, our competitors added 2.6 billion pounds of new
styrene capacity in Asia and an additional 1.6 billion
pounds in 2007. The remaining announced construction projects
are scheduled to start up in 2008 and beyond. If and when these
new units are completed, we anticipate more difficult market
conditions, especially in the export markets, until the
additional supply is absorbed by growth in styrene demand or
significant capacity rationalization occurs.
CMAI currently is projecting no additional capacity increases in
North America through 2010, with operating rates reaching a
trough of 75% in 2007, and less than 80% operating rates
projected through 2010, without any further industry
restructuring. Although we believe an improved North American
industry outlook is possible, this largely depends on a
significant industry restructuring. Previously, styrene and
polystyrene industry participants, including The DOW Chemical
Company and NOVA Chemicals Corporation, or NOVA Chemicals, have
announced a desire to seek transactions which would restructure
the North American styrene and polystyrene industries, thereby
improving the balance of supply and demand in North America.
More recently, on October 1, 2007, NOVA Chemicals expanded
its European joint venture with INEOS to include North American
styrene and solid
39
polystyrene assets, and, in May of 2008, Americas Styrenics
LLC, a joint venture between The Dow Chemical Company and
Chevron Phillips Chemical Company, which includes selected
styrene and polystyrene assets of the two companies in North
America and South America, began operations.
Recent
Developments
On May 27, 2008, we entered into our Amended Plasticizers
production agreement with BASF, with an effective date of
April 1, 2008. The Amended Plasticizers Production
agreement amends certain provisions of the Old Plasticizers
Production Agreement. The Amended Plasticizers Production
Agreement was entered into in connection with BASFs
nomination of zero pounds of PA under the Old Plasticizers
Production Agreement in response to deteriorating market
conditions which were not expected to improve over the next few
years, causing the shutdown of our PA unit.
The Amended Plasticizers Production Agreement relieves BASF of
most of its obligations under the Old Plasticizers Production
Agreement related to our PA manufacturing unit. BASFs
obligations under the Old Plasticizers Production Agreement
related to our esters manufacturing unit were not affected by
the Amended Plasticizers Production Agreement and are continuing
in accordance with the same terms as existed under the Old
Plasticizers Production Agreement. In exchange for being
relieved of its obligations related to our PA manufacturing
unit, BASF is required to pay us an aggregate amount of
approximately $3.2 million, $3.0 million of which was
paid in May 2008, and the balance of which is due and payable on
or before August 15, 2008. However, we are obligated to
refund 75% of this amount if we restart our PA manufacturing
unit before January 1, 2009, 50% of this amount if we
restart our PA manufacturing unit during 2009 and 25% of this
amount if we restart our PA manufacturing unit during 2010. The
$3.2 million represents the termination of BASFs
obligations under the Old Plasticizers Production Agreement with
respect to the operation of our PA manufacturing unit, and will
be recognized using the straight-line method over the restricted
period of April 1, 2008 through December 31, 2010
under the Amended Plasticizers Production Agreement. During the
first half of 2008, BASF is also required to pay us
approximately $3.7 million for reimbursement of certain
direct fixed and variable costs associated with the shutdown and
decontamination of our PA manufacturing unit, which amounts are
not subject to refund. All direct fixed and variable costs
associated with the shutdown and decontamination of our PA unit
have been incurred and expensed, and the $3.7 million in
cost reimbursements has been recognized as revenue in the first
six months of 2008. The quarterly fixed periodic payments under
the Old Plasticizers Production Agreement with respect to the
operation of our PA and esters manufacturing units will not
change; however, the quarterly fixed periodic payments are now
related to the operation of our esters manufacturing unit under
the Amended Plasticizers Production Agreement.
In addition, under the Amended Plasticizers Production
Agreement, (i) the methods for calculating payments
required to be made by BASF for achieving reductions in direct
fixed and variable costs and (ii) BASFs right to
terminate the Amended Plasticizers Production Agreement in the
event that direct fixed and variable costs exceed a specified
threshold (unless we elect to cap BASFs reimbursement
obligations) have both been modified to exclude costs savings
and direct fixed and variable costs pertaining to our PA
manufacturing unit.
After April 1, 2008, the Amended Plasticizers Production
Agreement also removed all restrictions or rights BASF formerly
had during the term of the Old Plasticizers Production Agreement
with respect to our use or disposition of the PA manufacturing
unit, including a limited purchase right, the right to request
capacity increases and consultation rights regarding future
capital expenditures with respect to our PA manufacturing unit.
As a result of the Amended Plasticizers Production Agreement and
subsequent permanent shutdown of our PA unit by BASF, our
management determined that a triggering event, as defined in
SFAS No. 144, Accounting for the Impairment or
Disposal of Long-Lived Assets, had occurred and during the
second quarter of 2008, we performed an asset impairment
analysis on our PA manufacturing unit. We analyzed the
undiscounted cash flow stream from our PA business over the
remaining life of the PA manufacturing unit and compared it to
the $6.6 million net book carrying value of our PA
manufacturing unit. This analysis showed that the undiscounted
projected cash flow stream from our PA business was less than
the net book carrying value of our PA manufacturing unit. As a
result, we performed a discounted cash flow analysis and
subsequently concluded that our PA manufacturing unit was
40
impaired and should be written down to zero. This write-down
caused us to record an impairment of $6.6 million in June
2008.
Other than the impairment discussed above, we do not believe the
shutdown of our PA manufacturing unit will have a material
adverse affect on our financial position, results of operations
or cash flows as the required quarterly fixed periodic payments
previously related to the PA manufacturing unit will continue
throughout the original term of the contract and have been
allocated to the operation of the esters manufacturing unit, and
all decontamination and shutdown costs were reimbursed by BASF.
Effective as of May 27, 2008, John V. Genova was appointed
as our President and Chief Executive Officer and was elected as
a member of our Board of Directors. Mr Genova succeeded Richard
K. Crump, who retired as President and Chief Executive Officer
as of May 27, 2008. Mr. Crump will remain a member of
our Board of Directors.
Discontinued
Operations
We operated our styrene manufacturing unit through early
December, as we completed our production of inventory and
exhausted our raw materials and purchase requirements and sold
substantially all of our inventory during the first quarter of
2008. During 2007 and the first quarter of 2008, we incurred
closure costs to decommission our styrene facility of
approximately $1 million and $9 million, respectively.
We expect to incur up to $4 million in additional
decommissioning costs related to the closure of our styrene
facility. In mid-July, with the decontamination process for the
styrene facility nearing completion, we announced a reduction in
work force in order to reduce our staffing to a level
appropriate for our existing operations and site development
projects. As a result, seven members of our salaried work force
were immediately laid off. In addition, we made offers for early
retirement to several members of our hourly work force and our
salaried administrative and process supervisors. Upon completion
of the down-sizing of our hourly work force and our
administrative and process supervisor positions, which will
occur after the period for accepting offers of early retirement
has closed in September, total staff reductions are expected to
be approximately 40 employees, and we expect to recognize
approximately $2.2 million in severance costs in the third
and fourth quarters of 2008, in accordance with
SFAS No. 146, Accounting for Costs Associated
with Exit of Disposal Activities.
On September 16, 2005, we announced that we were exiting
the acrylonitrile business and related derivative operations.
Our decision was based on a history of operating losses incurred
by our acrylonitrile and derivatives businesses, and was made
after a full review and analysis of our strategic alternatives.
Our acrylonitrile and derivatives businesses had sustained
losses in recent years and had been shut down since February of
2005.
Accordingly, consistent with the guidance EITF Abstracts, Topic
No. D-104,
Clarification of Transition Guidance in Paragraph 51
of FASB Statement No. 144, we have reported the
operating results of these businesses as discontinued operations
in our consolidated financial statements for the years ended
December 31, 2007, 2006 and 2005 and the three months ended
March 31, 2008 and 2007, respectively.
Results
of Operations
The following table sets forth revenues, gross profit (loss) and
net loss from continuing operations for 2007, 2006 and 2005 and
the three months ended March 31, 2008 and 2007:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Year Ended December 31,
|
|
|
Three Months Ended March 31,
|
|
|
|
2007
|
|
|
2006
|
|
|
2005
|
|
|
2008
|
|
|
2007
|
|
|
|
(Dollars in thousands)
|
|
|
Revenues
|
|
$
|
129,813
|
|
|
$
|
141,259
|
|
|
$
|
128,098
|
|
|
$
|
38,199
|
|
|
$
|
32,715
|
|
Gross profit
|
|
|
13,382
|
|
|
|
13,846
|
|
|
|
7,844
|
|
|
|
4,400
|
|
|
|
5,627
|
|
Loss from continuing operations
|
|
|
(7,713
|
)
|
|
|
(2,194
|
)
|
|
|
(5,856
|
)
|
|
|
(905
|
)
|
|
|
(56
|
)
|
41
Three
Months Ended March 31, 2008 Compared to Three Months Ended
March 31, 2007
Revenues
and income (loss) from continuing operations
Our revenues were $38.2 million for the first quarter of
2008, a 17% increase from the $32.7 million in revenues we
recorded for the first quarter of 2007. We recorded a net loss
from continuing operations of $0.9 million for the first
quarter of 2008, compared to a net loss from continuing
operations of less than $0.1 million in the first quarter
of 2007.
Revenues from acetic acid operations were $28.9 million for
the first quarter of 2008, a 17% increase from the
$24.8 million in revenues we received from these operations
in the first quarter of 2007. This increase in acetic acid
revenues in the first quarter of 2008 resulted primarily from an
increase in cost reimbursements received from BP Chemicals due
to an increase in the costs allocated to our acetic acid
operating segment as a result of our exit from the styrene
business. Gross profit from our acetic acid operations decreased
$1.8 million during the first quarter 2008 compared to the
first quarter of 2007. This decrease in gross profit was
primarily due to an increase in the costs allocated to our
acetic acid operating segment as a result of our exit from the
styrene business.
Revenues from plasticizers operations were $9.0 million in
the first quarter of 2008, a 20% increase from the
$7.5 million in revenues we recorded from these operations
in 2007. Gross profit for our plasticizers operations increased
$1.7 million in the first quarter of 2008. These increases
in revenues and gross profit resulted primarily from
reimbursement by BASF for cost savings approved in 2008 by BASF.
Interest
and debt related expenses
Our interest expense for the first quarter of 2008 was
$4.2 million, compared to $3.5 million for the first
quarter of 2007. This increase in the first quarter of 2008 was
primarily due to the higher principal amount of our senior
secured notes compared to our 2007 secured notes.
Interest
income
Our interest income for the first quarter of 2008 was
$1.3 million compared to the $0.1 million during the
first quarter of 2007. This increase in interest income was
primarily due to the higher average cash balances in the first
quarter of 2008 compared to the same period in 2007.
Discontinued
operations
During the first quarter of 2008, net loss from discontinued
operations was $6.2 million in the first quarter of 2008
compared to net income of $2.7 million in the first quarter
of 2007. This increase in net loss was primarily due to the
costs associated with the decommissioning of our styrene unit
that was shut down beginning in December 2007.
Comparison
of 2007 to 2006
Revenues
and loss from continuing operations
Our revenues were $129.8 million in 2007, a decrease of 8%
over the $141.3 million in revenues we recorded in 2006.
This decrease in revenues resulted primarily from a decrease in
plasticizers sales in 2007 due to the shutdown of our
oxo-alcohols facility in 2006, partially offset by a slight
increase in acetic acid revenues in 2007. We recorded a net loss
from continuing operations of $7.7 million in 2007,
compared to a net loss of $2.2 million in 2006. The
increase in our net loss was primarily due to increased interest
and debt related expenses associated with the exchange of
$100 million of our 2007 secured notes for
$150 million of new senior secured notes in early 2007.
Revenues from acetic acid operations were $100.8 million in
2007, a 4% increase from the $96.7 million in revenues we
recorded from these operations in 2006. The increase in acetic
acid revenues in 2007 resulted from increased profit sharing
revenue and an increase in cost reimbursements received from our
customer. Gross profit from our acetic acid operations decreased
$2.5 million during 2007 compared to 2006. This decrease
was due to the impact of the blend gas dispute with BP Chemicals
discussed below in Business Legal
Proceedings along with the absence of a one-time
$2.4 million utility cost reimbursement in 2006, partially
offset by the $3.4 million favorable impact
(year-over-year)
of the previously discussed conversion to higher profit sharing
under the Production Agreement that occurred in August 2006.
42
Revenues from plasticizers operations were $28.1 million in
2007, a 37% decrease from $44.5 million in revenues we
recorded from these operations in 2006. This decrease in revenue
in 2007 was primarily due to the permanent shut down of our
oxo-alcohols unit in the second half of 2006. Gross profit for
our plasticizers operations increased $1.7 million in 2007
primarily due to an increase in cost reimbursements received
from our customer, partially offset by decreased revenue.
Selling,
general & administrative expenses
Our selling, general and administrative expenses were
$8.7 million in 2007, compared to $7.1 million in
2006. This increase in 2007 was largely due to the incurrence of
over $1 million for professional fees in connection with
our pursuit of potential new business opportunities and
severance expense of $0.6 million.
Other
expense (income)
Other expense was $0.8 million in 2007, compared to other
income of $0.7 million for 2006. The decrease in 2007 was
due to other expense of $0.8 million that was recorded in
2007 for the write-down of our cost-method investment in an
e-commerce
commodity trading business to its fair value of less than
$0.2 million, after receiving notice of a distribution
pursuant to the pending sale of the business, and other income
of $0.7 million recorded in 2006 for an insurance claim
related to damages caused by a barge incident in 2005.
Interest
and debt related expenses, net of interest income
Our interest expense was $15.7 million in 2007 and
$10.1 million in 2006. The increase in 2007 was associated
with higher debt levels after our debt refinancing that occurred
in the first quarter of 2007, partially offset by a
$1.0 million increase in interest income received as a
result of higher average cash balances.
Provision
(benefit) for income taxes
During 2007, our effective tax rate was 23% compared to 12% in
2006. Income tax benefit of $5.5 million in 2007 represents
a $5.9 million tax benefit offset by $0.4 million of
federal alternative minimum tax and less than $0.1 million
of state income taxes. The 2007 effective rate of 23% resulted
in a decrease in the valuation allowance for other comprehensive
income adjustments related to amendments to our benefit plans
and a full valuation allowance recorded against our
2007 net loss. In 2006, the effective rate was impacted by
a $28 million increase in our valuation allowance as a
result of our analysis of the recoverability of our deferred tax
assets at December 31, 2006. Deferred tax assets are
regularly assessed for recoverability based on both historical
and anticipated earnings levels, and a valuation allowance is
recorded when it is more likely than not that these amounts will
not be recovered. As a result of our analysis, we concluded that
a valuation allowance was needed against our deferred tax
assets. As of December 31, 2007, our valuation allowance
was $36.2 million, an increase of $6.6 million from
December 31, 2006, which resulted in an overall net
deferred tax asset/liability balance of zero as of
December 31, 2007.
Loss from
discontinued operations, net of tax
We recorded a net loss from discontinued operations of
$11.2 million in 2007 compared to a net loss of
$103.5 million in 2006. The net loss in 2006 was primarily
due to the $127.7 million impairment charge to our styrene
assets that we recorded in the fourth quarter of 2006, partially
offset by a one-time reimbursement of $15 million in 2006
for an insurance claim related to the 2005 fire in the styrene
unit. There were no such transactions in 2007.
Comparison
of 2006 to 2005
Revenues
and loss from continuing operations
Our revenues were $141.3 million in 2006, an increase of
10% over the $128.1 million in revenues we recorded in
2005. This increase in revenues resulted primarily from an
increase in the acetic acid sales prices. Gross profit increased
to $13.8 million during 2006 from $7.8 million in
2005. We recorded a net loss from continuing operations of
$2.2 million in 2006, compared to the net loss of
$5.9 million we recorded in 2005. This decrease in our net
loss was primarily due to improved gross profit from our acetic
acid operations partially offset by a decrease in our benefit
for income taxes discussed below.
Revenues from acetic acid operations were $96.7 million in
2006, a 12% increase over the $86.1 million in revenues we
recorded from these operations in 2005. This increase in
revenues was primarily due to increases in sales prices. Gross
profit from our acetic acid operations increased
$5.0 million during 2006 compared to 2005. The
43
increase in gross profit was due to increased sales volumes and
sales margins during 2006, a one-time utility cost reimbursement
of $2.4 million; along with the $1.3 million favorable
impact of the previously discussed conversion to higher profit
sharing under the Production Agreement that occurred in August
2006, partially offset by the impact of the blend gas dispute
with BP Chemicals discussed below in Business
Legal Proceedings.
Revenues from plasticizers operations were $44.5 million in
2006, a 6% increase over the $42.0 million in revenues we
recorded from these operations in 2005. This increase was
primarily due to increases in cost reimbursements received from
our customer. Gross profit for our plasticizers business was
essentially unchanged between these two periods.
Other
expense (income)
We recorded other income of $0.7 million in 2006, which
primarily consisted of reimbursement for an insurance claim
related to damages caused by a barge incident in 2005.
Provision
(benefit) for income taxes
During 2006, our effective tax rate was 12% compared to 37% in
2005. This change in the effective rate was the result of a
$28 million increase in the valuation allowance during 2006.
Loss from
discontinued operations, net of tax
We recorded a net loss from discontinued operations of
$103.5 million in 2006 compared to a loss of
$23.7 million in 2005. The increase in our net loss in 2006
was due to an impairment of $127.7 million to write down
our styrene production unit in 2006, partially offset by
improved gross profit for our styrene unit and a one-time
reimbursement of $15 million in 2006 for an insurance claim
related to the 2005 fire in our styrene unit.
Liquidity
and Capital Resources
During March and April, 2007, we repurchased all
$100.6 million of our outstanding 2007 secured notes,
pursuant to a tender offer and redemption. Concurrently with our
tender offer, we solicited consents from the holders of our 2007
secured notes to, among other things, eliminate certain
covenants contained in the indenture governing our 2007 secured
notes and related security documents. On March 30, 2007, we
repurchased $58 million in aggregate principal amount of
2007 secured notes which were validly tendered prior to the
expiration of our tender offer, and paid the accrued interest
thereon and $0.1 million in consent fees. On April 27,
2007, we redeemed all of our 2007 secured notes that were not
tendered pursuant to our tender offer for $44 million,
which included $1.5 million in accrued interest.
On March 29, 2007, pursuant to a purchase agreement, or the
Purchase Agreement, we sold $150 million aggregate
principal amount of unregistered senior secured notes to
Jefferies & Company, Inc. and CIBC World Markets
Corp., as initial purchasers. Sterling Chemicals Energy, Inc.,
or Sterling Energy, one of our
wholly-owned
subsidiaries, was also a party to the Purchase Agreement as a
guarantor. On May 6, 2008, Sterling Energy was merged with and
into Sterling Chemicals, Inc. Upon consummation of the merger,
Sterling Energy no longer had independent existence and,
consequently, our senior secured notes are no longer guaranteed
by Sterling Energy. On March 29, 2007, we completed a
private offering of the unregistered senior secured notes
pursuant to the Purchase Agreement. In connection with that
offering, we entered into an indenture, dated March 29,
2007, among us, Sterling Energy, as guarantor, and U.
S. Bank National Association, as trustee and collateral
agent. On August 30, 2007, we made an initial filing of an
exchange offer registration statement, of which this prospectus
forms a part, to exchange our unregistered senior secured notes
for a new issue of substantially identical debt securities
registered under the Securities Act. Pursuant to a registration
rights agreement among us, Sterling Energy and the initial
purchasers, we agreed to use commercially reasonable efforts to
cause the registration statement to become effective by
December 24, 2007, and complete the exchange offer within
50 days of the effective date of the registration
statement. This prospectus forms a part of a registration
statement that was filed to comply with our obligations under
the registration rights agreement. However, as the registration
statement was not declared effective by December 24, 2007,
the interest rate on our senior secured notes increased by 0.25%
per annum on each of December 25, 2007, March 24, 2008
and June 23, 2008. The interest on our senior secured notes
will increase by
44
an additional 0.25% per annum on August 21, 2008 if the
registration statement is not declared effective by that date.
As such, penalty interest is expected to be between
$0.4 million and $0.5 million depending upon the
effectiveness date of the registration statement, of which
$0.2 million was accrued as of March 31, 2008, and we
expect to accrue an additional $0.2 million in the second
quarter of 2008. All of this additional interest will cease to
accrue when the registration statement is declared effective by
the SEC and the interest rate on our senior secured notes will
automatically decrease back to the face amount of
101/4%
per annum.
Our indenture contains affirmative and negative covenants and
customary events of default, including payment defaults,
breaches of covenants and certain events of bankruptcy,
insolvency and reorganization. If an event of default occurs and
is continuing, other than an event of default triggered upon
certain bankruptcy events, the trustee under our indenture or
the holders of at least 25% in principal amount of our
outstanding senior secured notes may declare the senior secured
notes to be due and payable immediately. Upon an event of
default, the trustee may also take actions to foreclose on the
collateral securing our outstanding senior secured notes,
subject to the terms of an intercreditor agreement dated
March 29, 2007, among us, Sterling Energy, the trustee and
The CIT Group/Business Credit, Inc. Our indenture does not
require us to maintain any financial ratios or satisfy any
financial maintenance tests. We are currently in compliance with
all of the covenants contained in our indenture.
Interest is due on our outstanding senior secured notes on April
1 and October 1 of each year. Our outstanding senior secured
notes, which mature on April 1, 2015, are senior secured
obligations and rank equally in right of payment with all of our
existing and future senior indebtedness. Subject to specified
permitted liens, our outstanding senior secured notes are
secured (i) on a first priority basis by all of any
guarantors fixed assets and certain related assets,
including, without limitation, all property, plant and
equipment, and (ii) on a second priority basis by any
guarantors other assets, including, without limitation,
accounts receivable, inventory, capital stock of our domestic
restricted subsidiaries, intellectual property, deposit accounts
and investment property.
On December 19, 2002, we entered into a Revolving Credit
Agreement with The CIT Group/Business Credit, Inc., as
administrative agent and a lender, and certain other lenders.
Our revolving credit facility had an initial term ending on
September 19, 2007. Our revolving credit facility is
secured by first priority liens on all of our accounts
receivable, inventory and other specified assets, and was also
secured by all of the issued and outstanding capital stock of
Sterling Energy before it was merged into us. On March 29,
2007, we amended and restated our revolving credit facility to,
among other things, extend the term of our revolving credit
facility until March 29, 2012, reduce the maximum
commitment thereunder to $50 million, make certain changes
to the calculation of the borrowing base and lower the interest
rates and fees charged thereunder. Borrowings under our
revolving credit facility now bear interest, at our option, at
an annual rate of either a base rate plus 0.0% to 0.50% or the
LIBOR rate plus 1.50% to 2.25%, depending on our borrowing
availability at the time. We are also required to pay an
aggregate commitment fee of 0.375% per year (payable monthly) on
any unused portion of our revolving credit facility. Available
credit under our revolving credit facility is subject to a
monthly borrowing base of 70% of eligible accounts receivable
plus 65% of eligible inventory. As of December 31, 2007,
our borrowing base exceeded the maximum commitment under our
revolving credit facility, making the total credit available
under our revolving credit facility $50 million. However,
since that time, the monetization of accounts receivable and
inventory associated with our exit from the styrene business
significantly decreased the borrowing base under our revolving
credit facility. In response to the expected continued lower
levels of accounts receivable and inventory, as well as our
lesser need for a working capital facility, on June 30,
2008, we reduced our commitment under our revolving credit
facility to $25 million. As of March 31, 2008, total
credit available under our revolving credit facility was limited
to $9.5 million. As of March 31, 2008, there were no
loans outstanding under our revolving credit facility, and we
had $4.1 million in letters of credit outstanding resulting
in borrowing availability of $5.4 million. Pursuant to
Emerging Issues Task Force Issue
No. 95-22,
Balance Sheet Classification of Borrowings under Revolving
Credit Agreements That Include both a Subjective Acceleration
Clause and a
Lock-Box
Arrangement, any balances outstanding under our revolving
credit facility would be classified as a current portion of
long-term debt.
Our revolving credit facility contains numerous covenants and
conditions, including, but not limited to, restrictions on our
ability to incur indebtedness, create liens, sell assets, make
investments, make capital expenditures, engage in mergers and
acquisitions and pay dividends. Our revolving credit facility
also includes various circumstances and conditions that would,
upon their occurrence and subject in certain cases to notice and
grace periods, create an event of
45
default thereunder. Our revolving credit facility does not
require us to maintain any financial ratios or satisfy any
financial maintenance tests. We are currently in compliance with
all of the covenants contained in our revolving credit facility.
Our liquidity (i.e., cash and cash equivalents plus total credit
available under our revolving credit facility) was
$176 million at March 31, 2008, an increase of
$38 million compared to our liquidity at December 31,
2007. This increase was primarily due to the monetization of the
working capital from our prior styrene business. As a result of
our exit from the styrene business, we expect our future cash
flows from operations to be significantly less volatile than
previous years. We expect to have positive cash flows from
continuing operations for the reasonably foreseeable future, and
we believe that our cash on hand and cash generated from
continuing operations, along with credit available under our
revolving credit facility, will be sufficient to meet our
short-term and long-term liquidity needs for the reasonably
foreseeable future.
Working
Capital
Our working capital, excluding assets and liabilities from
discontinued operations, was $163.7 million as of
March 31, 2008, an increase of $57.7 million from our
working capital of $106.0 million on December 31,
2007. This increase in working capital from continuing
operations resulted primarily from the monetization of the
working capital from our discontinued styrene business.
Cash
Flow
Net cash provided by our operations was $44.3 million in
2007, compared to the net cash used in our operations of
$14.2 million in 2006. This improvement in net cash flow in
2007 was primarily driven by the cash payment received from
INEOS NOVA discussed above and a portion of the monetization of
the styrene-related working capital as we shut down the styrene
unit during the fourth quarter of 2007.
Net cash flow used in our investing activities was
$6.2 million and $7.3 million in 2007 and 2006,
respectively. In 2007, the $6.2 million was primarily for
capital expenditures, whereas 2006 included insurance proceeds
of $2.0 million and proceeds from the sale of fixed assets
of $3.0 million, which partially offset the
$11.5 million of capital expenditures.
Net cash provided by financing activities was $41.4 million
in 2007 compared to zero in 2006, and was due to our debt
refinancing discussed above.
Net cash used in our operations was $14.2 million in 2006,
compared to net cash provided by our operations of
$68 million in 2005. This reduction in net cash flow
provided by our operations in 2006 was primarily driven by an
increase in accounts receivable and inventories due to an
increase in styrene production and sales volumes. As of
December 31, 2005, styrene production and sales volumes
were negatively affected by a fire in our styrene unit which
resulted in partial closure of our styrene unit while repairs
were being conducted.
Net cash flow used in our investing activities was
$7 million in 2006 and $10 million in 2005. Cash flows
from investing activities in 2006 included insurance proceeds of
$2 million and proceeds from the sale of fixed assets of
$3 million.
There were no net repayments under our revolving credit facility
during 2006 compared to $18 million of net repayments in
2005.
Net cash provided by our operations was $72.3 million for the
first quarter of 2008, compared to the $8.6 million in net cash
provided by our operations during the first quarter of 2007.
This improvement in net cash flow in the first quarter of 2008
was primarily due to the monetization of the working capital
from our prior styrene business of approximately $66 million.
Net cash flow used in our investing activities was $2.0 million
during the first quarter of 2008, compared to the $46.2 million
during the first quarter of 2007, primarily due to a change in
our restricted cash associated with the debt refinancing
discussed above. There was zero cash flow provided by financing
activities in the first quarter of 2008 compared to $85.2
million in the first quarter of 2007 related to our debt
refinancing discussed above.
46
Capital
Expenditures
Our capital expenditures in continuing operations were $3.8
million, $4.9 million and $4.9 million in 2007, 2006 and 2005,
respectively, and for discontinued operations were $2.6 million,
$6.6 million and $4.6 million in 2007, 2006 and 2005,
respectively. Our capital expenditures during the first quarter
of 2008 and 2007 for continuing operations were
$2.0 million and $0.7 million, respectively, and for
discontinued operations were zero and $1.5 million,
respectively, and were primarily for routine safety,
environmental and replacement capital.
We expect our remaining capital expenditures in 2008 to be
approximately $6.0 million, including $4.0 million for
a capital project to prevent the discharge of process wastewater
during periods of heavy rain at our Texas City site, and an
additional $2.0 million for routine safety, environmental
and replacement capital.
Our capital expenditures for environmentally related prevention,
containment and process improvements to continuing operations
were $0.5 million, $1.5 million and $1.0 million in 2007, 2006,
2005, respectively, and were zero, $0.5 million and $1.0 million
for discontinued operations in 2007, 2006 and 2005, respectively.
Contractual
Cash Obligations
The following table summarizes our significant contractual
obligations at December 31, 2007, and the effect such
obligations are expected to have on our liquidity and cash flows
in future periods:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Less than 1
|
|
|
|
|
|
|
|
|
More than
|
|
|
|
|
|
|
Year(1)
|
|
|
1-3 Years
|
|
|
4-5 Years
|
|
|
5 Years
|
|
|
Total
|
|
|
|
(Dollars in thousands)
|
|
|
Senior secured notes
|
|
$
|
|
|
|
$
|
|
|
|
$
|
|
|
|
$
|
150,000
|
|
|
$
|
150,000
|
|
Interest payments on
debt(2)
|
|
|
15,690
|
|
|
|
46,638
|
|
|
|
31,092
|
|
|
|
23,319
|
|
|
|
116,739
|
|
Operating leases
|
|
|
293
|
|
|
|
879
|
|
|
|
513
|
|
|
|
|
|
|
|
1,685
|
|
Purchase
obligations(3)
|
|
|
35,000
|
|
|
|
70,000
|
|
|
|
64,000
|
|
|
|
117,000
|
|
|
|
286,000
|
|
Pension and other postretirement benefits
|
|
|
4,458
|
|
|
|
2,346
|
|
|
|
2,279
|
|
|
|
4,959
|
|
|
|
14,042
|
|
Contractual obligations of discontinued operations
|
|
|
325
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
325
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total(4)(5)
|
|
$
|
55,766
|
|
|
$
|
119,863
|
|
|
$
|
97,884
|
|
|
$
|
295,278
|
|
|
$
|
568,791
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(1) |
|
Payment obligations under our
revolving credit facility are not presented because there were
no outstanding borrowings as of December 31, 2007, and
interest payments fluctuate depending on the interest rate and
outstanding balance under our revolving credit facility at any
point in time.
|
|
(2) |
|
On December 25, 2007,
March 24, 2008 and June 23, 2008, the interest rate on
our senior secured notes increased by 0.25% per annum because
our registration statement to exchange our unregistered notes
for registered notes having the same terms and conditions had
not been declared effective by the SEC. The interest on our
senior secured notes will increase by an additional 0.25% per
annum on August 21, 2008 if the registration statement is
not declared effective by this date. As such, penalty interest
is expected to be between $0.4 million and
$0.5 million depending upon the effectiveness date of the
registration statement, of which $0.2 million was accrued
as of March 31, 2008.
|
|
(3) |
|
For the purposes of this table, we
have considered contractual obligations for the purchase of
goods or services as agreements involving more than
$1 million that are enforceable and legally binding and
that specify all significant terms, including: fixed or minimum
quantities to be purchased, fixed, minimum or variable price
provisions and the approximate timing of the transaction. Most
of the purchase obligations identified include variable pricing
provisions. We have estimated the future prices of these items,
utilizing forward curves where available. The pricing estimated
for use in this table is subject to market risk.
|
|
(4) |
|
Our Series A Preferred Stock
is excluded from our contractual cash obligations as it is not
currently redeemable or probable of redemption. If the
Series A Preferred Stock had been redeemable as of
December 31, 2007, the redemption amount would have been
approximately $83.9 million. The liquidation value of our
Series A Preferred Stock as of December 31, 2007 is
$66.1 million.
|
|
(5) |
|
Unrecognized tax benefits are not
included in the table due to the high degree of uncertainty
associated with the realization of our net operating loss
carryforward.
|
As of March 31, 2008, there have been no significant
changes to the contractual obligations disclosed above.
Critical
Accounting Policies, Use of Estimates and Assumptions
A summary of our significant accounting policies is included in
Note 1 of the Notes to Consolidated Financial
Statements for the year ended December 31, 2007 and
the quarter ended March 31, 2008, included in this
47
prospectus. We believe that the consistent application of these
policies enables us to provide readers of our financial
statements with useful and reliable information about our
operating results and financial condition. The following
accounting policies are the ones we believe are the most
important to the portrayal of our financial condition and
results and require our most difficult, subjective or complex
judgments.
Revenue
Recognition
We produce acetic acid and plasticizers and recognize revenues
(and the related costs) when persuasive evidence of an
arrangement exists, delivery has occurred, the sales price is
fixed and determinable, and collectibility is reasonably assured.
Acetic Acid. Pursuant to a production
agreement, all acetic acid produced is sold to BP Chemicals, who
takes delivery, title and risk of loss at the time the acetic
acid is produced. BP Chemicals, in turn, markets and sells the
acetic acid and pays us a portion of the profits derived from
those sales. BP Chemicals reimburses us monthly for 100% of our
fixed and variable costs (excluding direct depreciation
associated with machinery and equipment used in the
manufacturing of acetic acid) of production and the revenue
associated with the reimbursement of these costs is matched
against our costs as they are incurred. We recognize revenue
related to the profit sharing component of the production
agreement based on quarterly estimates received from BP
Chemicals. These estimates are based on the profits from sales
of the acetic acid purchased from our acetic acid plant.
Plasticizers. We generate revenues from our
plasticizers operations through a tolling agreement with BASF.
BASF purchases all of our plasticizers and takes delivery,
title, and risk of loss at the time of production. We receive
fixed, level quarterly payments which are recognized on a
straight-line basis. In addition, BASF reimburses us monthly for
our actual fixed and variable production costs (excluding direct
depreciation associated with machinery and equipment used in the
manufacturing of plasticizers), and the revenue associated with
the reimbursement of these costs is matched against our costs as
they are incurred.
Deferred revenue. Deferred credits are
amortized over the life of the contracts which gave rise to
them. As of December 31, 2007 and 2006, we had a balance
in deferred income of approximately $11 million and
$10 million, respectively, related to continuing
operations, which primarily represent certain payments received
for our oxo-alcohol operations, which were part of our
plasticizers business, that are being amortized using the
straight-line method over the remaining life of the contract. As
of December 31, 2007, in discontinued operations, we had a
balance in deferred income of approximately $59 million
pertaining to the terminated NOVA supply agreement, which is
being amortized using the straight-line method over the
contractual non-compete period and is reflected in discontinued
operations.
As of March 31, 2008, we had a balance in deferred income
of approximately $10 million related to continuing
operations which primarily pertained to the oxo-alcohols payment
referred to above, and in discontinued operations, we had a
balance of $57 million pertaining to the terminated NOVA
supply agreement referred to above.
Styrene. Styrene revenue was recognized from
sales in the open market, raw materials conversion agreements
and long-term supply contracts. Styrene revenue (and
corresponding cost of sales) from raw materials conversion
agreements was recognized on a gross basis and does not include
raw material components supplied by our customers.
Inventories
Inventories are carried at the lower-of-cost-or-market value.
Cost is primarily determined on a
first-in,
first-out basis, except for stores and supplies, which are
valued at average cost. The comparison of cost to market value
involves estimation of the market value of our products. For the
years ended December 31, 2007, 2006 and 2005, this
comparison led to a lower-of-cost-or-market adjustment in
discontinued operations of $1.4 million, zero and
$2.7 million, respectively. The adjustments in 2007 and
2005 were due to decreasing benzene and styrene prices from
December to January during each period. For the quarter-ended
March 31, 2008, there were no such adjustments. Prior to
exiting the styrene business, we entered into agreements with
other companies to exchange chemical inventories in order to
minimize working capital requirements and to facilitate
distribution logistics.
48
Balances related to quantities due to or payable by us in
connection with these exchange agreements are included in
inventory. However, we do not expect to have any significant
exchange balances or activity subsequent to 2007.
Preferred
Stock Dividends
We record preferred stock dividends on our Series A
Preferred Stock in our consolidated statements of operations
based on the estimated fair value of dividends at each dividend
accrual date. Our Series A Preferred Stock has a dividend
rate of 4% per quarter of the liquidation value of the
outstanding shares of our Series A Preferred Stock, and is
payable in arrears in additional shares of our Series A
Preferred Stock on the first business day of each calendar
quarter. The liquidation value of each share of our
Series A Preferred Stock is $13,793.11 per share, and each
share of Series A Preferred Stock is convertible into
shares of our common stock (on a one to 1,000 share basis,
subject to adjustment). The carrying value of our redeemable
preferred stock in our consolidated balance sheets represents
the cumulative balance of the initial fair value at original
issuance in 2002 plus the fair value of each of the quarterly
dividends paid since issuance.
The fair value of our preferred stock dividends is determined
each quarter using valuation techniques that include a component
representing the intrinsic value of the dividends (which
represents the greater of the liquidation value of the preferred
shares being issued or the fair value of the common stock into
which the shares could be converted) and an option component
(which is determined using a Black-Scholes Option Pricing
Model). These dividends are recorded in our consolidated
statements of operations, with an offset to redeemable preferred
stock in our consolidated balance sheets. As we are in an
accumulated deficit position, these dividends are treated as a
reduction to additional paid-in capital. Assumptions utilized in
the Black-Scholes model include:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
2008
|
|
|
2007
|
|
|
2006
|
|
|
2005
|
|
|
Risk-free interest rate
|
|
|
2.5
|
%
|
|
|
3.5
|
%
|
|
|
4.7
|
%
|
|
|
4.4
|
%
|
Volatility
|
|
|
54.5
|
%
|
|
|
55.5
|
%
|
|
|
46.2
|
%
|
|
|
50.3
|
%
|
Dividend yield
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Expected term
|
|
|
5.0
|
|
|
|
5.0
|
|
|
|
5.0
|
|
|
|
5.0
|
|
Long-Lived
Assets
We assess our long-lived assets for impairment whenever facts
and circumstances indicate that the carrying amount may not be
fully recoverable. To analyze recoverability, we project
undiscounted net future cash flows over the remaining life of
the assets. If the projected cash flows from the assets are less
than the carrying amount, an impairment would be recognized. Any
impairment loss would be measured based upon the difference
between the carrying amount and the fair value of the relevant
assets. For these impairment analyses, impairment is determined
by comparing the estimated fair value of these assets, utilizing
the present value of expected net cash flows, to the carrying
value of these assets. In determining the present value of
expected net cash flows, we estimate future net cash flows from
these assets and the timing of those cash flows and then apply a
discount rate to reflect the time value of money and the
inherent uncertainty of those future cash flows. The discount
rate we use is based on our estimated cost of capital. The
assumptions we use in estimating future cash flows are
consistent with our internal planning.
Income
Taxes
Deferred income taxes are provided for revenue and expenses
which are recognized in different periods for income tax and
financial statement purposes. Deferred tax assets are regularly
assessed for recoverability based on both historical and
anticipated earnings levels, and a valuation allowance is
recorded when it is more likely than not that these amounts will
not be recovered. As a result of our analysis, we concluded that
a valuation allowance was needed against our deferred tax
assets. As of December 31, 2007 and March 31, 2008,
our valuation allowance was $36.2 million, for each period,
which resulted in an overall net deferred tax asset/liability
balance of zero as of December 31, 2007 and March 31,
2008. In July 2006, the Financial Accounting Standards Board, or
the FASB, issued FASB Interpretation No. 48,
Accounting for Uncertainty in Income Taxes an
interpretation of FASB Statement No. 109, or
FIN 48, to clarify the accounting for uncertain tax
positions accounted for in accordance with FASB Statement
No. 109, Accounting for Income Taxes. This
interpretation prescribes a two-step approach
49
for recognizing and measuring tax benefits and requires explicit
disclosure of any uncertain tax position. We adopted the
provisions of FIN 48 as of January 1, 2007, which had
no impact on our accumulated deficit.
Employee
Benefit Plans
We sponsor domestic defined benefit pension and other
postretirement plans. Major assumptions used in the accounting
for these employee benefit plans include the discount rate,
expected return on plan assets and health care cost increase
projections. Assumptions are determined based on our historical
data and appropriate market indicators, and are evaluated each
year as of the plans measurement dates. A change in any of
these assumptions would have an effect on net periodic pension
and postretirement benefit costs reported in our financial
statements. As mentioned below, in accordance with
SFAS No. 158, Employers Accounting for
Defined Benefit Pension and Other Postretirement Plans, or
SFAS No. 158, as of our fiscal year-ended December 31,
2006, we recognized the funded status of our defined benefit
postretirement plans in our balance sheet and provided the
required disclosures. We also measured the assets and benefit
obligations of our defined benefit postretirement plans as of
December 31, 2006. The effect of the adoption of
SFAS No. 158 was a reduction in our liabilities of
$10 million and a change in stockholders equity
(deficiency in assets), net of tax, of $7 million.
Effective July 1, 2007, we froze all accruals under our
defined benefit pension plan for our hourly employees, which
resulted in a plan curtailment under SFAS No. 88
Employers Accounting for Settlement and Curtailments
of Defined Benefit Pension Plans and for Termination
Benefits. As a result, we recorded a pre-tax curtailment
gain of $0.1 million in the second quarter of 2007. During
the third quarter of 2007, we approved an amendment (to be
effective December 31, 2007) to our postretirement
medical plan which ended Medicare-supplemental medical and
prescription drug coverage for retirees who are Medicare
eligible. This amendment affects the majority of participants
currently enrolled in the Sterling Retiree Medical Plan who are
either enrolled in Medicare due to disability or because they
are 65 or over, and was communicated to the participants during
the third quarter of 2007. This plan amendment reduced our other
postretirement benefit plan liability by $13 million with a
corresponding increase to accumulated other comprehensive income.
Plant
Turnaround Costs
As a part of normal recurring operations, each of our
manufacturing units is completely shut down from time to time,
for a period typically lasting two to four weeks, to replace
catalysts and perform major maintenance work required to sustain
long-term production. These periods are commonly referred to as
turnarounds or shutdowns. Costs of
turnarounds are expensed as incurred. As expenses for
turnarounds can be significant, the impact of expensing
turnaround costs as they are incurred can be material for
financial reporting periods during which the turnarounds
actually occur. Turnaround costs expensed during 2007, 2006 and
2005 for continuing operations were less than $0.1 million, $1.4
million and $2.9 million, respectively, and for
discontinued operations were zero, $8.5 million and $1.1
million, respectively. Turnaround costs expensed during the
first quarter of 2008 for continuing operations were less than
$0.1 million.
New
Accounting Standards
In September 2006, the FASB issued SFAS No. 157,
Fair Value Measurements, or SFAS No. 157.
This statement establishes a framework for measuring fair value
in generally accepted accounting principles and expands
disclosures about fair value measurements for financial assets
and liabilities, as well as for any other assets and liabilities
that are carried at fair value on a recurring basis in financial
statements. SFAS No. 157 is effective for financial
statements issued for fiscal years beginning after
November 15, 2007, and interim periods within those fiscal
years. We adopted SFAS No. 157 in the first quarter of
2008 and determined that it had no impact on our condensed
consolidated financial statements. In February 2008, the FASB
issued SFAS No. 157-2, Effective Date of FASB
Statement No. 157, or SFAS No. 157-2, which defers the
effective date of SFAS No. 157 to fiscal years beginning after
November 15, 2008, and interim periods within those fiscal
years, for all non-financial assets and non-financial
liabilities, except for items that are recognized or disclosed
at fair value in the financial statements on a recurring basis
(at least annually). An entity that has issued interim or annual
financial statements reflecting the application of the
measurement and disclosure provisions of SFAS No. 157 prior to
February 12, 2008, must
50
continue to apply all provisions of SFAS No. 157. We are
currently evaluating the impact of our adoption of the deferred
portion of SFAS No. 157, effective January 1, 2009, on
our condensed consolidated financial statements.
In February 2007, the FASB issued SFAS No. 159,
The Fair Value Option for Financial Assets and Financial
Liabilities, or SFAS No. 159.
SFAS No. 159, which amends SFAS No. 115,
Accounting for Certain Investments in Debt and Equity
Securities, allows certain financial assets and
liabilities to be recognized, at our election, at fair market
value, with any gains or losses for the period recorded in the
statement of operations. SFAS No. 159 is effective for
fiscal years beginning after November 15, 2007, and did not
have a material impact on our condensed consolidated financial
statements.
In December 2007, the FASB issued SFAS No. 141
(revised 2007), Business Combinations, or
SFAS No. 141R. SFAS No. 141R broadens the
guidance of SFAS No. 141, extending its applicability to
all transactions and other events in which one entity obtains
control over one or more other businesses. It broadens the fair
value measurement and recognition of assets acquired,
liabilities assumed, and interests transferred as a result of
business combinations. SFAS No. 141R expands on required
disclosures to improve the statement users abilities to
evaluate the nature and financial effects of business
combinations. SFAS No. 141R is effective for fiscal years
beginning after December 15, 2008. We do not expect the
adoption of SFAS No. 141R to have a material impact on our
condensed consolidated financial statements.
In December 2007, the FASB issued SFAS No. 160,
Noncontrolling Interests in Consolidated Financial
Statements; an amendment of ARB No. 51, or
SFAS No. 160. This statement establishes the
accounting and reporting standards for a noncontrolling interest
in a subsidiary and for the deconsolidation of a subsidiary.
This statement clarifies that a noncontrolling interest in a
subsidiary is an ownership interest in the consolidated entity
that should be reported as equity in the consolidated financial
statements. SFAS No. 160 requires retroactive adoption
of the presentation and disclosure requirements for existing
minority interests and applies prospectively to business
combinations for fiscal years beginning after December 15,
2008. We do not expect the adoption of SFAS No. 160 to have a
material impact on our condensed consolidated financial
statements.
In March 2008, the FASB issued SFAS No. 161,
Disclosures About Derivative Instruments and Hedging
Activities, or SFAS No. 161. This statement
requires enhanced disclosures about an entitys derivative
and hedging activities, with the intent to provide users of
financial statements with an enhanced understanding of
(a) how and why an entity uses derivative instruments,
(b) how derivative instruments and related hedged items are
accounted for under SFAS No. 133, Accounting for
Derivative Instruments and Hedging Activities and its
related interpretations and (c) how derivative instruments
and related hedged items affect an entitys financial
position, financial performance and cash flows.
SFAS No. 161 is effective for fiscal years beginning
after November 15, 2008. We are currently evaluating the
impact of the adoption of SFAS No. 161 on our condensed
consolidated financial statements.
Quantitative
and Qualitative Disclosures about Market Risk
The table below provides information about our market sensitive
financial instruments as of December 31, 2007 and
constitutes a forward-looking statement.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Fair Value
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
December 31,
|
|
Expected Maturity Dates
|
|
2008
|
|
|
2009
|
|
|
2010
|
|
|
2011
|
|
|
2012
|
|
|
Thereafter
|
|
|
Total
|
|
|
2007
|
|
|
|
(Dollars in thousands)
|
|
|
Outstanding senior secured notes
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
$
|
150,000
|
|
|
$
|
150,000
|
|
|
$
|
152,250
|
|
Our financial results can be affected by volatile changes in raw
materials, natural gas and finished product sales prices.
Borrowings under our revolving credit facility bear interest, at
our option, at an annual rate of either a base rate plus 0.0% to
0.50% or the LIBOR rate plus 1.50% to 2.25%, depending on our
borrowing availability at the time. There were no borrowings
under our revolving credit facility during the first quarter of
2008. Our $150 million of senior secured notes bear interest at
an annual rate of
101/4%,
payable semi-annually on April 1 and October 1 of each year. The
fair value of our outstanding senior secured notes is based on
broker quotes for private transactions. As of March 31,
2008, the fair value of our outstanding senior secured notes was
approximately $150 million.
51
BUSINESS
We are a North American producer of selected petrochemicals used
to manufacture a wide array of consumer goods and industrial
products. Our primary products are acetic acid and plasticizers.
Our acetic acid is used primarily to manufacture vinyl acetate
monomer, which is used in a variety of products, including
adhesives and surface coatings. Pursuant to the Production
Agreement that began in 1986 and extends to 2016, all of our
acetic acid production is sold to BP Chemicals and we are BP
Chemicals sole source of acetic acid production in the
Americas. BP Chemicals markets all of the acetic acid that we
produce and pays us, among other amounts, a portion of the
profits derived from its sales of the acetic acid we produce. In
addition, BP Chemicals reimburses us for 100% of our fixed and
variable costs of production. Prior to August 2006, BP Chemicals
also paid us a set monthly amount. However, under the terms of
this Production Agreement, beginning in August 2006, the portion
of the profits we receive from the sales of acetic acid produced
at our plant increased and BP Chemicals was no longer required
to pay us the set monthly amount. This change in payment
structure did not affect BP Chemicals obligation to
reimburse us for all of our fixed and variable costs of
production. We believe that we have one of the lowest cost
acetic acid facilities in the world. Our acetic acid facility
utilizes BP Chemicals Cativa Technology, which we believe
offers several advantages over competing production methods,
including lower energy requirements and lower fixed and variable
costs. We also jointly invest with BP Chemicals in capital
expenditures related to our acetic acid facility in the same
percentage as the profits from the business are divided. We
initially pay for 100% of the capital expenditures related to
our acetic acid business and then invoice BP Chemicals for its
portion. The net amount that is not reimbursed by BP Chemicals
represents our basis in the property, plant and equipment
related to our acetic acid business, which is capitalized and
depreciated over its useful life. Acetic acid production has two
major raw material requirements methanol and carbon
monoxide. BP Chemicals, a producer of methanol, supplies 100% of
our methanol requirements related to our production of acetic
acid. All of the required carbon monoxide is supplied by Praxair
from a partial oxidation unit constructed by Praxair on land
leased from us at our site in Texas City, Texas.
All of our plasticizers, which are used to make flexible
plastics, such as shower curtains, floor coverings, automotive
parts and construction materials, are sold to BASF pursuant to a
long-term production agreement that extends until 2013, subject
to some early termination rights held by BASF that begin in
2010. Under our agreement with BASF, BASF provides us with most
of the required raw materials, markets the plasticizers we
produce, and is obligated to make certain fixed quarterly
payments to us and to reimburse us monthly for our actual
production costs and capital expenditures related to our
plasticizers facility. In May 2008, we entered into an amended
production agreement with BASF, effective as of April 1,
2008. This amended agreement was entered into in connection with
BASFs nomination of zero pounds of PA under the existing
production agreement due to deteriorating market conditions
which were not expected to improve over the next few years,
which resulted in the shutdown of our PA unit. See
Contracts.
Prior to December 3, 2007, we manufactured styrene.
However, on September 17, 2007, we entered into a long-term
exclusive styrene supply agreement and a related railcar
purchase and sale agreement with NOVA. Under this supply
agreement, NOVA had the exclusive right to purchase 100% of our
styrene production (subject to existing contractual
commitments), the amount of styrene supplied in any particular
period being at NOVAs option, based on a full-cost
formula. In November 2007, the styrene supply agreement with
NOVA, which was subsequently assigned by NOVA to INEOS NOVA,
obtained clearance under the
Hart-Scott-Rodino
Act. This clearance caused the supply agreement and the railcar
agreement to become effective and triggered a $60 million
payment to us in November 2007. In addition, in accordance with
the terms of the supply agreement, INEOS NOVA assumed
substantially all of our contractual obligations for future
styrene deliveries. After the supply agreement became effective,
INEOS NOVA nominated zero pounds of styrene under the supply
agreement for the balance of 2007 and, in response, we exercised
our right to terminate the supply agreement and permanently shut
down our styrene facility. Under the supply agreement, we are
responsible for the closure costs of our styrene facility and
are also subject to a long-term commitment to not reenter the
styrene business until December of 2012. We operated our styrene
facility through early December 2007, as we completed our
production of inventory and exhausted our raw materials and
purchase requirements, and sold substantially all our inventory
during the first quarter of 2008. During 2007 and the first
quarter of 2008, we incurred closure costs to decommission our
styrene facility of approximately $1 million and $9 million,
respectively. We expect to incur up to $4 million in
additional
52
decommissioning costs related to the closure of our styrene
facility. In mid-July, with the decontamination process for the
styrene facility nearing completion, we announced a reduction in
work force in order to reduce our staffing to a level
appropriate for our existing operations and site development
projects. As a result, seven members of our salaried work force
were immediately laid off. In addition, we made offers for early
retirement to several members of our hourly work force and our
salaried administrative and process supervisors. Upon completion
of the down-sizing of our hourly work force and our
administrative and process supervisor positions, which will
occur after the period for accepting offers of early retirement
has closed in September, total staff reductions are expected to
be approximately 40 employees, and we expect to recognize
approximately $2.2 million in severance costs in the third
and fourth quarters of 2008, in accordance with
SFAS No. 146, Accounting for Costs Associated
with Exit of Disposal Activities.
We manufacture all of our petrochemicals products at our Texas
City facility. In terms of production capacity, our Texas City
site has the sixth largest acetic acid facility in the world.
Our Texas City site covers an area of 290 acres, and is
strategically located on Galveston Bay.
We own the acetic acid and plasticizers manufacturing units
located at our Texas City site. We also lease a portion of our
Texas City site to Praxair, who constructed a partial oxidation
unit on that land, and we lease a portion of our Texas City site
to S&L Cogeneration Company, a 50/50 joint venture between
us and Praxair Energy Resources, Inc., who constructed a
cogeneration facility on that land. We lease space for our
principal offices located in Houston, Texas. We currently
operate in two segments: acetic acid and plasticizers.
Business
Strategy
Grow Our Business. We believe that our acetic
acid facility is positioned for cost-effective future capacity
expansions at lower incremental cost due to previous investments
made by us and BP Chemicals, including the installation of a new
reactor in 2003 that is capable of producing up to
1.7 billion pounds of acetic acid annually. We intend to
grow our acetic acid business through capacity expansions that
take advantage of this positioning. Currently, we have low-cost
debottlenecking opportunities which could increase annual
capacity of our acetic acid facility to approximately
1.2 billion pounds, an increase of approximately 7%.
Our Texas City site offers approximately 160 acres for
future expansion by us or by other companies that can benefit
from our existing infrastructure and facilities, and includes a
greenbelt around the northern edge of the plant site. Our Texas
City site is strategically located on Galveston Bay and we
benefit from a deep water dock capable of handling ships with up
to a 40-foot draft, as well as four barge docks and direct
access to Union Pacific and Burlington Northern Santa Fe
railways with in-motion rail scales on site. Our Texas City site
also has truck loading racks, weigh scales, stainless and mild
steel storage tanks, three waste deepwells, 160 acres of
available land zoned for heavy industrial use and additional
land zoned for light industrial use, and a supportive political
environment for growth. In addition, we are in the heart of one
of the largest petrochemical complexes on the Gulf Coast and, as
a result, we have
on-site
access to a number of raw material pipelines and are in close
proximity to a number of the larger refinery complexes.
Given our under-utilized infrastructure, our management and
engineering expertise, as well as ample unoccupied land, we
believe that there are significant opportunities for further
development of our Texas City site. We are currently pursuing
numerous initiatives to attract new manufacturing and/or storage
related businesses to our Texas City site, including
opportunities involving renewable fuels projects, gasification,
energy projects and chemicals terminalling. Specifically, we are
seeking long-term contractual business arrangements or
partnerships that will provide us with an ability to realize the
value of our under-utilized assets through profit sharing or
other cash generating arrangements. For development projects
that may have significant capital expenditure requirements, we
are considering joint ventures or other arrangements where we
would contribute certain of our assets and management expertise
to minimize our share of the capital costs. In any case, we
expect any new facility constructed at our Texas City site to
lower the amount of overall fixed costs allocated to each of our
operating units and provide us with additional profit.
We plan to evaluate strategic acquisitions, focusing on chemical
businesses and assets which would allow us to increase our
market share of products we currently produce or those that
would provide upstream or downstream integration within our
existing businesses.
53
Improve Organization Efficiency and Cost
Structure. We continually seek to improve our
cost competitiveness through organizational efficiencies,
productivity enhancements, operating controls and general cost
reductions. We believe that the expansion of our acetic acid
business, the further development of our Texas City site and
acquisitions will lead to further cost efficiencies.
Industry
Overview
Acetic Acid. The North American acetic acid
industry has enjoyed a period of sustained domestic demand
growth, as well as substantial export demand. This has led to
North American industry utilization rates of 86% and Tecnon
projects utilization rates to increase to over 98% by 2013,
although the recent difficulties in the housing and automotive
sectors will likely cause reduced demand for vinyl acetate
monomer, and consequently acetic acid, in North America in the
short term. The North American acetic acid industry is
inherently less cyclical than many other petrochemical products
due to a number of important features. There are only four large
producers of acetic acid in North America and historically these
producers have made capacity additions in a disciplined and
incremental manner, primarily using small expansion projects or
exploiting debottlenecking opportunities. In addition, the
leading technology required to manufacture acetic acid is
controlled by two global companies, which permits these
companies to control the pace of new capacity additions through
the licensing or development of such additional capacity. We
believe the limited availability of this technology also creates
a significant barrier to entry into the acetic acid industry by
potential competitors.
Global production capacity of acetic acid as of
December 31, 2007 was approximately 24 billion pounds
per year, with current North American production capacity at
approximately 7 billion pounds per year. The North American
acetic acid market is mature and well developed and is dominated
by four major producers that account for approximately 94% of
the acetic acid production capacity in North America. Demand for
acetic acid is linked to the demand for vinyl acetate monomer, a
key intermediate in the production of a wide array of polymers.
Vinyl acetate monomer is the largest derivative of acetic acid,
representing over 40% of global demand. Annual global production
of vinyl acetate monomer is expected to increase from
10.4 billion pounds in 2005 to 12.2 billion pounds in
2010, although the recent difficulties in the housing and
automotive sectors will likely cause reduced demand for vinyl
acetate monomer in North America in the short term. The North
American acetic acid industry tends to sell most of its products
through long-term sales agreements having cost plus
pricing mechanisms, eliminating much of the volatility seen in
other petrochemicals products and resulting in more stable and
predictable earnings and profit margins.
Plasticizers. Plasticizers are produced from
either ethylene-based linear alpha-olefins feedstocks or
propylene-based technology. Linear plasticizers typically
receive a premium over competing propylene-based branched
products for customers that require enhanced performance
properties. However, the markets for competing plasticizers may
be affected by the cost of the underlying raw materials,
especially when the cost of one olefin rises faster than the
other, or by the introduction of new products. Over the last few
years, the price of linear alpha-olefins has increased sharply
as supply has declined, which has caused many consumers to
switch to lower cost branched products, despite the loss of some
performance properties. Ultimately, we expect branched
plasticizers to replace linear plasticizers for most
applications over the long-term. In addition, in 2005, BP
Chemicals announced the permanent closure of its linear
alpha-olefins production facility in Pasadena, Texas, the
primary source of supply of this feedstock to the oxo-alcohols
production unit at our plasticizers facility. As a result, we
modified our plasticizers facilities during the third quarter of
2006 to produce branched plasticizers products and, on
July 31, 2006, we permanently shut down our oxo-alcohols
production unit. Due to the closure of our oxo-alcohols unit and
our conversion to the production of branched plasticizers, the
phthalate esters production unit at our plasticizers facility
now uses oxo-alcohols supplied by BASF that have a different
chemical composition. In December 2007, BASF caused the shutdown
of our PA unit by nominating zero pounds of PA under the
existing production agreement.
On May 27, 2008, we entered into our Amended Plasticizers
Production Agreement with BASF, with an effective date of
April 1, 2008. The Amended Plasticizers Production
Agreement amends certain provisions of the Old Plasticizers
Production Agreement. The Amended Plasticizers Production
Agreement was entered into in connection with BASFs
nomination of zero pounds of PA under the Old Plasticizers
Production Agreement in
54
response to deteriorating market conditions which were not
expected to improve over the next few years, causing the
shutdown of our PA unit.
The Amended Plasticizers Production Agreement relieves BASF of
most of its obligations under the Old Plasticizers Production
Agreement related to our PA manufacturing unit. BASFs
obligations under the Old Plasticizers Production Agreement
related to our esters manufacturing unit were not affected by
the Amended Plasticizers Production Agreement and are continuing
in accordance with the same terms as existed under the Old
Plasticizers Production Agreement. In exchange for being
relieved of its obligations related to our PA manufacturing
unit, BASF is required to pay us an aggregate amount of
approximately $3.2 million, $3.0 million of which was
paid in May 2008, and the balance of which is due and payable on
or before August 15, 2008. However, we are obligated to
refund 75% of this amount if we restart our PA manufacturing
unit before January 1, 2009, 50% of this amount if we
restart our PA manufacturing unit during 2009 and 25% of this
amount if we restart our PA manufacturing unit during 2010. The
$3.2 million represents the termination of BASFs
obligations under the Old Plasticizers Production Agreement with
respect to the operation of our PA manufacturing unit, and will
be recognized using the straight-line method over the restricted
period of April 1, 2008 through December 31, 2010
under the Amended Plasticizers Production Agreement. During the
first half of 2008, BASF is also required to pay us
approximately $3.7 million for reimbursement of certain
direct fixed and variable costs associated with the shutdown and
decontamination of our PA manufacturing unit, which amounts are
not subject to refund. All direct fixed and variable costs
associated with the shutdown and decontamination of our PA unit
have been incurred and expensed, and the $3.7 million in
cost reimbursements has been recognized as revenue in the first
six months of 2008. The quarterly fixed periodic payments under
the Old Plasticizers Production Agreement with respect to the
operation of our PA and esters manufacturing units will not
change; however, the quarterly fixed periodic payments are now
related to the operation of our esters manufacturing unit under
the Amended Plasticizers Production Agreement.
In addition, under the Amended Plasticizers Production
Agreement, (i) the methods for calculating payments
required to be made by BASF for achieving reductions in direct
fixed and variable costs and (ii) BASFs right to
terminate the Amended Plasticizers Production Agreement in the
event that direct fixed and variable costs exceed a specified
threshold (unless we elect to cap BASFs reimbursement
obligations) have both been modified to exclude costs savings
and direct fixed and variable costs pertaining to our PA
manufacturing unit.
After April 1, 2008, the Amended Plasticizers Production
Agreement also removed all restrictions or rights BASF formerly
had during the term of the Old Plasticizers Production Agreement
with respect to our use or disposition of the PA manufacturing
unit, including a limited purchase right, the right to request
capacity increases and consultation rights regarding future
capital expenditures with respect to our PA manufacturing unit.
As a result of the Amended Plasticizers Production Agreement and
subsequent permanent shutdown of our PA unit by BASF, our
management determined that a triggering event, as defined in
SFAS No. 144, Accounting for the Impairment or
Disposal of Long-Lived Assets, had occurred and during the
second quarter of 2008, we performed an asset impairment
analysis on our PA manufacturing unit. We analyzed the
undiscounted cash flow stream from our PA business over the
remaining life of the PA manufacturing unit and compared it to
the $6.6 million net book carrying value of our PA
manufacturing unit. This analysis showed that the undiscounted
projected cash flow stream from our PA business was less than
the net book carrying value of our PA manufacturing unit. As a
result, we performed a discounted cash flow analysis and
subsequently concluded that our PA manufacturing unit was
impaired and should be written down to zero. This write-down
caused us to record an impairment of $6.6 million in
June 2008.
Other than the impairment discussed above, we do not believe the
shutdown of our PA manufacturing unit will have a material
adverse affect on our financial position, results of operations
or cash flows as the required quarterly fixed periodic payments
previously related to the PA manufacturing unit will continue
throughout the original term of the contract and have been
allocated to the operation of the esters manufacturing unit and
all decontamination and shutdown costs were reimbursed by BASF.
Styrene. The North American styrene industry
is currently in a protracted down cycle, primarily as a result
of over-supply. This extended down cycle resulted from two major
developments. Initially, export demand, which historically has
represented over 20% of North American production capacity, has
significantly diminished. In
55
recent months, U.S. styrene producers have seen an increase in
styrene exports, largely due to delays in the start up of
announced new capacity in the Middle East. However, this
increase is expected to reverse itself after the new styrene
plant being constructed in Al Jubail, Saudi Arabia is completed,
which is currently expected to occur later in 2008. Regional
cost pressures, in addition to new production capacity being
added in Asia and the Middle East, have made it difficult for
North American producers to compete in these export markets on a
continuous basis. In addition, a significant amount of styrene
capacity has been added globally over the past five to ten years
by producers of propylene oxide using so-called PO-SM
technology, which produces styrene as a co-product. Propylene
oxide is a key intermediate in the production of polyurethane,
and polyurethane demand growth has been significantly greater
than demand growth for styrene, exacerbating the over-supply of
styrene. During periods of over-supply, production rates for
styrene producers decrease significantly. When production rates
are low, unit production costs increase due to the allocation of
fixed costs over a lower production volume and a reduction in
the efficiency of the manufacturing unit, both in energy usage
and in the conversion rates for raw materials. Compounding these
cost impacts, prices for the principal styrene raw materials,
benzene and ethylene, are currently near historical highs,
putting pressure on margins on styrene sales even though styrene
contract prices are at near historic highs.
Over the last five years, China has been the driver for growth
in styrene demand, representing approximately 75% of the
worlds styrene demand growth in that period. Historically,
we have positioned ourselves to take advantage of peaks in the
Asian styrene markets, with a large portion of our styrene
capacity not being committed under long-term arrangements.
However, over the last several years, relatively high benzene
and domestic natural gas prices significantly limited our
ability to sell styrene into the Asian markets, and high styrene
prices have reduced styrene global demand growth rates. In
addition, several of our competitors announced their intention
to build new styrene production units outside the United States,
further complicating our ability to sell styrene into the Asian
markets. In 2006, our competitors added 2.6 billion pounds
of new styrene capacity in Asia and an additional 1.6 billion
pounds in 2007. The remaining announced construction projects
are scheduled to start up in 2008 and beyond. If and when these
new units are completed, we anticipate more difficult market
conditions, especially in the export markets, until the
additional supply is absorbed by growth in styrene demand or
significant capacity rationalization occurs.
CMAI currently is projecting no additional capacity increases in
North America through 2010, with operating rates reaching a
trough of 75% in 2007, and less than 80% operating rates
projected through 2010, without any further industry
restructuring. Although we believe an improved North American
industry outlook is possible, this largely depends on a
significant industry restructuring. Previously, styrene and
polystyrene industry participants, including The DOW Chemical
Company and NOVA Chemicals have announced a desire to seek
transactions which would restructure the North American styrene
and polystyrene industries, thereby improving the balance of
supply and demand in North America. More recently, on
October 1, 2007, NOVA Chemicals expanded its European joint
venture with INEOS to include North American styrene and solid
polystyrene assets, and, in May of 2008, Americas Styrenics
LLC, a joint venture between The Dow Chemical Company and
Chevron Phillips Chemical Company, which includes selected
styrene and polystyrene assets of the two companies in North
America and South America, began operations.
Product
Summary
The following table summarizes our principal products, including
our capacity, the primary end uses for each product, the raw
materials used to produce each product and the major competitors
for each product. Capacity represents rated annual
production capacity as of December 31, 2007, which is
calculated by estimating the number of days in a typical year
that a production facility is capable of operating after
allowing for downtime for regular maintenance, and multiplying
that number of days by an amount equal to the facilitys
optimal daily output based on the design feedstock mix. As the
capacity of a facility is an estimated amount, actual production
may be more or less
56
than capacity, and the following table does not reflect actual
operating rates of any of our production facilities for any
given period of time.
|
|
|
|
|
|
|
|
|
Sterling Product
|
|
Intermediate
|
|
|
|
|
|
|
(Capacity)
|
|
Products
|
|
Primary End Products
|
|
Raw Materials
|
|
Major Competitors
|
|
Acetic Acid (1.1 billion pounds per year)
|
|
Vinyl acetate monomer, terephthalic acid, and acetate solvents
|
|
Adhesives, PET bottles, fibers and surface coatings
|
|
Methanol and Carbon Monoxide
|
|
Celanese AG, Eastman Chemical Company and Lyondell Chemical
Company
|
Plasticizers (200 million pounds of esters and
130 million pounds of phthalic anhydride per year)
|
|
Flexible polyvinyl chloride
|
|
Flexible plastics, such as shower curtains and liners, floor
coverings, cable insulation, upholstery and plastic molding
|
|
Oxo-Alcohols and Orthoxylene
|
|
ExxonMobil Corporation, Eastman Chemical Company and BASF
Corporation
|
Products
Acetic Acid. Our acetic acid is used primarily
to manufacture vinyl acetate monomer, which is used in a variety
of products, including adhesives and surface coatings. We have
the third largest production capacity for acetic acid in North
America. Our acetic acid unit has a rated annual production
capacity of approximately 1.1 billion pounds, which
represents approximately 17% of total North American capacity.
All of our acetic acid production is sold to BP Chemicals, and
we are BP Chemicals sole source of production in the
Americas. We sell our acetic acid to BP Chemicals pursuant to a
Production Agreement that extends until 2016. For a further
description of our agreement with BP Chemicals, please refer to
Acetic
Acid-BP
Chemicals under Contracts.
Plasticizers. Our plasticizers business is
comprised of two separate products: phthalate esters and
phthalic anhydride, together commonly referred to as
plasticizers. Our phthalate esters are made from phthalic
anhydride and oxo-alcohols, and phthalic anhydride is also sold
as a separate product. All of our plasticizers, which are used
to make flexible plastics such as shower curtains, floor
coverings, automotive parts and construction materials, are sold
to BASF pursuant to a long-term production agreement that
extends until 2013, subject to some early termination rights
held by BASF beginning in 2010. In December 2007, BASF caused
the shutdown of our PA unit by nominating zero pounds of PA in
response to deteriorating market conditions which are not
expected to improve in the foreseeable future. This shutdown
will not have a material adverse affect on our financial
conditions or results of operations. For a further description
of our agreement with BASF, please refer to
Plasticizers-BASF under Contracts.
Styrene. Styrene was previously one of our
principal products. Styrene is a commodity chemical used to
produce intermediate products such as polystyrene, expandable
polystyrene resins and ABS plastics, which are used in a wide
variety of products such as household goods, foam cups and
containers, disposable food service items, toys, packaging and
other consumer and industrial products. As previously discussed,
we permanently shut down our styrene plant in the fourth quarter
of 2007 and exited the styrene business in 2008.
Sales and
Marketing
Our petrochemicals products are generally sold to customers for
use in the manufacture of other chemicals and products, which in
turn are used in the production of a wide array of consumer
goods and industrial products throughout the world. We have
long-term agreements that provide for the dedication of 100% of
our production of acetic acid and plasticizers, each to one
customer. Under our Production Agreement, we are reimbursed for
our actual fixed and variable manufacturing costs and also
receive an agreed share of the profits earned from this
business. Under our plasticizers agreement, we are reimbursed
for our manufacturing costs and also receive a
57
quarterly facility fee for each production unit
included in our plasticizers business, but do not share in the
profits or losses from that business. These agreements are
intended to:
|
|
|
|
|
optimize our capacity utilization rates;
|
|
|
|
lower our selling, general and administrative expenses;
|
|
|
|
reduce our working capital requirements;
|
|
|
|
insulate the financial results our plasticizers operations from
the effects of declining markets and changes in raw materials
prices; and
|
|
|
|
in some cases, gain access to certain improvements in
manufacturing process technology.
|
Prior to the effectiveness of the long-term styrene supply
contract with NOVA discussed above, we previously sold styrene
through multi-year contracts, conversion agreements and spot
transactions in both domestic and international markets.
For information regarding our export sales, see Note 10 of
the Notes to Consolidated Financial Statements for
the year ended December 31, 2007 included in this
prospectus.
Contracts
Our significant multi-year contracts are described below.
Acetic
Acid-BP
Chemicals
In 1986, we entered into the Production Agreement with BP
Chemicals, which has since been amended several times. BP
Chemicals markets all of the acetic acid that we produce and
pays us, among other amounts, a portion of the profits derived
from its sales of the acetic acid we produce. In addition, BP
Chemicals reimburses us for 100% of our fixed and variable costs
of production. Prior to August 2006, BP Chemicals also paid us a
set monthly amount. However, under the terms of this Production
Agreement, beginning in August 2006, the portion of the profits
we receive from the sales of acetic acid produced at our plant
increased and BP Chemicals was no longer required to pay us the
set monthly amount. This change in payment structure did not
affect BP Chemicals obligation to reimburse us for all of
our fixed and variable costs of production.
Plasticizers-BASF
Since 1986, we have provided all of our plasticizers production
exclusively to BASF pursuant to a production agreement, which
has been amended several times. Under this production agreement,
BASF provides us with most of the required raw materials and
markets the plasticizers we produce, and is obligated to make
certain fixed quarterly payments to us and to reimburse us
monthly for our actual production costs and capital expenditures
relating to our plasticizers facility. Effective January 1,
2006, we amended this production agreement to extend the term of
the agreement until 2013, subject to some early termination
rights held by BASF beginning in 2010, increase the quarterly
payments made to us by BASF and eliminate our participation in
the profits and losses realized by BASF in connection with the
sale of the plasticizers we produce. Additionally, on
April 28, 2006, BASF notified us that it was exercising its
right under the amended production agreement to terminate its
future obligations with respect to the operation of our
oxo-alcohols production unit effective July 31, 2006. In
December 2007, BASF caused the shutdown of our PA unit by
nominating zero pounds of PA in response to deteriorating market
conditions which are not expected to improve in the foreseeable
future. As a result of this shutdown, in May 2008, we entered
into an amended production agreement with BASF, effective as of
April 1, 2008. The amended agreement relieves BASF of most
of its obligations related to our PA manufacturing unit,
requires that BASF pay approximately $3.7 million to us for
reimbursement of certain direct fixed and variable costs
associated with the shutdown and decontamination of our PA
manufacturing unit. The amended agreement also requires that
BASF pay to us an aggregate amount of approximately
$3.2 million (the remaining $0.2 million of which is
required to be paid on or before August 15, 2008), subject
to a 25%-75% refund right in BASFs favor if we restart our
PA unit before the end of 2010, depending on the year in which
we restart the unit. Under the amended agreement, BASF is still
required to make the same quarterly fixed periodic payments as
previously required. In
58
addition, under the amended production agreement, the methods
for calculating (i) payments required to be made by BASF to
us for achieving reductions in direct fixed and variable costs
and (ii) BASFs right to terminate the agreement in
the event that direct fixed and variable costs exceed a
specified threshold (unless we elect to cap BASFs
reimbursement obligations), have both been modified to exclude
costs savings and direct fixed and variable costs pertaining to
our PA manufacturing unit. The amended agreement also removed
all restrictions or rights BASF formerly had with respect to our
use or disposition of the PA manufacturing unit, including a
purchase right, the right to request capacity increases and
consultation rights regarding future capital expenditures with
respect to our PA unit. For more discussion of our amended
agreement with BASF, see Industry Overview
Plasticizers.
Sales to major customers constituting more than 10% or more of
total revenues are included in Note 10 of the Notes
to Consolidated Financial Statements for the year ended
December 31, 2007 included in this prospectus.
Raw
Materials and Energy Resources
The aggregate cost of raw materials and energy resources used in
the production of our products is far greater than the total of
all other costs of production combined. As a result, an adequate
supply of raw materials and energy at reasonable prices and on
acceptable terms is critical to the success of our business.
Although we believe that we will continue to be able to secure
adequate supplies of raw materials and energy, we may be unable
to do so at acceptable prices or payment terms. See Risk
Factors. Under our agreements with BP Chemicals and BASF,
BP Chemicals is required to provide our methanol requirements to
produce acetic acid and BASF is required to provide us with most
of the major raw materials necessary to produce plasticizers.
These sources of raw materials tend to mitigate certain risks
typically associated with obtaining raw materials, as well as
decrease our working capital requirements.
Acetic Acid. Acetic acid is manufactured
primarily from carbon monoxide and methanol. Praxair is our sole
source for carbon monoxide and supplies us with all of the
carbon monoxide we require for the production of acetic acid
from its partial oxidation unit located on land leased from us
at our Texas City site. Currently, our methanol requirements are
supplied by BP Chemicals under the Production Agreement.
Plasticizers. The primary raw materials for
plasticizers are oxo-alcohols, orthoxylene and PA, which are
supplied by BASF under our long-term production agreement.
Technology
and Licensing
In 1986, we acquired our Texas City site from Monsanto Company,
or Monsanto. In connection with that acquisition, Monsanto
granted us a non-exclusive, irrevocable and perpetual right and
license to use Monsantos technology and other technology
Monsanto acquired through third-party licenses in effect at the
time of the acquisition. We use these licenses in the production
of acetic acid and plasticizers and also previously used those
licenses in the production of styrene.
During 1991, BP Chemicals Ltd., or BPCL, purchased
Monsantos acetic acid technology, subject to existing
licenses. Under a technology agreement with BP Chemicals and
BPCL, BPCL granted us a non-exclusive, irrevocable and perpetual
right and license to use acetic acid technology owned by BPCL
and some of its affiliates at our Texas City site, including any
new acetic acid technology developed by BPCL at its acetic acid
facilities in England or pursuant to the research and
development program provided by BPCL under the terms of such
agreement.
Although we do not engage in alternative process research, we do
monitor new technology developments and, when we believe it is
necessary, we typically seek to obtain licenses for process
improvements.
Competition
There are only four large producers of acetic acid in North
America and historically these producers have made capacity
additions in a disciplined and incremental manner, primarily
using small expansion projects or exploiting debottlenecking
opportunities. In addition, the leading technology required to
manufacture acetic acid is controlled by two global companies,
which permits these companies to control the pace of new
capacity additions through the licensing or development of such
additional capacity. The limited availability of this technology
also creates a
59
significant barrier to entry into the acetic acid industry by
potential competitors. The North American plasticizers industry
is a mature market, with phthalate esters like those produced by
us being subject to excess production capacity and diminishing
demand due to the ability of consumers to substitute different
raw materials based on relative costs at the time, as well as
increasing health concerns regarding these products. A list of
our principal competitors is set forth in the Product
Summary table above.
Environmental,
Health and Safety Matters
Our operations involve the handling, production, transportation,
treatment and disposal of materials that are classified as
hazardous or toxic and that are extensively regulated by
environmental and health and safety laws, regulations and permit
requirements. Environmental permits required for our operations
are subject to periodic renewal and may be revoked or modified
for cause or when new or revised environmental requirements are
implemented. Changing and increasingly strict environmental
requirements can affect the manufacture, handling, processing,
distribution and use of our chemical products and, if so
affected, our business and operations may be materially and
adversely affected. In addition, changes in environmental
requirements may cause us to incur substantial costs in
upgrading or redesigning our facilities and processes, including
our waste treatment, storage, disposal and other waste handling
practices and equipment.
A business risk inherent in chemical operations is the potential
for personal injury and property damage claims from employees,
contractors and their employees and nearby landowners and
occupants. While we believe our business operations and
facilities generally are operated in compliance with all
applicable environmental and health and safety requirements in
all material respects, we cannot be sure that past practices or
future operations will not result in material claims or
regulatory action, require material environmental expenditures
or result in exposure or injury claims by employees, contractors
or their employees or the public. Some risk of environmental
costs and liabilities is inherent in our operations and
products, as it is with other companies engaged in similar
businesses.
Our operating expenditures for environmental matters (mostly
waste management and compliance) for continuing operations were
approximately $11.2 million and $13.3 million in 2007
and 2006, respectively, and for discontinued operations were
approximately $6.6 million and $7.1 million in 2007
and 2006, respectively. For environmentally related capital
projects in continuing operations, we spent $0.5 million
and $2.0 million in 2007 and 2006, respectively, and zero
in both 2007 and 2006 for discontinued operations. In 2008, we
anticipate spending approximately $4 million for capital
projects related to waste management, incident prevention and
environmental compliance. We do not expect to make any capital
expenditures in 2008 related to remediation of environmental
conditions.
In light of our historical expenditures and expected future
results of operations and sources of liquidity, we believe we
will have adequate resources to conduct our operations in
compliance with applicable environmental, health and safety
requirements. Nevertheless, we may be required to make
significant site and operational modifications that are not
currently contemplated in order to comply with changing facility
permitting requirements and regulatory standards. Additionally,
we have incurred, and may continue to incur, liability for
investigation and cleanup of waste or contamination at our own
facilities or at facilities operated by third parties where we
have disposed of waste. We continually review all estimates of
potential environmental liabilities, but we may not have
identified or fully assessed all potential liabilities arising
out of our past or present operations or the amount necessary to
investigate and remediate any conditions that may be significant
to us. Based on information available at this time and reviews
undertaken to identify potential exposure, we believe any amount
reserved for environmental matters is adequate to cover our
potential exposure for
clean-up
costs.
Air emissions from our Texas City facility are subject to
certain permit requirements and self-implementing emission
limitations and standards under state and federal laws. Our
Texas City facility is subject to the federal governments
June 1997 National Ambient Air Quality Standards, or NAAQS,
which lowered the ozone and particulate matter concentration
thresholds for attainment. Our Texas City facility is located in
an area that the Environmental Protection Agency, or EPA, has
classified as not having achieved attainment under the NAAQS for
ozone, either on a
1-hour or an
8-hour
basis. Ozone is typically controlled by reduction of emissions
of volatile organic compounds, or VOCs, and nitrogen oxide, or
NOx. The Texas Commission for Environmental Quality, or TCEQ,
has imposed strict requirements on regulated facilities,
including our Texas City facility, to ensure that the
60
air quality control region will achieve attainment under the
NAAQS for ozone. Local authorities may also impose new ozone and
particulate matter standards. Compliance with these stricter
standards may substantially increase our future control costs
for emissions of NOx, VOCs and particulate matter, the amount
and full impact of which cannot be determined at this time.
In 2002, the TCEQ adopted a revised State Implementation Plan,
or SIP, in order to achieve compliance with the
1-hour
ozone standard under the Clean Air Act by 2007. The EPA approved
this
1-hour
SIP, which required an 80% reduction of NOx emissions, and
extensive monitoring of emissions of highly reactive volatile
organic carbons, or HRVOCs, such as ethylene, in the
Houston-Galveston-Brazoria area, or the HGB area. We are in full
compliance with these regulations. However, the HGB area failed
to attain compliance with the
1-hour ozone
standard, and Section 185 of the Clean Air Act requires
implementation of a program of emissions-based fees until the
standard is attained. These Section 185 fees
will be assessed on all NOx and VOC emissions in 2008 and beyond
in the HGB area which are in excess of 80% of the baseline year.
The method for calculating baseline emissions, as well as other
details of the program, has not yet been developed. At the
present time, we do not expect to be assessed any fee for our
emissions for 2008, primarily due to the reduction in emissions
from our Texas City facility following the closure of our
styrene facility.
In April 2004, the HGB area was designated a
moderate non-attainment area with respect to the
8-hour
ozone standard of the Clean Air Act, which resulted in mandated
compliance with the 8-hour ozone standard no later than
June 15, 2010. However, on June 15, 2007, the Governor
of the State of Texas requested that the EPA reclassify the HGB
area as a severe non-attainment area, which will
likely change the mandated compliance date for the
8-hour
ozone standard from June 15, 2010 to June 15, 2019, as
the EPA has begun the process of reclassification. On
May 23, 2007, the TCEQ formally adopted revisions to the
SIP designed to achieve compliance with the
8-hour
ozone standard in the HGB area, as a moderate
non-attainment area. This
8-hour
SIP calls for relatively modest additional controls at our Texas
City facility which will require very little expense on our
part. However, the
8-hour
SIP will need to be revised if and when the HGB area is
reclassified from moderate to severe.
The timing and content of any revised
8-hour
SIP have not yet been determined. Based on these developments,
it is difficult to predict our final cost of compliance under
these regulations. However, given the permanent shutdown of our
PA, styrene and ethylbenzene facilities, we estimate the
additional cost of compliance will range from zero to
$4 million for capital expenditures and the purchase of NOx
emissions allowances, depending on the terms of the final
8-hour
SIP.
To reduce the risk of offsite consequences from unanticipated
events, we acquired a greenbelt buffer zone adjacent to our
Texas City site in 1991. We also participate in a regional air
monitoring network to monitor ambient air quality in the Texas
City community.
Employees
As of March 31, 2008, we had 236 employees, of whom
approximately 39% (all of our hourly employees at our Texas City
site) were represented by the Union. On May 1, 2007, we
entered into a new collective bargaining agreement with the
Union which is effective through May 1, 2012. Under the new
collective bargaining agreement, we and the Union agreed to the
scope of work of the employees, hours of work, increases in
wages, benefits, vacation time, sick leave and other customary
terms. The new collective bargaining agreement also specifies
grievance procedures should any disputes arise between us and
any of our represented employees.
Insurance
We maintain insurance coverage at levels that we believe are
reasonable and typical for our industry. A portion of our
insurance coverage is provided by a captive insurance company
maintained by us and a few other chemical companies. However, we
are not fully insured against all potential hazards incident to
our business. Additionally, we may incur losses beyond the
limits of, or outside the coverage of, our insurance. We
maintain full replacement value insurance coverage for property
damage to our facilities and business interruption insurance.
Nevertheless, a significant interruption in the operation of one
or more of our facilities could have a material adverse effect
on our business. As a result of market conditions, premiums and
deductibles for certain insurance policies can increase
substantially and, in some instances, certain insurance may
become unavailable or available only for reduced amounts of
coverage.
61
We do not currently carry terrorism coverage on our Texas City
site. After the terrorist attacks of September 11, 2001,
many insurance carriers (including ours) created exclusions for
losses from terrorism from all risk property
insurance policies. While separate terrorism insurance coverage
is available, the premiums for such coverage are very expensive,
especially for chemical facilities, and these policies are
subject to very high deductibles. In addition, available
terrorism coverage typically excludes coverage for losses from
acts of foreign governments, as well as nuclear, biological and
chemical attacks. Consequently, we believe that it is not
economically prudent to obtain terrorism insurance on the terms
currently being offered in the industry.
Properties
Our petrochemicals site is located in Texas City, Texas,
approximately 45 miles south of Houston, on a
290-acre
site on Galveston Bay near many other chemical manufacturing
complexes and refineries. We own all of the real property which
comprises our Texas City site and we own the acetic acid and
plasticizers manufacturing facilities located at the site. We
also lease a portion of our Texas City site to Praxair, who
constructed a partial oxidation unit on that land, and lease a
portion of our Texas City site to S&L Cogeneration Company,
a 50/50
joint venture between us and Praxair Energy Resources, Inc., who
constructed a cogeneration facility on that land. Our Texas City
site offers approximately 160 acres for future expansion by
us or by other companies who could benefit from our existing
infrastructure and facilities, and includes a greenbelt around
the northern edge of the plant site. After giving effect to the
railcar sale to NOVA, we now own 97 railcars and, at our Texas
City site, we have facilities to load and unload our products
and raw materials in ocean-going vessels, barges, trucks and
railcars.
Substantially all of our Texas City, Texas site, and the
tangible properties located thereon, are subject to a lien
securing our obligations under our existing notes.
We lease the space for our principal executive offices, located
at 333 Clay Street, Suite 3600 in Houston, Texas.
We believe our properties and equipment are sufficient to
conduct our business.
Legal
Proceedings
On July 5, 2005, Patrick B. McCarthy, an employee of
Kinder-Morgan, Inc., or Kinder-Morgan, was seriously injured at
Kinder-Morgans
facilities near Cincinnati, Ohio while attempting to offload a
railcar containing one of our plasticizers products. On
October 28, 2005, Mr. McCarthy and his family filed a
suit in the Court of Common Pleas, Hamilton County, Ohio (Case
No. A0509 144) against us and six other defendants.
Since that time, the plaintiffs have added two additional
defendants to this lawsuit. In addition, we and some of the
other defendants have brought Kinder-Morgan into this lawsuit as
a third-party defendant. The plaintiffs are seeking in excess of
$32 million in alleged compensatory and punitive damages.
Discovery is ongoing in this case as to the underlying cause of
the accident and the parties respective liabilities, if
any. At this time, it is impossible to determine what, if any,
liability we will have for this incident and we will vigorously
defend the suit. We believe that all, or substantially all, of
any liability imposed upon us as a result of this suit and our
related out-of-pocket costs and expenses will be covered by our
insurance policies, subject to a $1 million deductible
which was met in January 2008. As of June 30, 2008, we
have received $0.2 million from our insurance carrier for
the reimbursement of amounts exceeding the deductible, and we
have accrued for an additional $0.2 million for the
reimbursement of amounts exceeding the deductible which were
incurred during the second quarter of 2008. We do not believe
that this incident will have a material adverse affect on our
business, financial position, results of operations or cash
flows, although we cannot guarantee that a material adverse
effect will not occur.
On August 17, 2006, we initiated an arbitration proceeding
against BP Chemicals to resolve a dispute involving the
interpretation of provisions of our acetic acid Production
Agreement with BP Chemicals. Under the Production Agreement, BP
Chemicals reimburses our manufacturing expenses and pays us a
percentage of the profits derived from the sales of the acetic
acid we produce. Historically, the costs of manufacturing
charged to our acetic acid business, and reimbursed by BP
Chemicals, included the amounts we paid Praxair for carbon
monoxide, hydrogen and a blend of carbon monoxide and hydrogen
commonly referred to as blend gas. Our acetic acid
business has always used all of the carbon monoxide produced by
Praxair, other than the small amount of carbon monoxide included
in the blend gas. Until July 1, 2006, all of the blend gas
produced by Praxair was used by the oxo-alcohols plant included
in our plasticizers business. During the period when the
oxo-alcohols plant was
62
operating, BP Chemicals was compensated for the use of this
blend gas by our oxo-alcohols plant through a credit to the
amount of our manufacturing expenses reimbursed by BP Chemicals.
Effective July 1, 2006, we permanently closed our
oxo-alcohols plant. BP Chemicals has taken the position that it
is entitled to continue to deduct a portion of the blend gas
credit from the reimbursement of our manufacturing expenses,
even though our oxo-alcohols plant has been closed and is no
longer taking any blend gas and the Praxair facilities have been
modified so that the carbon monoxide previously used in blend
gas can be used in our acetic acid operations. Effective
August 1, 2006, BP Chemicals began short paying our
invoices for manufacturing expenses by the portion of the credit
that BP Chemicals claims should continue through
July 31, 2016. The disputed portion of the credit averaged
approximately $0.3 million per month during 2006 and 2007,
before adjusting for the portion of the profits we receive from
BP Chemicals sale of the acetic acid we produce. We are
also seeking additional damages from BP Chemicals in the
arbitration based on what we believe are breaches of duty by BP
Chemicals. The parties have abated the arbitration proceedings
while they attempt to reach a negotiated settlement. As part of
the agreement to abate the arbitration proceedings,
BP Chemicals reimbursed us $0.8 million on
February 5, 2007, which was 50% of the disputed credit
through that date, and has continued and will continue to pay
50% of the disputed amount each month during the period of
negotiation. As of June 30, 2008, the disputed amount is
$8.1 million and we have received payments totaling
$3.8 million. We are not recording any revenue related to
any portion of the disputed amount until the matter is resolved.
The parties have stipulated that the payments are made without
prejudice, in that BP Chemicals is not admitting liability and
continues to insist that we remain liable for the disputed
portion of the blend gas credit. According to the agreement,
either party may reinstate the arbitration process at any time
after August 1, 2007. If the arbitration is reinstated and
an award is made, the amounts paid by BP Chemicals will be
credited against any sums awarded to us or refunded by us to BP
Chemicals, depending on the ruling of the arbitration panel. We
believe that our acetic acid Production Agreement does not
contemplate the continuation of any portion of the blend gas
credit under these circumstances and will vigorously pursue our
position. Although we are in a dispute with BP Chemicals over
the interpretation of this contractual provision, we believe
that we continue to have a constructive working relationship
with BP Chemicals, as has been the case since 1986. As part of
the on-going settlement negotiations over the blend gas issue,
we are discussing an extension of the term of the acetic acid
Production Agreement.
On February 21, 2007, we received a summons naming us,
several benefit plans and the plan administrators for those
plans as defendants in a class action suit, Case
No. H-07-0625
filed in the United States District Court, Southern District of
Texas, Houston Division. The plaintiffs seek to represent a
proposed class of retired employees of Sterling Fibers, Inc.,
one of our former subsidiaries that we sold in connection with
our emergence from bankruptcy in 2002. The plaintiffs are
alleging that we were not permitted to increase their premiums
for retiree medical insurance based on a provision contained in
the asset purchase agreement between us and Cytec Industries
Inc. and certain of its affiliates governing our purchase of our
former acrylic fibers business in 1997. During our bankruptcy
case, we specifically rejected this asset purchase agreement and
the bankruptcy court approved that rejection. The plaintiffs are
claiming that we violated the terms of the benefit plans and
breached fiduciary duties governed by the Employee Retirement
Income Security Act and are seeking damages, declaratory relief,
punitive damages and attorneys fees. The parties have
taken minimal discovery to date. The plaintiffs have moved for
partial summary judgment and for class certification related to
their claims for denial of benefits under our retiree medical
plans. The parties have fully briefed the issues and the motions
are pending before the court. However, the court has stayed all
proceedings while the plaintiffs pursue administrative remedies
under the terms of our retiree medical plans. The plaintiffs
appealed that denial as permitted in the applicable benefit plan
and an appeal with the plan administrator was heard on
July 29, 2008. On April 23, 2008, the plan administrator
denied the plaintiffs claims under the terms of our
retiree medical plans. We are vigorously defending this action
and are unable to state at this time if a loss is probable or
remote and are unable to determine the possible range of loss
related to this matter, if any.
On March 4, 2008, Gulf Hydrogen and Energy, L.L.C., or Gulf
Hydrogen, filed suit against us in the
212th District
Court of Galveston County, Texas (Cause No. 08CV0220) to
enforce the provisions of a Memorandum of Understanding, or MOU,
entered into between us and Gulf Hydrogen involving the possible
sale of our outstanding equity interests to Gulf Hydrogen for
approximately $390 million. This lawsuit also names certain
of our officers, a director and our primary stockholder as
defendants. Gulf Hydrogen does not allege a
63
specific amount of money damages in the lawsuit but has asked
the court to enforce certain MOU provisions which expired on
March 1, 2008 including restrictions on our ability to
engage in negotiations related to transactions that would result
in a change of control or to enter into mergers, stock sales or
other transactions relating to a material part of our business
or operations and other insignificant restrictions customary for
transactions of a similar nature. Gulf Hydrogen alleges that the
defendants breached the terms of the MOU and made certain
misrepresentations in connection therewith. We are vigorously
defending this lawsuit, which we believe is completely without
merit. We do not believe that this incident will have a material
adverse affect on our business, financial position, results of
operations or cash flows, although we cannot guarantee that a
material adverse effect will not occur.
We are subject to various other claims and legal actions that
arise in the ordinary course of our business. We do not believe
that any of these claims and actions, separately or in the
aggregate, will have a material adverse effect on our business,
financial position, results of operation or cash flows, although
we cannot guarantee that a material adverse effect will not
occur.
64
MANAGEMENT
Executive
Officers and Directors
Our board of directors is composed of seven directors. The
following table sets forth the names, ages and titles of the
individuals who are our executive officers and directors. All of
our directors are elected until the next annual meeting of
stockholders and until their successors are elected and
qualified. All executive officers hold office until their
successors are elected and qualified.
|
|
|
|
|
|
|
Name
|
|
Age
|
|
Position with Company
|
|
John V. Genova
|
|
|
53
|
|
|
President, Chief Executive Officer and Director
|
John R. Beaver
|
|
|
47
|
|
|
Chief Financial Officer and Senior Vice President
Finance
|
Kenneth M. Hale
|
|
|
46
|
|
|
Senior Vice President, General Counsel and Corporate Secretary
|
Paul C. Rostek
|
|
|
52
|
|
|
Senior Vice President Commercial
|
Walter B. Treybig
|
|
|
52
|
|
|
Senior Vice President Manufacturing
|
Bruce E. Moore
|
|
|
43
|
|
|
Treasurer
|
Richard K. Crump
|
|
|
62
|
|
|
Director
|
Steven L. Gidumal
|
|
|
50
|
|
|
Director
|
Byron J. Haney
|
|
|
47
|
|
|
Director
|
Karl W. Schwarzfeld
|
|
|
32
|
|
|
Director
|
Philip M. Sivin
|
|
|
36
|
|
|
Director
|
Dr. Peter Ting Kai Wu
|
|
|
71
|
|
|
Director
|
John W. Gildea
|
|
|
64
|
|
|
Director
|
John V. Genova. Mr. Genova became our
President and Chief Executive Officer and a director on
May 27, 2008. Mr. Genova most recently served as Vice
President of Corporate Planning for Tesoro Corporation, an
independent refiner of oil and gas products, where he was
responsible for business plan development, capital management
programs, competitor assessment and benchmarking programs, as
well as a corporate performance scorecard process. Prior to
becoming Vice President at Tesoro in 2005, Mr. Genova served as
Executive Vice President Refining and Marketing of
Holly Corporation since 2004. Mr. Genova began his career
as an engineer with ExxonMobil Corporation in 1976, working in a
variety of positions, including Executive Assistant to the
Chairman and General Manager, Corporate Planning, responsible
for development of ExxonMobils corporate plans
during 2002 and 2003. He also serves as a member of the
Board of Directors of Encore Acquisition Company, which is
engaged in the development of onshore North American oil and
natural gas reserves. In addition, Mr. Genova has provided
consulting services to investment banks, private equity
companies and hedge funds.
John R. Beaver. Mr. Beaver has been our
Chief Financial Officer and our Senior Vice
President Finance since May 4, 2007. Prior to
that time, Mr. Beaver served as our Corporate Controller
since March of 2001 and one of our Vice Presidents since January
of 2003. Prior to joining us, Mr. Beaver was Vice President
and Corporate Controller for Pioneer Companies, Inc. from 1997
until December of 2000 and Corporate Controller for Borden
Chemicals and Plastics Limited Partnership from 1995 though
1996. Mr. Beaver held several financial management
positions with us from 1987 through 1995 and with Monsanto
Company from 1981 through 1987.
Kenneth M. Hale. Mr. Hale has been our
General Counsel since January of 2001 and our Senior Vice
President and Corporate Secretary since January of 2003. On
January 1, 2005, Mr. Hale also became the head of our
Human Resources & Administration Department. Prior to
becoming one of our Senior Vice Presidents, Mr. Hale served
as one of our Vice Presidents from October of 2002 through
January of 2003. Prior to becoming General Counsel,
Mr. Hale served as our Senior Counsel from July of 2000
through January of 2001, and as Assistant General Counsel from
December of 1997 through July of 2000. Prior to joining us,
Mr. Hale was an associate attorney at the law firm of
Andrews & Kurth L.L.P. from January 1994 until
December of 1997, and at the law firm of Honigman Miller
Schwartz and Cohn from May of 1990 until December of 1993, where
he specialized in mergers and acquisitions, finance, securities
and general corporate matters.
65
Paul C. Rostek. Mr. Rostek has been our
Senior Vice President Commercial since August of
2004. Prior to attaining this position, Mr. Rostek was our
Vice President Nitriles from December 1996 to
December 2002, and then served as our Vice President
Corporate Alliance & New Ventures from January 2003 to
July 2004. Mr. Rostek joined us when we acquired our
previously owned pulp chemicals business from Tenneco Inc. in
August 1992 and initially served as our Vice President ERCO
System Group based out of Toronto, Canada from August of 1992
through November of 1996.
Walter B. Treybig. Mr. Treybig joined us
in 1993 and has been our Senior Vice President
Manufacturing since January of 2003. Prior to that time,
Mr. Treybig served as our Plant Manager since 1998 and our
Manager of Environmental, Health and Safety. Before joining us,
Mr. Treybig held various positions at PPG Industries, Inc.,
Cain Chemical Inc., Occidental Chemical Corporation and Ausimont
USA Incorporated. Mr. Treybig also serves as a Director of
the Galveston County Health District.
Bruce E. Moore. Mr. Moore has been our
Treasurer since January of 2003. Prior to becoming our
Treasurer, Mr. Moore served as our Director of Treasury
Operations from May of 2001 through January of 2003 and our
Petrochemicals Division Controller from November of 1998
through May of 2001. Prior to that time, Mr. Moore served
in a variety of financial positions since joining us in December
of 1989, including positions in internal audit, tax and
financial reporting. Prior to joining us, Mr. Moore held
various positions in the audit and tax departments of KPMG LLP.
Richard K. Crump. Mr. Crump has been a
director since December 2001. Mr. Crump recently retired from
his position as our President and Chief Executive Officer,
positions he held since January of 2003. Prior to that time,
Mr. Crump served as our Co-Chief Executive Officer from
December of 2001 through January of 2003, our Executive Vice
President Operations from May of 2000 through
December of 2001, our Vice President Strategic
Planning from December of 1996 through May of 2000, our Vice
President Commercial from October of 1991 through
December 1, 1996 and our Director Commercial
from August of 1986 through October of 1991. Prior to joining
us, Mr. Crump was Vice President of Sales for Rammhorn
Marketing from 1984 through August of 1986 and Vice President of
Materials Management for El Paso Products Company from 1976
through 1983.
Steven L. Gidumal. Mr. Gidumal has been a
director since November 2006. Mr. Gidumal is a Managing
Director and a Co-Chief Investment Officer of Resurgence Asset
Management, L.L.C. or Resurgence, which beneficially owns a
substantial majority of the voting power of our securities.
Mr. Gidumal joined Resurgence in 2006. Prior to joining
Resurgence, Mr. Gidumal served as Founder, Managing
Director and Portfolio Manager of Virtus Capital, a New
York-based hedge fund since February 2004. Before launching his
own company, Mr. Gidumal served as head of distressed
research for Trilogy Capital from 2001 through February 2004.
Prior to that time, Mr. Gidumal had served as a portfolio
manager of Tribeca Investments (Citigroups distressed
securities operations), a distressed securities specialist for
Bear Stearns and an investment banker for Rothschild Inc.
Mr. Gidumal also currently serves as a member of the Board
of Directors of RDA Sterling Holdings Corporation and Mirant
Corp. Asset Recovery Trust.
Byron J. Haney. Mr. Haney has been a
director since December 2002. Mr. Haney is a Managing
Director and a Co-Chief Investment Officer of Resurgence, which
beneficially owns a substantial majority of the voting power of
our securities. Prior to becoming Managing Director and Co-Chief
Investment Officer in 2006, Mr. Haney served as Managing
Director of Resurgence since 1994. Mr. Haney joined
Resurgence in 1994. Mr. Haney also currently serves as a
member of the Board of Directors of RDA Sterling Holdings
Corporation, Furniture.com, Inc. and Fifth Street Finance
Corp. and as an Executive Officer and member of the Board of
Directors of First Commercial Credit Corp.
Karl W. Schwarzfeld. Mr. Schwarzfeld has
been a director since March 2006. Mr. Schwarzfeld is a Vice
President of Resurgence, which beneficially owns a substantial
majority of the voting power of our securities. Prior to
becoming Vice President in 2006, Mr. Schwarzfeld as
Director of Operations of Resurgence from 2004 through 2006,
Vice President of Operations from 2003 through 2004, Assistant
Vice President of Operations from 2002 through 2003, Operations
Manager from August 2000 through 2002 and a Portfolio
Administrator of Resurgence from August of 1998 through July
2000.
66
Philip M. Sivin. Mr. Sivin has been a
director since July 2004. Mr. Sivin is Senior Vice
President of M.D. Sass Macquarie Financial
Strategies Management Company, L.L.C. and a Vice President of
Resurgence, which beneficially owns a substantial majority of
the voting power of our securities. Mr. Sivin joined
Resurgence in 2004 and became a Vice President in 2005. Prior to
becoming Senior Vice President of M.D. Sass
Macquarie Financial Strategies Management Company, L.L.C. in
2005, Mr. Sivin had served as Senior Vice President and
General Counsel of M.D. Sass Investors Services, Inc. and M.D.
Sass Associates, Inc. since 2000. Prior to joining M.D. Sass in
2000, Mr. Sivin was an attorney at Sullivan &
Cromwell LLP in New York specializing in corporate, securities,
real estate and investment management transactions.
Mr. Sivin also currently serves as a member of the Board of
Directors and Executive Officer of M.D. Sass Investors Services,
Inc. (which owns Resurgence) and M.D. Sass Associates,
Inc., and as a member of the Board of Directors of RDA Sterling
Holdings Corporation, Furniture.com, Inc. and First Commercial
Credit Corp.
Dr. Peter Ting Kai Wu. Dr. Wu has
been a director since March 2004. Dr. Wu currently serves
as Chairman of the Board of Boston Life Science Venture Corp., a
corporation based in Taiwan, and Chairman Emeritus of
Continental Carbon India Limited. He is also a director and a
member of the audit committee of TSRC Group, a synthetic rubber
manufacturer in Taiwan and China. Previously, Dr. Wu served
as Vice Chairman and Chief Executive Officer of Continental
Carbon Company, a Houston, Texas based subsidiary of China
Synthetic Rubber Corporation, from 1995 until his retirement in
2004, and as the President and Chief Executive Officer of China
Synthetic Rubber Corporation, a petrochemicals company based in
Taipei, Taiwan, from 1992 until his retirement in 2004. Prior to
that time, Dr. Wu served as President and Chief Executive
Officer of Grand Pacific Petrochemical Corporation, a Taipei,
Taiwan based producer of styrene, polystyrene and ABS plastics,
from 1990 through 1992, and as Executive Vice President of USI
Far East Corporation, a Taipei, Taiwan based producer of
polyethylene, from 1989 through 1990. Dr. Wu was also a
Vice President and General Director of Industrial Technology
Research Institute Union Chemical Laboratories, an
industrial chemical technology research organization in Hsin
Chu, Taiwan, from 1985 through 1989, and held various positions
related to polymer research at E.I. du Pont de
Nemours & Company in Wilmington, Delaware from 1975
through 1985. The Chinese Institute of Chemical Engineers has
awarded Dr. Wu the prestigious Chemical Engineering Medal
for his contributions to the development of chemical industries
in Taiwan, and Dr. Wu has also been awarded Distinguished
Service Medals from both the Chinese Chemical Society and the
Polymer Society of Taiwan. In 2005, Dr. Wu was bestowed a
Life-Time Achievement Award at the 2005 Asia Pacific
Carbon Black Conference in Suzhou, China and in 2007 was
bestowed a similar award by the Polymer Society of Taiwan for
his life-time contributions to the polymers industry.
John W. Gildea. Mr. Gildea has been a
director since December 2002. Mr. Gildea has been a
managing director and principal of Gildea Management Company
since 1990. Gildea Management Company and its affiliates have
been the investment advisor to The Network Funds, which
specializes in distressed company and special situation
investments. Mr. Gildea has served on the Board of
Directors of a number of restructured or restructuring
companies, including Amdura Corporation, American Healthcare
Management, Inc., America Service Group Inc., GenTek, Inc.,
Konover Property Trust, Inc. and UNC Incorporated.
Mr. Gildea also serves as a member of the Board of
Directors of Universal Aerospace Company, Inc., America Service
Group Inc. and Misonix, Inc. and several United Kingdom based
investment trusts. He is also a member of the Audit Committee
and the Compensation Committee of Misonix, Inc.
Board of
Directors
Director
Independence
Mr. Gildea and Dr. Wu are considered independent under
the listing standards of the New York Stock Exchange. Each of
Messrs. Gidumal, Haney, Schwarzfeld and Sivin are employed
by Resurgence, which has beneficial ownership of a substantial
majority of the voting power of our securities due to its
investment and disposition authority over securities owned by
its and its affiliates managed funds and accounts. As a
result of this beneficial ownership, Resurgence is considered to
be our affiliate under Securities and Exchange Commission
guidelines and, consequently, Messrs. Gidumal, Haney,
Schwarzfeld and Sivin may be considered not independent under
the listing standards of the New York Stock Exchange due to
their employment by Resurgence. Mr. Sivin is also the
son-in-law
of Martin Sass, the Chief Executive Officer of Resurgence and of
M.D. Sass Investors Services, Inc., the owner of Resurgence, and
Mr. Sivin is member of the Board of Directors and executive
officer of M.D. Sass Investors Services, Inc. Mr. Genova is
our President and Chief Executive Officer and, consequently, is
considered
67
not independent under the listing standards of the New York
Stock Exchange. Mr. Crump is considered not independent under
the listing standards of the New York Stock Exchange due to
his prior service as our President and Chief Executive Officer.
Committees
of the Board
Our board of directors has created various standing committees
to help carry out its duties, including an Audit Committee, a
Compensation Committee, a Corporate Governance Committee and an
Environmental, Health and Safety Committee. Generally speaking,
our board committees work on key issues in greater detail than
would be possible at full meetings of our board of directors.
Each of our committees consults, from time to time, with outside
experts concerning the performance of its duties. As part of its
duties, our Corporate Governance Committee acts as our
nominating committee.
Audit
Committee
Our Audit Committee is currently comprised of two of our
non-employee directors, Byron J. Haney (Chairman) and John W.
Gildea. Our Audit Committee operates under a written charter
adopted by our Board, a current copy of which is posted on our
website at www.sterlingchemicals.com, and is also an Exhibit to
our Annual Report on
Form 10-K
for the year ended December 31, 2007. Our Audit Committee
oversees our accounting and financial reporting processes and
the audits of our financial statements, and monitors the
qualifications, independence and performance of our internal and
independent auditors. Our Audit Committee is directly
responsible for the appointment, compensation and oversight of
our independent external and internal auditors, and approves the
audit, audit-related or tax services to be provided by these
auditors, as well as all non-audit related services to be
provided by our independent external auditors. In addition, our
Audit Committee reviews our
Form 10-K
and
Form 10-Q
reports, our practices in preparing published financial
statements and our internal and disclosure controls. Upon the
recommendation of our Audit Committee, our board of directors
adopted a Code of Ethics for the Chief Executive Officer and
Senior Financial Officers, a current copy of which is posted on
our website at www.sterlingchemicals.com. This Code of Ethics,
which applies to our Chief Executive Officer, our Chief
Financial Officer, our Controller and anyone performing similar
functions on our behalf, is administered by our Audit Committee
and provides for the reporting of violations to our Audit
Committee on a confidential and anonymous basis.
Mr. Gildea is considered independent under the listing
standards of the New York Stock Exchange for purposes of serving
on our Audit Committee, while Mr. Haney may be considered
not independent under these listing standards due to his
employment by Resurgence. However, as Mr. Haney qualifies
as a financial expert, as discussed below, our board
of directors determined that it was appropriate to appoint
Mr. Haney to our Audit Committee. Under the charter of our
Audit Committee, each member of our Audit Committee must:
|
|
|
|
|
be independent of management and be free from any relationship
that, in the opinion of our Board, would interfere with the
exercise of his independent judgment;
|
|
|
|
have, in the opinion of our board of directors and in the
opinion of each member of our Audit Committee, sufficient time
available to devote reasonable attention to the responsibilities
of our Audit Committee;
|
|
|
|
be financially literate (i.e., have the ability to read
and understand fundamental financial statements, including a
balance sheet, income statement and statement of cash flows, and
the ability to understand key financial risks and related
controls and control processes); and
|
|
|
|
not simultaneously serve on the audit committee of more than
three public companies.
|
In addition, at least one member of our Audit Committee must, in
the opinion of our Board, be an audit committee financial
expert or have accounting or related financial management
expertise. Our Board has determined that Mr. Haney is an
audit committee financial expert within the meaning
ascribed to such term under the rules promulgated under the
Sarbanes-Oxley Act of 2002, due to his education, training and
employment as a certified public accountant, service as a member
of the audit committee of other companies and other relevant
experience acquired through his work at Resurgence and other
companies.
68
Compensation
Committee
Our Compensation Committee is currently comprised of two of our
non-employee directors, John W. Gildea (Chairman) and Steven L.
Gidumal. Our Compensation Committee operates under a written
charter adopted by our Board, a current copy of which is posted
on our website at www.sterlingchemicals.com. Our Compensation
Committee is responsible for discharging the compensation
responsibilities of our Board, including:
|
|
|
|
|
reviewing and approving corporate goals and objectives relevant
to compensation of our Chief Executive Officer, evaluating our
Chief Executive Officers performance in light of those
goals and objectives and determining and approving our Chief
Executive Officers compensation level based on this
evaluation;
|
|
|
|
determining and approving the compensation levels for our other
executive officers;
|
|
|
|
making recommendations to our board of directors with respect to
the adoption, amendment or termination of our incentive
compensation plans and equity-based plans;
|
|
|
|
administering our compensation programs for executive officers
(including bonus plans, stock option and other equity-base
programs, deferred compensation plans and other cash or stock
incentive programs);
|
|
|
|
reviewing and making recommendations to our board of directors
with respect to other significant employee benefit
programs; and
|
|
|
|
reviewing and approving our annual merit budget.
|
In addition, our Compensation Committee establishes the annual
fees and meeting fees to be paid to our non-employee directors.
The roles of our executive officers and of consultants in
determining compensation of our executive officers and
directors, and the ability of the Compensation Committee to
delegate its authority, is discussed under Compensation
Discussion and Analysis below.
As discussed above, Mr. Gildea is considered independent
under the listing standards of the New York Stock Exchange,
while Mr. Gidumal may be considered not independent under
these listing standards due to his employment by and other
relationships to Resurgence. Under the charter of our
Compensation Committee, each member of our Compensation
Committee must be independent of management and be free from any
relationship that, in the opinion of our Board, would interfere
with the exercise of his independent judgment, and have, in the
opinion of our board of directors and in the opinion of each
member of our Compensation Committee, sufficient time available
to devote reasonable attention to the responsibilities of our
Compensation Committee.
Corporate
Governance Committee
Our Corporate Governance Committee is currently comprised of two
of our non-employee directors, Dr. Peter T.K. Wu (Chairman)
and John W. Gildea. Our Corporate Governance Committee operates
under a written charter adopted by our Board, a current copy of
which is posted on our website at www.sterlingchemicals.com. Our
Corporate Governance Committee considers all matters related to
our corporate governance. In discharging its duties, our
Corporate Governance Committee makes recommendations to our
board of directors with respect to changes to our Certificate of
Incorporation, Bylaws, committee structure and corporate
governance guidelines, reviews all stockholder proposals,
considers questions of independence of our board of directors
members and possible conflicts of interest, reviews succession
plans relating to positions held by our senior executive
officers and reviews our insurance and indemnity arrangements
for our directors and officers. Our Corporate Governance
Committee also provides oversight with respect to the
establishment of and adherence to corporate compliance programs,
codes of conduct and other policies and procedures concerning
our business and our compliance with all relevant laws.
Our Corporate Governance Committee also acts as our nominating
committee. In this capacity, our Corporate Governance Committee
considers, recommends and recruits candidates to fill new or
vacant positions on our board of directors and conducts
inquiries into the backgrounds and qualifications of possible
candidates for positions on our board of directors (unless any
person or entity has the power to designate the individual to
fill such position under our Certificate of Incorporation, any
contract to which we are a party or the terms of any series of
our preferred stock). Our
69
Corporate Governance Committee, in accordance with its charter
and subject to the terms of our Certificate of Incorporation and
Bylaws, reviews candidates recommended by our stockholders for
positions on our Board.
As discussed above, Mr. Gildea and Dr. Wu are
considered independent under the listing standards of the
New York Stock Exchange. Under the charter of our Corporate
Governance Committee, each member of our Corporate Governance
Committee must be independent of management and be free from any
relationship that, in the opinion of our Board, would interfere
with the exercise of his independent judgment, and have, in the
opinion of our board of directors and in the opinion of each
member of our Corporate Governance Committee, sufficient time
available to devote reasonable attention to the responsibilities
of our Corporate Governance Committee.
Environmental,
Health & Safety Committee
Our Environmental, Health and Safety Committee is currently
comprised of two of our directors, Richard K. Crump (Chairman)
and Dr. Peter T.K. Wu. Our Environmental, Health and Safety
Committee establishes policies, practices and procedures for
employee safety and health, environmental protection and product
safety to ensure that our operations are conducted in compliance
with environmental laws, rules, regulations, permits and
licenses. Our Environmental, Health and Safety Committee also
conducts ongoing environmental planning activities and makes
recommendations to our board of directors concerning the
selection of external environmental auditors, including their
compensation and the proposed terms of their engagement.
70
EXECUTIVE
COMPENSATION
Compensation
Discussion and Analysis
Compensation
Philosophy and Objectives
Our senior executive compensation program is designed to
motivate, reward and retain the management talent needed to
achieve our business goals and maintain a leadership position in
the petrochemicals industry. Under our program, a significant
portion of the potential compensation of our senior executives
is dependent on our financial performance and increased
stockholder value. Our program offers our senior executives
salary levels and compensation incentives designed to:
|
|
|
|
|
attract, motivate and retain talented and productive executives;
|
|
|
|
recognize individual performance and our overall corporate
performance relative to the performance of our competitors and
other companies of comparable size; and
|
|
|
|
support our short-term and long-term goals.
|
We believe that this approach ensures an appropriate link
between the compensation of our senior executives and the
accomplishment of our goals and our stockholders
objectives.
Processes
and Procedures for Determining Compensation
Our Compensation Committee is responsible for discharging the
primary compensation responsibilities of our Board, and has the
authority to determine and approve the compensation paid to each
of our senior executive officers, including the Named Executive
Officers (as defined below). Our Compensation Committee also
administers our compensation programs for our senior executive
officers (including bonus plans, stock option and other
equity-base programs, deferred compensation plans and other cash
or stock incentive programs), and makes recommendations to our
Board with respect to whether any of those plans should be
changed or terminated, or whether new plans should be adopted.
The charter for our Compensation Committee does not contemplate
any delegation by our Compensation Committee, or any of its
members, of the duties delegated by our Board to our
Compensation Committee.
Our Compensation Committee uses a number of sources to determine
the compensation paid to each of our senior executives. One of
the primary sources of information used by our Compensation
Committee is data from independent compensation consultants. The
extent of data received from these consultants varies from year
to year. Once every several years, an in-depth analysis of each
element of our senior executive compensation program, as well as
the overall compensation paid to each of our senior executives,
is performed by an independent consulting firm. Historically,
this analysis was performed in tandem with similar analyses
performed for all our salaried employees by the same
compensation consulting firm directly engaged by us rather than
our Compensation Committee. However, in January of 2007, our
Compensation Committee directly engaged The Hay Group, Inc., a
different firm from that engaged by us to review our
compensation program for our other salaried employees, to
perform an in depth analyses of our senior executive
compensation program. In those years when an in-depth analysis
is performed, the compensation consulting firm issues a final
report to our Compensation Committee that provides its view of
the appropriateness of the compensation paid to each of our
senior executives and the appropriateness of our senior
executive compensation program as a whole. The compensation
consulting firm also typically makes several recommendations for
changes to our program. This report and analysis provides our
Compensation Committee with the ability to compare our senior
executive compensation program to those offered by other
chemical manufacturers and a select group of non-chemical
companies of comparable size and performance, and determine
whether the compensation paid to each of our senior executives
is both competitive and reasonable in relation to the duties
required of that executive. Our Compensation Committee does not,
however, compare our compensation program against the
compensation offered by all of the companies included in the
S&P Chemicals Index used in the Performance Graph contained
in our
Form 10-K
because many of those companies are not considered to be our
competitors, either in the market for our products or for
executive talent.
71
In the years falling in between these more in-depth analyses,
the head of our Human Resources and Administration Department
(currently Mr. Hale, one of our Named Executive Officers)
provides our Compensation Committee with summary market data
from several compensation consulting firms. Our Compensation
Committee uses this data to assess general trends in the levels
of base salaries paid to senior executives in our industry, in
our geographic locale and in the United States as whole. The
compensation consulting firms from whom summary market data is
obtained may vary from year to year. For example, in 2006, our
Compensation Committee received summary market data from The Hay
Group, Inc., Hewitt Associates, Inc., Business and Legal
Reports, Inc. and Mercer Human Resource Consulting LLC, while
for 2008 our Compensation Committee received summary market data
from Hewitt Associates, Inc., World at Work, Sibson Consulting,
Salary.com, Mercer Human Resources Consulting, LLC and Buck
Consultants. After reviewing the summary market data, our
Compensation Committee determines an overall budget for
increases in the base salaries of our senior executives as a
group. Once this overall budget is established, our Compensation
Committee confers with our Chief Executive Officer to discuss
the performance of each of our senior executives and, following
that discussion, our Compensation Committee determines the
amount of increase in base salary for each of our senior
executives, including our Chief Executive Officer.
Total
Compensation
The major components of our senior executive compensation
program are base salary, annual incentive compensation and
stock-based compensation, in addition to a few perquisites and
other personal benefits to our senior executives, such as group
life insurance. In addition, we maintain a 401(k) Plan for all
of our employees, and currently match the contributions into our
401(k) Plan made by each of our salaried employees, on a
dollar-for-dollar basis, up to 6% of the participants base
salary. We also provide all of our senior executives with
post-employment compensation in the form of our salaried
employees pension plan and our Key Employee Protection
Plan. However, benefit accruals under our salaried
employees pension plan were frozen as of January 1,
2005. Our Compensation Committee seeks to set base salaries for
our senior executives at competitive rates, and also provides
annual compensation opportunities linked to both our financial
performance and the individuals performance in each year
and long-term stock-based compensation opportunities linked to
our overall financial performance over an extended period. We
believe that focusing executive compensation on variable
incentive pay helps us meet our performance goals and enhances
long-term stockholder value. In 2007, we did not pay any
non-equity incentive compensation under our Bonus Plan, although
we did pay discretionary bonuses to our senior executives, which
averaged about 32% of the total cash compensation paid to our
senior executives (excluding Mr. Vanderhoven, who retired
on May 1, 2007, and, consequently, was not paid a
discretionary bonus).
Base
Salaries
Under our compensation program, we place lower emphasis on fixed
compensation for our senior executives and position their base
salaries at industry levels. Initially, each executives
base salary is set at a level intended to reflect that
executives experience, level of responsibility, job
classification and competence. Dramatic changes in base salaries
are uncommon and typically only occur if needed to adjust for
market movements, promotions or significant changes in
responsibility or individual performance. Each year, our
Compensation Committee determines the amount of increases in the
base salaries of our senior executives. Once every several
years, an in-depth analysis of each element of our senior
executive compensation program, including base salaries, is
performed by an independent consulting firm. In those years, our
Compensation Committee receives a report from the compensation
consulting firm that includes an analysis of an appropriate
range for the base salary of each of our senior executives.
Depending on the results of the analysis, our Compensation
Committee may elect to make a significant increase, or make a
lower than expected increase, in the base salary of one or more
of our senior executives in that year in order to align that
executives base salary with the market rate for the
position in question. In all other years, our Compensation
Committee establishes an overall budget for increases in the
base salaries of our senior executives as a group. Once this
overall budget is established, our Compensation Committee
confers with our Chief Executive Officer to discuss the
performance of each of our senior executives and, following that
discussion, our Compensation Committee determines the increase
in base salary for each of our senior executives, including our
Chief Executive Officer.
72
As noted above, in January of 2007, our Compensation Committee
directly engaged The Hay Group, Inc. to perform an in-depth
analyses of our senior executive compensation program. The
report prepared by The Hay Group, Inc. indicated that each of
our Named Executive Officers was earning total compensation in
excess of the average total compensation earned by similar
executives at the companies that The Hay Group, Inc. used for
comparison purposes. However, our Compensation Committee was of
the opinion that the report by The Hay Group, Inc. had placed
undue emphasis on the valuation for stock options granted in
2003 (and, in one case, 2004) and elected to grant raises
in base salaries to Messrs. Hale, Rostek and Treybig. Our
Compensation Committee felt that the valuation of stock options
was given too much weight because our practice of making one
large grant of stock options to each of our Named Executive
Officers, rather than annual grants, artificially skewed the
compensation expense reported for the year of the grant. For
2008, our Compensation Committee received summary market data
from Hewitt Associates, Inc., World at Work, Sibson Consulting,
Salary.com, Mercer Human Resources Consulting, LLC and Buck
Consultants and, on February 8, 2008, our Compensation
Committee approved increases in the annual base salaries
(effective as of March 1, 2008) of each of our Named
Executive Officers consistent with the market data it reviewed.
The following table sets forth the existing and new annual base
salary levels for each of our Named Executive Officers:
|
|
|
|
|
|
|
|
|
|
|
2007
|
|
|
2008
|
|
|
Richard K. Crump
|
|
$
|
390,000
|
|
|
$
|
405,000
|
|
John R. Beaver
|
|
|
205,000
|
|
|
|
223,250
|
|
Kenneth M. Hale
|
|
|
234,000
|
|
|
|
243,500
|
|
Paul C. Rostek
|
|
|
221,750
|
|
|
|
230,750
|
|
Walter B. Treybig
|
|
|
204,750
|
|
|
|
213,000
|
|
Annual
Incentive Compensation
In addition to base salaries, our senior executives and other
qualified employees can earn additional cash incentive
compensation each year under our Bonus Plan. The additional
compensation available under this plan is intended to reward the
achievement of annual corporate financial goals and personal
performance. Under our Bonus Plan, the amount paid to each of
our salaried employees, including our Named Executive Officers,
is based on our EBITDA and the employees Bonus
Target (which is a percentage of his or her base salary),
with 50% of that amount being subject to adjustment based on the
employees performance during the year.
Mr. Crumps Bonus Target is 100% and the Bonus Target
of each of our other Named Executive Officers is 40% (other than
Mr. Vanderhoven, who retired on May 1, 2007, and
previously had a Bonus Target of 50%). If we attain our
threshold level of EBITDA ($35 million of
EBITDA) in any calendar year, each of our salaried employees,
including our Named Executive Officers, is entitled to a bonus
of up to 50% of their Bonus Target. If we attain our
target level of EBITDA ($70 million of EBITDA)
in any calendar year, each of our salaried employees is entitled
to a bonus of up to 100% of their Bonus Target. Finally, if we
attain our maximum level of EBITDA
($140 million of EBITDA) in any calendar year, each of our
salaried employees is entitled to a bonus of up to 200% of their
Bonus Target. No additional amounts are payable under our Bonus
Plan for exceeding $140 million of EBITDA in any calendar
year. If our EBITDA is between any of the specified levels, the
maximum payment under the Bonus Plan for each salaried employee
is pro-rated between the two levels on a straight-line basis.
For example, if we attained $52.5 million in EBITDA in a
year, each of our salaried employees would be entitled to a
bonus of up to 75% of their Bonus Target. EBITDA, which we
define as income/(loss) before tax, interest expense (net),
depreciation, amortization and write-downs is a non-GAAP measure
we use as an approximation of cash flow from operations before
tax. Our definition of EBITDA may differ from that of other
companies. Our Compensation Committee is currently considering
revising the manner in which bonuses are earned under our Bonus
Plan to reflect our exit from the styrene business, although no
determination has been made as to what, if any, changes will be
made.
Our Bonus Plan is administered by our Compensation Committee,
who determines the amount of annual incentive compensation paid
to each of our senior executive officers, including the Named
Executive Officers, in those years when we achieve the minimum
level of financial performance required for a payment under our
Bonus Plan. In evaluating an individuals performance, our
Compensation Committee relies, to some extent, on the assessment
by our Chief Executive Officer of that individual. The maximum
amount payable under our Bonus Plan for any year is not
determined until the audit of our financial statements has been
completed and our
Form 10-K
for
73
that year has been approved by our Audit Committee and our
Board. Generally, a senior executive must still be employed by
us at the time the bonus is paid in order to receive a bonus
payment. We believe that the potential to earn above market
bonuses in any given year helps us attract, motivate and retain
talented and productive senior executives and supports our
short-term goals for that year. In addition, by requiring
minimum levels of financial performance in order to earn a bonus
under our Bonus Plan, and making 50% of the maximum bonus
payable dependent upon individual performance, we believe that
our Bonus Plan provides an effective tool for recognizing both
individual performance and our overall corporate performance.
On January 27, 2006, our Compensation Committee amended our
Bonus Plan to provide our salaried employees the ability to earn
a bonus based on their individual performance, irrespective of
our financial performance during the year. However, if a bonus
is paid based on achieving our financial performance targets, no
additional bonus is paid under this provision of our Bonus Plan.
Our Compensation Committee considered a variety of factors
before electing to make this change to our Bonus Plan, including
the marked increase in compensation paid to, and intense
competition to attract and retain, employees in the
petrochemicals and oil and gas industries resulting from the
dramatic increase in oil prices over the last several years and
the reconstruction efforts following Hurricane Katrina. Our
Chief Executive Officer and our four Senior Vice Presidents are
excluded, however, from this new portion of our Bonus Plan.
Whether a bonus is paid to our Chief Executive Officer or any of
our Senior Vice Presidents in any year when we do not attain the
minimum financial performance required for a payment under our
Bonus Plan, and if so, the amount to be paid, is determined by
our Compensation Committee at that time based upon its review of
their individual performance during the year in question.
For 2007, we did not achieve the threshold level of EBITDA
required for the payment of a bonus under our Bonus Plan.
However, on February 8, 2008, our Compensation Committee
authorized the payment of discretionary bonuses to each of our
Named Executive Officers in recognition of their significant
efforts during 2007 in connection with, among other things,
successfully refinancing our long-term indebtedness in March of
2007, successfully consummating the long-term exclusive styrene
supply agreement between us and NOVA in November of 2007 and
achieving significant progress in the pursuit of numerous
strategic transactions designed to more fully utilize the
infrastructure at our Texas City facility. The following table
sets forth the amount of bonuses paid to our Named Executive
Officers:
|
|
|
|
|
Richard K. Crump
|
|
$
|
390,000
|
|
John R. Beaver
|
|
|
82,000
|
|
Kenneth M. Hale
|
|
|
118,600
|
|
Paul C. Rostek
|
|
|
88,700
|
|
Walter B. Treybig
|
|
|
81,900
|
|
Our Compensation Committee also authorized the payment of
discretionary bonuses to each of our named Executive Officers on
February 24, 2006, even though we did not attain the
minimum level of EBITDA in 2005 required for the payment of a
bonus under our Bonus Plan. The discretionary bonuses were paid
to our Named Executive Officers to reward them for achieving our
goal of reducing fixed costs by at least $20 million during
2005.
In evaluating the amounts of bonuses paid to each of our Named
Executive Officers for each year, whether they were paid under
our Bonus Plan or were discretionary, our Compensation Committee
and our Board considered numerous factors, including, among
others, his influence in the development and implementation of
the results obtained in connection with the refinancing of our
long-term indebtedness, our long-term exclusive styrene supply
agreement with NOVA and our cost reduction strategies, his
performance in driving results, his dedication to and
participation in maintaining an ethical culture and his
responsibility for maintaining high standards for environmental,
health and safety performance. In addition, in setting these
bonus amounts, our Compensation Committee gave due regard to its
philosophy that our management team functions as a team and that
our success is dependent on the efforts of all of the members of
our senior management as a group.
Stock-Based
Compensation
Under the stock-based portion of our senior executive
compensation program, our senior executives and other key
employees are eligible for awards of incentive stock options,
non-qualified stock options, stock appreciation
74
rights, restricted stock awards, performance awards and phantom
stock awards under our 2002 Stock Plan. Our Compensation
Committee or our full Board determines the terms and amounts of
each award granted under our 2002 Stock Plan based upon a
variety of factors, including:
|
|
|
|
|
the recipients level of responsibility and job
classification;
|
|
|
|
the recipients job performance;
|
|
|
|
the recipients present and potential contributions to our
long-term success; and
|
|
|
|
the extent that the base salary of the recipient is below
industry levels based on the compensation survey described above.
|
The primary purpose of our stock-based compensation program is
to provide our senior executives and other key employees with
incentives to concentrate on our performance over the long term.
We believe that stock-based compensation is an appropriate and
effective method for aligning the interests of our senior
executives with our long-term goal of maximizing stockholder
value because our senior executives will not receive any benefit
from this form of compensation unless our overall value, based
on stock prices, increases over time.
Our Compensation Committee or our Board specifies the number of
shares covered by each award under our 2002 Stock Plan and the
associated vesting schedule. A three-year vesting schedule has
been used for all awards that have been granted under our 2002
Stock Plan. We believe that this length of vesting schedule
provides an incentive to our senior executives to increase
stockholder value over time, since the full benefit of the
awards cannot be realized unless there is appreciation in stock
value over a number of years. While we impose a three-year
vesting schedule, options granted under our 2002 Stock Plan
become fully exercisable in the event of the optionees
termination of employment by reason of death, disability or
retirement, or in the event of a change of control,
which includes the acquisition of beneficial ownership by any
person (other than Resurgence and its affiliates) of at least
50% of our outstanding common stock or at least 50% of the
combined voting power of all our outstanding securities entitled
to vote generally in the election of directors, (ii) the
sale, lease, exchange or transfer of substantially all of our
properties and assets or (iii) our merger or consolidation
with another entity if the holders of our existing voting
securities own less than a majority of the voting securities of
the surviving entity.
Historically, only one grant of awards under our 2002 Stock Plan
has been made to any individual. Our 2002 Stock Plan was
authorized and established on December 19, 2002, when we
emerged from bankruptcy protection under Chapter 11 of the
Bankruptcy Code. Shortly thereafter, on February 11, 2003,
our Compensation Committee and our Board made an initial grant
of stock options to our executive officers and certain other
employees in amounts our Compensation Committee felt were
adequate to provide the appropriate incentives and achieve the
desired alignment with the long-term interests of our
stockholders. Our Compensation Committee has only approved three
additional grants of any award under our 2002 Stock Plan since
that time, which grants were made (i) on November 5,
2004 to Mr. Rostek in connection with Mr. Rostek being
promoted to our Senior Vice President Commercial so
that his overall compensation and incentives would be aligned
with those of our other Named Executive Officers, (ii) on
May 2, 2008 to Mr. Beaver in connection with his promotion
to Senior Vice President Chief Financial
Officer for similar reasons and (iii) on May 27, 2008
to Mr. Genova in connection with his engagement as our President
and Chief Executive Officer. All of the outstanding options held
by our Named Executive Officers have vested and are exercisable.
No option may be exercised after the tenth anniversary of the
date of grant or the earlier termination of the option. All
options have been granted with an exercise price at or above the
fair market value of a share of our common stock on the date of
grant.
We do not have any program, plan or practice in place for
selecting grant dates for awards under our 2002 Stock Plan in
coordination with the release of material non-public
information. With three exceptions, all of the awards under our
2002 Stock Plan were granted on February 11, 2003, at the
first meeting of our new Board following our emergence from
bankruptcy in December of 2002. The other awards were granted in
connection with the promotion of Mr. Rostek to our Senior
Vice President Commercial, the promotion of
Mr. Beaver to our Senior Vice President Chief
Financial Officer and the engagement of Mr. Genova as our
President and Chief Executive Officer. Each of these awards was
a grant of non-qualified stock options to acquire shares of our
common stock at an exercise price of $31.60 per share. Our Board
based the exercise price for each of these awards on an
approximation of the amount invested by our new stockholders in
connection with our emergence from bankruptcy That amount
75
was far in excess of the trading price of a share of our common
stock on the over-the-counter market on each of the two grant
dates. Neither our Board nor our Compensation Committee is
prohibited from granting options at times when they are in
possession of material non-public information. However, no
inside information was taken into account in determining the
number of options previously awarded or the exercise price for
those awards, and we did not time the release of any
material non-public information to affect the value of those
awards.
Under our Code of Ethics and Conduct, all of our employees,
including each of the Named Executive Officers and directors,
are prohibited from directly or indirectly purchasing or selling
any of our securities while they are in possession of material
inside information, communicating any material inside
information to others who may trade in our securities or
recommending to others that they purchase or sell any of any
securities while they are in the possession of material inside
information. Generally, all of our directors, officers and
members of senior management are required to pre-clear all sales
and purchases of our securities through our Legal Department.
Our other employees only need to pre-clear sales and purchases
of our securities that are intended to take place outside a
window period through our Legal Department. For this purpose,
the only window periods are the
30-day
period commencing one week after our annual report has been
mailed to stockholders and the
15-day
period beginning on the third business day following the
official release of our quarterly or annual financial results.
Notwithstanding the foregoing policies, our General Counsel may,
with the approval of our Corporate Governance Committee, exempt
any director from these pre-clearance procedures if our General
Counsel reasonably believes that such director possesses
adequate sophistication and access to legal advisors to make his
or her own determination of whether a given sale or purchase of
our securities is otherwise in compliance with these policies.
Our General Counsel and our Corporate Governance Committee have
exempted all of our directors who are employed by Resurgence
from these pre-clearance procedures. Our Code of Ethics and
Conduct also discourages
in-and-out
trading in our securities and prohibits any of our directors,
officers or employees from engaging in short sales or sales
against the box of any of our securities or trading in puts,
calls or options, in each case, unless approved by a majority of
the disinterested members of our Board.
Tax
Treatment
Our Compensation Committee considers the anticipated tax
treatment of our executive compensation program when setting
levels and types of compensation. Section 162(m) of the
Internal Revenue Code generally disallows a tax deduction to
public companies for compensation paid to a companys chief
executive officer or any of its other four most highly
compensated executive officers in excess of $1 million in
any year, with certain performance-based compensation being
specifically exempt from this deduction limit. In 2007, none of
our employees subject to this limit received compensation in
excess of $1 million. Consequently, the requirements of
Section 162(m) should not affect the tax deductions
available to us in connection with our senior executive
compensation program for 2007.
76
Compensation
Tables
Summary
Compensation Table
The following table shows certain information regarding the
compensation we paid each individual who served as our Chief
Executive Officer or our Chief Financial Officer (or acted in a
similar capacity during 2007) and our other three most
highly compensated executive officers during 2007, or our Named
Executive Officers, for fiscal years ended December 31,
2007, December 31, 2006 and December 31, 2005,
respectively. In 2007, base salaries accounted for approximately
61.27% of the total cash compensation paid to our Named
Executive Officers.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Change in
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Pension
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Value and
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Non-
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Non-Equity
|
|
|
Qualified
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Incentive
|
|
|
Deferred
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Plan
|
|
|
Compen-
|
|
|
All Other
|
|
|
|
|
|
|
Fiscal
|
|
|
|
|
|
|
|
|
Option
|
|
|
Compen-
|
|
|
sation
|
|
|
Compen-
|
|
|
|
|
Name And Principal Position
|
|
Year
|
|
|
Salary(2)
|
|
|
Bonus
|
|
|
Awards(3)
|
|
|
sation
|
|
|
Earnings(4)
|
|
|
sation(5)
|
|
|
Total
|
|
|
Richard K.
Crump(1)
|
|
|
2007
|
|
|
$
|
390,000
|
|
|
$
|
390,000
|
|
|
$
|
0
|
|
|
$
|
0
|
|
|
$
|
25,341
|
|
|
$
|
28,589
|
|
|
$
|
833,930
|
|
President and Chief
|
|
|
2006
|
|
|
|
388,333
|
|
|
|
0
|
|
|
|
30,973
|
|
|
|
267,003
|
|
|
|
46,588
|
|
|
|
28,145
|
|
|
|
761,042
|
|
Executive Officer
|
|
|
2005
|
|
|
|
378,500
|
|
|
|
46,875
|
|
|
|
294,245
|
|
|
|
0
|
|
|
|
74,359
|
|
|
|
25,562
|
|
|
|
819,541
|
|
John R.
Beaver(6)
|
|
|
2007
|
|
|
|
190,617
|
|
|
|
82,000
|
|
|
|
0
|
|
|
|
0
|
|
|
|
0
|
|
|
|
13,879
|
|
|
|
286,496
|
|
Senior VP Finance and
|
|
|
2006
|
|
|
|
156,583
|
|
|
|
7,500
|
|
|
|
5,807
|
|
|
|
37,812
|
|
|
|
4,443
|
|
|
|
11,424
|
|
|
|
223,569
|
|
Chief Financial Officer
|
|
|
2005
|
|
|
|
149,250
|
|
|
|
18,750
|
|
|
|
55,171
|
|
|
|
0
|
|
|
|
7,091
|
|
|
|
10,178
|
|
|
|
240,440
|
|
Paul G.
Vanderhoven(7)
|
|
|
2007
|
|
|
|
86,640
|
|
|
|
0
|
|
|
|
0
|
|
|
|
0
|
|
|
|
5,511
|
|
|
|
459,727
|
|
|
|
551,878
|
|
Senior VP Finance and
|
|
|
2006
|
|
|
|
255,167
|
|
|
|
0
|
|
|
|
8,518
|
|
|
|
87,974
|
|
|
|
26,504
|
|
|
|
16,316
|
|
|
|
394,479
|
|
Chief Financial Officer
|
|
|
2005
|
|
|
|
244,417
|
|
|
|
40,625
|
|
|
|
80,917
|
|
|
|
0
|
|
|
|
42,303
|
|
|
|
15,662
|
|
|
|
423,924
|
|
Kenneth M. Hale
|
|
|
2007
|
|
|
|
232,042
|
|
|
|
118,600
|
|
|
|
0
|
|
|
|
0
|
|
|
|
0
|
|
|
|
15,269
|
|
|
|
365,911
|
|
Senior VP, General
|
|
|
2006
|
|
|
|
220,583
|
|
|
|
0
|
|
|
|
7,098
|
|
|
|
60,863
|
|
|
|
3,562
|
|
|
|
15,335
|
|
|
|
307,441
|
|
Counsel and Secretary
|
|
|
2005
|
|
|
|
209,583
|
|
|
|
34,375
|
|
|
|
67,431
|
|
|
|
0
|
|
|
|
5,685
|
|
|
|
14,440
|
|
|
|
331,514
|
|
Paul C. Rostek
|
|
|
2007
|
|
|
|
220,000
|
|
|
|
88,700
|
|
|
|
32,972
|
|
|
|
0
|
|
|
|
0
|
|
|
|
14,604
|
|
|
|
356,276
|
|
Senior VP Commercial
|
|
|
2006
|
|
|
|
209,667
|
|
|
|
0
|
|
|
|
89,024
|
|
|
|
57,851
|
|
|
|
9,879
|
|
|
|
14,474
|
|
|
|
380,895
|
|
|
|
|
2005
|
|
|
|
200,458
|
|
|
|
34,375
|
|
|
|
197.832
|
|
|
|
0
|
|
|
|
13,232
|
|
|
|
14,087
|
|
|
|
459,984
|
|
Walter B. Treybig
|
|
|
2007
|
|
|
|
203,125
|
|
|
|
81,900
|
|
|
|
0
|
|
|
|
0
|
|
|
|
627
|
|
|
|
13,603
|
|
|
|
299,255
|
|
Senior VP Manufacturing
|
|
|
2006
|
|
|
|
193,583
|
|
|
|
0
|
|
|
|
6,453
|
|
|
|
53,401
|
|
|
|
7,161
|
|
|
|
12,923
|
|
|
|
273,521
|
|
|
|
|
2005
|
|
|
|
185,250
|
|
|
|
34,375
|
|
|
|
61,301
|
|
|
|
0
|
|
|
|
11,429
|
|
|
|
15,354
|
|
|
|
307,709
|
|
|
|
|
(1) |
|
Mr. Crump retired effective
May 27, 2008. Prior to that time, Mr. Crump served as our
President and Chief Executive Officer.
|
|
(2) |
|
Includes amounts deferred under our
401(k) Savings and Investment Plan.
|
|
(3) |
|
Please refer to Footnote 2 of our
Consolidated Financial Statements for the fiscal year ended
December 31, 2007 included in this prospectus for a
description of the assumptions used in determining compensation
cost for the stock options reflected in this column which were
granted in 2003 or, in the case of Mr. Rostek, in 2004.
|
|
(4) |
|
Pension value changes in 2007 for
Messrs Beaver, Hale and Rostek were -$575, -$576 and -$16,433,
respectively.
|
|
(5) |
|
Includes (i) values of group
life insurance provided by us in excess of $50,000,
(ii) amounts paid for clubs and associations,
(iii) premiums for executive life insurance paid by us,
(iv) matching contributions paid by us under our 401(k)
Savings and Investment Plan and (v) values of parking paid
by us in excess of Internal Revenue Service limitations, as
follows:
|
77
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Fiscal
|
|
|
|
Clubs and
|
|
401(k) Matching
|
|
Executive
|
|
|
Year
|
|
Group Life
|
|
Associations
|
|
Contributions
|
|
Parking
|
|
Richard K. Crump
|
|
|
2007
|
|
|
$
|
7,326
|
|
|
$
|
0
|
|
|
$
|
13,500
|
|
|
$
|
685
|
|
|
|
|
2006
|
|
|
|
7,277
|
|
|
|
0
|
|
|
|
13,200
|
|
|
|
590
|
|
|
|
|
2005
|
|
|
|
4,615
|
|
|
|
585
|
|
|
|
12,600
|
|
|
|
684
|
|
John R. Beaver
|
|
|
2007
|
|
|
|
746
|
|
|
|
1,240
|
|
|
|
11,437
|
|
|
|
456
|
|
|
|
|
2006
|
|
|
|
614
|
|
|
|
1,415
|
|
|
|
9,395
|
|
|
|
0
|
|
|
|
|
2005
|
|
|
|
388
|
|
|
|
835
|
|
|
|
8,955
|
|
|
|
0
|
|
Paul G. Vanderhoven
|
|
|
2007
|
|
|
|
613
|
|
|
|
0
|
|
|
|
5,198
|
|
|
|
228
|
|
|
|
|
2006
|
|
|
|
1,616
|
|
|
|
910
|
|
|
|
13,200
|
|
|
|
590
|
|
|
|
|
2005
|
|
|
|
1,543
|
|
|
|
835
|
|
|
|
12,600
|
|
|
|
684
|
|
Kenneth M. Hale
|
|
|
2007
|
|
|
|
944
|
|
|
|
825
|
|
|
|
13,500
|
|
|
|
0
|
|
|
|
|
2006
|
|
|
|
600
|
|
|
|
1,535
|
|
|
|
13,200
|
|
|
|
0
|
|
|
|
|
2005
|
|
|
|
565
|
|
|
|
1,340
|
|
|
|
12,535
|
|
|
|
0
|
|
Paul C. Rostek
|
|
|
2007
|
|
|
|
1,366
|
|
|
|
0
|
|
|
|
12,553
|
|
|
|
685
|
|
|
|
|
2006
|
|
|
|
1,304
|
|
|
|
0
|
|
|
|
12,580
|
|
|
|
590
|
|
|
|
|
2005
|
|
|
|
809
|
|
|
|
585
|
|
|
|
12,008
|
|
|
|
685
|
|
Walter B. Treybig
|
|
|
2007
|
|
|
|
1,250
|
|
|
|
165
|
|
|
|
12,188
|
|
|
|
0
|
|
|
|
|
2006
|
|
|
|
1,193
|
|
|
|
115
|
|
|
|
11,615
|
|
|
|
0
|
|
|
|
|
2005
|
|
|
|
741
|
|
|
|
500
|
|
|
|
11,096
|
|
|
|
0
|
|
|
|
|
|
|
Mr. Crumps All
Other Compensation includes executive life insurance
premiums paid by us of $7,078 in each of 2007, 2006 and 2005.
Mr. Vanderhovens All Other Compensation
includes payment of $68,188 for unused vacation time and a
severance payment of $385,500 paid upon
Mr. Vanderhovens retirement from employment.
Mr. Treybigs All Other Compensation
includes $3,017 paid in 2005 for travel expenses related to
obtaining his Masters in Business Administration Degree from
Tulane University.
|
|
(6) |
|
Mr. Beaver was promoted to our
Senior Vice President Financial and Chief Financial
Officer on May 4, 2007. Prior to that, Mr. Beaver
served as one of our Vice Presidents and our Corporate
Controller. Consequently, Mr. Beavers compensation
for 2007 reflects compensation paid to him in his capacity as
our Senior Vice President Finance and Chief
Financial Officer for approximately eight months and
compensation paid to him in his capacity as one of our Vice
Presidents and our Corporate Controller for approximately four
months, and Mr. Beavers compensation for 2006 and
2005 reflects compensation paid to him in his capacity as one of
our Vice Presidents and our Corporate Controller.
|
|
(7) |
|
Mr. Vanderhoven retired on
May 1, 2007. Prior to that time, Mr. Vanderhoven
served as our Senior Vice President Finance and
Chief Financial Officer.
|
Indemnification
Agreements
We have entered into indemnification agreements with each of our
directors and executive officers, including each of our Named
Executive Officers. These indemnification agreements require us
to, among other things, indemnify these individuals against
certain liabilities that may arise in connection with their
status or service as one of our directors or executive officers
and to advance their expenses incurred as a result of any
proceeding for which they may be entitled to indemnification.
These indemnification agreements are intended to provide
indemnification rights to the fullest extent permitted under the
General Corporation Law of the State of Delaware and are in
addition to any other rights these individuals may have under
our organizational documents or applicable law. We believe that
these indemnification agreements enhance our ability to attract
and retain knowledgeable and experienced directors and executive
officers.
Employment
Agreements
Mr. Genovas employment as our President and Chief
Executive Officer is governed by an Employment Agreement dated
effective as of May 27, 2008. Under his employment
agreement, Mr. Genova earns a base salary initially set at
$395,000 per year (subject to annual increases at the discretion
of our Board of Directors) and he participates in our bonus and
incentive plans and all of our other employee benefit plans made
available to our executive officers generally.
Under his employment agreement, Mr. Genova is eligible for
severance benefits if his employment is terminated in specified
ways and for specified reasons. That termination must either
result from the expiration of the
78
term of his employment agreement, Mr. Genova resigning for
Good Reason or Mr. Genova being terminated by
us without Cause (as these terms are defined in his
employment agreement). The agreement is initially for a
three-year
term with automatic one-year extensions each year unless we
elect to stop the automatic extensions. If
Mr. Genovas employment with us is terminated in a way
that results in his being eligible for severance benefits under
his agreement with us, Mr. Genova is entitled to a lump sum
payment determined by multiplying his annual base salary plus
his Target Bonus (as defined in the agreement) by 2.75. Once the
base amount of the lump sum payment is determined, the final
amount of the lump sum payment depends on whether a Change
of Control (as defined in the agreement) occurs during the
period starting two years prior to the termination of his
employment and ending 180 days after the date of the
termination of his employment. If a Change of Control has not
(and does not) occur within that specified period, the amount of
the lump sum payment is reduced by 50%. However, if the lump sum
payment is payable in connection with a Change of Control, up to
50% of the lump sum payment is subject to repayment by
Mr. Genova if he, within one year after the termination of
his employment, owns, manages, operates or controls (or joins in
the ownership, management, operation or control of), or becomes
employed by or connected in any manner with, any business
engaged in the manufacture or sale of acetic acid acetic acid,
propylene, biodiesel or renewable fuels anywhere in Texas or any
of its contiguous states.
Currently, if Mr. Genova terminated his employment for Good
Reason or was terminated by Sterling for Cause, he would be paid
a lump sum amount equal to $2,172,500 if a Change of Control
occurs during his protection period or $1,086,250 if no Change
of Control occurs during his protection period.
In addition to the lump sum payment, Mr. Genova would also
be entitled to his accrued but unpaid salary, compensation for
unused vacation time and any unpaid vested benefits earned or
accrued under any of Sterlings benefit plans (other than
qualified plans). Also, for a period of 18 months,
Mr. Genova (and the members of his family who are currently
eligible to receive benefits under our primary group medical
plan) would continue to be covered by all of our life, health
care, medical and dental insurance plans and programs (excluding
disability) to the extent we continue to provide such coverage
to our executive officers generally, as long as he makes a
timely COBRA election and pays the regular employee premiums
required under our plans and programs. In addition, our
obligation to continue to provide coverage under our plans and
programs with respect to any particular type of plan or program
ends if and when Mr. Genova becomes eligible for similar
coverage under a subsequent employers plan without being
subject to any preexisting-condition exclusion under that plan.
If any payment or distribution to Mr. Genova under his
employment agreement is subject to excise tax pursuant to
Section 4999 of the Internal Revenue Code, he is also
entitled to receive a
gross-up
payment from us in an amount such that, after payment by
Mr. Genova of all taxes on the
gross-up
payment, the amount of the
gross-up
payment remaining is equal to the lesser of (i) the excise
tax imposed under Section 4999 of the Internal Revenue Code
and (ii) 25% of the sum of Mr. Genovas annual
base compensation plus his Bonus Target under our Bonus Plan for
the year of payment.
Grants
of Plan-Based Awards
None of our Named Executive Officers were granted any equity
incentive plan awards, other stock awards or other option awards
in 2007 under our 2002 Stock Plan discussed above in
Compensation Discussion & Analysis, or
otherwise. The following table provides information with respect
to each grant of an award made to a Named Executive Officer in
2007 under our Bonus Plan.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Estimated Possible Payouts Under
|
|
|
|
Non-Equity Incentive Plan Awards
|
|
Name
|
|
Threshold
|
|
|
Target
|
|
|
Maximum
|
|
|
Richard K. Crump
|
|
$
|
195,000
|
|
|
$
|
390,000
|
|
|
$
|
780,000
|
|
John R. Beaver
|
|
|
41,000
|
|
|
|
82,000
|
|
|
|
164,000
|
|
Paul G. Vanderhoven
|
|
|
64,250
|
|
|
|
128,500
|
|
|
|
257,000
|
|
Kenneth M. Hale
|
|
|
46,800
|
|
|
|
93,600
|
|
|
|
187,200
|
|
Paul C. Rostek
|
|
|
44,350
|
|
|
|
88,700
|
|
|
|
177,400
|
|
Walter B. Treybig
|
|
|
40,950
|
|
|
|
81,900
|
|
|
|
163,800
|
|
79
As noted below under Non-Equity Incentive Plan
Information Bonus Plan, we did not exceed the
threshold level of EBITDA required for a payment under our Bonus
Plan in 2007. However, on February 8, 2008, our
Compensation Committee did authorize the payment of
discretionary bonuses to each of our Named Executive Officers
(other than Mr. Vanderhoven, who retired on May 1,
2007).
Non-Equity
Incentive Plan Information Bonus Plan
As discussed above in Compensation Discussion &
Analysis, we maintain a Bonus Plan that pays additional
compensation to our salaried employees in the form of a cash
bonus. The amount of additional incentive compensation available
under our Bonus Plan is based on our EBITDA and formulae set for
the individuals job classification (with individuals
having greater management responsibility having the opportunity
to earn larger percentages). Payments under our Bonus Plan are
also impacted by individual performance, with 50% of the maximum
bonus amount that can be earned by each senior executive being
subject to adjustment based on that executives performance
during the year. If a bonus is earned under our Bonus Plan in
any year, the bonus is paid after the audit of our financial
statements for that year has been completed.
We did not exceed the threshold level of EBITDA required for a
payment under our Bonus Plan in 2007. However, on
February 8, 2008, our Compensation Committee authorized the
payment of discretionary bonuses to each of our Named Executive
Officers (other than Mr. Vanderhoven, who retired on
May 1, 2007) in recognition of their significant
efforts during 2007 in connection with, among other things,
successfully refinancing our long-term indebtedness in March of
2007, successfully consummating the long-term exclusive styrene
supply agreement between us and NOVA in November of 2007 and
achieving significant progress in the pursuit of numerous
strategic transactions designed to more fully utilize the
infrastructure at our Texas City facility. The following table
sets forth the amount of bonuses paid to our Named Executive
Officers:
|
|
|
|
|
Richard K. Crump
|
|
$
|
390,000
|
|
John R. Beaver
|
|
|
82,000
|
|
Kenneth M. Hale
|
|
|
118,600
|
|
Paul C. Rostek
|
|
|
88,700
|
|
Walter B. Treybig
|
|
|
81,900
|
|
Equity
Incentive Plan Information 2002 Stock Plan
Under our 2002 Stock Plan, our Board or Compensation Committee
may issue stock options, stock awards, stock appreciation rights
or stock units to our senior executives, other key employees and
consultants. Our 2002 Stock Plan is administered by our Board,
in consultation with our Compensation Committee, and may be
amended or modified from time to time by our Board. Our Board or
our Compensation Committee determines the exercise price of
stock options, any applicable vesting provisions and the other
terms and provisions of each award granted under our 2002 Stock
Plan. Options granted under our 2002 Stock Plan become fully
exercisable in the event of the optionees termination of
employment by reason of death, disability or retirement, and may
become fully exercisable in the event of a change of
control. For purposes of our 2002 Stock Plan, a
change of control means:
|
|
|
|
|
the acquisition of beneficial ownership by any person (other
than Resurgence and its affiliates) of at least 50% of our
outstanding common stock or at least 50% of the combined voting
power of all our outstanding securities entitled to vote
generally in the election of directors;
|
|
|
|
the sale, lease, exchange or transfer of substantially all of
our properties and assets; or
|
|
|
|
our merger or consolidation with another entity if the holders
of our existing voting securities own less than a majority of
the voting securities of the surviving entity.
|
In no event can any option be exercised after the tenth
anniversary of the date of grant or the earlier termination of
the option. We have reserved 363,914 shares of our common
stock for issuance under our 2002 Stock Plan (subject to
adjustment).
Under our 2002 Stock Plan, we have granted awards on only four
occasions. On February 11, 2003, we granted options to
purchase an aggregate of 326,000 shares of our common
stock, at an exercise price of $31.60 per share, to
80
our senior executives and certain of our other key employees,
all of which vested over the next three years in three equal
installments. On November 5, 2004, we granted options to
purchase 27,500 shares of our common stock, at an exercise
price of $31.60 per share, to Mr. Rostek in connection with
his promotion to Senior Vice President Commercial.
Mr. Rosteks stock options also had a three-year
vesting schedule, with the final installment vesting on
November 5, 2007. On May 2, 2008, we granted options
to purchase 5,000 shares of our common stock, at an
exercise price of $31.60 per share, to Mr. Beaver in
connection with his promotion to Senior Vice
President Chief Financial Officer.
Mr. Beavers options also have a three year vesting
schedule, with the first installment vesting on March 2,
2009. When Mr. Genova signed his employment agreement with us in
May 2008, we granted Mr. Genova options to purchase
120,000 shares of our common stock at an exercise price of
$31.60 per share. These options also have a
three-year
vesting schedule, with the first installment vesting and
becoming exercisable on May 27, 2009. As of
December 31, 2007, of the options awarded under our 2002
Stock Plan, 15,833 of those options had been exercised and
92,167 of those options had lapsed or expired without being
exercised.
The following table provides information regarding securities
authorized for issuance under our 2002 Stock Plan as of
December 31, 2007:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Number of Securities
|
|
|
|
|
|
|
|
|
|
Remaining
|
|
|
|
|
|
|
Weighted-Average
|
|
|
Available for Future
|
|
|
|
Number of Securities to
|
|
|
Exercise
|
|
|
Issuance Under
|
|
|
|
be Issued Upon Exercise
|
|
|
Price of Outstanding
|
|
|
Equity Compensation Plans
|
|
|
|
of Outstanding Options,
|
|
|
Options, Warrants
|
|
|
(Excluding Securities
|
|
Plan Category
|
|
Warrants and Rights
|
|
|
and Rights
|
|
|
Reflected in Column (a))
|
|
|
Equity compensation plans approved by security
holders(1)
|
|
|
245,500
|
|
|
$
|
31.60
|
|
|
|
118,414
|
|
Equity compensation plans not approved by security holders
|
|
|
|
|
|
|
|
|
|
|
|
|
Total
|
|
|
245,500
|
|
|
$
|
31.60
|
|
|
|
118,414
|
|
|
|
|
(1) |
|
Our 2002 Stock Plan was authorized
and established under our confirmed Joint Plan of Reorganization
Under Chapter 11, Title 11, United States Code, or our
Plan of Reorganization, which became effective on
December 19, 2002. Our Plan of Reorganization provides
that, without any further act or authorization, confirmation of
our Plan of Reorganization and entry of the confirmation order
is deemed to satisfy all applicable federal and state law
requirements and all listing standards of any securities
exchange for approval by the board of directors or the
stockholders of our 2002 Stock Plan. No additional stockholder
approval of our 2002 Stock Plan has been obtained.
|
Outstanding
Equity Awards at 2007 Fiscal Year-End
The following table provides information on the value of
unexercised stock options as of December 31, 2007 held by
each of our Named Executive Officers. There were no exercises of
options or stock appreciation rights during the 2007 fiscal year
by any of our Named Executive Officers, and none of our Named
Executive Officers held any shares or units of stock or stock
appreciation rights at December 31, 2007.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Option Awards
|
|
|
|
|
|
|
|
|
|
Equity
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Incentive Plan
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Awards:
|
|
|
|
|
|
|
|
|
|
Number of
|
|
|
Number of
|
|
|
Number of
|
|
|
|
|
|
|
|
|
|
Securities
|
|
|
Securities
|
|
|
Securities
|
|
|
|
|
|
|
|
|
|
Underlying
|
|
|
Underlying
|
|
|
Underlying
|
|
|
|
|
|
|
|
|
|
Unexercised
|
|
|
Unexercised
|
|
|
Unexercised
|
|
|
Option
|
|
|
Option
|
|
|
|
Options
|
|
|
Options
|
|
|
Unearned
|
|
|
Exercise
|
|
|
Expiration
|
|
Name
|
|
Exercisable
|
|
|
Unexercisable
|
|
|
Options
|
|
|
Price
|
|
|
Date
|
|
|
Richard K. Crump
|
|
|
120,000
|
|
|
|
0
|
|
|
|
0
|
|
|
$
|
31.60
|
|
|
|
02/11/13
|
|
John R. Beaver
|
|
|
22,500
|
|
|
|
0
|
|
|
|
0
|
|
|
$
|
31.60
|
|
|
|
02/11/13
|
|
Paul G. Vanderhoven
|
|
|
0
|
|
|
|
0
|
|
|
|
0
|
|
|
|
|
|
|
|
|
|
Kenneth M. Hale
|
|
|
27,500
|
|
|
|
0
|
|
|
|
0
|
|
|
$
|
31.60
|
|
|
|
02/11/13
|
|
Paul C. Rostek
|
|
|
27,500
|
|
|
|
0
|
|
|
|
0
|
|
|
$
|
31.60
|
|
|
|
11/05/14
|
|
Walter B. Treybig
|
|
|
25,000
|
|
|
|
0
|
|
|
|
0
|
|
|
$
|
31.60
|
|
|
|
02/11/13
|
|
81
Option
Exercises and Stock Vesting
None of our Named Executive Officers exercised any stock options
or stock appreciation rights during the 2007 fiscal year or held
any restricted stock, stock appreciation rights or similar
equity awards during the 2007 fiscal year.
Pension
Benefits
The following table provides information with respect to each
plan that provides for payments or other benefits at, following
or in connection with the retirement of our Named Executive
Officers.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Number
|
|
|
Present Value
|
|
|
|
|
|
|
|
|
of Years
|
|
|
of
|
|
|
Payments
|
|
|
|
|
|
Credited
|
|
|
Accumulated
|
|
|
During Last
|
|
Name
|
|
Plan Name
|
|
Service
|
|
|
Benefit(1)
|
|
|
Fiscal Year
|
|
|
Richard K. Crump
|
|
Salaried Employees Pension Plan
|
|
|
19
|
|
|
|
481,604
|
|
|
|
0
|
|
|
|
Pension Benefit Equalization Plan
|
|
|
19
|
|
|
|
0
|
|
|
|
0
|
|
|
|
Supplemental Employee Retirement Plan
|
|
|
19
|
|
|
|
400,556
|
|
|
|
0
|
|
John R. Beaver
|
|
Salaried Employees
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Pension Plan
|
|
|
12
|
|
|
|
81,132
|
|
|
|
0
|
|
|
|
Pension Benefit Equalization Plan
|
|
|
12
|
|
|
|
0
|
|
|
|
0
|
|
|
|
Supplemental Employee Retirement Plan
|
|
|
12
|
|
|
|
0
|
|
|
|
0
|
|
Paul G. Vanderhoven
|
|
Salaried Employees
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Pension Plan
|
|
|
28
|
|
|
|
429,164
|
|
|
|
0
|
|
|
|
Pension Benefit Equalization Plan
|
|
|
28
|
|
|
|
0
|
|
|
|
0
|
|
|
|
Supplemental Employee Retirement Plan
|
|
|
28
|
|
|
|
63,792
|
|
|
|
0
|
|
Kenneth M. Hale
|
|
Salaried Employees
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Pension Plan
|
|
|
7
|
|
|
|
64,932
|
|
|
|
0
|
|
|
|
Pension Benefit Equalization Plan
|
|
|
7
|
|
|
|
0
|
|
|
|
0
|
|
|
|
Supplemental Employee Retirement Plan
|
|
|
7
|
|
|
|
0
|
|
|
|
0
|
|
Paul C. Rostek
|
|
Salaried Employees
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Pension Plan
|
|
|
24
|
|
|
|
166,043
|
|
|
|
0
|
|
|
|
Pension Benefit Equalization Plan
|
|
|
24
|
|
|
|
0
|
|
|
|
0
|
|
|
|
Supplemental Employee Retirement Plan
|
|
|
24
|
|
|
|
0
|
|
|
|
0
|
|
Walter B. Treybig
|
|
Salaried Employees
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Pension Plan
|
|
|
12
|
|
|
|
131,696
|
|
|
|
0
|
|
|
|
Pension Benefit Equalization Plan
|
|
|
12
|
|
|
|
0
|
|
|
|
0
|
|
|
|
Supplemental Employee Retirement Plan
|
|
|
12
|
|
|
|
0
|
|
|
|
0
|
|
|
|
|
(1) |
|
Please refer to Footnote 8 of our
Consolidated Financial Statements for the fiscal year ended
December 31, 2007 included in this prospectus for a
description of the valuation methods utilized to determine the
present value of accumulated benefits under our Salaried
Employees Pension Plan, our Pension Benefit Equalization
Plan and our Supplemental Employee Retirement Plan and all
material assumptions used in quantifying such present values.
|
Pension
Plans
Salaried Employees Pension Plan. When we
were formed in 1986, we established our defined benefit Salaried
Employees Pension Plan as a component of our overall
compensation program in recognition of the contributions of our
employees to our operations, and as a tool for encouraging
employee retention by providing a method for ensuring adequate
income during retirement. Most of our salaried employees,
including each of our Named Executive Officers, participate in
our Salaried Employees Pension Plan. However, effective as
of January 1, 2005, we amended our Salaried Employees
Pension Plan to cease further benefit accruals for all of the
participants. Under the amendments, the Credited
Service we use in the calculation of each employees
pension was frozen at the number of years of Credited Service he
or she had earned as of January 1, 2005. In addition, the
Average Earnings we use in the calculation of each
employees pension (discussed in detail below) was frozen
at his or her average monthly earnings calculated as of
January 1, 2005. The Vesting Service we use to
determine eligibility for benefits and to calculate the amount
of any early retirement penalty was not frozen and continues to
accrue at the same rate and manner as it did prior to the
amendment. At the time we froze benefit accruals under our
Salaried
82
Employees Pension Plan, we also increased our match of
each participants contributions into our 401(k) Plan to
100% of his or her contributions into our 401(k) Plan, up to 6%
of his or her base salary.
Prior to the time we froze benefit accruals under our Salaried
Employees Pension Plan, each participant was granted one
year of Credited Service for each year in which he or she worked
at least 1,000 hours. A participant that worked less than
1,000 hours in a given year was given a partial year of
Credited Service based on the number of hours worked in that
year. In order to be entitled to any payments under our Salaried
Employees Pension Plan, a participant must have at least
five years of Vesting Service. Currently, an eligible
participant that retires at age 65 (or, if later, after
attaining five years of Vesting Service) is entitled to a
monthly payment equal to the greater of:
|
|
|
|
|
if he or she worked at Monsanto Company prior to April 1,
1986 and was employed by us as of September 30, 1986, 1.4%
of his or her Average Earnings times his or her number of
years of Credited Service;
|
|
|
|
1.2% of his or her Average Earnings times his or her
number of years of Credited Service plus 0.45% of his or
her average monthly earnings in excess of the average taxable
wage bases under Section 230 of the Social Security Act)
times the lesser of 35 and his or her number of years of
Credited Service; and
|
|
|
|
if he or she was employed by us prior to June 1, 1996, $35
times his or her number of years of Credited Service.
|
Mr. Vanderhoven is receiving monthly payments under the
first and third bullet points above. Upon their retirement and
reaching at least age 55, Messrs. Crump, Beaver, Hale,
Rostek and Treybig will be entitled to receive monthly payments
under the second bullet point above and Messrs. Crump,
Beaver, Rostek and Treybig will be entitled to receive monthly
payments under the third bullet point above.
A participant under our Salaried Employees Pension Plan
may elect to receive his or her pension payment from a slate of
several options. These options include a single life annuity, a
100% joint and survivor annuity, a 75% joint and survivor
annuity, a 50% joint and survivor annuity, a 25% joint and
survivor annuity, a
pop-up 100%
joint and survivor annuity, a
pop-up 75%
joint and survivor annuity, a
pop-up 50%
joint and survivor annuity, a
pop-up 25%
joint and survivor annuity, a ten-year certain and life annuity
and a social security adjustment annuity.
We do not have an official policy with respect to granting extra
years of Credited Service under our Salaried Employees
Pension Plan. We did, however, grant past service
credit under our Salaried Employees Pension Plan to
our employees who had previously worked for Monsanto Company
when we acquired our Texas City, Texas facility from Monsanto
Company in 1986, and to our employees who had previously worked
for Albright & Wilson when we acquired our former pulp
chemicals business from Albright & Wilson in 1992. We
have not granted any extra years of Credited Service (in the
form of past service credit or otherwise) since 1992 and, given
the frozen status of our Salaried Employees Pension Plan,
we do not expect to grant any service credit to anyone in the
future.
Under our Salaried Employees Pension Plan, a
participants Average Earnings is the average
monthly earnings received by the employee during the three-year
period ending December 31, 2004 or, if larger, the average
monthly earnings received by the employee during the three years
in which the employee was paid the most during the five year
period ending December 31, 2004. For purposes of our
Salaried Employees Pension Plan, earnings are,
for the most part, limited to base pay, with amounts paid to the
participant as a bonus, commission or other incentive plan
payment and amounts paid by us for insurance or other welfare or
benefit plans not taken into account. In any case, however, a
participants Average Earnings is capped based on certain
limitations imposed under the Internal Revenue Code. These
limitations, as of the time we ceased benefit accruals under our
Salaried Employees Pension Plan, effectively limit the
amount payable to a participant under our Salaried
Employees Pension Plan to the amount of benefit he or she
would have received if his or her Average Earnings were
$201,667. In addition, for those participants who were given
past service credit for employment with Monsanto Company or
Albright & Wilson, the monthly payment under our
Salaried Employees Pension Plan is reduced by the amount
of his or her accrued benefit payable under the pension plans
maintained by those employers.
A participant who has at least five years of Vesting Service,
which includes all of our Named Executive Officers, may retire
and receive payments under our Salaried Employees Pension
Plan at any time after he or she reaches 55 years of age.
However, the monthly payment made to that participant is reduced
by 0.25% times the number of months remaining before his
or her normal retirement date unless the Participants age
plus years of
83
Vesting Service equals at least 80. Mr. Crump is our only
Named Executive Officer who meets this criteria. If a
participant retires directly from active employment between the
ages of 55 and 62, he or she is also entitled to a retirement
supplement in the amount of $4 times his or her years of Vesting
Service. In addition, effective as of January 1, 2008, each
participant in our Salaried Employees Pension Plan may,
once he or she has attained 62 years of age and has at
least five years of Vesting Service, elect to take early
retirement while continuing to work for us, or In-Service
Retirement. Under the In-Service Retirement option, a
participants monthly benefit is determined in the same
manner as if he or she had actually retired on that date.
Mr. Crump is the only one of our Named Executive Officers
who is eligible for In-Service Retirement at this time, although
he has not elected to take In-Service Retirement.
A participant in our Salaried Employees Pension Plan may
also receive the equivalent of an undiscounted pension payment
prior to reaching normal retirement age if he or she has at
least
21/2 years
of Vesting Service and his or her employment ends prior to his
or her normal retirement date due to a long-term disability. The
participant may not, however, receive this payment under our
Salaried Employees Pension Plan if he or she is also
receiving payments under our long-term disability plan.
Pension Benefit Equalization Plan. Each of our
salaried employees who is eligible to participate in our
Salaried Employees Pension Plan is also eligible to
participate in our Pension Benefit Equalization Plan. Our
Pension Benefit Equalization Plan pays additional benefits to
employees whose benefits under our Salaried Employees
Pension Plan are limited as a result of specified limitations
included in the Internal Revenue Code. The amount of benefits
payable under our Pension Benefit Equalization Plan is designed
to eliminate the effect of these limitations on the aggregate
annual pension benefits payable to the participants, but not
provide any additional benefits beyond that amount. These
benefits are generally payable at the times we pay benefits
under our Salaried Employees Pension Plan. Effective as of
January 1, 2005, we amended our Pension Benefit
Equalization Plan to cease benefit accruals for all participants.
Supplemental Employee Retirement Plan. Each of
our employees who is a part of management or is considered
highly compensated, and is subject to limitations on
the amount of pension plan benefits he or she may receive under
the Internal Revenue Code, is also eligible to participate in
our Supplemental Employee Retirement Plan. Our Supplemental
Employee Retirement Plan pays additional benefits to employees
whose benefits under our Salaried Employees Pension Plan
are limited as a result of his or her Average Earnings exceeding
$201,667, or due to the removal of certain Social Security
integration benefits from our Salaried Employees Pension
Plan. The amount of benefits payable under our Supplemental
Employee Retirement Plan is designed to eliminate the effect of
these limitations on the aggregate pension benefits payable to
the participants, but not provide any additional benefits beyond
that amount. These benefits are generally payable at the same
time as when we pay benefits under our Salaried Employees
Pension Plan. Effective as of January 1, 2005, we amended
our Supplemental Employee Retirement Plan to cease benefit
accruals for all participants.
For our Named Executive Officers, the compensation covered by
our three pension plans is reported under the salary column in
the Summary Compensation Table appearing in this Proxy Statement
(and similar types of compensation for prior calendar years).
Assuming retirement at age 65, the annual retirement
benefits payable to each Named Executive Officer, excluding
Mr. Vanderhoven, who retired on May 1, 2007, under
these plans would be:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net Payment
|
|
|
|
Gross Payment
|
|
|
Reduction for Payments
|
|
|
Under Equalization
|
|
|
|
Under All Plans
|
|
|
Under Pension Plan
|
|
|
and Supplemental Plans
|
|
|
Richard K. Crump
|
|
$
|
103,340
|
|
|
$
|
56,417
|
|
|
$
|
46,923
|
|
John R. Beaver
|
|
|
23,224
|
|
|
|
23,224
|
|
|
|
0
|
|
Kenneth M. Hale
|
|
|
19,417
|
|
|
|
19,417
|
|
|
|
0
|
|
Paul C. Rostek
|
|
|
38,315
|
|
|
|
38,315
|
|
|
|
0
|
|
Walter B. Treybig
|
|
|
28,304
|
|
|
|
28,304
|
|
|
|
0
|
|
All of the benefits appearing in the pension benefits table are
computed on the assumption that the Named Executive Officer
elects to be paid on a single-life annuity basis and the
payments are not subject to any deduction for Social Security or
other similar offset amounts. However, our Supplemental Employee
Retirement Plan does
84
contain an alternative formula for determining benefits which
includes a Social Security offset. We have never used this
alternative formula to determine the amount of any benefits paid
under our Supplemental Employee Retirement Plan.
Nonqualified
Deferred Compensation
As of December 31, 2007, none of our Named Executive
Officers had any balances of nonqualified deferred compensation.
In 2007, none of our Named Executive Officers made any
contributions to nonqualified deferred compensation plans or
programs, had any contributions made by us for them to any
nonqualified deferred compensation plans or programs, or
realized any earnings on, made any withdrawals of or received
any distributions on any nonqualified deferred compensation.
Other
Retirement and Post-Employment Compensation
401(k)
Savings and Investment Plan
We maintain a Savings and Investment Plan, or our 401(k) Plan
for the benefit of all of our employees, including our Named
Executive Officers. Under our 401(k) Plan, participants may
elect to contribute a portion of their base salaries into
individual accounts on a pre-tax basis (up to statutory
maximums), and may also contribute additional portions of their
base salaries into their accounts on an after-tax basis (up to
statutory maximums). We match each participants
contributions into our 401(k) Plan on a dollar-for-dollar basis,
up to 6% of the participants base salary. Each participant
directs the investment of all contributions into his or her
account among a slate of investment options chosen by our
Employee Benefits Plans Committee (which is made up of members
of senior management). Our stock is not one of the available
investment options under our 401(k) Plan.
Key
Employee Protection Plan
On January 26, 2000, our Board approved the initial form of
our Key Employee Protection Plan, which has subsequently been
amended several times, or our Key Employee Protection Plan. Our
Named Executive Officers are the only current participants under
our Key Employee Protection Plan and their respective
multipliers and other variables for determining benefits have
been set by our Compensation Committee. Our Compensation
Committee is also authorized to designate additional members of
our management or highly compensated employees as participants
under our Key Employee Protection Plan and set their
multipliers. Our Compensation Committee may terminate any
participants participation under our Key Employee
Protection Plan on 60 days notice if it determines
that the participant is no longer one of our key employees.
Under our Key Employee Protection Plan, a participant can only
become eligible for benefits if his or her employment is
terminated in specified ways and for specified reasons. That
termination must either result from the participant resigning
for Good Reason or the participant being terminated
by us for any reason other than Misconduct or
Disability. A termination by the participant is only
considered to be for Good Reason if the participant
resigns within 90 days after he or she acquires actual
knowledge of any of the following actions or omissions by us:
|
|
|
|
|
for participants with multipliers of at least 2.00 (which
includes each of our Named Executive Officers):
|
|
|
|
|
|
we make a material change in his or her reporting
responsibilities, titles or elected or appointed offices
(excluding changes resulting from the participants death,
disability or retirement); or
|
|
|
|
we assign him or her duties or responsibilities that are
materially inconsistent with his or her status, positions,
duties, responsibilities or functions;
|
|
|
|
|
|
we reduce the participants compensation by a material
amount;
|
|
|
|
we fail to maintain employee benefit plans, programs,
arrangements and practices providing benefits to the participant
that are, in the aggregate, as favorable as those under our
current plans, programs, arrangements and practices (excluding
changes or terminations that apply generally to all of our
salaried work force and do not have a disparate impact on the
participant);
|
85
|
|
|
|
|
we change the location of the participants principal place
of employment by more than 75 miles;
|
|
|
|
we purport to terminate the participant for Misconduct or
Disability in a manner not consistent with our Key Employee
Protection Plan; or
|
|
|
|
we purport to terminate the participants participation in
our Key Employee Protection Plan (unless our Compensation
Committee determines in good faith he or she is no longer one of
our key employees and follows the procedures for termination set
out in our Key Employee Protection Plan).
|
However, changes in a participants reporting
responsibilities, titles or elected or appointed offices,
assignments of duties or responsibilities to the participant and
reductions in the participants compensation will not
constitute Good Reason if our action was isolated and
inadvertent and not taken in bad faith and we promptly remedy
the issue after receiving notice from the participant.
A participant is also entitled to benefits under our Key
Employee Protection Plan if we terminate him or her for any
reason other than Misconduct or Disability.
Misconduct under our Key Employee Protection Plan
covers only specified actions or omissions by the participant
and is limited to:
|
|
|
|
|
acts of dishonesty or gross misconduct that are demonstrably
injurious to us (monetarily or otherwise) in any material
respect;
|
|
|
|
the failure to comply with our published policies relating to
alcohol and drugs, harassment or compliance with laws;
|
|
|
|
the failure to comply with any of our other policies if that
failure continues unremedied for 30 days after receiving
written notice of the failure;
|
|
|
|
the willful failure to comply with any lawful and ethical
directions and instructions of our Board or our Chief Executive
Officer;
|
|
|
|
the refusal or willful failure by the participant to perform, in
any material respect, his or her duties if that failure is not
caused by disability or incapacity and continues unremedied for
30 days after receiving written notice of that failure;
|
|
|
|
a conviction for a felony offense; or
|
|
|
|
any willful conduct that prejudices, in any material respect,
our reputation in our fields of business, with the investment
community or with the public at large if the participant knew,
or should have known, that his or her conduct could have that
result.
|
However, acts and failures to act are not considered
willful if done or not done in good faith and with
the reasonable belief that the action or omission was in our
best interests. Disability under our Key Employee
Protection Plan is limited to a physical or mental condition
that, in the opinion of a licensed physician reasonably
acceptable to us and the participant, prevents the participant
from being able to perform his or her job responsibilities, has
continued for at least 180 days during any period of 12
consecutive months and is reasonably expected to continue. In
order to terminate a participant for Misconduct or Disability,
we must give the participant written notice of termination
specifying his or her termination date, stating that the
termination is for Misconduct or Disability and setting forth
the facts and circumstances deemed to be Misconduct or to result
in a finding of Disability.
If a participants employment with us is terminated in a
way that results in him or her being eligible for benefits under
our Key Employee Protection Plan, the participant is entitled to
a lump sum payment. The amount of the lump sum payment is
determined by multiplying the participants multiplier by
the sum of his or her highest annual base salary during the last
three years plus his or her current Bonus Target under our Bonus
Plan. This amount is reduced, however, by the amount of any
other separation, severance or termination payments received
from us under any of our other plans or which we are required to
pay by law. Once the base amount of the lump sum payment is
determined, the final amount of the lump sum payment depends on
whether a Change of Control occurs within a
specified period before or after the date of termination. If a
Change of Control has not (and does not) occur within that
specified period, the participants applicable multiplier
is reduced by 50%. However, if the higher lump sum
86
payment is payable in connection with a Change of Control to one
of our most highly compensated employees, including each of our
Named Executive Officers, the incremental amount is subject to
repayment by the participant if the participant, within one year
after his or her termination, owns, manages, operates or
controls (or joins in the ownership, management, operation or
control of), or becomes employed by or connected in any manner
with, any business engaged in the manufacture or sale of
styrene, acrylonitrile or acetic acid anywhere in the world. The
precise amount repaid by the participant is a percentage of the
incremental amount determined by dividing the number of days
left in the one-year restricted period when he or she first
engages in the competitive activity by 365.
Under our Key Employee Protection Plan, a Change of Control can
occur through individuals acquiring our securities, changes in
the membership of our Board, participation by us in major
corporate transactions or upon our dissolution. Specifically,
under our Key Employee Protection Plan, a Change of
Control occurs if:
|
|
|
|
|
any individual, entity or group acquires, in the aggregate,
beneficial ownership of 50% or more of the combined voting power
of our then outstanding securities that vote generally in the
election of directors, or Voting Securities, if:
|
|
|
|
|
|
the individual, entity or group is not Resurgence or any of its
or its affiliates managed funds or accounts (referred to
collectively as the Resurgence Group) or one or more of our
employee benefit plans; and
|
|
|
|
the acquisition is not made through an Excluded Transaction
(defined below);
|
|
|
|
|
|
a majority of the members of our Board were not one of our
directors on March 12, 2004 or directors whose election or
nomination for election was approved by those directors and all
previously approved new directors (referred to as our Incumbent
Board), although, for this purpose, anyone who initially became
one of our directors in connection with an actual or threatened
contested election of directors or contested removal of
directors, or an actual or threatened solicitation of proxies or
consents, is not considered to be a member of our Incumbent
Board, irrespective of any approval given by our Incumbent Board;
|
|
|
|
we are involved in a reorganization, merger, statutory share
exchange, consolidation or similar corporate transaction, we
dispose of our assets or we acquire the assets or stock of
another entity and the transaction is not an Excluded
Transaction which, for this purpose, means a transaction
where, after the transaction:
|
|
|
|
|
|
the beneficial holders of our outstanding Voting Securities
prior to the transaction beneficially own more than 50% of the
outstanding Voting Securities of the corporation that results
from the transaction or that owns our assets after the
transaction, in substantially the same proportions as their
pre-transaction ownership;
|
|
|
|
no individual, entity or group (other than the Resurgence Group
or one of our employee benefit plans) beneficially owns 50% or
more of the Voting Securities of any corporation that results
from the transaction; and
|
|
|
|
at least a majority of the members of the board of directors of
the corporation resulting from the transaction were members of
our Incumbent Board at the time the initial documentation for
the transaction was signed or the time the transaction was
approved by our Board; or
|
|
|
|
our stockholders or other relevant stakeholders approve our
complete liquidation or dissolution.
|
Whether a participant is eligible for the higher lump sum
payment associated with a Change of Control depends on whether
his or her termination occurred within his or her
Protection Period. Every participants
Protection Period starts 180 days prior to the date on
which the Change of Control occurs. A participants
Protection Period ends either two years or 18 months after
the date on which the Change of Control occurs, depending on the
size of the participants multiplier. The Protection Period
for each of our Named Executive Officers ends two years after
the date on which the Change of Control occurs.
If each of our Named Executive Officers (excluding
Mr. Vanderhoven, who retired on May 1,
2007) terminated their employment for Good Reason on
December 31, 2007, or were terminated by us for any reason
other than
87
Misconduct or Disability on that date, our Named Executive
Officers would be paid the following lump sum amounts under our
Key Employee Protection Plan:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Change of
|
|
|
Non-Change
|
|
|
|
|
|
|
|
|
|
|
|
|
Control
|
|
|
of Control
|
|
|
|
|
|
|
|
|
|
|
|
|
Payment
|
|
|
Payment
|
|
|
|
|
|
|
Bonus
|
|
|
Applicable
|
|
|
Under the
|
|
|
Under the
|
|
|
|
Base Salary
|
|
|
Target
|
|
|
Multiplier
|
|
|
KEP
Plan(1)
|
|
|
KEP
Plan(2)
|
|
|
Richard K. Crump
|
|
$
|
390,000
|
|
|
$
|
390,000
|
|
|
|
2.75
|
|
|
$
|
2,145,000
|
|
|
$
|
1,072,500
|
|
John R. Beaver
|
|
|
205,000
|
|
|
|
82,000
|
|
|
|
2.00
|
|
|
|
574,000
|
|
|
|
287,000
|
|
Kenneth M. Hale
|
|
|
234,000
|
|
|
|
93,600
|
|
|
|
2.00
|
|
|
|
655,200
|
|
|
|
327,600
|
|
Paul C. Rostek
|
|
|
221,750
|
|
|
|
88,700
|
|
|
|
2.00
|
|
|
|
620,900
|
|
|
|
310,450
|
|
Walter B. Treybig
|
|
|
204,750
|
|
|
|
81,900
|
|
|
|
2.00
|
|
|
|
573,300
|
|
|
|
286,650
|
|
|
|
|
(1) |
|
Payment if a Change of Control
occurred between December 31, 2005 and December 31,
2007 or occurs on or before June 28, 2008.
|
|
(2) |
|
Payment if no Change of Control
occurred between December 31, 2005 and December 31,
2007 or occurs before June 28, 2008.
|
In addition to the lump sum payment, each participant eligible
for benefits under our Key Employee Protection Plan is entitled
to receive his or her accrued but unpaid compensation,
compensation for unused vacation time and any unpaid vested
benefits earned or accrued under any of our benefit plans (other
than qualified plans). Also, for a period of 24 months
(including 18 months of COBRA coverage), that participant
will continue to be covered by all of our life, health care,
medical and dental insurance plans and programs (other than
disability), as long as he or she makes a timely COBRA election
and pays the regular employee premiums required under our plans
and programs and by COBRA. In addition, our obligation to
continue to provide coverage under our plans and programs to a
participant ends if and when that participant becomes employed
on a full-time basis by a third party which provides the
participant with substantially similar benefits. If each of our
Named Executive Officers (excluding Mr. Vanderhoven, who
retired on May 1, 2007) terminated their employment
for Good Reason or were terminated by us for any reason other
than Misconduct or Disability on December 31, 2007, the
value of these life, health care, medical and dental insurance
benefits to our Named Executive Officers would have been:
|
|
|
|
|
Richard K. Crump
|
|
$
|
41,266
|
|
John R. Beaver
|
|
|
32,489
|
|
Kenneth M. Hale
|
|
|
32,521
|
|
Paul C. Rostek
|
|
|
42,653
|
|
Walter B. Treybig
|
|
|
42,634
|
|
If any payment or distribution under our Key Employee Protection
Plan to a participant is subject to excise tax pursuant to
Section 4999 of the Internal Revenue Code, the participant
is also entitled to receive a
gross-up
payment from us in an amount such that, after payment by the
participant of all taxes on the
gross-up
payment, the amount of the
gross-up
payment remaining is equal to the excise tax imposed under
Section 4999 of the Internal Revenue Code. However, the
maximum amount of any
gross-up
payment is 25% of the sum of the participants highest
annual base compensation during the last three years plus the
participants Bonus Target under our Bonus Plan for the
year of payment.
We may terminate our Key Employee Protection Plan at any time
and for any reason but a termination will not become effective
until 90 days after we give the participants notice of the
termination. In addition, we may amend our Key Employee
Protection Plan at any time and for any reason, but any
amendment that reduces, alters, suspends, impairs or prejudices
the rights or benefits of any participant in any material
respect will not become effective as to that participant until
90 days after we give him or her notice of the amendment.
No termination of our Key Employee Protection Plan, or any of
these types of amendments, will be effective with respect to any
participant if the termination or amendment is related to, in
anticipation of or during the pendency of a Change of Control,
is for the purpose of encouraging or facilitating a Change of
Control or is made within 180 days prior to any Change of
Control. Finally, no termination or amendment of our Key
Employee Protection Plan can affect the rights or benefits of
any participant that were accrued at the time of termination or
amendment, or that accrue later due to a Change of Control that
occurs prior to the termination or amendment or within
180 days after the termination or amendment.
88
On May 1, 2007, Mr. Vanderhoven retired from his
employment with us. In connection with his retirement, we
entered into a separation and release agreement with
Mr. Vanderhoven and he received a severance package
consisting of a lump-sum severance payment in the amount of
$385,500, or 1.0 times his last years base salary plus his
Bonus Target (or 50% of his base salary) under our Bonus Plan
and the continuation of coverage under our life, health care,
medical and dental insurance plans and programs (other than
disability), as long as he makes a timely COBRA election and
pays the regular employee premiums required under our plans and
programs and by COBRA for a period of 24 months (including
18 months of COBRA coverage). At the time
Mr. Vanderhoven retired, the value of these life, health
care, medical and dental insurance benefits was $30,230.
Director
Compensation
In 2007, none of our directors were paid any form of
compensation other than fees earned or paid in cash, which we
paid in the following amounts:
|
|
|
|
|
|
|
|
|
|
|
Fees Earned or
|
|
|
|
|
|
|
Paid In
Cash(1)
|
|
|
Total
|
|
|
Richard K.
Crump(2)
|
|
$
|
0
|
|
|
$
|
0
|
|
Steven L.
Gidumal(3)
|
|
|
37,000
|
|
|
|
37,000
|
|
John W. Gildea
|
|
|
48,250
|
|
|
|
48,250
|
|
Byron J.
Haney(3)
|
|
|
43,000
|
|
|
|
43,000
|
|
Karl W.
Schwarzfeld(3)
|
|
|
33,750
|
|
|
|
33,750
|
|
Philip M.
Sivin(3)
|
|
|
36,250
|
|
|
|
36,250
|
|
Dr. Peter T.K. Wu
|
|
|
43,750
|
|
|
|
43,750
|
|
|
|
|
(1) |
|
Includes amounts paid for attendance as a member at meetings of
the following Committees: |
|
|
|
Steven L. Gidumal
|
|
Compensation Committee
|
John W. Gildea
|
|
Audit Committee
|
Byron J. Haney
|
|
Compensation Committee (Chairman) Corporate Governance Committee
Audit Committee (Chairman)
|
Dr. Peter T.K. Wu
|
|
Corporate Governance Committee (Chairman) Environmental, Health
& Safety Committee
|
|
|
|
(2) |
|
Mr. Crump is one of our employees and, consequently, is not
paid any compensation for his service as a director. |
|
(3) |
|
All compensation for service as a director earned by
Messrs. Gidumal, Haney, Schwarzfeld and Sivin, who are
employees of Resurgence, was paid to Resurgence pursuant to
established policies of Resurgence. |
For the 2007 fiscal year, each of our directors was paid an
annual retainer of $25,000 for his service as a director, and
meeting attendance fees of $2,500 for each Board meeting held in
person and $1,250 for each telephonic Board meeting. Our
directors serving on our Board Committees were also paid
attendance fees of $1,500 for each Committee meeting held in
person and $750 for each telephonic Committee meeting. In March
2008, our Board approved changes to the director fees for the
fiscal year. Each of our directors will be paid an annual
retainer of $30,000 and meeting attendance fees of $3,000 for
each Board meeting whether held in person or telephonically.
Additionally, directors serving on our Board Committees will
receive attendance fees of $2,000 for each Committee meeting
held in person and $1,000 for each telephonic Committee meeting.
Our Board members who are also our employees do not receive any
retainers or attendance fees, although all of our directors are
reimbursed for their travel expenses related to their services
as a director. With the exception of compensation paid to, and
stock-based awards granted to, Mr. Crump in his capacity as
our President and Chief Executive Officer, we have never granted
any stock, options or other equity-based awards to any of our
current directors, and our current directors have never
participated in any of our non-equity incentive plans, pension
plans or other non-qualified compensation plans. As described
above under Indemnification Agreements, we have
entered into indemnification agreements with each of our
directors.
89
SECURITY
OWNERSHIP OF CERTAIN
BENEFICIAL OWNERS AND MANAGEMENT
The following table sets forth certain information regarding the
beneficial ownership of our Series A Preferred Stock and
common stock as of June 30, 2008 by (i) each of our
directors and each person nominated to become one of our
directors, (ii) each of our Named Executive Officers,
(iii) each person known by us to be the beneficial owner of
more than 5% of our outstanding Series A Preferred Stock or
common stock and (iv) all of our directors and executive
officers as a group. Each share of our Preferred Stock is
currently convertible into 1,000 shares of our common stock
at the election of the holder. Unless otherwise noted, the
mailing address of each such beneficial owner is 333 Clay
Street, Suite 3600, Houston, Texas
77002-4312,
and we believe, based on information provided by the beneficial
owners listed below, that the named beneficial owner has sole
voting power and sole investment power with respect to the
shares shown below, except to the extent that power is shared
with such persons spouse pursuant to applicable law.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Shares of
|
|
|
Percentage
|
|
|
Certain
|
|
|
Percentage
|
|
|
Shares of
|
|
|
Percentage
|
|
|
|
Preferred
|
|
|
of
|
|
|
Common
|
|
|
of Certain
|
|
|
Common
|
|
|
of All
|
|
|
|
Stock
|
|
|
Outstanding
|
|
|
Stock
|
|
|
Outstanding
|
|
|
Stock
|
|
|
Outstanding
|
|
|
|
Beneficially
|
|
|
Preferred
|
|
|
Beneficially
|
|
|
Common
|
|
|
Beneficially
|
|
|
Common
|
|
Name
|
|
Owned
|
|
|
Stock
|
|
|
Owned(1)
|
|
|
Stock(1)
|
|
|
Owned(2)
|
|
|
Stock(2)
|
|
|
Richard K.
Crump(3)
|
|
|
0
|
|
|
|
0
|
%
|
|
|
120,000
|
|
|
|
*
|
|
|
|
120,000
|
|
|
|
*
|
|
John V. Genova
|
|
|
0
|
|
|
|
0
|
%
|
|
|
0
|
|
|
|
0
|
%
|
|
|
0
|
|
|
|
0
|
%
|
Steven L.
Gidumal(4)
|
|
|
4,923.837
|
|
|
|
98.8
|
%
|
|
|
1,919,175
|
|
|
|
60.4
|
%
|
|
|
6,843,012
|
|
|
|
84.5
|
%
|
John W. Gildea
|
|
|
0
|
|
|
|
0
|
%
|
|
|
0
|
|
|
|
0
|
%
|
|
|
0
|
|
|
|
0
|
%
|
Byron J.
Haney(4)
|
|
|
4,923.837
|
|
|
|
98.8
|
%
|
|
|
1,919,175
|
|
|
|
60.4
|
%
|
|
|
6,843,012
|
|
|
|
84.5
|
%
|
Karl W.
Schwarzfeld(4)
|
|
|
4,923.837
|
|
|
|
98.8
|
%
|
|
|
1,919,175
|
|
|
|
60.4
|
%
|
|
|
6,843,012
|
|
|
|
84.5
|
%
|
Philip M.
Sivin(4)(5)
|
|
|
4,923.837
|
|
|
|
98.8
|
%
|
|
|
1,919,175
|
|
|
|
60.4
|
%
|
|
|
6,843,012
|
|
|
|
84.5
|
%
|
Dr. Peter Ting Kai Wu
|
|
|
0
|
|
|
|
0
|
%
|
|
|
0
|
|
|
|
0
|
%
|
|
|
0
|
|
|
|
0
|
%
|
John R.
Beaver(3)
|
|
|
0
|
|
|
|
0
|
%
|
|
|
22,500
|
|
|
|
*
|
|
|
|
22,500
|
|
|
|
*
|
|
Paul G. Vanderhoven
|
|
|
0
|
|
|
|
0
|
%
|
|
|
0
|
|
|
|
0
|
%
|
|
|
0
|
|
|
|
0
|
%
|
Kenneth M.
Hale(3)
|
|
|
0
|
|
|
|
0
|
%
|
|
|
27,500
|
|
|
|
*
|
|
|
|
27.500
|
|
|
|
*
|
|
Paul C.
Rostek(3)
|
|
|
0
|
|
|
|
0
|
%
|
|
|
27,500
|
|
|
|
*
|
|
|
|
27,500
|
|
|
|
*
|
|
Walter B.
Treybig(3)
|
|
|
0
|
|
|
|
0
|
%
|
|
|
25,000
|
|
|
|
*
|
|
|
|
25,000
|
|
|
|
*
|
|
Resurgence Asset Management,
L.L.C.(5)
|
|
|
4,923.837
|
|
|
|
98.8
|
%
|
|
|
1,919,175
|
|
|
|
60.4
|
%
|
|
|
6,843,012
|
|
|
|
84.5
|
%
|
Resurgence Asset Management International,
L.L.C.(5)
|
|
|
4,923.837
|
|
|
|
98.8
|
%
|
|
|
1,919,175
|
|
|
|
60.4
|
%
|
|
|
6,843,012
|
|
|
|
84.5
|
%
|
Re/Enterprise Asset Management,
L.L.C.(5)
|
|
|
4,923.837
|
|
|
|
98.8
|
%
|
|
|
1,919,175
|
|
|
|
60.4
|
%
|
|
|
6,843,012
|
|
|
|
84.5
|
%
|
M.D. Sass Management,
Inc.(5)
|
|
|
4,923.837
|
|
|
|
98.8
|
%
|
|
|
1,919,175
|
|
|
|
60.4
|
%
|
|
|
6,843,012
|
|
|
|
84.5
|
%
|
Martin D.
Sass(5)
|
|
|
4,923.837
|
|
|
|
98.8
|
%
|
|
|
1,919,175
|
|
|
|
60.4
|
%
|
|
|
6,843,012
|
|
|
|
84.5
|
%
|
Avenue Capital Management II,
L.P.(6)
|
|
|
0
|
|
|
|
0
|
%
|
|
|
467,589
|
|
|
|
16.3
|
%
|
|
|
467,589
|
|
|
|
6.0
|
%
|
Mariner Investment Group,
Inc.(7)
|
|
|
0
|
|
|
|
0
|
%
|
|
|
145,684
|
|
|
|
5.0
|
%
|
|
|
145,684
|
|
|
|
1.8
|
%
|
Merrill Lynch, Pierce, Fenner & Smith,
Incorporated(8)
|
|
|
0
|
|
|
|
0
|
%
|
|
|
186,787
|
|
|
|
6.6
|
%
|
|
|
186,787
|
|
|
|
2.4
|
%
|
Northeast Investors
Trust(9)
|
|
|
0
|
|
|
|
0
|
%
|
|
|
250,827
|
|
|
|
8.9
|
%
|
|
|
250,827
|
|
|
|
3.2
|
%
|
Directors and current executive officers as a group
(13 persons)(3)
through(5)
|
|
|
4,923.837
|
|
|
|
98.8
|
%
|
|
|
2,141,675
|
|
|
|
63.0
|
%
|
|
|
7,065,512
|
|
|
|
84.9
|
%
|
|
|
|
*
|
|
Less than 1%
|
|
(1) |
|
Includes outstanding shares of
common stock and shares of common stock issuable upon exercise
of warrants and options, but excludes shares of common stock
issuable upon conversion of outstanding Series A Preferred Stock.
|
|
(2) |
|
Includes outstanding shares of
common stock, shares of common stock issuable upon exercise of
warrants and options and shares of common stock issuable upon
conversion of outstanding Series A Preferred Stock.
|
90
|
|
|
(3) |
|
Represents shares of our common
stock issuable upon exercise of options granted under the 2002
Stock Plan which are or will become exercisable within
60 days of May 31, 2008.
|
|
(4) |
|
Represents shares of our Series A
Preferred Stock and shares of our common stock (including shares
of our common stock issuable upon the exercise of warrants which
are exercisable within 60 days of March 7,
2008) that are beneficially owned by funds and accounts
managed by Resurgence and its affiliates (see Note 5).
Messrs. Gidumal and Haney are Managing Directors and
Co-Chief Investment Officers of Resurgence and
Messrs. Schwarzfeld and Sivin are Vice Presidents of
Resurgence. As such, Messrs. Gidumal, Haney, Schwarzfeld
and Sivin may be deemed to have beneficial ownership of such
shares. Each of Messrs. Gidumal, Haney, Schwarzfeld and
Sivin disclaims beneficial ownership of all such shares.
|
|
(5) |
|
Includes
(a) 2,635.782 shares of our Series A Preferred Stock
(convertible into 2,635,782 shares of our common stock),
837,562 shares of our common stock and an additional
186,783 shares of our common stock issuable upon the
exercise of warrants which are exercisable within 60 days
of May 31, 2008 that may be deemed to be beneficially owned
by Resurgence, (b) 716.427 shares of our Series A
Preferred Stock (convertible into 716,427 shares of our
common stock), 229,054 shares of our common stock and an
additional 50,769 shares of our common stock issuable upon
the exercise of warrants which are exercisable within
60 days of May 31, 2008 that may be deemed to be
beneficially owned by Resurgence Asset Management International,
L.L.C., or RAMI, (c) 1,551.499 shares of our Series A
Preferred Stock (convertible into 1,551,499 shares of our
common stock), 497,212 shares of our common stock and an
additional 109,942 shares of our common stock issuable upon
the exercise of warrants which are exercisable within
60 days of May 31, 2008 that may be deemed to be
beneficially owned by Re/Enterprise Asset Management, L.L.C., or
REAM, and (d) 20.129 shares of our Series A Preferred
Stock (convertible into 20,129 shares of our common stock),
6,427 shares of our common stock and an additional
1,426 shares of our common stock issuable upon the exercise
of warrants which are exercisable within 60 days of
May 31, 2008 that may be deemed to be beneficially owned by
M.D. Sass Management, Inc., or Sass Management. Mr. Sass
serves as Chairman and Chief Executive Officer of Resurgence,
RAMI, REAM and Sass Management and, as such, may be deemed to
beneficially own all of these securities. Mr. Sivin is
Mr. Sasss
son-in-law
and, as such, may be deemed to beneficially own all of these
securities. Each of Messrs. Sass and Sivin disclaim
beneficial ownership of all of these securities. Each share of
our Series A Preferred Stock is currently convertible into
1,000 shares of our common stock at the election of the
holder.
|
|
|
|
In its capacity as investment
advisor, Resurgence exercises voting and investment power over
our securities held for the accounts of M.D. Sass Corporate
Resurgence Partners, L.P., or Resurgence I, M.D. Sass
Corporate Resurgence Partners II, L.P., or Resurgence
II, M.D. Sass Corporate Resurgence Partners III, L.P., or
Resurgence III, and the Resurgence Asset Management, L.L.C.
Employment Retirement Plan, or the Plan. Accordingly,
Resurgence may be deemed to share voting and investment power
with respect to our securities held by Resurgence I,
Resurgence II, Resurgence III and the Plan.
|
|
|
|
In its capacity as investment
advisor, RAMI exercises voting and investment power over our
securities held for the account of M.D. Sass Corporate
Resurgence International, Ltd., or Resurgence International.
Accordingly, RAMI may be deemed to share voting and investment
power with respect to our securities held by Resurgence
International.
|
|
|
|
In its capacity as investment
advisor, REAM exercises voting and investment power over our
securities held for the accounts of two employee pension plans,
or the Pension Plans, the M.D. Sass Associates, Inc. Employee
Profit Sharing Plan, or Sass Employee Plan, M.D. Sass
Re/Enterprise Portfolio Company, L.P., or
Re/Enterprise, M.D. Sass Re/Enterprise II, L.P., or
Re/Enterprise II, and M.D. Sass Re/Enterprise International,
Ltd., or Sass International. Accordingly, REAM may be deemed to
share voting and investment power with respect to our securities
held by each of the Pension Plans, the Sass Employee Plan,
Re/Enterprise, Re/Enterprise II and Sass International.
|
|
|
|
In addition, funds which have
invested
side-by-side
with funds managed by Resurgence, RAMI and REAM beneficially own
in the aggregate 60.503 shares of our Series A Preferred
Stock (convertible into 60,503 shares of our common stock),
19,288 shares of our common stock and an additional
4,287 shares of our common stock issuable upon the exercise
of warrants which are exercisable within 60 days of
May 31, 2008.
|
|
|
|
The mailing address of each of
Messrs. Gidumal, Haney, Schwarzfeld and Sivin,
Mr. Sass, Resurgence, RAMI, REAM and Sass Management is
1185 Avenue of the Americas, 18th Floor, New York, New York
10036.
|
|
|
|
The foregoing information is based
on the Schedule 13D filed by Resurgence, RAMI and REAM with
the SEC on December 19, 2002, as amended by
(A) Schedule 13D/A, Amendment No. 1, filed by
Resurgence, RAMI and REAM with the SEC on February 13,
2004, (B) Schedule 13D/A, Amendment No. 2, filed
by Martin D. Sass, Resurgence, RAMI and REAM with the SEC on
June 25, 2004, (C) Schedule 13D/A, Amendment
No. 3, filed by Martin D. Sass, Resurgence, RAMI and REAM
with the SEC on February 14, 2005,
(D) Schedule 13D/A, Amendment No. 4, filed by
Martin D. Sass, Resurgence, RAMI and REAM with the SEC on
March 8, 2005, (E) Schedule 13D/A, Amendment
No. 5, filed by Martin D. Sass, Resurgence, RAMI and REAM
with the SEC on March 2, 2006,
(F) Schedule 13D/A, Amendment No. 6, filed by
Martin D. Sass, Resurgence, RAMI and REAM with the SEC on
February 28, 2007 and (G) Schedule 13D/A,
Amendment No. 7, filed by Martin D. Sass, Resurgence, RAMI, REAM
and Sass Management with the SEC on March 10, 2008.
|
|
(6) |
|
Includes 39,118 shares of our
common stock issuable upon exercise of warrants that are
exercisable within 60 days of May 31, 2008.
Collectively, these securities are held by Avenue Investments,
L.P., a Delaware limited partnership, Avenue Special Situations
Fund V, L.P., a Delaware limited partnership, Avenue
Special Situations Fund IV, L.P., a Delaware limited
partnership, Avenue Special Situations Fund II, L.P., a Delaware
limited partnership, Avenue-CDP Global Opportunities Fund, L.P.,
a Cayman Islands exempted limited partnership, and Avenue
International Master, L.P., a Cayman Islands exempted limited
partnership, which we refer to collectively as the Avenue
Entities. Avenue Special Situations Fund V, L.P. is the
only Avenue Entity that holds more than 5% of the shares of our
common stock. Avenue Capital Partners V, LLC is the General
Partner of Avenue Special Situations Fund V, L.P. GL
Partners V, LLC is the Managing Member of Avenue Capital
Partners V, LLC and Marc Lasry is the Managing Member of GL
Partners V, LLC. Avenue Capital Management II, L.P. is an
investment adviser to each of the Avenue Entities. Avenue
Capital Management II GenPar, LLC is the General Partner of
Avenue Capital Management II, L.P. and Marc Lasry is the
Managing Member of Avenue Capital Management II GenPar,
LLC. This information is based on
|
91
|
|
|
|
|
the Schedule 13G filed by
Avenue Capital Management II, L.P., Avenue Capital
Management II GenPar, LLC and Marc Lasry with the SEC on
May 30, 2007, as amended by Schedule 13G/A, Amendment
No. 1, filed by Avenue Capital Management II, L.P., Avenue
Capital Management II GenPar, LLC, Avenue Special
Situations Fund V, L.P., Avenue Capital Partners V,
LLC, GL Partners V, LLC and Marc Lasry with the SEC on
November 26, 2007 and Schedule 13G/A, Amendment
No. 2, filed by Avenue Capital Management II, L.P., Avenue
Capital Management II GenPar, LLC, Avenue Special
Situations Fund V, L.P., Avenue Capital Partners V,
LLC, GL Partners V, LLC, and Marc Lasry with the SEC on
March 11, 2008. The mailing address of each of the Avenue
Entities and of Marc Lasry is
c/o Avenue
Capital Management II, L.P., 535 Madison Avenue, 15th Floor, New
York, New York 10022.
|
|
(7) |
|
Includes 64,554 shares of our
common stock issuable upon exercise of warrants that are
exercisable within 60 days of May 31, 2008. Mariner
Investment Group, Inc., or Mariner, is an investment adviser
registered under Section 203 of the Investment Advisers Act
of 1940. Mariner furnishes investment advice to several
investment companies exempt from the Investment Company Act of
1940, and also serves as investment manager to certain other
separate accounts. In its role as investment adviser and
manager, Mariner possesses voting and/or investment power over
all of the shares of our common stock and warrants owned by
these investment companies and accounts, which is 100% of the
shares of our common stock and warrants described in the table
above as being held by Mariner. Mariner disclaims beneficial
ownership of all of these shares of our common stock and
warrants. The mailing address of Mariner is 500 Mamaroneck
Avenue, 4th Floor, Harrison, New York 10528. This information is
based on the Schedule 13G filed by Mariner with the SEC on
February 14, 2005, as amended by Schedule 13G/A,
Amendment No. 1, filed by Mariner on April 11, 2005,
Schedule 13G/A, Amendment No. 2, filed by Mariner on
February 13, 2007 and Schedule 13G/A, Amendment
No. 3, filed by Mariner on February 14, 2008.
|
|
(8) |
|
The mailing address of Merrill
Lynch, Pierce, Fenner & Smith, Incorporated is 4 World
Financial Center, New York, New York 10080. This information is
based on the Schedule 13G filed by Merrill Lynch, Pierce,
Fenner & Smith, Incorporated and Merrill
Lynch & Co., Inc. with the SEC on February 13,
2006.
|
|
(9) |
|
The mailing address of Northeast
Investors Trust is 150 Federal Street, Boston, Massachusetts
02110. This information is based on the Schedule 13G filed
by Northeast Investors Trust with the Securities and Exchange
Commission on February 13, 2003, as amended by Schedule
13G/A, Amendment No. 1, filed by Northeast Investors Trust
with the SEC on January 19, 2007.
|
None of the shares listed in the Beneficial Ownership Table have
been pledged by any of our Named Executive Officers, directors
or director nominees. We are not aware of any of our significant
stockholders pledging any of the shares listed in the Beneficial
Ownership Table in a manner that may result in a change of
control. We do not have any director qualifying shares.
92
CERTAIN
RELATIONSHIPS AND RELATED PARTY TRANSACTIONS
Transactions
Resurgence has beneficial ownership of a substantial majority of
the voting power of our securities due to its investment and
disposition authority over securities owned by its and its
affiliates managed funds and accounts. Currently,
Resurgence has beneficial ownership of 99% of our Series A
Preferred Stock and over 60% of our common stock, representing
ownership of over 84.837% of the total voting power of our
equity. Each share of our Series A Preferred Stock is
currently convertible at the option of the holder thereof at any
time into 1,000 shares of our common stock, subject to
adjustments. The holders of our Series A Preferred Stock
are entitled to designate a number of our directors roughly
proportionate to their overall equity ownership, but in any
event not less than a majority of our directors as long as they
hold in the aggregate at least 35% of the total voting power of
our equity. As a result, Resurgence has the ability to control
our management, policies and financing decisions, elect a
majority of our board of directors and control the vote on most
matters presented to a vote of our stockholders. In addition,
our shares of Series A Preferred Stock, almost all of which
are beneficially owned by Resurgence, carry a cumulative
dividend rate of 4% per quarter, payable in additional shares of
Series A Preferred Stock. Each dividend paid in additional
shares of our Series A Preferred Stock has a dilutive
effect on our shares of common stock and increases the
percentage of the total voting power of our equity beneficially
owned by Resurgence. In 2007 and the first two quarters of 2008,
we issued an additional 695.874 and 391.078 shares of our
Series A Preferred Stock, respectively (convertible into
695,874 and 391,078 shares of our common stock), in dividends,
which represents 13.6% of the current total voting power of our
equity securities and carries an aggregate liquidation value of
$14,992,449. Since the initial issuance of our Series A
Preferred Stock, we have issued an additional
3,008.713 shares of our Series A Preferred Stock
(convertible into 3,008,713 shares of our common stock,
respectively) in dividends, which represents 38.0% of the
current total voting power of our equity securities and carries
an aggregate liquidation value of $41,499,509. Four of our
directors, Messrs. Gidumal, Haney, Schwarzfeld and Sivin,
are employed by Resurgence. Pursuant to established policies of
Resurgence, all director compensation earned by employees of
Resurgence is paid to Resurgence. During 2007, we paid
Resurgence an aggregate amount equal to $150,000 for director
compensation earned by Messrs. Gidumal, Haney, Schwarzfeld
and Sivin. There were no expenses reimbursed by us to Resurgence
during 2007.
Approval
Process for Related Person Transactions and Other Conflicts of
Interest
Our Code of Ethics and Conduct. Under our Code
of Ethics and Conduct, each of our directors, officers and
employees is restricted from being subject, or even appearing to
be subject, to influences, interests or relationships that
conflict with our best interests. Specifically, our officers and
directors are prohibited from having any conflict of interest
unless the underlying transaction or relationship has been
specifically approved by our board of directors in accordance
with Delaware law and other applicable laws. Our Code of Ethics
and Conduct lists certain circumstances and situations that are
always considered to involve a conflict of interest, including
where one of our directors, officers or employees (or any other
person having a close personal relationship with him or her,
such as a family member, in-law, business associate or person
living in the same household):
|
|
|
|
|
obtains a significant financial or other beneficial interest in
one of our suppliers, customers or competitors;
|
|
|
|
engages in a significant personal business transaction involving
us for profit or gain;
|
|
|
|
accepts money, gifts of other than nominal value, excessive
hospitality, loans or other special treatment from one of our
suppliers, customers or competitors;
|
|
|
|
participates in any sale, loan or gift of our property; or
|
|
|
|
learns of a business opportunity through association with us and
discloses that opportunity to a third party or invests in that
opportunity without first offering us the right to invest in or
otherwise participate in that opportunity.
|
Each of our directors and officers, and each of our employees
who has the authority to direct or influence the use or
disposition of any significant amount of our funds or other
assets, is required to certify to us annually that he or she is
in full compliance with the provisions of our conflict of
interest policy (or disclose any potential or actual conflicts
with those provisions). Our directors make this certification
each year through their director and officer
93
questionnaires sent to them in advance of preparing our proxy
statement. The rest of our employees, including each of our
Named Executive Officers, make this certification each year as a
part of our annual ethics training program.
Our Corporate Governance Committee and Our Governance
Principles. Under the Charter for our Corporate
Governance Committee, our Corporate Governance Committee
considers all questions of independence of our board members and
possible conflicts of interest between us and one or more of our
board members or senior executives. If a conflict of interest
issue arises involving one of our directors or senior executive
officers, our Corporate Governance Committee makes
recommendation to our board of directors with respect to how
that conflict of interest should be resolved. As part of its
duties, our Corporate Governance Committee also acts on behalf
of our board of directors in overseeing all material aspects of
our compliance functions, including the development and revision
of corporate governance guidelines and principles for adoption
by our Board. Our General Counsel is in charge of our compliance
and monitoring programs, corporate information and reporting
systems, codes of conduct, policies, standards, practices and
procedures, including the day-to-day monitoring of compliance
matters by our officers and other employees. Through our
Governance Principles, which were adopted by our board of
directors on the recommendation of our Corporate Governance
Committee, our board of directors expressed its expectation that
all of our directors, officers and employees will act ethically
at all times and comply with our Code of Ethics and Conduct and
our Code of Ethics for Chief Executive Officer and Senior
Financial Officers. Our Corporate Governance Principles require
each of our directors to report any actual or potential conflict
of interest that may arise for that director to our Corporate
Governance Committee and our General Counsel, and to recuse
himself or herself from any discussion or decision affecting his
or her personal, business or professional interest. Our Board is
authorized to consider and resolve any issues involving a
potentially interested director without that directors
participation, and may exclude that director from consideration
of specified Board matters. Our Board is also authorized to
consider and resolve any conflict of interest questions
involving our Chief Executive Officer or any of our Senior Vice
Presidents. Our Chief Executive Officer is authorized to
consider and resolve any conflict of interest questions
involving any of our other officers, with appropriate
observation of the principles and policies set by our Board.
As the payment of the fees and expenses of Resurgence and the
other items involving Resurgence referred to in
Transactions above did not present a conflict of
interest between us and any of our directors, officers or
employees, our procedures and policies described above did not
require a review of those transactions.
94
DESCRIPTION
OF CERTAIN INDEBTEDNESS
Unregistered
Notes
On March 29, 2007, we issued $150 million aggregate
principal amount of
101/4% senior
secured notes due 2015. Our unregistered notes are governed by
an indenture dated March 29, 2007 among us, Sterling
Energy, and U. S. Bank National Association, as trustee and
collateral agent. The terms of the unregistered notes are
identical to the terms of the registered notes in all material
respects, except for the transfer restrictions, registration
rights and additional interest provisions that relate only to
the unregistered notes.
Revolving
Credit Facility
Concurrently with the closing of the offering of unregistered
notes, we amended and restated our revolving credit facility.
Under our revolving credit facility, our borrowing capacity is
$50 million and our borrowing base, as of December 31,
2007, exceeded the maximum commitment under our revolving credit
facility, making the total credit available under our revolving
credit facility $50 million. However, the monetization of
accounts receivable and inventory associated with our exit from
the styrene business significantly decreased the borrowing base
under our revolving credit facility. As of March 31,2008,
total credit available under our revolving credit facility was
limited to $9.5 million due to this reduced borrowing base. In
response to the expected continued lower levels of accounts
receivable and inventory, as well as our lesser need for a
working capital facility, on June 30, 2008, we reduced our
commitment under our revolving credit facility to
$25 million. As of March 31, 2008, there were no loans
outstanding under our revolving credit facility, and we
had $4.1 million in letters of credit outstanding,
resulting in borrowing availability of $5.4 million. The
revolving credit facility has an initial term ending in 2012.
Our revolving credit facility is secured by first priority liens
on all of our accounts receivable, inventory and other specified
assets, as well as all of the issued and outstanding capital
stock of our guarantors, which is subject to a second priority
lien to secure the obligations under the notes and guarantees.
Borrowings under our revolving credit facility bear interest, at
our option, at an annual rate of either a base rate plus 0.0% to
0.50% or the LIBOR Rate plus 1.50% to 2.25%, depending on our
borrowing availability at such time. We are also required to pay
an aggregate commitment fee of 0.375% per year (payable monthly)
on any unused portion. Available credit is subject to a monthly
borrowing base of 85% of eligible accounts receivable plus 65%
of eligible inventory.
Our revolving credit facility contains numerous covenants and
conditions, including, but not limited to, restrictions on our
ability to incur indebtedness, create liens, sell assets, make
investments, make capital expenditures, engage in mergers and
acquisitions and pay dividends. Our revolving credit facility
also includes various circumstances and conditions that would,
upon their occurrence and subject in certain cases to notice and
grace periods, create an event of default thereunder.
95
DESCRIPTION
OF NOTES
You can find the definitions of certain terms used in this
description under Certain
Definitions. In this description, Sterling
Chemicals, we, us or
our refers only to Sterling Chemicals, Inc., the
issuer of the notes, and not to any of its Subsidiaries.
Sterling Chemicals issued the unregistered notes, and will issue
the registered notes, under the indenture among itself, the
Guarantors from time to time thereunder and U. S. Bank
National Association, as trustee and collateral agent. The terms
of the notes include those stated in the indenture and those
made part of the indenture by reference to the
Trust Indenture Act of 1939, as amended (the
TIA). The Collateral Documents described
below under Collateral define the
terms of the security interests securing the notes and the Note
Guarantees.
The following description is a summary of the material
provisions of the indenture and the Collateral Documents. It
does not restate the indenture and the Collateral Documents in
their entirety. We urge you to read the indenture and the
Collateral Documents because they, and not this description,
define your rights as Holders. Copies of the indenture and the
Collateral Documents are available as set forth below under
Where You Can Find More Information. Certain
defined terms used in this description but not defined below
under Certain Definitions have
the meanings assigned to them in the indenture and the
Collateral Documents.
The Holder of a note is treated as the owner of it for all
purposes.
Brief
Description of the Notes
The unregistered notes are and the registered notes will be:
|
|
|
|
|
general obligations of Sterling Chemicals;
|
|
|
|
secured, on a first priority basis, by security interests in all
of the assets of Sterling Chemicals and the Guarantors that
comprise the Primary Collateral, subject to Permitted Liens and
certain exceptions described under
Collateral below;
|
|
|
|
secured, on a second priority basis, by security interests in
all of the assets of Sterling Chemicals and the Guarantors that
comprise the Secondary Collateral, subject to Permitted Liens
and certain exceptions described under
Collateral below;
|
|
|
|
effectively subordinated to all Credit Facility Obligations, to
certain purchase money security interests, to certain capital
lease obligations and to all obligations secured by Permitted
Liens;
|
|
|
|
effectively senior to all existing and future unsecured senior
Indebtedness of Sterling Chemicals to the extent of the Note
Collateral owned by Sterling Chemicals;
|
|
|
|
senior in right of payment to any future subordinated
Indebtedness of Sterling Chemicals; and
|
|
|
|
unconditionally guaranteed on a joint and several basis by the
Guarantors.
|
Under certain circumstances, purchase money indebtedness and
capitalized lease obligations of Sterling Chemicals may be
secured by first priority security interests in the Note
Collateral, and the portion of the proceeds of such Note
Collateral to which Holders would be entitled, if any, would be
further diluted.
The Note
Guarantees
The unregistered notes are and the registered notes will be
guaranteed by substantially all of Sterling Chemicals
current and future Domestic Subsidiaries (other than Domestic
Subsidiaries that we designate as Unrestricted Subsidiaries).
Currently, we do not have any domestic subsidiaries.
Any Note Guarantee will be:
|
|
|
|
|
a general obligation of each Guarantor;
|
|
|
|
secured, on a first priority basis, by security interests in the
Primary Collateral owned by such Guarantor, subject to Permitted
Liens and certain exceptions described under
Collateral below;
|
96
|
|
|
|
|
secured, on a second priority basis, by security interests in
the Secondary Collateral owned by such Guarantor, subject to
Permitted Liens and certain exceptions described under
Collateral below;
|
|
|
|
effectively subordinated to all Credit Facility Obligations, to
certain purchase money security interests, to certain capital
lease obligations and to all obligations secured by Permitted
Liens;
|
|
|
|
effectively senior to all existing and future unsecured senior
Indebtedness of each Guarantor to the extent of the Note
Collateral owned by such Guarantor; and
|
|
|
|
senior in right of payment to any future subordinated
Indebtedness of the Guarantors.
|
Under certain circumstances, purchase money indebtedness and
capitalized lease obligations of a Guarantor may be secured by
first priority security interests in the Note Collateral, and
the portion of the proceeds of such collateral to which Holders
would be entitled, if any, would be further diluted.
Principal,
Maturity and Interest
Sterling Chemicals will issue the registered notes in fully
registered form in denominations of $1,000 and integral
multiples thereof. The notes are unlimited in aggregate
principal amount, of which $150.0 million in aggregate
principal amount were previously issued. Sterling Chemicals may
issue additional notes (additional notes)
from time to time, subject to the limitations set forth under
Certain Covenants Incurrence of
Indebtedness and Issuance of Preferred Stock. The
notes offered hereby and any additional notes will be
substantially identical to our outstanding unregistered notes
other than the issuance dates and the dates from which interest
will accrue. Unless the context otherwise requires, for all
purposes of the indenture and this Description of
Notes, references to the notes include the notes
offered hereby, our outstanding unregistered notes and all other
senior secured notes issued under the indenture. Any
unregistered notes that remain outstanding after the completion
of the exchange offer, together with the registered notes issued
in connection with the exchange offer, will be treated as a
single class of securities under the indenture. However, our
notes will not be fungible for U.S. federal income tax
purposes unless the issuance of additional notes satisfies the
requirements for a qualified reopening under the applicable
Regulations (as defined in Material U.S. Federal
Income Tax Consequences). Regardless of whether our notes
are fungible for U.S. federal income tax purposes, they may
have different CUSIP numbers, be represented by different global
notes or otherwise treated as separate classes of notes for
other purposes. Any additional notes issued after this offering
will be secured, equally and ratably, with the notes. As a
result, the issuance of additional notes will have the effect of
diluting the security interest of the Note Collateral for the
then outstanding notes.
The notes will mature on April 1, 2015.
Interest on the notes will accrue at the rate of
101/4%
per annum and will be payable in cash semi-annually in
arrears on April 1 and October 1. Interest on overdue
principal and interest will accrue at a rate that is 2% higher
than the then applicable interest rate on the notes. Sterling
Chemicals will make each interest payment to the holders of
record on the immediately preceding March 15 and
September 15.
Interest on the notes will accrue from the Issue Date or, if
interest has already been paid, from the date it was most
recently paid. Interest will be computed on the basis of a
360-day year
comprised of twelve
30-day
months. Additional Interest may accrue on the notes in certain
circumstances pursuant to the registration rights agreement
relating to the notes issued in connection with the offering of
our unregistered notes and will be due and payable when interest
on the notes is due and payable. Except to the extent the
context otherwise requires, references in this
Description of Notes to interest shall be
deemed to include the Additional Interest, if any.
Methods
of Receiving Payments on the Notes
If a Holder has given wire transfer instructions to Sterling
Chemicals, the paying agent will remit on behalf of Sterling
Chemicals all principal, interest and premium, if any, on that
Holders notes in accordance with those instructions. All
other payments on the notes will be made by check mailed to the
Holders at their addresses set forth in the register of Holders.
97
Paying
Agent and Registrar for the Notes
The trustee will initially act as paying agent and registrar.
Sterling Chemicals may change the paying agent or registrar
without prior notice to the Holders, and Sterling Chemicals or
any of its Subsidiaries may act as paying agent or registrar.
Transfer
and Exchange
A Holder may transfer or exchange notes in accordance with the
provisions of the indenture. Sterling Chemicals, the registrar
and the trustee may require a Holder, among other things, to
furnish appropriate endorsements and transfer documents in
connection with a transfer of notes. Holders will be required to
pay all taxes due on transfer. Neither Sterling Chemicals nor
the registrar will be required to transfer or exchange any note
selected for redemption. Also, neither Sterling Chemicals nor
the registrar will be required to transfer or exchange any note
for a period of 15 days before a selection of notes to be
redeemed.
Depository
Procedures
The following description of the operations and procedures of
DTC, Euroclear and Clearstream are provided solely as a matter
of convenience. These operations and procedures are solely
within the control of the respective settlement systems and are
subject to changes by them. Sterling Chemicals takes no
responsibility for these operations and procedures and urges
investors to contact the systems or their participants directly
to discuss these matters.
DTC has advised Sterling Chemicals that DTC is a limited-purpose
trust company organized under the laws of the State of New York,
a member of the Federal Reserve System, a banking
organization within the meaning of the New York Banking
Law, a clearing corporation within the meaning of
the New York Uniform Commercial Code and a clearing
agency registered under the Exchange Act. DTC was created
to hold the securities of its participating organizations, which
we refer to in this prospectus as participants, and to
facilitate the clearance and settlement of securities
transactions among its participants in such securities through
electronic book-entry changes in accounts of the participants,
thereby eliminating the need for physical movement of securities
certificates. DTCs participants include securities brokers
and dealers (which may include the initial purchasers), banks,
trust companies, clearing corporations and certain other
organizations some of whom (or their representatives) have
ownership interests in DTC. Access to DTCs book-entry
system is also available to others, such as banks, brokers,
dealers and trust companies, which we refer to in this
prospectus as indirect participants, that clear through or
maintain a custodial relationship with a participant, either
directly or indirectly. Persons who are not participants may
beneficially own notes held by or on behalf of DTC only through
the participants or the indirect participants. The ownership
interests in, and transfers of ownership interests in, each note
held by or on behalf of DTC are recorded on the records of the
participants and indirect participants.
All interests in a global note, including those held through
Euroclear or Clearstream, may be subject to the procedures and
requirements of DTC. Those interests held through Euroclear or
Clearstream also may be subject to the procedures and
requirements of such systems. Ownership of beneficial interests
in a global note will be shown on, and the transfer of that
ownership interest will be effected only through, records
maintained by DTC (with respect to participants interests)
or by the participants and the indirect participants (with
respect to the owners of beneficial interests in such global
note other than participants).
The laws of some jurisdictions require that certain purchasers
of securities take physical delivery of such securities in
definitive form. Such limits and such laws may impair the
ability to transfer beneficial interests in a global note.
Because DTC, Euroclear and Clearstream can act only on behalf of
their respective participants, which in turn act on behalf of
indirect participants and certain banks, the ability of a person
having beneficial interests in a global note to pledge such
interests to persons or entities that do not participate in the
DTC, Euroclear or Clearstream system, as applicable, or
otherwise take actions in respect of such interests, may be
affected by the lack of a physical certificate evidencing such
interests.
Payment of principal of and interest on notes represented by a
global note will be made in immediately available funds to DTC
or its nominee, as the case may be, as the sole registered owner
and the sole holder of the
98
notes represented thereby for all purposes under the indenture.
Under the terms of the indenture, Sterling Chemicals and the
trustee will treat the persons in whose names the notes,
including the global notes, are registered as the owners of the
notes for the purpose of receiving payments and for all other
purposes. Consequently, neither Sterling Chemicals, the trustee
nor any agent of Sterling Chemicals or the trustee has or will
have any responsibility or liability for:
|
|
|
|
|
any aspect of DTCs records or any participants or
indirect participants records relating to or payments made
on account of beneficial ownership interest in the global notes
or for maintaining, supervising or reviewing any of DTCs
records or any participants or indirect participants
records relating to the beneficial ownership interests in the
global notes; or
|
|
|
|
any other matter relating to the actions and practices of DTC or
any of its participants or indirect participants.
|
Sterling Chemicals has been advised by DTC that upon receipt of
any payment of principal of or interest on any global note, DTC
will immediately credit, on its book-entry registration and
transfer system, the accounts of participants with payments in
amounts proportionate to their respective beneficial interests
in the principal or face amount of such global note as shown on
the records of DTC. Sterling Chemicals expects that payments by
participants or indirect participants to owners of beneficial
interests in a global note held through such participants or
indirect participants will be governed by standing instructions
and customary practices as is now the case with securities held
for customer accounts registered in street name and
will be the sole responsibility of such participants and
indirect participants.
Neither Sterling Chemicals nor the trustee will be liable for
any delay by DTC or any of its participants in identifying the
beneficial owners of the notes, and Sterling Chemicals and the
trustee may conclusively rely on and will be protected in
relying on instructions from DTC or its nominee for all purposes.
Transfers between participants in DTC will be effected in
accordance with DTCs procedures, and will be settled in
same-day
funds, and transfers between participants in Euroclear and
Clearstream will be effected in accordance with their respective
rules and operating procedures. Cross-market transfers between
the participants in DTC, on the one hand, and Euroclear or
Clearstream participants, on the other hand, will be effected
through DTC in accordance with DTCs rules on behalf of
Euroclear or Clearstream, as the case may be, by its respective
depositary; however, such cross-market transactions will require
delivery of instructions to Euroclear or Clearstream, as the
case may be, by the counterparty in such system in accordance
with the rules and procedures and within the established
deadlines (Brussels time) of such system. Euroclear or
Clearstream, as the case may be, will, if the transaction meets
its settlement requirements, deliver instructions to its
respective depositary to take action to effect final settlement
on its behalf of delivering or receiving interests in the
relevant global note in DTC, and making or receiving payment in
accordance with normal procedures for
same-day
funds settlement applicable to DTC. Euroclear participants and
Clearstream participants may not deliver instructions directly
to the depositories for Euroclear or Clearstream.
DTC has advised Sterling Chemicals that it will take any action
permitted to be taken by a holder of notes only at the direction
of one or more participants to whose account DTC has credited
the interests in the global notes and only in respect of such
portion of the aggregate principal amount of the notes as to
which such participant or participants has or have given such
direction. However, if there is an event of default under the
notes, DTC reserves the right to exchange the global notes for
legended notes in certificated form, and to distribute such
notes to its participants.
So long as DTC or any successor depositary for a global note, or
any nominee, is the registered owner of such global note, DTC or
such successor depositary or nominee, as the case may be, will
be considered the sole owner or holder of the notes represented
by such global note for all purposes under the indenture and the
notes. Except as set forth above, owners of beneficial interests
in a global note will not be entitled to have the notes
represented by such global note registered in their names, will
not receive or be entitled to receive physical delivery of
certificated notes in definitive form and will not be considered
to be the owners or holders of any notes under such global note.
Accordingly, each person owning a beneficial interest in a
global note must rely on the procedures of DTC or any successor
depositary, and, if such person is not a participant, on the
procedures of the participant through which such person owns its
interest, to exercise any rights of a holder under the
indenture. Sterling Chemicals understands that
99
under existing industry practices, in the event that Sterling
Chemicals requests any action of holders or that an owner of a
beneficial interest in a global note desires to give or take any
action which a holder is entitled to give or take under the
Indenture, DTC or any successor depositary would authorize the
participants holding the relevant beneficial interest to give or
take such action and such participants would authorize
beneficial owners owning through such participants to give or
take such action or would otherwise act upon the instructions of
beneficial owners owning through them.
Although DTC has agreed to the foregoing procedures in order to
facilitate transfers of interests in global notes among
participants of DTC, it is under no obligation to perform or
continue to perform such procedures, and such procedures may be
discontinued at any time. Neither Sterling Chemicals nor the
trustee will have any responsibility for the performance by DTC
or its participants or indirect participants of their respective
obligations under the rules and procedures governing their
operations.
Certificated
Securities
Notes in certificated registered form shall be transferred to
all beneficial owners in exchange for their beneficial interests
in the global notes if (i) DTC notifies Sterling Chemicals
that it is unwilling or unable to continue as depository for the
global notes and a successor depository is not appointed by
Sterling Chemicals within 90 days of such notice or
(ii) an event of default has occurred under the indenture
and is continuing and the registrar has received a request from
the depository to issue notes in certificated registered form.
Note
Guarantees
A Guarantor may not sell or otherwise dispose of all or
substantially all of its assets to, or consolidate with or merge
with or into (whether or not such Guarantor is the surviving
Person), another Person, other than Sterling Chemicals or
another Guarantor, unless:
(1) immediately after giving effect to that transaction, no
Default or Event of Default exists; and
(2) either
(a) the Person acquiring the property in any such sale or
disposition or the Person formed by or surviving any such
consolidation or merger (if other than the Guarantor or Sterling
Chemicals):
(1) is a corporation, limited liability company or limited
liability partnership organized and existing under the laws of
the United States or any State thereof or the District of
Columbia; and
(2) assumes all the obligations of that Guarantor under the
indenture and its Note Guarantee pursuant to a supplemental
indenture and appropriate Collateral Documents reasonably
satisfactory to the trustee and in connection therewith shall
cause such instruments and Uniform Commercial Code financing
statements to be filed and recorded in such jurisdictions and
take such other actions as may be required by applicable law to
perfect or continue the perfection of the Note Lien created
under the Collateral Documents on the Note Collateral owned by
or transferred to such Person; or
(b) in the case of any such sale or disposition (including
by way of any such consolidation or merger), the Net Proceeds of
such sale or other disposition are applied in accordance with
the applicable provisions of the indenture.
The Note Guarantee of a Guarantor will be released:
(1) in connection with any sale or other disposition of all
or substantially all of the assets of that Guarantor (including
by way of merger, consolidation or otherwise) by Sterling
Chemicals or a Restricted Subsidiary of Sterling Chemicals, if
the sale or other disposition complies with the Asset
Sale provisions of the indenture;
(2) in connection with any sale or other disposition of all
of the Capital Stock of a Guarantor by Sterling Chemicals or a
Subsidiary of Sterling Chemicals, if the sale or other
disposition complies with the Asset Sale provisions
of the indenture;
100
(3) if Sterling Chemicals designates any Restricted
Subsidiary that is a Guarantor to be an Unrestricted Subsidiary
in accordance with the applicable provisions of the indenture;
(4) if Sterling Chemicals exercises its legal defeasance
option or its covenant defeasance option as described below
under Legal Defeasance and Covenant
Defeasance; or
(5) upon satisfaction and discharge of the indenture or
payment in full of the principal and premium, if any, and
accrued and unpaid interest on the notes and all other Note
Obligations that are then due and payable.
Collateral
Primary
Collateral
The payment of the principal of and interest and premium on the
unregistered notes are, and on the registered notes will be, and
the payment and performance of all other Note Obligations are
secured, on a first priority basis (to the extent attainable by
filing, recording, control or possession), by security interests
in the Primary Collateral as provided in the Collateral
Documents.
The Note Obligations are secured on a first priority basis by
all of the following property of Sterling Chemicals and the
Guarantors (whether now owned or existing or acquired or arising
after the Issue Date) (the Primary
Collateral):
(1) all equipment (including but not limited to the
Facilities);
(2) certain owned real property, improvements thereon,
plans related thereto, and permits and licenses in respect
thereof;
(3) contracts pertaining to the construction, use,
occupancy, possession, operation, management, leasing,
maintenance
and/or
ownership of such real property and improvements (but only to
the extent necessary or appropriate for the continued operation
of the Facilities located thereon and excluding contracts
relating to accounts receivable or inventory);
(4) all rights as lessor under leases for real property and
rents payable in connection therewith and as lessee under leases
for equipment;
(5) all books and records to the extent relating primarily
to any or all of the foregoing; and
(6) all proceeds of and all other profits, products, rents
or receipts arising from the collection, sale, lease, exchange,
assignment, licensing or other disposition or realization upon
the Primary Collateral described in clauses (1) through
(5) above, including, without limitation, proceeds of
insurance with respect to any or all of the foregoing
clauses (1) through (5); provided, however,
that in no event shall the Primary Collateral include any
proceeds, profits, products, rents or receipts that constitute
Secondary Collateral or general intangibles or other rights
arising under any contract, instrument, license or other
document as to which the grant of a security interest would
constitute a violation of a valid and enforceable restriction on
such grant in favor of the Person(s) (other than such grantor)
obligated on such contract, instrument, license or other
document (other than to the extent that any such prohibition
would be rendered ineffective pursuant to Sections 9-406, 9-407,
9-408 or
9-409 of the Uniform Commercial Code of any relevant
jurisdiction or any other applicable law or principles of
equity), unless and until any required consents shall have been
obtained.
Secondary
Collateral
The payment of the principal of and interest and premium on the
unregistered notes are, and on the registered notes will be, and
the payment and performance of all other Note Obligations are
secured, on a second priority basis (to the extent attainable by
filing, recording, control or possession), by security interests
in the Secondary Collateral as provided in the Collateral
Documents.
The Note Obligations are secured on a second priority basis by
all of the assets of Sterling Chemicals and the Guarantors not
constituting Primary Collateral pledged to secure the Credit
Facility Obligations (the Secondary
101
Collateral), including without limitation (whether
now owned or existing or acquired or arising after the Issue
Date):
(1) all accounts receivable;
(2) all inventory;
(3) the capital stock of Sterling Chemicals and the
guarantors direct subsidiaries;
(4) intellectual property;
(5) deposit accounts;
(6) investment property; and
(7) all proceeds of and all other profits, products, rents
or receipts arising from the collection, sale, lease, exchange,
assignment, licensing or other disposition or realization upon
the Secondary Collateral described above, including, without
limitation, proceeds of insurance with respect to any or all of
the foregoing; provided, however, that in no event
shall the Secondary Collateral include any proceeds, profits,
products, rents or receipts that constitute Primary Collateral
or general intangibles or other rights arising under any
contract, instrument, license or other document as to which the
grant of a security interest would constitute a violation of a
valid and enforceable restriction on such grant in favor of the
Person(s) (other than such grantor) obligated on such contract,
instrument, license or other document (other than to the extent
that any such prohibition would be rendered ineffective pursuant
to
Sections 9-406,
9-407, 9-408 or 9-409 of the Uniform Commercial Code of any
relevant jurisdiction or any other applicable law or principles
of equity), unless and until any required consents shall have
been obtained.
To the extent otherwise specifically permitted pursuant to the
terms of the indenture and the Collateral Documents as described
under Certain Definitions
Permitted Liens, the unregistered notes are, and the
registered notes will be, effectively subordinated to certain
existing and future secured Indebtedness to the extent of any of
Sterling Chemicals or its Subsidiaries assets
serving as collateral for such Indebtedness. For example, the
Credit Facility Obligations under the ABL Facility are secured
by a first priority lien on the Secondary Collateral, and
therefore the lenders thereunder would have the first right to
liquidate such Note Collateral following the occurrence of an
event of default under the ABL Facility. Therefore, the
unregistered notes are, and the registered notes will be,
effectively subordinated to the Credit Facility Obligations
under the ABL Facility to the extent that the proceeds of the
Secondary Collateral, on which the trustee for the unregistered
notes has (and the registered notes will have) a second priority
lien, are used to satisfy the Credit Facility Obligations under
the ABL Facility. In that event, any such amount of the
Secondary Collateral would no longer be available to satisfy the
Note Obligations.
After-Acquired
Property; Excluded Assets; Permitted Liens
The indenture and the Collateral Documents require that Sterling
Chemicals and its Restricted Subsidiaries grant to the trustee,
for its benefit and for the benefit of the Holders of notes, a
first priority Lien on all after-acquired property of the kinds
described above as Primary Collateral and a second priority Lien
on all after-acquired property of the kinds described above as
Secondary Collateral. In addition, any future Restricted
Subsidiaries will be required to guarantee the notes and
similarly grant Liens on their assets to the trustee, for its
benefit and for the benefit of the Holders of notes. The notes
will not be secured by a Lien on any assets constituting
Excluded Assets (as defined below).
In addition, the indenture permits Sterling Chemicals to incur
an aggregate of up to $5.0 million of capitalized lease
obligations and purchase money obligations, in each case,
without securing the notes with the assets securing such
obligations so long as the Liens securing such obligations are
Permitted Liens and the Indebtedness secured thereby otherwise
prohibits any other Liens thereon (together, the
Excluded Assets). The notes may also be
effectively subordinated to security interests on acquired
property or assets of acquired companies which are secured prior
to (and not in connection with) such acquisition; such security
interests will constitute Permitted Liens so long as they do not
extend to any assets other than those acquired. The indenture
also permits Sterling Chemicals and its Restricted Subsidiaries
to create other Permitted Liens.
102
Possession
and Use
Subject to and in accordance with the provisions of the
Collateral Documents and the indenture, so long as the trustee
or, with respect to the Secondary Collateral, the lenders under
the ABL Facility have not exercised their respective rights with
respect to the Note Collateral upon the occurrence and during
the continuance of an Event of Default, Sterling Chemicals will
have the right to remain in possession and retain exclusive
control of the Note Collateral, to operate the Note Collateral,
to alter or repair the Note Collateral and to collect, invest
and dispose of any income therefrom.
Release
of Note Liens
The Note Liens will be released in whole:
(1) if Sterling Chemicals exercises its legal defeasance
option or its covenant defeasance option as described below
under Legal Defeasance and Covenant
Defeasance;
(2) upon satisfaction and discharge of the indenture or
payment in full of the principal and premium, if any, and
accrued and unpaid interest on the notes and all other Note
Obligations that are then due and payable; or
(3) with the written consent of at least 75% in aggregate
principal amount of the outstanding notes.
The Note Liens will be released in part with respect to any
asset constituting Note Collateral:
(1) upon delivery by Sterling Chemicals to the collateral
agent of an Officers Certificate certifying that the asset
has been sold or otherwise disposed of by Sterling Chemicals or
a Restricted Subsidiary to a Person other than Sterling
Chemicals or a Guarantor in a transaction permitted by the
indenture, at the time of such sale or disposition;
(2) upon delivery by Sterling Chemicals to the collateral
agent of an Officers Certificate certifying that the asset
is owned or has been acquired by a Guarantor that has been
released from its Note Guarantee (including by virtue of
(x) a Guarantor becoming an Unrestricted Subsidiary or
(y) a sale by Sterling Chemicals or a Subsidiary thereof of
all of the Capital Stock of a Guarantor); or
(3) upon delivery by Sterling Chemicals to the collateral
agent of an Officers Certificate certifying that, to the
extent any of such Note Collateral is comprised of Secondary
Collateral, such release is required pursuant to the terms of
the Intercreditor Agreement.
Disposition
of Note Collateral Without Release
Notwithstanding the provisions of Release
of Note Liens above, so long as no Default or Event of
Default under the indenture shall have occurred and be
continuing or would result therefrom and so long as such
transaction would not violate the indenture, Sterling Chemicals
and the Guarantors may, to the extent permitted by applicable
law, without any release or consent by the trustee, conduct
ordinary course activities with respect to inventory and
accounts receivable, including selling inventory or otherwise
disposing of, in any transaction or series of related
transactions, any property subject to the lien of the Collateral
Documents which has become worn out, defective or obsolete or
not used or useful in the business and which is, to the extent
required by the indenture or the Collateral Documents, replaced
by property of substantially equivalent or greater value which
becomes subject to the Lien of the Collateral Documents as
After-Acquired Property. Sterling Chemicals is obligated to
deliver to the trustee, within 30 calendar days following the
end of each year, an officers certificate to the effect
that all releases and withdrawals during the preceding
twelve-month period in which no release or consent of the
trustee was obtained were in the ordinary course of Sterling
Chemicals business and were not prohibited by the
indenture.
Enforcement
and Foreclosure
If an Event of Default occurs under the indenture, the trustee,
on behalf of the Holders of the notes, in addition to any rights
or remedies available to it under the indenture, will be
entitled to take such actions as the trustee deems advisable to
protect and enforce its rights in the Note Collateral,
including, without limitation, the institution of
103
foreclosure proceedings in accordance with the Collateral
Documents and applicable law. However, the rights and remedies
available to the trustee under the Collateral Documents and the
actions permitted to be taken by it thereunder are subject to
the provisions of the Intercreditor Agreement.
The trustee will apply the proceeds received by the trustee from
any foreclosure of the Note Collateral,
|
|
|
|
|
first, to pay the expenses of such foreclosure and fees and
other amounts then payable to the trustee under the indenture
and the Collateral Documents, and
|
|
|
|
thereafter, to pay the principal of, premium, if any, and
accrued interest on the notes;
|
provided, that the application of any such proceeds of
Note Collateral that constitutes Secondary Collateral shall be
subject to the terms of the Intercreditor Agreement.
Under the terms of the indenture and the Collateral Documents,
except as described under Possession and
Use and Release of Note
Liens, the trustee (upon the written instruction of a
specified percentage of the Holders of the notes to the extent
required by the trustee or the TIA) will determine the
circumstances under, and manner in, which to dispose of the
Primary Collateral, including, without limitation, the
determination of whether to release all or any portion of
Primary Collateral from the Note Liens created by the Collateral
Documents and whether to foreclose on such Primary Collateral
following an Event of Default. The ability of the trustee to
control any foreclosure with respect to any of the Secondary
Collateral (including, without limitation, the time or method)
is limited by the terms of the Intercreditor Agreement. See
Intercreditor Agreement. The
trustee may also have rights with respect to other assets
included as Note Collateral but which are subject to a Permitted
Lien.
The right of the trustee to repossess and dispose of Note
Collateral upon the occurrence of an Event of Default under the
indenture is, in the case of the Secondary Collateral, subject
to the provisions of the Intercreditor Agreement. With respect
to any of the Note Collateral, the right of the trustee to
repossess and dispose of Note Collateral upon the occurrence of
an Event of Default under the indenture, is likely to be
significantly impaired by applicable bankruptcy law if a
bankruptcy case were to be commenced by or against Sterling
Chemicals or any applicable Guarantor prior to the trustee
having repossessed and disposed of the Note Collateral. In the
case of real property Note Collateral, such right could be
significantly impaired by restrictions under state law.
The indenture permits the release of Note Collateral without the
substitution of additional Note Collateral under the
circumstances described under Certain
Covenants Asset Sales. Note Collateral of
a Guarantor will also be released as security for the applicable
Note Guarantee upon the release of such Guarantors Note
Guarantee. See Release of Note
Liens.
The amounts realizable by the trustee in respect of the Note
Collateral in the event of a liquidation will depend upon market
and economic conditions at such time, the availability of
buyers, certain existing Liens and similar factors.
The fact that the lenders under the ABL Facility have a first
priority Lien on the Secondary Collateral and that other
obligors may benefit from other Permitted Liens could have a
material adverse effect on the amount that would be realized
upon a liquidation of the Primary Collateral. Although Sterling
Chemicals has received an appraisal of the assets constituting a
portion of the Note Collateral, it cannot assure you that
proceeds of any sale of the Note Collateral pursuant to the
indenture and the related Collateral Documents following an
Event of Default will be sufficient to satisfy amounts due under
the notes. In addition, the trustee will not have any Liens on
Excluded Assets. See Risk Factors Risks
Related to the Notes There may not be sufficient
collateral to pay all or any of the notes. If the
proceeds of the Note Collateral are not sufficient to repay all
amounts due on the notes, the Holders of the notes (to the
extent not repaid from the proceeds of the sale of the Note
Collateral) will have only an unsecured claim against the
remaining assets, if any, of Sterling Chemicals and any
Guarantors. See Intercreditor
Agreement.
Some or all of the Note Collateral, particularly the Primary
Collateral, is illiquid and may have no readily ascertainable
market value. Moreover, there can be no assurance that such Note
Collateral will be saleable, or, if saleable, that there will
not be substantial delays in its liquidation. To the extent that
Liens, rights or easements granted to third parties encumber
assets owned by Sterling Chemicals and the Guarantors, including
the Secondary Collateral, those third parties may be entitled to
exercise rights and remedies with respect to the property
subject to
104
such Liens that could adversely affect the value of the Note
Collateral and the ability of the trustee or the Holders of the
notes to realize or foreclose on the Note Collateral. See
Risk Factors Risks Related to the
Notes There may not be sufficient collateral to pay
all or any of the notes.
Certain
Bankruptcy Limitations
Bankruptcy law could prevent the trustee from repossessing and
disposing of, or otherwise exercising remedies in respect of,
the Note Collateral upon the occurrence of an Event of Default
if a bankruptcy proceeding were to be commenced by or against
Sterling Chemicals or the Guarantors prior to the trustee having
repossessed and disposed of, or otherwise exercised remedies in
respect of, the Note Collateral. Under the Bankruptcy Code, a
secured creditor such as the trustee is prohibited from
repossessing its security from a debtor in a bankruptcy case, or
from disposing of security repossessed from such debtor, without
bankruptcy court approval. Moreover, the Bankruptcy Code permits
the debtor to continue to retain and to use collateral even
though the debtor is in default under the applicable debt
instruments; provided that the secured creditor is given
adequate protection. The meaning of the term
adequate protection may vary according to
circumstances, but it is intended in general to protect the
value of the secured creditors interest in the collateral.
The court may find adequate protection if the debtor
pays cash or grants additional security, if and at such times as
the court in its discretion determines, for any diminution in
the value of the collateral during the pendency of the
bankruptcy case. In view of the lack of a precise definition of
the term adequate protection and the broad
discretionary powers of a bankruptcy court, it is impossible to
predict how long payments with respect to the notes could be
delayed following commencement of a bankruptcy case, whether or
when the trustee could repossess or dispose of the Note
Collateral or whether or to what extent Holders would be
compensated for any delay in payment or loss of value of the
Note Collateral through the requirement of adequate
protection.
In addition, the trustee may need to evaluate the impact of
potential liabilities before determining to foreclose on the
Note Collateral, because lenders that hold a security interest
in real property may be held liable under environmental laws for
the costs of remediating or preventing release or threatened
releases of hazardous substances at the secured property. In
this regard, the trustee may decline to foreclose on the secured
property or exercise remedies available if it does not receive
indemnification to its satisfaction from the Holders. Finally,
the trustees ability to foreclose on the Note Collateral
on your behalf may be subject to lack of perfection, the consent
of third parties, prior Liens and practical problems associated
with the realization of the trustees Note Lien on the Note
Collateral.
Intercreditor
Agreement
First Lien Obligations; Notes Effectively Subordinated to
First Lien Obligations. The Credit Facility
Obligations are, and certain other Indebtedness permitted under
the indenture may be, secured by a Lien on the Secondary
Collateral, which Lien is contractually senior to the Lien
thereon that secures the notes and the Note Guarantees pursuant
to the Intercreditor Agreement. The Credit Facility Obligations
are referred to in this discussion of the Intercreditor
Agreement as First Lien Obligations, which Obligations are
entitled to the benefits of the provisions of the Intercreditor
Agreement to the extent that the aggregate principal amount
thereof does not exceed $55.0 million. By their acceptance
of the unregistered notes, the Holders were deemed to have
authorized the collateral agent to enter into the Intercreditor
Agreement with the Credit Facility Agent. As a result, the notes
are effectively subordinated to the First Lien Obligations to
the extent of the value of the Secondary Collateral
Relative Priorities. The Intercreditor
Agreement provides that notwithstanding the date, manner or
order of grant, attachment or perfection of any Lien on
Secondary Collateral securing the notes or Note Guarantees (a
Second Priority Lien) or any Lien on
Secondary Collateral securing the First Lien Obligations (a
First Priority Lien), and notwithstanding any
provision of the Uniform Commercial Code of any applicable
jurisdiction or any other applicable law or the provisions of
any Indenture Document or any agreement, instrument or other
document evidencing or governing any First Lien Obligations
(collectively, the First Priority Debt
Documents and, together with the Indenture Documents,
the Debt Documents) or any other circumstance
whatsoever, each Agent (i.e., the Credit Facility Agent
and the collateral agent), for itself and on behalf of the
Secured Parties (i.e., the holders of the First Lien
Obligations and the Credit Facility Agent (collectively, the
First Priority Secured Parties) and the
Holders, the trustee and the collateral agent (collectively, the
Second Priority Secured Parties)) on whose
behalf
105
it acts in such capacity therefor, has agreed that, so long as
the First Lien Obligations have not been paid in full in cash,
(a) any First Priority Lien on Secondary Collateral then or
thereafter held by or for the benefit of any First Priority
Secured Party is senior in right, priority, operation, effect
and all other respects to any and all Second Priority Liens on
Secondary Collateral and (b) any Second Priority Lien on
Secondary Collateral then or thereafter held by or for the
benefit of any Second Priority Secured Party is junior and
subordinate in right, priority, operation, effect and all other
respects to any and all First Priority Liens on Secondary
Collateral, and the First Priority Liens on Secondary Collateral
is and remains senior in right, priority, operation, effect and
all other respects to any Second Priority Liens on Secondary
Collateral for all purposes, whether or not any First Priority
Liens on Secondary Collateral are subordinated in any respect to
any other Lien securing any other obligation of Sterling
Chemicals, any Guarantor or any other Person.
Prohibition on Contesting Liens. The
Intercreditor Agreement also provides that each Agent, for
itself and on behalf of the other Secured Parties on whose
behalf it acts in such capacity therefor, agrees that it will
not, and will waive any right to, contest or support any other
Person in contesting, in any proceeding (including any
insolvency or liquidation proceeding), the priority, validity or
enforceability of any Second Priority Lien on Secondary
Collateral or any First Priority Lien on Secondary Collateral,
as the case may be; provided that nothing in the
Intercreditor Agreement will be construed to prevent or impair
the rights of any Agent or any other Secured Party to enforce
the Intercreditor Agreement to the extent provided thereby.
Exercise of Rights and Remedies;
Standstill. In addition, the Intercreditor
Agreement provides that the Credit Facility Agent and the other
holders of First Lien Obligations have, at all times prior to
the payment in full in cash of the First Lien Obligations, have
the exclusive right to enforce rights and exercise remedies
(including any right of setoff) with respect to the Secondary
Collateral, or to commence or seek to commence any action or
proceeding with respect to such rights or remedies (including
any foreclosure action), in each case, without any consultation
with or the consent of the Collateral Agent or any other Second
Priority Secured Party and no Second Priority Secured Party has
any such right; provided, however, that
(i) the Second Priority Secured Parties are entitled to
take certain actions to preserve and protect their claims with
respect to the Secondary Collateral and actions to which
unsecured creditors are entitled to take (which in any event
cannot be in contravention to the limitations imposed on the
Second Priority Secured Parties in the Intercreditor Agreement),
in each case, to the extent set forth in the Intercreditor
Agreement and (ii) after a period of 180 days has
elapsed since the date on which the Collateral Agent has
delivered to the Credit Facility Agent written notice of the
acceleration of all or any portion of the notes (the
Standstill Period) the Second Priority
Secured Parties may enforce or exercise any rights or remedies
with respect to any Secondary Collateral subject to the
following proviso; provided further, however, that
notwithstanding the expiration of the Standstill Period or
anything in the Intercreditor Agreement to the contrary, in no
event may the Collateral Agent or any other Second Priority
Secured Party enforce or exercise any rights or remedies with
respect to any Secondary Collateral, or commence, join with any
Person at any time in commencing, or petition for or vote in
favor of any resolution for, any such action or proceeding, if
the Credit Facility Agent or any other First Priority Secured
Party shall have commenced, and shall be diligently pursuing,
the enforcement or exercise of any rights or remedies with
respect to such Secondary Collateral or any such action or
proceeding.
Automatic Release of Second Priority
Liens. The Intercreditor Agreement also provides
that if, in connection with (i) any disposition of any
Secondary Collateral permitted under the terms of the First
Priority Debt Documents or (ii) the enforcement or exercise
of any rights or remedies with respect to the Secondary
Collateral, including any disposition of Secondary Collateral,
the Credit Facility Agent, for itself and on behalf of the other
First Priority Secured Parties, releases any of the First
Priority Liens (in each case, a Release),
then the Second Priority Liens on such Secondary Collateral, and
the obligations of such Guarantor under its guarantee of the
notes, are automatically, unconditionally and simultaneously
released, and the collateral agent will, for itself and on
behalf of the other Second Priority Secured Parties, promptly
execute and deliver to the Credit Facility Agent, Sterling
Chemicals or such Guarantor, as the case may be, such
termination statements, releases and other documents as the
Credit Facility Agent, Sterling Chemicals or such Guarantor, as
the case may be, may reasonably request to effectively confirm
such Release; provided that, in the case of a disposition
of all or substantially all of the Secondary Collateral (other
than any such disposition in connection with the enforcement or
exercise of any rights or remedies with respect to the Secondary
Collateral), such release shall require the consent of the
Collateral Agent.
106
Waterfall. The Intercreditor Agreement also
provides that any Secondary Collateral or proceeds thereof
received by any Secured Party in connection with any disposition
of, or collection on, such Secondary Collateral upon the
enforcement or exercise of any right or remedy (including any
right of setoff) is applied as follows:
first, to the payment of costs and expenses of the
applicable Secured Party in connection with such enforcement or
exercise,
second, after all such costs and expenses have been paid
in full in cash, to the payment of the First Lien Obligations,
third, after all such costs and expenses and First Lien
Obligations have been paid in full in cash, to the payment of
the Note Obligations, and
fourth, after all such costs and expenses, all First Lien
Obligations and all Note Obligations have been paid in full in
cash, any surplus Secondary Collateral or proceeds then
remaining will be returned to Sterling Chemicals, the applicable
Guarantor or to whosoever may be lawfully entitled to receive
the same or as a court of competent jurisdiction may direct.
Turnover. The Intercreditor Agreement also
provides that so long as the First Lien Obligations have not
been paid in full in cash, any Secondary Collateral or any
proceeds thereof received by the collateral agent or any other
Second Priority Secured Party in connection with any disposition
of, or collection on, such Secondary Collateral upon the
enforcement or the exercise of any right or remedy (including
any right of setoff) with respect to the Secondary Collateral,
or in connection with any insurance policy claim or any
condemnation award (or deed in lieu of condemnation), will be
segregated and held in trust and forthwith transferred or paid
over to the Credit Facility Agent for the benefit of the First
Priority Secured Parties in the same form as received, together
with any necessary endorsements, or as a court of competent
jurisdiction may otherwise direct.
Insolvency or Liquidation Proceedings. The
Intercreditor Agreement also provides that:
Finance and Sale Matters. (a) Until the
First Lien Obligations have been paid in full, the collateral
agent, for itself and on behalf of the other Second Priority
Secured Parties, has agreed that, in the event of any insolvency
or liquidation proceeding, the Second Priority Secured Parties:
(i) will not oppose or object to the use of any Secondary
Collateral constituting cash collateral under Section 363
of the Bankruptcy Code, or any comparable provision of any other
bankruptcy law, unless the First Priority Secured Parties, or a
representative authorized by the First Priority Secured Parties,
shall oppose or object to such use of cash collateral;
(ii) will not oppose or object to any post-petition
financing, whether provided by the First Priority Secured
Parties or any other Person, under Section 364 of the
Bankruptcy Code, or any comparable provision of any other
bankruptcy law (a DIP Financing), or the
Liens on Secondary Collateral to secure any DIP Financing
(DIP Financing Liens), unless the First
Priority Secured Parties, or a representative authorized by the
First Priority Secured Parties, shall then oppose or object to
such DIP Financing or such DIP Financing Liens, and, to the
extent that such DIP Financing Liens are senior to, or rank
pari passu with, the First Priority Liens, the Collateral
Agent will, for itself and on behalf of the other Second
Priority Secured Parties, subordinate the Second Priority Liens
on Secondary Collateral to the First Priority Liens and the DIP
Financing Liens thereon in accordance with the terms of the
Intercreditor Agreement;
(iii) except to the extent permitted by paragraph
(b) below, in connection with the use of cash collateral as
described in clause (i) above or a DIP Financing, will not
request adequate protection or any other relief in connection
with such use of cash collateral, DIP Financing or DIP Financing
Liens; and
(iv) will not oppose or object to any disposition of any
Secondary Collateral free and clear of the Second Priority Liens
or other claims under Section 363 of the Bankruptcy Code,
or any comparable provision of any other bankruptcy law, if the
First Priority Secured Parties, or a representative authorized
by the First Priority Secured Parties, shall consent to such
disposition.
107
(b) The collateral agent, for itself and on behalf of the
other Second Priority Secured Parties, has agreed that no Second
Priority Secured Party may contest, or support any other Person
in contesting, (i) any request by the Credit Facility Agent
or any other First Priority Secured Party for adequate
protection in respect of any First Lien Obligations or
(ii) any objection, based on a claim of a lack of adequate
protection with respect of any First Lien Obligations, by the
Credit Facility Agent or any other First Priority Secured Party
to any motion, relief, action or proceeding. Notwithstanding the
immediately preceding sentence, if, in connection with any DIP
Financing or use of cash collateral, any First Priority Secured
Party is granted adequate protection in the form of a Lien on
additional collateral, the collateral agent may, for itself and
on behalf of the other Second Priority Secured Parties, seek or
request adequate protection in the form of a Lien on such
additional collateral, which Lien will be subordinated to the
First Priority Liens and DIP Financing Liens on the same basis
as the other Second Priority Liens are subordinated to the First
Priority Liens under the Intercreditor Agreement.
(c) Notwithstanding the foregoing, the applicable
provisions of paragraphs (a) and (b) above are only be
binding on the Second Priority Secured Parties with respect to
any DIP Financing so long as (i) the principal amount of
such DIP Financing, when taken together with the aggregate
principal amount of the First Lien Obligations, does not exceed
$55.0 million and (ii) such DIP Financing is not
secured by any Primary Collateral.
Relief from the Automatic Stay. The Collateral
Agent, for itself and on behalf of the other Second Priority
Secured Parties, has agreed that, so long as the First Lien
Obligations have not been paid in full, no Second Priority
Secured Party may, without the prior written consent of the
Credit Facility Agent, seek or request relief from or
modification of the automatic stay or any other stay in any
insolvency or liquidation proceeding in respect of any part of
the Secondary Collateral, any proceeds thereof or any Second
Priority Lien.
Reorganization Securities. If, in any
insolvency or liquidation proceeding, debt obligations of the
reorganized debtor secured by Liens upon any property of the
reorganized debtor are distributed, pursuant to a plan of
reorganization or similar dispositive restructuring plan, on
account of the First Lien Obligations and the notes and Note
Guarantees, then, to the extent the debt obligations distributed
on account of the First Lien Obligations and on account of the
notes and Note Guarantees, the provisions of the Intercreditor
Agreement will survive the distribution of such debt obligations
pursuant to such plan and will apply with like effect to the
Liens securing such debt obligations.
Post-Petition Interest. The collateral agent,
for itself and on behalf of the other Second Priority Secured
Parties, has agreed that no Second Priority Secured Party may
oppose or seek to challenge any claim by the Credit Facility
Agent or any other First Priority Secured Party for allowance in
any insolvency or liquidation proceeding of First Lien
Obligations consisting of post-petition interest, fees or
expenses to the extent of the value of the First Priority Liens
(it being understood and agreed that such value will be
determined without regard to the existence of the Second
Priority Liens on the Secondary Collateral). The Credit Facility
Agent, for itself and on behalf of the other First Priority
Secured Parties, have agreed that the collateral agent or any
other Second Priority Secured Party may make a claim for
allowance in any insolvency or liquidation proceeding of Note
Obligations consisting of post-petition interest, fees or
expenses to the extent of the value of (i) the Second
Priority Liens (provided, however, that that if the First
Lien Secured Parties shall have made any such claim, such claim
shall have been approved prior to, or will be approved
contemporaneous with, the approval of any such claim by any
Second Lien Secured Party) and (ii) the Liens securing the
Note Obligations on the Primary Collateral.
Certain Waivers by the Second Priority Secured
Parties. The collateral agent, for itself and on
behalf of the other Second Priority Secured Parties, waives any
claim any Second Priority Secured Party may have against any
First Priority Secured Party arising out of (a) the
election by any First Priority Secured Party of the application
of Section 1111(b)(2) of the Bankruptcy Code, or any
comparable provision of any other bankruptcy law, or
(b) any use of cash collateral or financing arrangement, or
any grant of a security interest in the Secondary Collateral, in
any insolvency or liquidation proceeding, in each case, with
respect to the Secondary Collateral.
108
Certain Voting Matters. Each of the Credit
Facility Agent, on behalf of the First Priority Secured Parties
and the collateral agent on behalf of the Second Priority
Secured Parties, have agreed that, without the written consent
of the other, it will not seek to vote with the other as a
single class in connection with any plan of reorganization in
any insolvency or liquidation proceeding.
Postponement of Subrogation. The Intercreditor
Agreement also provides that the collateral agent has agreed
that no payment or distribution to any First Priority Secured
Party pursuant to the provisions of the Intercreditor Agreement
entitles any Second Priority Secured Party to exercise any
rights of subrogation in respect thereof until the First Lien
Obligations shall have been paid in full in cash.
Purchase Option. The Intercreditor Agreement
also provides that notwithstanding anything in the Intercreditor
Agreement to the contrary, following the acceleration of the
Indebtedness then outstanding under the First Priority Debt
Documents, the Second Priority Secured Parties may, at their
sole expense and effort, upon notice to Sterling Chemicals and
the Credit Facility Agent, require the First Priority Secured
Parties to transfer and assign to the Second Priority Secured
Parties, without warranty or representation or recourse, all
(but not less than all) of the First Lien Obligations;
provided that (x) such assignment may not conflict
with any law, rule or regulation or order of any court or other
governmental authority having jurisdiction, and (y) the
Second Priority Secured Parties shall have paid to the Credit
Facility Agent, for the account of the First Priority Secured
Parties, in immediately available funds, an amount equal to 100%
of the principal of such Indebtedness plus all accrued and
unpaid interest thereon plus all accrued and unpaid fees (other
than any fees that become due as a result of the prepayment the
loans and other advances under, or early termination of, the
First Priority Debt Documents (such fees, the
Termination Fees)) plus all the other First
Lien Obligations then outstanding (which will include, with
respect to (i) the aggregate face amount of the letters of
credit outstanding under the First Priority Debt Documents, an
amount in cash equal to 105% thereof, and (ii) each
interest rate hedging, cap, collar, swap or other similar
agreements that evidence any First Lien Obligations, 100% of the
aggregate amount of such First Lien Obligations, after giving
effect to any netting arrangements, that Sterling Chemicals or
the applicable Guarantor as the case may be, would be required
to pay if such interest rate hedging, cap, collar, swap or other
similar agreements were terminated at such time). In order to
effectuate the foregoing, the Credit Facility Agent will
calculate, upon the written request of the collateral agent from
time to time, the amount in cash that would be necessary to so
purchase the First Lien Obligations. If the right set forth in
this paragraph is exercised, the parties will agree to endeavor
to close promptly thereafter but in any event within ten
business days of the request set forth in the first sentence of
this paragraph. If the Second Priority Secured Parties exercise
the right set forth in this paragraph, it will be exercised
pursuant to documentation mutually acceptable to each of the
Credit Facility Agent and the collateral agent.
Optional
Redemptions
Optional Redemption Prior to April 1,
2011. Prior to April 1, 2011, Sterling
Chemicals may, at its option, on any one or more occasions
redeem all or a part of the notes upon not less than 30 nor more
than 60 days prior notice to the trustee, at a
redemption price equal to 100% of the principal amount of the
notes redeemed plus the Applicable Premium plus accrued and
unpaid interest, if any, to (but not including) the redemption
date.
Optional Redemption on or After April 1,
2011. On or after April 1, 2011, Sterling
Chemicals may, at its option, on any one or more occasions
redeem all or a part of the notes upon not less than
30 days nor more than 60 days prior notice
to the trustee, at the redemption prices (expressed as
percentages of principal amount) set forth below plus accrued
and unpaid interest to (but not including) the redemption date,
if redeemed during the twelve-month period beginning on April 1
of the years set forth below:
|
|
|
|
|
Year
|
|
Percentage
|
|
|
2011
|
|
|
105.125%
|
|
2012
|
|
|
102.563%
|
|
2013 and thereafter
|
|
|
100.000%
|
|
Optional Redemption Upon Equity
Offerings. At any time prior to April 1,
2010, Sterling Chemicals may, at its option, on any one or more
occasions redeem, in whole or in part, up to 35% of the
aggregate principal amount of
109
notes originally issued under the indenture (including any
additional notes issued after the Issue Date) at a redemption
price of 110.25% of the principal amount of the notes redeemed,
plus accrued and unpaid interest on the notes redeemed to (but
not including) the applicable redemption date, with the net cash
proceeds of one or more Equity Offerings; provided that
(1) at least 65% of the aggregate principal amount of notes
originally issued under the indenture (including any additional
notes issued after the Issue Date) remains outstanding
immediately after the occurrence of such redemption and
(2) notice of redemption is mailed within 180 days
after the date of the closing of any such Equity Offering.
Selection and Notice. If less than all of the
notes are to be redeemed at any time, the trustee will select
notes for redemption as follows:
(1) if the notes are listed on any national securities
exchange, in compliance with the requirements of the principal
national securities exchange on which the notes are
listed; or
(2) if the notes are not listed on any national securities
exchange, on a pro rata basis.
No notes of $1,000 or less shall be redeemed in part. Notices of
redemption shall be mailed by first class mail at least
30 days but not more than 60 days before the
redemption date to each Holder of notes to be redeemed at its
registered address, except that redemption notices may be mailed
more than 60 days prior to a redemption date if the notice
is issued in connection with a defeasance of the notes or a
satisfaction and discharge of the indenture. Notices of
redemption may not be conditional.
If any note is to be redeemed in part only, the notice of
redemption that relates to that note will state the portion of
the principal amount of that note that is to be redeemed. A new
note in principal amount equal to the unredeemed portion of the
original note will be issued in the name of the Holder upon
cancellation of the original note. Notes called for redemption
become due on the date fixed for redemption. Unless Sterling
Chemicals defaults in the payment of the redemption price,
interest will cease to accrue on the notes or portions thereof
called for redemption on the applicable redemption date.
Mandatory
Redemption; Offers to Purchase; Open Market Purchases
Sterling Chemicals is not required to make mandatory redemption
or sinking fund payments with respect to the notes. However,
under certain circumstances, Sterling Chemicals may be required
to offer to purchase the notes as described under
Repurchase upon Change of Control,
Event of Loss and
Certain Covenants Asset
Sales. Sterling Chemicals may at any time and from
time to time purchase notes in the open market or otherwise.
Repurchase
upon Change of Control
If a Change of Control occurs, each Holder will have the right
to require Sterling Chemicals to repurchase all or any part
(equal to $1,000 or an integral multiple of $1,000) of such
Holders notes pursuant to a Change of Control Offer on the
terms set forth in the indenture. In the Change of Control
Offer, Sterling Chemicals will offer (a Change of
Control Offer) a Change of Control Payment in cash
equal to 101% of the aggregate principal amount of notes
repurchased plus accrued and unpaid interest, if any, on the
notes repurchased, to the date of repurchase (the
Change of Control Payment Date). Within
30 days following any Change of Control, Sterling Chemicals
will or will cause the Trustee to mail a notice to each Holder
describing the transaction or transactions that constitute the
Change of Control and offer to purchase all of the notes on the
Change of Control Payment Date specified in the notice, which
date will be no earlier than 30 days and no later than
60 days from the date such notice is mailed, pursuant to
the procedures required by the indenture and described in such
notice. Sterling Chemicals will comply with the requirements of
Rule 14e-1
under the Exchange Act and any other securities laws and
regulations thereunder to the extent those laws and regulations
are applicable in connection with the repurchase of the notes as
a result of a Change of Control. To the extent that the
provisions of any securities laws or regulations conflict with
the Change of Control provisions of the indenture, Sterling
Chemicals will comply with the applicable securities laws and
regulations and will not be deemed to have breached its
obligations under the Change of Control provisions of the
indenture by virtue of such compliance.
110
On the Change of Control Payment Date, Sterling Chemicals will,
to the extent lawful:
(1) accept for repurchase all notes or portions of notes
properly tendered pursuant to the Change of Control Offer;
(2) deposit with the paying agent an amount equal to the
Change of Control Payment in respect of all notes or portions of
notes properly tendered; and
(3) deliver or cause to be delivered to the trustee the
notes properly accepted together with an Officers
Certificate stating the aggregate principal amount of notes or
portions of notes being purchased by Sterling Chemicals.
The paying agent will promptly mail or wire transfer to each
Holder of notes properly tendered and so accepted the Change of
Control Payment for such notes, and the trustee will promptly
authenticate and mail (or cause to be transferred by book entry)
to each Holder a new note equal in principal amount to any
unpurchased portion of the notes surrendered, if any;
provided that each new note will be in a principal amount
of $1,000 or an integral multiple of $1,000. Any note so
accepted for repurchase will cease to accrue interest on and
after the Change of Control Payment Date. Sterling Chemicals
will publicly announce the results of the Change of Control
Offer on or as soon as reasonably practicable after the Change
of Control Payment Date.
The provisions described above that require Sterling Chemicals
to make a Change of Control Offer following a Change of Control
are applicable whether or not any other provisions of the
indenture are applicable. Except as described above with respect
to a Change of Control, the indenture does not contain
provisions that permit the Holders to require that Sterling
Chemicals repurchase the notes in the event of a takeover,
recapitalization or similar transaction.
Notwithstanding the above, Sterling Chemicals is not required to
make a Change of Control Offer upon a Change of Control if
(1) a third party makes the Change of Control Offer in the
manner, at the times and otherwise in compliance with the
requirements set forth in the indenture applicable to a Change
of Control Offer made by Sterling Chemicals and purchases all
notes properly tendered and not withdrawn under the Change of
Control Offer, or (2) a notice with respect to redemption
of all of the notes has been given pursuant to the indenture as
described above under Optional
Redemptions and Sterling Chemicals shall have redeemed
all such notes.
The definition of Change of Control includes a phrase relating
to the direct or indirect sale, lease, transfer, conveyance or
other disposition of all or substantially all of the
properties or assets of Sterling Chemicals and its Subsidiaries
taken as a whole. Although there is a limited body of case law
interpreting the phrase substantially all, there is
no precise established definition of the phrase under the laws
of the State of New York (which is the governing law of the
indenture). Accordingly, the ability of a Holder to require
Sterling Chemicals to repurchase its notes as a result of a
sale, lease, transfer, conveyance or other disposition of less
than all of the assets of Sterling Chemicals and its
Subsidiaries taken as a whole to another Person or group may be
uncertain.
Event of
Loss
In the event of an Event of Loss, Sterling Chemicals or the
affected Restricted Subsidiary of Sterling Chemicals, as the
case may be, may apply the Net Loss Proceeds from such Event of
Loss, with no concurrent obligation to offer to purchase any of
the notes either:
(a) to the rebuilding, repair, replacement or construction
of improvements to the property affected by such Event of Loss;
(b) to make capital expenditures with respect to Primary
Collateral or to acquire properties or assets that will:
(i) constitute Primary Collateral; and
(ii) be used in any Permitted Business of Sterling
Chemicals and its Restricted Subsidiaries, or
(c) for a combination of the actions set forth in the
foregoing clauses (a) and (b).
111
Any Net Loss Proceeds that are not reinvested as provided in the
first sentence of this covenant within 360 days of such
Event of Loss will be deemed Excess Loss
Proceeds. When the aggregate amount of Excess Loss
Proceeds exceeds $5.0 million, Sterling Chemicals will make
an offer (an Event of Loss Offer) to all
Holders to repurchase with the proceeds of Events of Loss the
maximum principal amount of notes that may be prepaid out of the
Excess Loss Proceeds. The offer price in any Event of Loss Offer
will be equal to 100% of the principal amount plus accrued and
unpaid interest to the date of repurchase, and will be payable
in cash. If any Excess Loss Proceeds remain after consummation
of an Event of Loss Offer, Sterling Chemicals may use such
Excess Loss Proceeds for any purpose not otherwise prohibited by
the indenture; provided that any remaining Net Loss
Proceeds shall remain subject to the Note Lien. If the aggregate
principal amount of notes tendered pursuant to an Event of Loss
Offer exceeds the Excess Loss Proceeds, the trustee will select
the notes to be repurchased on a pro rata basis based on
the aggregate principal amount of notes outstanding. Upon
completion of each Event of Loss Offer, the amount of Excess
Loss Proceeds will be reset at zero.
All Net Loss Proceeds shall, pending their application in
accordance with this covenant or the release thereof in
accordance with the provisions described under
Collateral Release of Note
Liens, be invested in Cash Equivalents or applied to
temporarily reduce revolving Indebtedness.
With respect to any Event of Loss pursuant to clause (4) of
the definition of Event of Loss that has a Fair
Market Value (or replacement cost, if greater) in excess of
$2.5 million, Sterling Chemicals (or the affected
Guarantor, as the case may be), shall be required to receive
consideration (i) at least equal to 75% of the Fair Market
Value (evidenced by a resolution of its Board of Directors set
forth in an Officers Certificate delivered to the trustee)
of the assets subject to the Event of Loss and (ii) at
least 75% of which is in the form of cash or Cash Equivalents.
To the extent that the provisions of any applicable laws or
regulations conflict with the Event of Loss provisions of the
indenture, Sterling Chemicals will comply with the applicable
laws and regulations and shall not be deemed to have breached
its obligations under the Event of Loss provisions of the
indenture by virtue of such compliance.
Sterling Chemicals will comply with the requirements of
Rule 14e-1
under the Exchange Act and any other securities laws and
regulations thereunder to the extent such laws or regulations
are applicable in connection with the repurchase of the notes
pursuant to an Event of Loss Offer. To the extent that the
provisions of any applicable securities laws or regulations
conflict with the provisions of the indenture, Sterling
Chemicals will comply with such securities laws and regulations
and shall not be deemed to have breached its obligations
described in the indenture by virtue thereof.
Certain
Covenants
The indenture contains, among others, the following covenants:
Restricted
Payments
Sterling Chemicals will not, and will not permit any of its
Restricted Subsidiaries to, directly or indirectly:
(1) declare or pay any dividend or make any other payment
or distribution on account of Sterling Chemicals or any of
its Restricted Subsidiaries Equity Interests (including,
without limitation, any payment in connection with any merger or
consolidation involving Sterling Chemicals or any of its
Restricted Subsidiaries) or to the direct or indirect holders of
Sterling Chemicals or any of its Restricted
Subsidiaries Equity Interests in their capacity as such
(other than dividends, payments or distributions payable in
Equity Interests (other than Disqualified Stock) of Sterling
Chemicals and other dividends, payments or distributions payable
to Sterling Chemicals or another Restricted Subsidiary of
Sterling Chemicals);
(2) purchase, redeem or otherwise acquire or retire for
value (including, without limitation, in connection with any
merger or consolidation involving Sterling Chemicals) any Equity
Interests of Sterling Chemicals or any direct or indirect parent
of Sterling Chemicals other than those Equity Interests owned by
Sterling Chemicals or any Restricted Subsidiary of Sterling
Chemicals;
112
(3) make any payment on or with respect to, or purchase,
redeem, repurchase, defease or otherwise acquire or retire for
value, any Indebtedness of Sterling Chemicals or any Guarantor
that is contractually subordinated in right of payment to the
notes or any Note Guarantee (excluding (x) any intercompany
Indebtedness between or among Sterling Chemicals and any of the
Guarantors or (y) the purchase, repurchase or other
acquisition or retirement for value of Indebtedness that is
contractually subordinated to the notes or to any Note
Guarantee, as the case may be, purchased in anticipation of
satisfying a sinking fund obligation, principal installment or
final maturity, in each case due within one year of the date of
purchase, repurchase or acquisition or retirement for value),
except a payment of interest or principal at the Stated Maturity
thereof; or
(4) make any Restricted Investment
(all such payments and other actions set forth in these
clauses (1) through (4) above being collectively
referred to as Restricted Payments),
unless, at the time of and after giving effect to such
Restricted Payment:
(1) no Default or Event of Default has occurred and is
continuing or would occur as a consequence of such Restricted
Payment;
(2) Sterling Chemicals would, at the time of such
Restricted Payment and after giving pro forma effect
thereto as if such Restricted Payment had been made at the
beginning of the applicable four-quarter period, have been
permitted to incur at least $1.00 of additional Indebtedness
pursuant to the Fixed Charge Coverage Ratio test set forth in
the first paragraph of the covenant described below under
Incurrence of Indebtedness and Issuance of
Preferred Stock; and
(3) such Restricted Payment, together with the aggregate
amount of all other Restricted Payments made by Sterling
Chemicals and its Restricted Subsidiaries since the Issue Date
(excluding Restricted Payments permitted by clauses (2), (3),
(4), (6), (8) and (9) of the next succeeding
paragraph), is less than the sum, without duplication, of:
(a) 50% of the Consolidated Net Income of Sterling
Chemicals for the period (taken as one accounting period) from
the beginning of the first fiscal quarter commencing after the
Issue Date to the end of Sterling Chemicals most recently
ended fiscal quarter for which internal financial statements are
available at the time of such Restricted Payment (or, if such
Consolidated Net Income for such period is a deficit, less 100%
of such deficit), plus
(b) 100% of the aggregate net proceeds, including cash and
the Fair Market Value of the property other than cash, received
by Sterling Chemicals since the Issue Date as a contribution to
its common equity capital and from the issue or sale of Equity
Interests of Sterling Chemicals (other than Disqualified Stock)
or from the issue or sale of convertible or exchangeable
Disqualified Stock or convertible or exchangeable debt
securities of Sterling Chemicals that have been converted into
or exchanged for such Equity Interests (other than Equity
Interests (or Disqualified Stock or debt securities) sold to a
Subsidiary of Sterling Chemicals); provided,
however, that Sterling Chemicals may not include the net
cash proceeds to the extent that any such common equity capital
or Equity Interests are repurchased, redeemed or otherwise
acquired or retired pursuant to clauses (2) and (5)(x) of
the subsequent paragraph of this covenant or applied to redeem
any notes pursuant to Optional
Redemption Optional Redemption Upon Equity
Offerings, plus
(c) to the extent that any Restricted Investment that was
made after the Issue Date is sold for cash or otherwise
liquidated or repaid for cash, the cash and the Fair Market
Value of property other than cash received as return of capital
with respect to such Restricted Investment (less the cost of
disposition, if any), plus
(d) to the extent that any Unrestricted Subsidiary of
Sterling Chemicals designated as such after the Issue Date is
redesignated as a Restricted Subsidiary after the Issue Date or
has been merged into, consolidated or amalgamated with or into,
or transfers or conveys its assets to, Sterling Chemicals or a
Restricted Subsidiary of Sterling Chemicals, the Fair Market
Value of Sterling Chemicals Investment in such Subsidiary
as of the date of such redesignation, combination or transfer
(or of the assets transferred
113
or conveyed, as applicable) after deducting any Indebtedness
associated with the Unrestricted Subsidiary so designated or
combined or any Indebtedness associated with the assets so
transferred or conveyed, plus
(e) 50% of any dividends or distributions received by
Sterling Chemicals or a Wholly-Owned Restricted Subsidiary of
Sterling Chemicals that is a Guarantor after the Issue Date from
an Unrestricted Subsidiary of Sterling Chemicals, to the extent
that such dividends or distributions were not otherwise included
in Consolidated Net Income of Sterling Chemicals for such period.
In the case of clause (3)(b) above, any net cash proceeds from
issuances and sales of Capital Stock of Sterling Chemicals
financed directly or indirectly using funds borrowed from
Sterling Chemicals or any Subsidiary of Sterling Chemicals,
shall be excluded until and to the extent such borrowing is
repaid.
The preceding provisions do not prohibit:
(1) the payment, by Sterling Chemicals or any Restricted
Subsidiary, of any dividend or distribution or the consummation
of any redemption within 60 days after the date of
declaration of the dividend or distribution or giving of the
redemption notice, as the case may be, if at the date of
declaration or notice, the dividend, distribution or redemption
payment would have complied with the provisions of the indenture;
(2) the making of any Restricted Payment in exchange for,
or out of the net cash proceeds of the substantially concurrent
sale (other than to a Subsidiary of Sterling Chemicals) of,
Equity Interests of Sterling Chemicals (other than Disqualified
Stock) or from the substantially concurrent contribution of
common equity capital to Sterling Chemicals; provided
that the amount of any such net cash proceeds that are
utilized for any such Restricted Payment will be excluded from
clause (3)(b) of the preceding paragraph;
(3) the defeasance, redemption, repurchase, retirement or
other acquisition or retirement for value of Indebtedness of
Sterling Chemicals or any Restricted Subsidiary that is
contractually subordinated in right of payment to the notes or
to any Note Guarantee with, in exchange for, by conversion into
or out of the net cash proceeds from a substantially concurrent
incurrence of, or in exchange for, Permitted Refinancing
Indebtedness;
(4) the payment of any dividend (or, in the case of any
limited partnership or limited liability company, any similar
distribution) by a Restricted Subsidiary of Sterling Chemicals
to Sterling Chemicals or another Restricted Subsidiary of
Sterling Chemicals;
(5) the repurchase, redemption or other acquisition or
retirement for value of any Equity Interests of Sterling
Chemicals or any Restricted Subsidiary of Sterling Chemicals
held by any current or former officer, director or employee of
Sterling Chemicals or any of its Restricted Subsidiaries
pursuant to any equity subscription agreement, stock option
agreement, shareholders or members agreement or
similar agreement, plan or arrangement, provided that the
aggregate price paid for all such repurchased, redeemed,
acquired or retired Equity Interests may not exceed
$2.0 million for each fiscal year (with unused amounts in
any calendar year being permitted to be carried over into
succeeding calendar years) and $5.0 million in the
aggregate during the term of the notes; provided further that
the amount in any calendar year may be increased by an amount
not to exceed the sum of (x) in each case net of the
aggregate net cash proceeds received from such persons after the
Issue Date from the issuance of or equity contributions with
respect to our Equity Interests (other than Disqualified Stock)
of Sterling Chemicals to officers, employees, directors or
consultants of Sterling Chemicals and its Restricted
Subsidiaries that occurs after the Issue Date, to the extent
such net cash proceeds have not otherwise been previously
applied to the payment of any Restricted Payments and
(y) the cash proceeds of key man insurance received by
Sterling Chemicals or any Restricted Subsidiary after the Issue
Date, to the extent such cash proceeds have not otherwise been
previously applied to the payment of Restricted Payments
(Sterling Chemicals being entitled to elect to use all or any
portion of the aggregate increase contemplated by
clauses (x) and (y) within one year of such net cash
proceeds being received by Sterling Chemicals);
(6) the repurchase of Equity Interests deemed to occur upon
the exercise of stock options, warrants or similar rights to the
extent such Equity Interests represent a portion of the exercise
price of those stock options, warrants or similar rights or the
payment of related withholding taxes;
114
(7) the declaration and payment of regularly scheduled or
accrued dividends to holders of any class or series of
Disqualified Stock of Sterling Chemicals or any Restricted
Subsidiary of Sterling Chemicals issued on or after the Issue
Date in accordance with the Fixed Charge Coverage Ratio test
described below under Incurrence of
Indebtedness and Issuance of Preferred Stock;
(8) the satisfaction of change of control obligations once
Sterling Chemicals has fulfilled its obligations under the
indenture with respect to a Change of Control;
(9) the repayment of intercompany debt to Sterling
Chemicals or any Guarantor that was permitted to be incurred
under the indenture;
(10) other Restricted Payments in an aggregate amount then
outstanding not to exceed $5.0 million since the Issue
Date; and
(11) the pledge by Sterling Chemicals or any Restricted
Subsidiary of the Capital Stock of an Unrestricted Subsidiary of
Sterling Chemicals or such Restricted Subsidiary, as applicable,
to secure Non-Recourse Debt of such Unrestricted Subsidiary.
The amount of all Restricted Payments (other than cash) will be
the Fair Market Value on the date of the Restricted Payment of
the asset(s) or securities proposed to be transferred or issued
by Sterling Chemicals or such Restricted Subsidiary, as the case
may be, pursuant to the Restricted Payment. The Fair Market
Value of any assets or securities that are required to be valued
by this covenant will be determined by Sterling Chemicals or, if
such Fair Market Value is in excess of $5.0 million, by the
relevant Board of Directors, whose resolution with respect
thereto will be delivered to the trustee. In the case of a
determination of Fair Market Value in excess of
$10.0 million, such Board of Directors determination
must be based upon an opinion or appraisal issued by an
accounting, appraisal or investment banking firm of national
standing. In determining whether any Restricted Payment is
permitted by the covenant described above, Sterling Chemicals
may allocate all or any portion of such Restricted Payment among
the categories described in clauses (1) through
(11) of the immediately preceding paragraph or among such
categories and the types of Restricted Payments described in the
first paragraph under Restricted
Payments above; provided that at the time of
such allocation, all such Restricted Payments, or allocated
portions thereof, would be permitted under the various
provisions of the covenant described above.
Incurrence
of Indebtedness and Issuance of Preferred Stock
Sterling Chemicals will not, and will not permit any of its
Restricted Subsidiaries to, directly or indirectly, create,
incur, issue, assume, guarantee or otherwise become directly or
indirectly liable, contingently or otherwise, with respect to
(collectively, incur) any Indebtedness
(including Acquired Debt), and Sterling Chemicals will not issue
any Disqualified Stock and will not permit any of its Restricted
Subsidiaries to issue any shares of preferred stock other than
to Sterling Chemicals or another Restricted Subsidiary;
provided, however, that Sterling Chemicals or any
Guarantor may incur Indebtedness (including Acquired Debt) or
issue Disqualified Stock and any of its Restricted Subsidiaries
may incur Indebtedness (including Acquired Debt) or issue
preferred stock, if the Fixed Charge Coverage Ratio for Sterling
Chemicals most recently ended four full fiscal quarters
for which internal financial statements are available
immediately preceding the date on which such additional
Indebtedness is incurred or such Disqualified Stock or preferred
stock is issued would have been at least 2.0 to 1 determined on
a pro forma basis (including a pro forma
application of the net proceeds therefrom), as if such
additional Indebtedness had been incurred or Disqualified Stock
or the preferred stock had been issued, as the case may be, at
the beginning of such four-quarter period.
The first paragraph of this covenant does not prohibit the
incurrence of any of the following items of Indebtedness
(collectively, Permitted Debt):
(1) Indebtedness evidenced by the Existing Notes in
aggregate principal amount of up to $101.6 million and any
related Guarantees;
(2) Indebtedness under the Credit Facilities in an
aggregate principal amount not exceeding $50.0 million at
any time outstanding and any related Guarantees;
(3) Indebtedness represented by the notes and the related
Note Guarantees issued on the Issue Date;
115
(4) Indebtedness solely represented by premium financing or
similar deferred payment obligations incurred with respect to
insurance policies purchased in the ordinary course of business
and consistent with past practice;
(5) the incurrence by Sterling Chemicals or any of its
Restricted Subsidiaries of Indebtedness represented by Capital
Lease Obligations, mortgage financings, purchase money
obligations or other Indebtedness or preferred stock, or
synthetic lease obligations, in each case incurred for the
purpose of financing all or any part of the purchase price or
cost of design, development, construction, installation or
improvement of property (real or personal and including
acquisitions of Capital Stock), plant or equipment used in a
Permitted Business of Sterling Chemicals or such Restricted
Subsidiary (in each case, whether through the direct purchase of
such assets or the Equity Interests of any Person owning such
assets), or repairs, additions or improvements to such assets,
in an aggregate principal amount, including all Permitted
Refinancing Indebtedness incurred to refund, refinance or
replace any Indebtedness incurred pursuant to this clause (5),
not to exceed $5.0 million at any time outstanding;
(6) the incurrence by Sterling Chemicals or any of its
Restricted Subsidiaries of Permitted Refinancing Indebtedness in
exchange for, or the net proceeds of which are used to extend,
renew, refund, refinance, replace, defease or discharge,
Indebtedness (other than intercompany Indebtedness) that was
permitted by the indenture to be incurred under the first
paragraph of this covenant or clauses (3), (6) and
(14) of this paragraph;
(7) the incurrence by Sterling Chemicals or any of its
Restricted Subsidiaries of intercompany Indebtedness between or
among Sterling Chemicals and any of its Restricted Subsidiaries;
provided, however, that:
(a) if Sterling Chemicals or any Guarantor is the obligor
on such Indebtedness and the payee is not Sterling Chemicals or
a Guarantor, such Indebtedness must be (i) permitted as a
Permitted Investment described in clause (1)(b) of the
definition thereof and (ii) expressly subordinated to the
prior payment in full in cash of all Obligations then due with
respect to the notes, in the case of Sterling Chemicals, or the
Note Guarantee, in the case of a Guarantor; and
(b) (i) any subsequent issuance or transfer of Equity
Interests that results in any such Indebtedness being held by a
Person other than Sterling Chemicals or a Restricted Subsidiary
of Sterling Chemicals and (ii) any sale or other transfer
of any such Indebtedness to a Person that is not any of Sterling
Chemicals, a Guarantor or, in the case where the payor on such
intercompany Indebtedness is not Sterling Chemicals or a
Guarantor, any Restricted Subsidiary of Sterling Chemicals will
be deemed, in each case, to constitute an incurrence of such
Indebtedness by Sterling Chemicals or such Restricted
Subsidiary, as the case may be, that was not permitted by this
clause (7);
(8) the issuance by any of Sterling Chemicals
Restricted Subsidiaries to Sterling Chemicals or to any of its
Restricted Subsidiaries of shares of Disqualified Stock or
preferred stock; provided, however, that if the issuer of
such shares of Disqualified Stock or preferred stock is a
Restricted Subsidiary of Sterling Chemicals that is not a
Guarantor and the purchaser of such shares is Sterling Chemicals
or a Guarantor, such Investment must be permitted as a Permitted
Investment described in clause (1)(b) of the definition
thereof and
(a) any subsequent issuance or transfer of Equity Interests
that results in any such Disqualified Stock or preferred stock
being held by a Person other than Sterling Chemicals or a
Restricted Subsidiary of Sterling Chemicals; and
(b) any sale or other transfer of any such Disqualified
Stock or preferred stock to a Person that is not any of Sterling
Chemicals, a Guarantor or, in the case where the issuer of such
Disqualified Stock or preferred stock is not a Guarantor, any
Restricted Subsidiary of Sterling Chemicals,
will be deemed, in each case, to constitute an issuance of such
Disqualified Stock or preferred stock by such Restricted
Subsidiary that was not permitted by this clause (8);
(9) the incurrence by Sterling Chemicals or any of its
Restricted Subsidiaries of Hedging Obligations in the ordinary
course of business;
116
(10) the Guarantee by Sterling Chemicals or any Restricted
Subsidiary of Sterling Chemicals of Indebtedness of Sterling
Chemicals or a Guarantor that was permitted to be incurred by
another provision of this covenant; provided that if the
Indebtedness being guaranteed is subordinated in right of
payment to the notes or a Note Guarantee, then the Guarantee
shall be subordinated in right of payment to the same extent as
the Indebtedness guaranteed;
(11) the Guarantee by any Restricted Subsidiary of Sterling
Chemicals that is not a Guarantor of Indebtedness of Sterling
Chemicals or any other Restricted Subsidiary that was permitted
to be incurred by another provision of this covenant;
(12) the incurrence by Sterling Chemicals or any of the
Restricted Subsidiaries of Indebtedness in respect of letters of
credit and bankers acceptances issued in the ordinary course and
not supporting Indebtedness, including in respect of
workers compensation claims, payment obligations in
connection with health or other types of social security
benefits, unemployment or other insurance or self-insurance
obligations, performance and surety, appeal, environmental
assurance and similar bonds or indemnification, adjustment of
purchase price or similar obligations incurred in connection
with the disposition of any business or assets;
(13) the incurrence by Sterling Chemicals or any of the
Restricted Subsidiaries of Indebtedness arising from the
honoring by a bank or other financial institution of a check,
draft or similar instrument inadvertently (except in the case of
daylight overdrafts) drawn against insufficient funds;
provided, however, that such Indebtedness is
extinguished within three business days of incurrence;
(14) Indebtedness, Disqualified Stock or preferred equity
of any Person that is acquired by Sterling Chemicals or any of
its Restricted Subsidiaries or merged into or consolidated with,
or transfers substantially all of its assets to, a Restricted
Subsidiary in accordance with the terms of the indenture;
provided, however, that all such Indebtedness,
Disqualified Stock or preferred equity does not exceed
$5.0 million in the aggregate at any time outstanding and
is not incurred or issued in contemplation of such acquisition
or merger or to provide all or a portion of the funds or credit
support required to consummate such acquisition or
merger; and
(15) the incurrence by Sterling Chemicals or any of the
Restricted Subsidiaries of additional Indebtedness or issuance
of shares of Disqualified Stock or preferred stock in an
aggregate principal amount (or accreted value, as applicable) at
any time outstanding not to exceed $5.0 million.
Sterling Chemicals will not incur, and will not permit any
Guarantor to incur, any Indebtedness (including Permitted Debt)
that is contractually subordinated in right of payment to any
other Indebtedness of Sterling Chemicals or such Guarantor
unless such Indebtedness is also contractually subordinated in
right of payment to the notes and the applicable Note Guarantee
on substantially identical terms.
For purposes of determining compliance with this
Incurrence of Indebtedness and Issuance of Preferred
Stock covenant, in the event that an item of proposed
Indebtedness meets the criteria of more than one of the
categories of Permitted Debt described in clauses (1)
through (15) above, or is entitled to be incurred pursuant
to the first paragraph of this covenant, Sterling Chemicals will
be permitted to classify such item of Indebtedness, Disqualified
Stock or preferred equity or any portion thereof on the date of
its incurrence, and will only be required to include the amount
and, type of such Indebtedness, Disqualified Stock or preferred
equity in one of the above clauses or as having been incurred
pursuant to the first paragraph of this covenant, although
Sterling Chemicals may divide and classify an item of
Indebtedness, Disqualified Stock or preferred equity in one or
more of the categories of Permitted Debt described in such
clauses or as having been incurred pursuant to the first
paragraph of this covenant and may later reclassify all or a
portion of such item of Indebtedness, Disqualified Stock or
preferred equity, in any manner that complies with this
covenant. The accrual of interest or dividends, the accretion of
accreted value or amortization of original issue discount, the
payment of interest on any Indebtedness in the form of
additional Indebtedness with the same terms, the
reclassification of preferred equity as Indebtedness due to a
change in accounting principles, and the payment of dividends on
Disqualified Stock or preferred stock in the form of additional
shares of the same class of Disqualified Stock or preferred
stock will not be deemed to be an incurrence of Indebtedness or
an issuance of Disqualified Stock or preferred stock for
purposes of this covenant; provided, in each such case
(other than preferred stock that is not Disqualified Stock),
that the amount of any such accrual, accretion or amortization
or payment (without duplication) is included in Fixed Charges of
Sterling Chemicals as accrued,
117
accreted or amortized or paid. Notwithstanding any other
provision of this covenant, the maximum amount of Indebtedness
that Sterling Chemicals or any Restricted Subsidiary may incur
pursuant to this covenant shall not be deemed to be exceeded
solely as a result of fluctuations in exchange rates or currency
values.
The amount of any Indebtedness outstanding as of any date will
be:
(1) the accreted value of the Indebtedness, in the case of
any Indebtedness issued with original issue discount;
(2) the principal amount of the Indebtedness, in the case
of any other Indebtedness; and
(3) in respect of Indebtedness of another Person secured by
a Lien on the assets of the specified Person, the lesser of:
(A) the Fair Market Value of such asset at the date of
determination, and
(B) the amount of such Indebtedness of the other Person.
Notwithstanding anything to the contrary under this covenant,
the Indebtedness described in clause (1) of the second
paragraph of this covenant shall be repaid in full no later than
the 31st day following the date that the notes are
initially issued under the indenture with the proceeds thereof.
Asset
Sales
Sterling Chemicals will not, and will not permit any of its
Restricted Subsidiaries to, consummate an Asset Sale unless:
(1) Sterling Chemicals or the Restricted Subsidiary, as the
case may be, receives consideration at the time of the Asset
Sale at least equal to the Fair Market Value of the assets or
Equity Interests issued or sold or otherwise disposed
of; and
(2) at least 75% of the consideration received in the Asset
Sale by Sterling Chemicals or such Restricted Subsidiary is in
the form of cash or Cash Equivalents. For purposes of this
provision, each of the following will be deemed to be cash:
(a) any liabilities of Sterling Chemicals or any Restricted
Subsidiary that would otherwise be required to be included on
Sterling Chemicals consolidated balance sheet (other than
contingent liabilities and liabilities that are by their terms
subordinated in right of payment to the notes or any Note
Guarantee) that are assumed by the transferee of any such assets
pursuant to a customary novation agreement that releases
Sterling Chemicals or such Restricted Subsidiary from further
liability;
(b) any securities, notes or other obligations received by
Sterling Chemicals or any such Restricted Subsidiary from such
transferee that are converted by Sterling Chemicals or such
Restricted Subsidiary into cash or Cash Equivalents within
90 days after receipt thereof, to the extent of the cash or
Cash Equivalents received in that conversion; and
(c) any property or assets that are used or useful in a
Permitted Business or all of the Capital Stock (other than
Disqualified Stock) of any Person engaged in a Permitted
Business if, as a result of the acquisition by Sterling
Chemicals or any Restricted Subsidiary thereof, that Person
becomes a Guarantor (provided, that if the assets that
were the subject of such Asset Sale constituted Primary
Collateral or the Capital Stock of a Guarantor, this
clause (c) shall only be limited to such property or assets
that constitute Primary Collateral or all of the Capital Stock
(other than Disqualified Stock) of any such Person that is or
becomes a Guarantor); and
(3) if such Asset Sale involves the disposition of
Secondary Collateral, the proceeds are applied in accordance
with the Intercreditor Agreement to the extent required therein.
Clauses (1) and (2) of the foregoing paragraph need
not be satisfied to the extent the Notes Collateral to be
released consists solely of Secondary Collateral with respect to
which the required lenders under the ABL Facility have given
their consent and authorized the release of same or to the
extent the Secondary Collateral to be released is
118
disposed of by such Credit Facility Agent on behalf of the
lenders in connection with the exercise of rights or remedies
under the ABL Facility, in each case so long as (x) the
collateral agent is required to release its lien thereon
pursuant to the terms of the Intercreditor Agreement and
(y) the proceeds therefrom are applied in accordance with
the Intercreditor Agreement.
The 75% requirement referred to in clause (2) above will
not apply to any Asset Sale in which the cash or Cash
Equivalents portion of the consideration received therefrom,
determined in accordance with subclauses (a), (b) and
(c) above, is equal to or greater than what the after-tax
proceeds would have been had that Asset Sale complied with the
aforementioned 75% limitation.
Within 360 days after the receipt of any Net Proceeds from
an Asset Sale, Sterling Chemicals (or the applicable Restricted
Subsidiary, as the case may be) may:
(a) apply those Net Proceeds, at its option:
(1) to acquire all or substantially all of the assets of,
or all of the Capital Stock (other than Disqualified Stock) of,
another Permitted Business, if, after giving effect to any such
acquisition of Capital Stock (other than Disqualified Stock),
the Permitted Business is or becomes a Guarantor;
(2) in the case where the asset that was the subject of
such Asset Sale was not Primary Collateral or the Capital Stock
of a Guarantor, to make a capital expenditure;
(3) to acquire other, or make improvements to, assets that
constitute Primary Collateral and that are used or useful in a
Permitted Business; or
(4) to any combination of the foregoing; or
(b) enter into a binding commitment for any such
application pursuant to clause (a) above; provided
that such binding commitment shall be treated as a permitted
application of the Net Proceeds from the date of such commitment
until the earlier of (x) the date on which such
acquisition, or expenditure is consummated, and (y) the
180th day following the expiration of the aforementioned
360-day
period. If the acquisition or expenditure contemplated by such
binding commitment is not consummated on or before such
180th day and Sterling Chemicals or such Restricted
Subsidiary shall not have otherwise applied such Net Proceeds
pursuant to clause (1), (2), (3) or (4) of this
paragraph on or before such 180th day, such commitment
shall be deemed not to have been a permitted application of Net
Proceeds.
Pending the final application of any Net Proceeds, Sterling
Chemicals may temporarily reduce revolving Indebtedness or
otherwise invest the Net Proceeds in Cash Equivalents.
Any Net Proceeds from Asset Sales that are not applied or
invested as provided in the preceding paragraph will constitute
Excess Proceeds. When the aggregate amount of
Excess Proceeds exceeds $7.5 million, within 30 days
thereof, Sterling Chemicals will make an Asset Sale Offer to all
Holders to purchase the maximum principal amount of notes that
may be repurchased out of the Excess Proceeds. The offer price
in any Asset Sale Offer will be equal to 100% of principal
amount plus accrued and unpaid interest to the date of
repurchase, and will be payable in cash. If any Excess Proceeds
remain after consummation of an Asset Sale Offer, Sterling
Chemicals may use those Excess Proceeds for any purpose not
otherwise prohibited by the indenture. If the aggregate
principal amount of notes tendered into such Asset Sale Offer
exceeds the amount of Excess Proceeds, the trustee will select
the notes to be repurchased on a pro rata basis. Upon
completion of each Asset Sale Offer, the amount of Excess
Proceeds will be reset at zero.
Sterling Chemicals will comply with the requirements of
Rule 14e-1
under the Exchange Act and any other securities laws and
regulations thereunder to the extent those laws and regulations
are applicable in connection with each repurchase of notes
pursuant to an Asset Sale Offer. To the extent that the
provisions of any securities laws or regulations conflict with
the Asset Sale provisions of the indenture, Sterling Chemicals
will comply with the applicable securities laws and regulations
and will not be deemed to have breached its obligations under
the Asset Sale provisions of the indenture by virtue of such
compliance.
The agreements governing Sterling Chemicals other
Indebtedness contain, and future agreements may contain,
prohibitions of certain events, including events that would
constitute a Change of Control, Event of Loss or
119
an Asset Sale. The exercise by the Holders of their right to
require Sterling Chemicals to purchase the notes upon a Change
of Control, an Asset Sale or an Event of Loss could cause a
default under these other agreements, even if the Change of
Control, Asset Sale or Event of Loss itself does not, due to the
financial effect of such repurchases on Sterling Chemicals. In
addition, Sterling Chemicals ability to pay cash to the
Holders upon a repurchase may be limited by Sterling
Chemicals then existing financial resources.
Liens
Sterling Chemicals will not, and will not permit any Guarantor
to, directly or indirectly, create, incur, assume or suffer to
exist any Lien of any kind on any asset now owned or hereafter
acquired, except Permitted Liens.
Dividend
and Other Payment Restrictions Affecting
Subsidiaries
Sterling Chemicals will not, and will not permit any of its
Restricted Subsidiaries to, directly or indirectly, create or
permit to exist or become effective any consensual encumbrance
or restriction on the ability of any Restricted Subsidiary to:
(a) pay dividends or make any other distributions on its
Capital Stock to Sterling Chemicals or any of its Restricted
Subsidiaries, or with respect to any other interest or
participation in, or measured by, its profits, or pay any
Indebtedness owed to Sterling Chemicals or any of its Restricted
Subsidiaries;
(b) make loans or advances to Sterling Chemicals or any of
its Restricted Subsidiaries; or
(c) transfer any of its properties or assets to Sterling
Chemicals or any of its Restricted Subsidiaries.
However, the preceding restrictions do not apply to encumbrances
or restrictions existing under or by reason of:
(1) agreements governing Indebtedness outstanding on the
Issue Date, the Credit Agreement and Credit Facilities as in
effect on the date of the indenture and any amendments,
modifications, restatements, renewals, increases, supplements,
refundings, replacements or refinancings of those agreements;
provided that the amendments, modifications,
restatements, renewals, increases, supplements, refundings,
replacement or refinancings are not, in the good faith judgment
of the Board of Directors of Sterling Chemicals, materially more
restrictive, taken as a whole, with respect to such dividend and
other payment restrictions than those contained in those
agreements on the Issue Date;
(2) the indenture, the notes, the Note Guarantees and the
Collateral Documents;
(3) applicable law, rule, regulation, order, approval,
license, permit or similar restriction;
(4) (a) any instrument governing Indebtedness or
Capital Stock of a Person acquired by Sterling Chemicals or any
of its Restricted Subsidiaries as in effect at the time of such
acquisition (except to the extent such Indebtedness or Capital
Stock was incurred in connection with or in contemplation of
such acquisition), which encumbrance or restriction is not
applicable to any Person, or the properties or assets of any
Person, other than the Person, or the property or assets of the
Person, so acquired; provided that, in the case of
Indebtedness, such Indebtedness was permitted by the terms of
the indenture to be incurred; and (b) any amendment,
modification, replacement or refinancing thereof; provided,
however, that such encumbrances or restrictions are not, in
the good faith judgment of the Board of Directors of Sterling
Chemicals, materially more restrictive, taken as a whole, with
respect to consensual encumbrances or restrictions set forth in
clauses (a), (b) or (c) of the preceding paragraph
than on such encumbrance or restriction prior to such amendment,
modification, replacement or refinancing;
(5) customary non-assignment provisions in contracts and
licenses entered into in the ordinary course of business;
(6) any agreement for the sale or other disposition of all
or substantially all of the Capital Stock or assets of a
Restricted Subsidiary that restricts distributions, loans or
transfers by that Restricted Subsidiary pending the sale or
other disposition;
120
(7) Permitted Refinancing Indebtedness; provided
that the restrictions contained in the agreements governing
such Permitted Refinancing Indebtedness are, in the good faith
judgment of Sterling Chemicals Board of Directors, not
materially more restrictive, taken as a whole, with respect such
consensual encumbrance or restriction set forth in clauses (a),
(b) or (c) of the preceding paragraph than those
contained in the agreements governing the Indebtedness being
refinanced, extended, renewed, refunded, refinanced, replaced,
defeased or discharged;
(8) Liens permitted to be incurred under the provisions of
the covenant described above under Certain
Covenants Liens that limit the right of
the debtor to dispose of the assets subject to such Liens;
(9) provisions in joint venture agreements, asset sale
agreements, limited liability company organizational documents,
sale-leaseback agreements, stock sale agreements and other
similar agreements entered into with the approval of Sterling
Chemicals Board of Directors, which limitation is
applicable only to the assets that are the subject of such
agreements;
(10) restrictions on cash or other deposits or net worth
imposed by customers under contracts entered into in the
ordinary course of business;
(11) other Indebtedness or Disqualified Stock or preferred
stock of Restricted Subsidiaries permitted to be incurred
subsequent to the Issue Date pursuant to the provisions of the
covenant described under Certain
Covenants Incurrence of Indebtedness and Issuance of
Preferred Stock; provided that such
restrictions, taken as a whole, are, in the good faith judgment
of Sterling Chemicals Board of Directors, no more
materially restrictive, taken as a whole, with respect to
consensual encumbrances or restrictions set forth in clauses
(a), (b) or (c) of the preceding paragraph, than those
customary in comparable financings (as reasonably determined by
Sterling Chemicals Board of Directors);
(12) encumbrances on property that exist at the time the
property was acquired by Sterling Chemicals or a Restricted
Subsidiary; and
(13) contractual encumbrances or restrictions in effect on
the Issue Date, and any amendments, restatements, modifications,
supplements, renewals, extensions, refundings, replacements or
refinancings of those agreements; provided that the
amendments, restatements, modifications, supplements, renewals,
extensions, refundings, replacements or refinancings are not, in
the good faith judgment of Sterling Chemicals Board of
Directors, materially more restrictive, taken as a whole, with
respect to consensual encumbrances or restrictions set forth in
clauses (a), (b) or (c) of the preceding paragraph
than those contained in those agreements on the Issue Date.
Merger,
Consolidation or Sale of Assets
Sterling Chemicals may not, directly or indirectly,
(1) consolidate or merge with or into another Person
(whether or not Sterling Chemicals is the surviving entity); or
(2) sell, assign, transfer, convey, lease or otherwise
dispose of all or substantially all of the properties or assets
of Sterling Chemicals and its Restricted Subsidiaries, taken as
a whole, in one or more related transactions, to another Person,
unless:
(1) either (a) Sterling Chemicals is the surviving
entity; or (b) the Person formed by or surviving any such
consolidation or merger (if other than Sterling Chemicals) or to
which such sale, assignment, transfer, conveyance, lease or
other disposition has been made is a corporation organized or
existing under the laws of the United States, any state of the
United States or the District of Columbia;
(2) the Person formed by or surviving any such
consolidation or merger (if other than Sterling Chemicals) or
the Person to which such sale, assignment, transfer, conveyance,
lease or other disposition has been made assumes all the
obligations of Sterling Chemicals under the notes, the
indenture, and the Collateral Documents pursuant to agreements
reasonably satisfactory to the trustee and in connection
therewith shall cause such instruments and Uniform Commercial
Code financing statements to be filed and recorded in such
jurisdictions and take such other actions as may be required by
applicable law to perfect or continue the perfection of the Note
Lien created under the Collateral Documents on the Note
Collateral owned by or transferred to such Person;
121
(3) immediately before and after giving effect to such
transaction, no Default or Event of Default shall have occurred
and is continuing;
(4) Sterling Chemicals or the Person formed by or surviving
any such consolidation or merger (if other than Sterling
Chemicals), or to which such sale, assignment, transfer,
conveyance, lease or other disposition has been made, will, on
the date of such transaction after giving pro forma
effect thereto and any related financing transactions as if
the same had occurred at the beginning of the applicable
four-quarter period, be permitted to incur at least $1.00 of
additional Indebtedness pursuant to the Fixed Charge Coverage
Ratio test set forth in the first paragraph of the covenant
described above under Certain
Covenants Incurrence of Indebtedness and Issuance of
Preferred Stock; and
(5) Sterling Chemicals or such other Person shall have
delivered to the trustee an Officers Certificate and an
Opinion of Counsel, each stating that the consummation of such
consolidation, merger, sale, assignment, transfer, conveyance,
lease or other disposition on the terms proposed and, if such an
assumption is required in connection with such transaction, such
assumption, will comply with the applicable provisions of the
indenture and that all conditions precedent in the indenture
relating to such transaction as proposed will, upon consummation
of such transaction as proposed, will be satisfied.
The indenture provides that upon any consolidation, combination
or merger or any transfer of all or substantially all of the
assets of Sterling Chemicals in accordance with the foregoing in
which Sterling Chemicals is not surviving or the continuing
corporation, the successor Person formed by such consolidation
or into which Sterling Chemicals is merged or to which such
conveyance, lease or transfer is made shall succeed to, and be
substituted for, and may exercise every right and power of,
Sterling Chemicals under the indenture and the notes with the
same effect as if such surviving entity had been named as such.
Upon such substitution, Sterling Chemicals and any Guarantors
that remain Subsidiaries of Sterling Chemicals shall be released
from their obligations under the indenture and the Note
Guarantees.
The conditions set forth in clauses (3) and (4) of the
first paragraph of this Merger, Consolidation or Sale
of Assets covenant will not apply to:
(1) a merger of Sterling Chemicals with an Affiliate solely
for the purpose of reincorporating Sterling Chemicals in another
jurisdiction or reorganizing into a holding company
structure; or
(2) any consolidation or merger, or any sale, assignment,
transfer, conveyance, lease or other disposition of assets
between or among Sterling Chemicals and any of its Restricted
Subsidiaries that are or become Guarantors.
Transactions
with Affiliates
Sterling Chemicals will not, and will not permit any of its
Restricted Subsidiaries to, make any payment to, or sell, lease,
transfer or otherwise dispose of any of its properties or assets
(other than Non-Facility Assets) to, or purchase any property or
assets from, or enter into or make or amend any transaction,
contract, agreement, understanding, loan, advance or guarantee
with, or for the benefit of, any Affiliate of Sterling Chemicals
(each, an Affiliate Transaction), in one or
more transactions involving aggregate consideration in excess of
$1.0 million, unless:
(1) the Affiliate Transaction is on terms that are not
materially less favorable to Sterling Chemicals or the relevant
Restricted Subsidiary than those that might reasonably have been
obtained in a comparable transaction by Sterling Chemicals or
such Restricted Subsidiary on an arms length basis with an
unrelated Person; and
(2) Sterling Chemicals delivers to the trustee:
(a) with respect to any Affiliate Transaction or series of
related Affiliate Transactions involving aggregate consideration
in excess of $5.0 million, a resolution of its Board of
Directors set forth in an Officers Certificate certifying
that such Affiliate Transaction complies with this covenant and
that such Affiliate Transaction has been approved by a majority
of the disinterested members of its Board of Directors; and
122
(b) with respect to any Affiliate Transaction or series of
related Affiliate Transactions involving aggregate consideration
in excess of $10.0 million, an opinion as to the fairness
to Sterling Chemicals or such Subsidiary of such Affiliate
Transaction from a financial point of view issued by an
accounting, appraisal or investment banking firm of national
standing.
The following items will not be deemed to be Affiliate
Transactions and, therefore, will not be subject to the
provisions of the prior paragraph:
(1) any employment agreement, employee benefit plan,
officer and director indemnification agreement or any similar
arrangement entered into by Sterling Chemicals or any of its
Restricted Subsidiaries (including the payment of, or an
agreement providing for the payment of, reasonable
directors fees) in the ordinary course of business;
(2) transactions between or among Sterling Chemicals
and/or its
Restricted Subsidiaries;
(3) any issuance of Equity Interests (other than
Disqualified Stock) of Sterling Chemicals to Affiliates of
Sterling Chemicals and the grant and performance of registration
rights;
(4) Permitted Investments described in clauses (6), (8),
(9) or (16) of the definition thereof or Restricted
Payments that do not violate the provisions of the indenture
described above under Certain
Covenants Restricted Payments;
(5) any transaction in which Sterling Chemicals or any of
its Restricted Subsidiaries, as the case may be, delivers to the
trustee a letter from an accounting, appraisal or investment
banking firm of national standing stating that such transaction
is fair to Sterling Chemicals or such Restricted Subsidiary from
a financial point of view or that such transaction meets the
requirements of clause (1) of the preceding paragraph;
(6) if such Affiliate Transaction is with a Person in its
capacity as a holder of Indebtedness or Capital Stock of
Sterling Chemicals or any Restricted Subsidiary where such
Person is treated no more favorably than the other holders of
Indebtedness or Capital Stock of Sterling Chemicals or any
Restricted Subsidiary;
(7) transactions effected pursuant to agreements in effect
on the Issue Date and any amendment, modification or replacement
of such agreement (so long as such amendment or replacement is
not in the good faith judgment of Sterling Chemicals Board
of Directors materially more disadvantageous to the Holders,
taken as a whole, than the original agreement as in effect on
the Issue Date);
(8) transactions with Unrestricted Subsidiaries, customers,
clients, suppliers, joint venture partners or purchasers or
sellers of goods or services, or lessors or lessees of property,
in each case in the ordinary course of business and otherwise in
compliance with the terms of the indenture which are, in the
aggregate (taking into account all the costs and benefits
associated with such transactions), materially no less favorable
to Sterling Chemicals and its Restricted Subsidiaries than those
that would have been obtained in a comparable transaction by
Sterling Chemicals or such Restricted Subsidiary with an
unrelated Person, in the good faith judgment of Sterling
Chemicals Board of Directors or senior management thereof,
or are on terms at least as favorable as might reasonably have
been obtained at such time on an arms-length basis from an
unaffiliated party;
(9) operating or similar agreements with Affiliates
pursuant to which Sterling Chemicals or a Restricted Subsidiary
operates the properties or assets of any Affiliate in exchange
for reimbursement of costs, with or without any additional
consideration;
(10) any capital contribution to any Affiliate otherwise
permitted by the indenture or any other Permitted Investment in
an Affiliate;
(11) ground leases of Non-Facility Assets for nominal or no
consideration.
Business
Activities
Sterling Chemicals will not, and will not permit any of its
Restricted Subsidiaries to, engage in any business other than
Permitted Businesses.
123
Additional
Note Guarantees
If Sterling Chemicals or any of its Restricted Subsidiaries
acquires or creates another Domestic Subsidiary that is not an
Unrestricted Subsidiary after the Issue Date, then that newly
acquired or created Domestic Subsidiary that is not an
Unrestricted Subsidiary will, within 10 business days of the
date on which it was acquired or created, (a) become a
Guarantor and execute a Note Guarantee, a supplement to the
Security Agreement and such other Collateral Documents as may be
applicable; (b) cause such instruments and Uniform
Commercial Code financing statements to be filed and recorded in
such jurisdictions and take such other actions as may be
required by applicable law to perfect the Note Lien created
under the Security Agreement and such other Collateral
Documents, if any, on the Note Collateral owned by Domestic
Subsidiary; and (c) deliver to the trustee within 10
business days of the date on which it was acquired or created a
customary Opinion of Counsel addressed to the trustee and
covering, among other things, the enforceability of such
Indenture Documents and the perfection of the Note Liens
purportedly created thereby.
Designation
of Restricted and Unrestricted Subsidiaries
The relevant Board of Directors may designate any Restricted
Subsidiary (including any newly acquired or newly formed
Subsidiary or Person becoming a Subsidiary through merger or
consolidation or Investment therein) to be an Unrestricted
Subsidiary if that designation would not cause a Default. If a
Restricted Subsidiary is designated as an Unrestricted
Subsidiary, the aggregate Fair Market Value of all outstanding
Investments owned by Sterling Chemicals and its Restricted
Subsidiaries in the Subsidiary designated as Unrestricted will
be deemed to be an Investment made as of the time of the
designation and, unless such Investment is a Permitted
Investment, will reduce the amount available for Restricted
Payments under the covenant described above under
Certain Covenants Restricted
Payments or under one or more clauses of the
definition of Permitted Investments, as determined by Sterling
Chemicals. That designation will only be permitted if the
Investment would be permitted at that time and if the Restricted
Subsidiary otherwise meets the definition of an Unrestricted
Subsidiary. The relevant Board of Directors may redesignate any
Unrestricted Subsidiary to be a Restricted Subsidiary if that
redesignation would not cause a Default.
Limitation
on Issuances and Sales of Equity Interests in Restricted
Subsidiaries
Sterling Chemicals will not, and will not permit any of its
Restricted Subsidiaries to, transfer, convey, sell or otherwise
dispose of any Capital Stock in any Restricted Subsidiary of
Sterling Chemicals to any Person (other than Sterling Chemicals
or a Wholly-Owned Restricted Subsidiary of Sterling Chemicals
and except for such issuances of shares of Capital Stock
constituting directors qualifying shares or issuances to
foreign nationals of shares of Capital Stock of a Foreign
Subsidiary, in each case to the extent required by applicable
law), unless:
(1) such transfer, conveyance, sale or other disposition is
of all the Equity Interests in such Restricted Subsidiary;
(2) the Net Proceeds from such transfer, conveyance, sale
or other disposition are applied in accordance with the covenant
described above under Certain
Covenants Asset Sales; and
(3) if, immediately after giving effect to such issuance or
sale, such Restricted Subsidiary would no longer constitute a
Restricted Subsidiary and any Investment in such Person
remaining after giving effect to such issuance or sale would
have been permitted to be made pursuant to the covenant
described above under Certain
Covenants Restricted Payments if made on
the date of such issuance or sale.
Impairment
of Security Interest
Neither Sterling Chemicals nor any of its Restricted
Subsidiaries will take or omit to take any action which would
adversely affect or impair in any material respect the Note
Liens in favor of the trustee with respect to the Note
Collateral, except in the case where such Collateral constitutes
Secondary Collateral, to the extent required or permitted under
the Intercreditor Agreement. Neither Sterling Chemicals nor any
Guarantor shall grant to any Person (other than the trustee), or
permit any Person (other than the trustee), to retain any
interest whatsoever in the Note Collateral other than Permitted
Liens. Neither Sterling Chemicals nor any Guarantor will enter
into any
124
agreement that requires the proceeds received from any sale of
Note Collateral to be applied to repay, redeem, defease or
otherwise acquire or retire any Indebtedness of any Person,
other than as permitted by the indenture, the notes and the
Collateral Documents. Sterling Chemicals shall, and shall cause
each Guarantor to, at their sole cost and expense, execute and
deliver all such agreements and instruments as the trustee shall
reasonably request to more fully or accurately describe the
property intended to be Note Collateral or the obligations
intended to be secured by the Collateral Documents. Sterling
Chemicals shall, and shall cause each Guarantor to, at their
sole cost and expense, file any such notice filings or other
agreements or instruments as may be reasonably necessary or
desirable under applicable law to perfect the Note Liens created
by the Collateral Documents at such times and at such places as
the trustee may reasonably request.
Payments
for Consent
Sterling Chemicals will not, and will not permit any of its
Restricted Subsidiaries to, directly or indirectly, pay or cause
to be paid any consideration to or for the benefit of any Holder
for or as an inducement to any consent, waiver or amendment of
any of the terms or provisions of any Indenture Document, the
registration rights agreement with respect to which such Holder
is a beneficiary or the Intercreditor Agreement unless such
consideration is offered to be paid and is paid to all Holders
that consent, waive or agree to amend in the time frame set
forth in the solicitation documents relating to such consent,
waiver or agreement.
Reports
to Holders
The indenture provides that, whether or not required by the
rules and regulations of the SEC, so long as any notes are
outstanding, Sterling Chemicals will furnish the Holders of the
notes:
(a) all quarterly and annual financial information that
would be required to be contained in a filing with the SEC on
Forms 10-Q
and 10-K if
Sterling Chemicals were required to file such Forms, including a
Managements Discussion and Analysis of Financial
Condition and Results of Operations that describes the
financial condition and results of operations of Sterling
Chemicals and its consolidated Subsidiaries (showing in
reasonable detail, either on the face of the financial
statements or in the footnotes thereto and in
Managements Discussion and Analysis of Financial
Condition and Results of Operations, the financial
condition and results of operations of Sterling Chemicals and
its Restricted Subsidiaries separate from the financial
condition and results of operations of the Unrestricted
Subsidiaries of Sterling Chemicals, if any) and, with respect to
the annual information only, a report thereon by Sterling
Chemicals certified independent accountants within the
time periods specified in the SECs rules and
regulations; and
(b) all current reports that would be required to be filed
with the SEC on
Form 8-K
if Sterling Chemicals were required to file such reports,
in each case, within the time periods required for filing such
forms and reports as specified in the SECs rules and
regulations.
In addition, following the consummation of this exchange offer,
whether or not required by the rules and regulations of the SEC,
Sterling Chemicals will file a copy of all such information and
reports with the SEC for public availability within the time
periods specified in the SECs rules and regulations
(unless the SEC will not accept such a filing) and make such
information available to securities analysts and prospective
investors upon request. In addition, Sterling Chemicals has
agreed that, for so long as any notes remain outstanding, it
will furnish to the Holders and to securities analysts and
prospective investors, upon their request, the information
required to be delivered pursuant to Rule 144A(d)(4) under
the Securities Act.
Events of
Default and Remedies
Each of the following is an Event of Default:
(1) default for 30 consecutive days in the payment when due
of interest on, the notes;
(2) default in payment when due of the principal of, or
premium, if any, on the notes;
125
(3) default in the payment of principal of and interest on
notes required to be repurchased pursuant to an offer to
purchase as described under Change of
Control, Event of Loss
and Certain Covenants Asset
Sales above when due and payable;
(4) failure to perform or comply with any of the provisions
described under Certain
Covenants Mergers, Consolidations or Sale of
Assets above;
(5) failure by Sterling Chemicals or any of its Restricted
Subsidiaries to perform any other covenant or agreement in the
Indenture Documents, and the default continues for 45 days
after written notice to Sterling Chemicals by the trustee or
Holders of at least 25% in aggregate principal amount of the
notes then outstanding voting as a single class;
(6) default under any mortgage, indenture or instrument
under which there may be issued or by which there may be secured
or evidenced any Indebtedness for money borrowed by Sterling
Chemicals or any of its Significant Subsidiaries or group of
Restricted Subsidiaries that taken as a whole would constitute a
Significant Subsidiary (or the payment of which is guaranteed by
Sterling Chemicals or any of its Significant Subsidiaries),
whether such Indebtedness or guarantee now exists or is created
after the date of the indenture (but excluding Indebtedness
owing to Sterling Chemicals or a Guarantor), if that default:
(a) is caused by a failure to pay any portion of the
principal of such Indebtedness when due and payable after the
expiration of the grace period provided in such Indebtedness (a
Payment Default); or
(b) results in the acceleration of such Indebtedness prior
to its Stated Maturity (which acceleration is not rescinded,
annulled or otherwise cured within 20 days of receipt by
Sterling Chemicals or such Restricted Subsidiary of notice of
any such acceleration),
and, in each case, the principal amount of any such Indebtedness
so due and payable or that has been accelerated, together with
the principal amount that is so due and payable or that has been
accelerated of any other such Indebtedness under which there has
been a Payment Default or the maturity of which has been so
accelerated, aggregates $10.0 million or more;
(7) the rendering of a final judgment or judgments (not
subject to appeal) against Sterling Chemicals or any of its
Restricted Subsidiaries in an amount in excess of
$10.0 million (net of any amounts which are covered by
insurance or bonded) which judgments are not paid, waived,
satisfied, discharged or stayed for a period of 60 days
after the date on which the right to appeal has expired;
(8) the denial or disaffirmation by Sterling Chemicals or
any of its Restricted Subsidiaries, or any Person acting on
behalf of any of them, in writing, of any material obligation of
Sterling Chemicals or any of its Restricted Subsidiaries set
forth in or arising under any Collateral Documents (other than
by reason of a release from such obligation or the Note Lien
related thereto in accordance with the terms of the indenture
and the Collateral Documents) and such denial or disaffirmance
continues for 5 days;
(9) certain events of bankruptcy, insolvency or
reorganization described in the indenture with respect to
Sterling Chemicals or any of its Restricted Subsidiaries that is
a Significant Subsidiary or any group of Restricted Subsidiaries
that, taken together, would constitute a Significant Subsidiary;
(10) any Note Guarantee from a Significant Subsidiary, or
any group of Restricted Subsidiaries that, taken together, would
constitute a Significant Subsidiary, ceases to be in full force
and effect or is declared null and void and unenforceable or is
found to be invalid or a Guarantor denies in writing its
liability under the Note Guarantee (other than by reason of a
release of such Guarantor from the Note Guarantee in accordance
with the terms of the Indenture Documents); and
(11) except as permitted by any Indenture Document, any
Collateral Document or any Note Lien purported to be granted
thereby on an asset or assets having an aggregate net book value
or Fair Market Value in excess of $2.5 million fails to
constitute a valid and (to the extent required by the Collateral
Documents) perfected Lien on Note Collateral purported to be
subject thereto.
In the case of an Event of Default arising from certain events
of bankruptcy or insolvency, with respect to Sterling Chemicals,
any Restricted Subsidiary that is a Significant Subsidiary or
any group of Restricted
126
Subsidiaries that, taken together, would constitute a
Significant Subsidiary, all outstanding notes will become due
and payable immediately without further action or notice. If any
other Event of Default occurs and is continuing, the trustee or
the Holders holding at least 25% in aggregate principal amount
of the then outstanding notes voting as a single class may
declare all the notes to be due and payable immediately.
Subject to certain limitations, Holders of a majority in
aggregate principal amount of the then outstanding notes voting
as a single class may direct the trustee in its exercise of any
trust or power. The trustee may withhold from Holders notice of
any continuing Default or Event of Default if it determines that
withholding notice is in their interest, except a Default or
Event of Default relating to the payment of principal or
interest.
Subject to the provisions of the indenture relating to the
duties of the trustee, in case an Event of Default occurs and is
continuing, the trustee will be under no obligation to exercise
any of the rights or powers under the indenture at the request
or direction of any Holder notes unless such Holder has offered
to the trustee reasonable indemnity or security against any
loss, liability or expense. Except to enforce the right to
receive payment of principal, premium (if any) or interest when
due, no Holder may pursue any remedy with respect to the
indenture or the notes unless:
(1) such Holder has previously given the trustee notice
that an Event of Default is continuing;
(2) Holders holding at least 25% in aggregate principal
amount of the then outstanding notes voting as a single class
have requested the trustee to pursue the remedy;
(3) such Holders have offered the trustee reasonable
security or indemnity against any loss, liability or expense;
(4) the trustee has not complied with such request within
60 days after the receipt thereof and the offer of security
or indemnity; and
(5) Holders holding a majority in aggregate principal
amount of the outstanding notes have not given the trustee a
direction inconsistent with such request within such
60-day
period.
The Holders holding a majority in aggregate principal amount of
the notes then outstanding by notice to the trustee may, on
behalf of the Holders holding all of the notes, rescind an
acceleration or waive any existing Default or Event of Default
and its consequences under the indenture except a continuing
Default or Event of Default in the payment of interest or the
principal of, the notes.
Sterling Chemicals is required to deliver to the trustee
annually a statement regarding compliance with the indenture.
Upon becoming aware of any Default or Event of Default, Sterling
Chemicals is required to deliver to the trustee a statement
specifying such Default or Event of Default.
No
Personal Liability of Directors, Officers, Employees,
Stockholders and Members
No director, manager, officer, employee, incorporator,
stockholder or member of Sterling Chemicals, or any Subsidiary,
as such, will have any liability for any obligations of Sterling
Chemicals or the Guarantors under the notes, the indenture, the
Note Guarantees or the Collateral Documents or for any claim
based on, in respect of, or by reason of, such obligations or
their creation. Each Holder by accepting a note waives and
releases all such liability. The waiver and release are part of
the consideration for issuance of the notes. The waiver may not
be effective to waive liabilities under the federal securities
laws.
Amendment,
Supplement and Waiver
Except as provided in the next three succeeding paragraphs, the
Indenture Documents and the Intercreditor Agreement may be
amended, amended and restated or supplemented with the consent
of the Holders holding at least a majority in principal amount
of the notes then outstanding voting as a single class
(including, without limitation, consents obtained in connection
with a purchase of, or tender offer or exchange offer for,
notes), and any existing Default or Event of Default or
compliance with any provision of the Indenture Documents or the
Intercreditor Agreement may be waived with the consent of the
Holders holding a majority in principal amount of the then
outstanding notes voting as a single class (including, without
limitation, consents obtained in connection with a purchase of,
or tender offer or exchange offer for, notes).
127
Without the consent of
(a) each Holder affected, no such amendment, amendment and
restatement or waiver may (with respect to any notes held by a
non-consenting Holder):
(1) reduce the principal amount of notes held by Holders
whose holders must consent to an amendment, amendment and
restatement, supplement or waiver;
(2) reduce the principal of or change the fixed maturity of
any note or alter the provisions described above under
Optional Redemptions;
(3) reduce the rate of or change the time for payment of
interest (including default interest but excluding Additional
Interest) on any note;
(4) waive a Default or Event of Default in the payment of
principal of, or interest or premium, if any, on the notes
(except a rescission of acceleration of the notes by Holders
holding at least a majority in aggregate principal amount of the
notes and a waiver of the payment default that resulted from
such acceleration);
(5) make any notes payable in currency other than that
stated in the indenture;
(6) make any change in the provisions of the indenture
relating to waivers of past Defaults (other than to add sections
of the indenture subject thereto) or the rights of Holders to
receive payments of principal of, or interest or premium, if
any, on the notes;
(7) amend, change or modify in any material respect the
obligation of Sterling Chemicals to make and consummate a Change
of Control Offer after the occurrence of a Change of Control,
make and consummate and Event of Loss Offer after the occurrence
of an Event of Loss or make and consummate an Asset Sale Offer
with respect to any Asset Sale that has been consummated or
modify any of the provisions or definitions with respect thereto;
(8) release any Guarantor from any of its obligations under
its Note Guarantee or the indenture, except in accordance with
the terms of the indenture;
(9) contractually subordinate the notes or any Note
Guarantee to any other indebtedness; or
(10) make any change in the preceding amendment and waiver
provisions; or
(b) the Holders holding at least 75% in aggregate principal
amount of the notes, no such amendment, amendment and
restatement or waiver may adversely change the priority of the
Holders Liens in the Note Collateral or release all or
substantially all of the Note Collateral from the Liens created
by the Collateral Documents except as specifically provided for
in the indenture and the Collateral Documents.
Notwithstanding the preceding, without the consent of any
Holder, Sterling Chemicals, the Guarantors and the trustee may
amend, amend and restate, supplement or otherwise modify the
Indenture Documents or the Intercreditor Agreement:
(1) to cure any ambiguity, defect or inconsistency;
(2) to provide for uncertificated notes in addition to or
in place of certificated notes;
(3) to provide for the assumption of Sterling
Chemicals obligations to Holders in the case of a merger
or consolidation or sale of all or substantially all of Sterling
Chemicals assets;
(4) to make any change that would provide any additional
rights or benefits to the Holders or that does not, in the good
faith judgment of Sterling Chemicals Board of Directors
adversely affect the legal rights under Indenture Documents or
the Intercreditor Agreement of any such Holder in any material
respect;
(5) to comply with requirements of the SEC in order to
effect or maintain the qualification of the indenture under the
TIA;
128
(6) to conform the text of any Indenture Document or the
Intercreditor Agreement to any provision of this
Description of Notes to the extent that such
provision in this Description of Notes was
intended to be a verbatim recitation of a provision of such
Indenture Document or the Intercreditor Agreement, as the case
may be;
(7) to add any additional assets to the Note Collateral;
(8) to add a Guarantor;
(9) to comply with the rules of any applicable securities
depositary;
(10) to provide for a successor trustee in accordance with
the terms of the indenture or to otherwise comply with any
requirement of the indenture;
(11) to reflect the grant of Liens on the Note Collateral
for the benefit of an additional secured party, to the extent
that such Indebtedness and the Lien securing such Indebtedness
is permitted by the terms of the indenture; or
(12) to release Note Collateral from the Lien of the
indenture and the Collateral Documents when permitted or
required by the indenture or the Collateral Documents (including
in the case where such Note Collateral constitutes Secondary
Collateral, the Intercreditor Agreement).
The consent of the Holders is not necessary under the indenture
to approve the particular form of any proposed amendment, waiver
or consent. It is sufficient if such consent approves the
substance of the proposed amendment, waiver or consent.
Governing
Law
The indenture provides that it, the notes and the Note
Guarantees and (except for Mortgages) the Collateral Documents
are governed by, and construed in accordance with, the laws of
the State of New York.
Legal
Defeasance and Covenant Defeasance
Sterling Chemicals may, at its option and at any time, elect to
have its obligations and the obligations of the Guarantors
discharged with respect to the outstanding notes (Legal
Defeasance). Such Legal Defeasance means that Sterling
Chemicals shall be deemed to have paid and discharged the entire
Indebtedness represented by the outstanding notes, except for:
(1) the rights of Holders to receive payments in respect of
the principal of, premium, if any, and interest on the notes
when such payments are due;
(2) Sterling Chemicals obligations with respect to
the notes concerning issuing temporary notes, registration of
notes, mutilated, destroyed, lost or stolen notes and the
maintenance of an office or agency for payments;
(3) the rights, powers, trust, duties and immunities of the
trustee and Sterling Chemicals obligations in connection
therewith; and
(4) the Legal Defeasance provisions of the indenture.
In addition, Sterling Chemicals may, at its option and at any
time, elect to have the obligations of Sterling Chemicals
released with respect to certain covenants that are described in
the indenture (Covenant Defeasance) and
thereafter any omission to comply with such obligations shall
not constitute a Default or Event of Default with respect to the
notes. In the event Covenant Defeasance occurs, certain events
(not including non-payment, bankruptcy, receivership,
reorganization and insolvency events) described under
Events of Default will no longer constitute
an Event of Default with respect to the notes.
In order to exercise either Legal Defeasance or Covenant
Defeasance:
(1) Sterling Chemicals must irrevocably deposit with the
trustee, in trust, for the benefit of the Holders cash in
U.S. dollars, non-callable U.S. government
obligations, or a combination thereof, in such amounts and
129
at such times as will be sufficient, in the opinion of a
nationally recognized firm of independent public accountants, to
pay the principal of, premium, if any and interest on the notes
on the stated date for payment thereof or on the applicable
redemption date, as the case may be;
(2) in the case of Legal Defeasance, Sterling Chemicals
shall have delivered to the trustee an Opinion of Counsel in the
United States reasonably acceptable to the trustee confirming
that:
(a) Sterling Chemicals has received from, or there has been
published by, the Internal Revenue Service a ruling; or
(b) since the Issue Date, there has been a change in the
applicable federal income tax law,
in either case to the effect that, and based thereon such
Opinion of Counsel shall confirm that, the Holders will not
recognize income, gain or loss for federal income tax purposes
as a result of such Legal Defeasance and will be subject to
federal income tax on the same amounts, in the same manner and
at the same times as would have been the case if such Legal
Defeasance had not occurred;
(3) in the case of Covenant Defeasance, Sterling Chemicals
shall have delivered to the trustee an Opinion of Counsel in the
United States reasonably acceptable to the trustee confirming
that the Holders will not recognize income, gain or loss for
federal income tax purposes as a result of such Covenant
Defeasance and will be subject to federal income tax on the same
amounts, in the same manner and at the same times as would have
been the case if such Covenant Defeasance had not occurred;
(4) no Default or Event of Default shall have occurred and
be continuing on the date of such deposit pursuant to
clause (1) of this paragraph (except such Default or Event
of Default resulting from the failure to comply with
Certain Covenants Incurrence of
Indebtedness and Issuance of Preferred Stock or
Certain Covenants
Liens as a result of the borrowing of funds required
to effect such deposit);
(5) such Legal Defeasance or Covenant Defeasance shall not
result in a breach of, or constitute a default under any other
material agreement or instrument to which Sterling Chemicals or
any of its Subsidiaries is a party or by which Sterling
Chemicals or any of its Subsidiaries is bound;
(6) Sterling Chemicals shall have delivered to the trustee
an Officers Certificate stating that the deposit was not
made by Sterling Chemicals with the intent of preferring the
Holders over any other creditors of Sterling Chemicals or with
the intent of defeating, hindering, delaying or defrauding any
other creditors of Sterling Chemicals or others;
(7) Sterling Chemicals shall have delivered to the Trustee
an Opinion of Counsel to the effect that, assuming no
intervening bankruptcy of Sterling Chemicals between the date of
deposit and the 91st day following the date of deposit and
that no Holder is an insider of Sterling Chemicals, after the
91st day following the date of deposit, the trust funds
will not be subject to the effect of any applicable bankruptcy,
insolvency or similar laws affecting creditors rights
generally; and
(8) Sterling Chemicals shall have delivered to the trustee
an Officers Certificate and an Opinion of Counsel, each
stating that all conditions precedent provided for or relating
to the Legal Defeasance or the Covenant Defeasance have been
complied with.
Satisfaction
and Discharge
The indenture will be discharged and will cease to be of further
effect as to all notes issued thereunder, when:
(1) either:
(a) all notes that have been authenticated and, except
lost, stolen or destroyed notes that have been replaced or paid
and notes for whose payment money has been deposited in trust or
segregated and held in trust by Sterling Chemicals and
thereafter repaid to Sterling Chemicals, have been delivered to
the trustee for cancellation; or
(b) all notes that have not been delivered to the trustee
for cancellation have become due and payable by reason of the
mailing of a notice of redemption or otherwise or will become
due and payable
130
within one year and Sterling Chemicals or any Guarantor has
irrevocably deposited or caused to be deposited with the trustee
as trust funds in trust solely for the benefit of the Holders,
cash in U.S. dollars, non-callable U.S. government
obligations, or a combination of cash in U.S. dollars and
non-callable U.S. government obligations, in amounts as
will be sufficient, without consideration of any reinvestment of
interest, to pay and discharge the entire Indebtedness
(including all principal and interest) on the notes not
delivered to the trustee for cancellation;
(2) Sterling Chemicals or any Guarantor has paid or caused
to be paid all other sums payable by it under the indenture;
(3) Sterling Chemicals has delivered irrevocable
instructions to the trustee under, the indenture to apply the
deposited money toward the payment of the notes at maturity or
on the redemption date, as the case may be; and
(4) Sterling Chemicals has delivered to the trustee an
Officers Certificate and an Opinion of Counsel stating
that all conditions precedent under the indenture relating to
the satisfaction and discharge of the indenture have been
complied with.
Concerning
the Trustee
If the trustee becomes a creditor of Sterling Chemicals or any
Guarantor, the indenture limits the right of the trustee to
obtain payment of claims in certain cases, or to realize on
certain property received in respect of any such claim as
security or otherwise. The trustee will be permitted to engage
in other transactions; however, if it acquires any conflicting
interest it must (i) eliminate such conflict within
90 days, (ii) apply to the SEC for permission to
continue as trustee (if the indenture has been qualified under
the TIA) or (iii) resign. The Holders of a majority in
aggregate principal amount of the then outstanding notes will
have the right to direct the time, method and place of
conducting any proceeding for exercising any remedy available to
the trustee, subject to certain exceptions. The indenture
provides that in case an Event of Default occurs and is
continuing, the trustee will be required, in the exercise of its
power, to use the degree of care of a prudent man in the conduct
of his own affairs. Subject to such provisions, the trustee will
be under no obligation to exercise any of its rights or powers
under the indenture at the request of any Holder, unless such
Holder has offered to the trustee security and indemnity
satisfactory to it against any loss, liability or expense.
Certain
Definitions
Set forth below are certain defined terms used in the indenture.
Reference is made to the indenture for a full disclosure of all
such terms, as well as any other capitalized terms used herein
for which no definition is provided.
ABL Facility means the amended and restated
revolving credit agreement dated as of March 29, 2007,
among Sterling Chemicals, the lenders and issuers party thereto,
and The CIT Group/Business Credit, Inc., as Administrative
Agent, as amended, restated, modified, increased, renewed,
refunded, replaced (whether upon or after termination or
otherwise) or refinanced (including by means of sales of debt
securities to institutional investors) in whole or in part from
time to time, including any agreement increasing the amount of
Indebtedness incurred thereunder or available to be borrowed
thereunder to the extent permitted under clause (2) or
(15) of the definition of the term Permitted
Debt.
ABL Facility Lien Security Documents means
one or more security agreements, pledge agreements, collateral
assignments, or other grants or transfers for security executed
and delivered by Sterling Chemicals or any Guarantor creating a
Lien upon assets constituting Secondary Collateral owned or to
be acquired by Sterling Chemicals or such Guarantor in favor of
any holder or holders of ABL Facility Lien Debt, or any
administrative agent, agent or representative acting for any
such holders, as security for any Credit Facility Obligations
under the ABL Facility.
Acquired Debt means, with respect to any
specified Person:
(1) Indebtedness of any other Person existing at the time
such other Person is merged with or into or became a Restricted
Subsidiary of such specified Person, whether or not such
Indebtedness is incurred in
131
connection with, or in contemplation of, such other Person
merging with or into, or becoming a Restricted Subsidiary of,
such specified Person; and
(2) Indebtedness secured by a Lien encumbering any asset
acquired by such specified Person.
Affiliate of any specified Person means any
other Person directly or indirectly controlling or controlled by
or under direct or indirect common control with such specified
Person. For purposes of this definition, control, as
used with respect to any Person, means the possession, directly
or indirectly, of the power to direct or cause the direction of
the management or policies of such Person, whether through the
ownership of voting securities, by agreement or otherwise. For
purposes of this definition, the terms controlling,
controlled by and under common control
with have correlative meanings.
After-Acquired Property means any and all
assets or property acquired after the Issue Date, including any
assets or property acquired by Sterling Chemicals or any
Guarantor from a transfer from Sterling Chemicals or a Wholly
Owned Subsidiary of Sterling Chemicals that is a Guarantor.
Applicable Premium means, with respect to a
note on any date of redemption, the greater of (1) 1.0% of
the principal amount of such note and (2) the excess of
(a) the present value at such time of (i) the
redemption price of such note on April 1, 2011 (such
redemption price being described under
Optional Redemptions Optional
Redemption on or After April 1, 2011) plus
(ii) all required interest payments due on such note
through April 1, 2011 (but excluding accrued and unpaid
interest to the redemption date), computed using a discount rate
equal to the Treasury Rate plus 50 basis points, over
(b) the then-outstanding principal amount of such note.
Asset Sale means:
(1) the sale, lease, conveyance or other disposition of any
assets or rights of Sterling Chemicals or any Restricted
Subsidiary; provided that the sale, conveyance or other
disposition of all or substantially all of the assets of
Sterling Chemicals and its Restricted Subsidiaries taken as a
whole will be governed by the provisions of the indenture
described above under Change of
Control
and/or the
provisions described above under Certain
Covenants Merger, Consolidation or Sale of
Assets and not by the provisions of the covenant
described under Certain
Covenants Asset Sales; and
(2) the issuance of Equity Interests in any of Sterling
Chemicals Restricted Subsidiaries other than
directors qualifying shares or the sale of Equity
Interests in any of its Restricted Subsidiaries.
Notwithstanding the preceding, none of the following items will
be deemed to be an Asset Sale:
(1) any single transaction or series of related
transactions that involves assets or all of the Equity Interests
of any Restricted Subsidiary having a Fair Market Value of less
than $2.0 million;
(2) (a) a transfer of assets or Equity Interests
between or among Sterling Chemicals and the Guarantors or
(b) a transfer of assets or Equity Interests between or
among the Restricted Subsidiaries of Sterling Chemicals that are
not Guarantors;
(3) an issuance of Equity Interests by a Restricted
Subsidiary of Sterling Chemicals to Sterling Chemicals or to a
Restricted Subsidiary of Sterling Chemicals;
(4) the sale, disposition or lease of products, services,
inventory, equipment, accounts receivable or other assets in the
ordinary course of business, any sale or other disposition of
damaged, worn-out or obsolete or no longer useful assets or the
licensing or sublicensing, lease, assignment or sub-lease of any
real or personal property, in each case, in the ordinary course
of business;
(5) the sale or other disposition of cash or Cash
Equivalents;
(6) a Restricted Payment that does not violate the covenant
described above under Certain
Covenants Restricted Payments or a
Permitted Investment;
(7) the grant in the ordinary course of business of any
non-exclusive license of patents, trademarks, registrations
therefor and other similar intellectual property;
132
(8) any Lien (or foreclosure thereon) securing Indebtedness
to the extent such Lien was granted in compliance with the
covenant described above under Certain
Covenants Liens;
(9) any sale, lease, conveyance or other disposition of
Non-Facility Assets;
(10) the granting of Liens not otherwise prohibited by the
indenture;
(11) the surrender or waiver of contract rights or
settlement, release or surrender of contract, tort or other
claims;
(12) the exchange of assets held by Sterling Chemicals or a
Restricted Subsidiary for assets held by any Person or entity;
provided that (i) the assets received by Sterling Chemicals
or such Restricted Subsidiary in any such exchange will
immediately constitute, be part of, or be used by Sterling
Chemicals or such Restricted Subsidiary; and (ii) any such
assets received are of comparable fair market value to the
assets exchanged as determined in good faith by Sterling
Chemicals;
(13) any exchange of like property pursuant to
Section 1031 of the Internal Revenue Code of 1986, as
amended, for use in a Permitted Business; provided that
(i) the assets received by Sterling Chemicals or such
Restricted Subsidiary in any such exchange will immediately
constitute, be part of, or be used by Sterling Chemicals or such
Restricted Subsidiary; and (ii) any such assets received
are of comparable Fair Market Value to the assets exchanged as
determined in good faith by Sterling Chemicals; and
(14) any disposition of Equity Interests in, or
Indebtedness or other securities of, an Unrestricted Subsidiary.
Asset Sale Offer has the meaning assigned to
that term in the indenture governing the notes.
Attributable Debt in respect of a sale and
leaseback transaction means, at the time of determination, the
present value of the obligation of the lessee for net rental
payments during the remaining term of the lease included in such
sale and leaseback transaction including any period for which
such lease has been extended or may, at the option of the
lessor, be extended. Such present value shall be calculated
using a discount rate equal to the rate of interest implicit in
such transaction, determined in accordance with GAAP;
provided, however, that if such sale and leaseback
transaction results in a Capital Lease Obligation, the amount of
Indebtedness represented thereby will be determined in
accordance with the definition of Capital Lease
Obligation.
Beneficial Owner has the meaning assigned to
such term in
Rule 13d-3
and
Rule 13d-5
under the Exchange Act. The terms Beneficially
Owns and Beneficially Owned have a
corresponding meaning.
Board of Directors means:
(1) with respect to a corporation, the board of directors
of the corporation or any committee thereof duly authorized to
act on behalf of such board;
(2) with respect to a partnership, the board of directors
or other governing body of the general partner of the
partnership;
(3) with respect to a limited liability company, the board
of directors or other governing body, and in the absence of
same, the manager or board of managers or the managing member or
members or any controlling committee of managing members
thereof; and
(4) with respect to any other Person, the board or
committee of such Person or other individual or entity serving a
similar function.
Capital Lease Obligation means, at the time
any determination is to be made, the amount of the liability in
respect of a capital lease that would at that time be required
to be capitalized on a balance sheet in accordance with GAAP,
and the Stated Maturity thereof shall be the date of the last
payment of rent or any other amount due under such lease.
Capital Stock means:
(1) in the case of a corporation, corporate stock;
133
(2) in the case of an association or business entity that
is not a corporation, any and all shares, interests,
participations, rights or other equivalents (however designated)
similar to corporate stock;
(3) in the case of a partnership or limited liability
company, partnership interests (whether general or limited) or
membership interests; and
(4) any other interest or participation that confers on a
Person the right to receive a share of the profits and losses
of, or distributions of assets of, the issuing Person.
Cash Equivalents means:
(1) securities issued or directly and fully guaranteed or
insured by the United States or any agency or instrumentality
thereof (provided that the full faith and credit of the
United States is pledged in support thereof) having maturities
of not more than one year from the date of acquisition;
(2) dollar denominated time deposits and certificates of
deposit of any commercial bank having, or which is the principal
banking subsidiary of a bank holding company having, a long-term
unsecured debt rating of at least A or the
equivalent thereof from S&P or A2 or the
equivalent thereof from Moodys with maturities of not more
than one year from the date of acquisition;
(3) repurchase obligations for underlying securities of the
types described in clause (1) above entered into with any
bank meeting the qualifications specified in clause (2)
above;
(4) commercial paper issued by any Person incorporated in
the United States rated at least
A-1 or the
equivalent thereof by S&P or at least
P-1 or the
equivalent thereof by Moodys and in each case maturing not
more than one year after the date of acquisition;
(5) marketable direct obligations issued by the District of
Columbia or any state of the United States or any political
subdivision of any such state or any public instrumentality
thereof maturing within one year from the date of acquisition
and, at the time of acquisition, having one of the two highest
ratings obtainable from either S&P or Moodys;
(6) Investments in money market funds substantially all of
whose assets are comprised of Cash Equivalents of the types
described in clauses (1) through (5) above; and
(7) in the case of Investments by Foreign Subsidiaries,
other short-term investments in accordance with normal
investment practices for cash management of a type analogous to
the foregoing.
Change of Control means the occurrence of any
of the following:
(1) any person or persons acting together that would
constitute a group (for purposes of Section 13(d) of the
Exchange Act, or any successor provision thereto) (a
group), together with any Affiliates or
related Persons thereof, other than any such Person, Persons,
Affiliates or related Person who are Permitted Holders, shall
Beneficially Own, directly or indirectly, at least 40% of the
voting power of Sterling Chemicals outstanding Voting
Stock, and the Permitted Holders own less than such Person or
group (in doing the own less than comparison, the
holdings of the Permitted Holders who are members of the new
group shall not be counted in the shares held in the aggregate
by Permitted Holders);
(2) any sale, lease or other transfer (other than by way of
merger or consolidation), in one transaction or a series of
related transactions, is made by Sterling Chemicals or any of
its Restricted Subsidiaries of all or substantially all of the
consolidated assets of Sterling Chemicals and the Restricted
Subsidiaries, taken as a whole to any Person other than a
Permitted Holder;
(3) Sterling Chemicals consolidates with or merges with or
into another Person or any Person consolidates with, or merges
with or into, Sterling Chemicals, in any such event pursuant to
a transaction in which immediately after the consummation
thereof Persons owning a majority of Sterling Chemicals
Voting Stock voting immediately prior to such consummation shall
cease to own a majority of Sterling Chemicals Voting Stock
or, if Sterling Chemicals is not the surviving entity, a
majority of the Voting Stock of such surviving entity;
134
(4) during any period of two consecutive years, Continuing
Directors cease to constitute at least a majority of the Board
of Directors of Sterling Chemicals; or
(5) Sterling Chemicals stockholders approve any plan
or proposal for Sterling Chemicals liquidation or
dissolution.
In no event would the sale of Sterling Chemicals common
stock to an underwriter or group of underwriters in privity of
contract with Sterling Chemicals (or anybody in privity of
contact with such underwriters) be deemed to be a Change of
Control or be deemed the acquisition of more than 40% of the
voting power of Sterling Chemicals outstanding Voting
Stock by a Person or any group unless such common stock is held
in an investment account, in which case the investment account
would be treated without giving effect to the foregoing part of
this sentence.
Change of Control Offer has the meaning
assigned to it in the indenture governing the notes.
Consolidated Cash Flow means, with respect to
any specified Person for any period, the Consolidated Net Income
of such Person for such period plus, without duplication:
(1) an amount equal to any extraordinary loss plus any net
loss realized by such Person or any of its Restricted
Subsidiaries in connection with an Asset Sale, to the extent
such losses were deducted in computing such Consolidated Net
Income; plus
(2) provision for taxes based on income or profits of such
Person and its Restricted Subsidiaries for such period, to the
extent that such provision for taxes was deducted in computing
such Consolidated Net Income; plus
(3) the Fixed Charges of such Person and its Restricted
Subsidiaries for such period, to the extent that such Fixed
Charges were deducted in computing such Consolidated Net Income;
plus
(4) depreciation and amortization (including amortization
of intangibles, debt issuance or deferred financing costs or
fees) and other non-cash charges (including write-downs or
write-offs (including any write-offs of debt issuance or
deferring financing costs or fees) and impairment charges and
the impact of purchase accounting) of such Person and its
Restricted Subsidiaries for such period to the extent that such
depreciation, amortization and other non-cash charges were
deducted in computing such Consolidated Net Income; plus
(5) expenses and charges of Sterling Chemicals related to
our tender offer, the consent solicitation and redemption, in
each case, relating to the Existing Notes, the offering of the
notes hereby and the amendment and restatement of the ABL
Facility (including any refinancing fees and other costs
incurred in connection with any of the foregoing), to the extent
such expenses and charges were deducted in computing such
Consolidated Net Income; plus
(6) any non-capitalized transaction costs incurred in
connection with actual, proposed or abandoned financings,
Investments, acquisitions or divestitures, including any
expensing of any bridge or other financing fees or expenses, to
the extent such costs were deducted in computing such
Consolidated Net Income; plus
(7) the amount of any restructuring charges (including
retention, severance, systems establishment cost, post
employment benefits, curtailment or other excess charges), to
the extent such charges were deducted incorporating such
Consolidated Not Income; plus
(8) other non-operating expenses, to the extent such
expenses were deducted incorporating such Consolidated Net
Income; plus
(9) non-cash items to the extent deducted from Consolidated
Net Income for such period, other than any non-cash charges that
represent accruals of, or reserves for, cash disbursements to be
made in any future accounting period;
in each case, on a consolidated basis and determined in
accordance with GAAP.
135
Consolidated Net Income means, with respect
to any specified Person for any period, the aggregate of the Net
Income of such Person and its Restricted Subsidiaries for such
period, on a consolidated basis, determined in accordance with
GAAP; provided that:
(1) the Net Income (but not loss) of any Person that is not
a Restricted Subsidiary or that is accounted for by the equity
method of accounting will be included only to the extent of the
amount of dividends or similar distributions paid in cash to the
specified Person or a Restricted Subsidiary of the Person;
(2) the Net Income of any Restricted Subsidiary will be
excluded to the extent that the declaration or payment of
dividends or similar distributions by that Restricted Subsidiary
of that Net Income is not at the date of determination permitted
without any prior governmental approval (that has not been
obtained) or, directly or indirectly, by operation of the terms
of its charter or any agreement, instrument, judgment, decree,
order, statute, rule or governmental regulation applicable to
that Restricted Subsidiary or its stockholders or otherwise;
provided, however, that this exclusion shall not apply in
determining the principal amount of Indebtedness that may be
incurred pursuant to the proviso to the first sentence under the
Certain
Covenants Incurrence of Indebtedness and
Issuance of Preferred Stock covenant so long as such
Restricted Subsidiary is a Guarantor;
(3) the cumulative effect of a change in accounting
principles will be excluded; and
(4) non-cash gains and losses due solely to fluctuations in
currency values will be excluded.
Continuing Directors means, as of any date of
determination, any member of the Board of Directors of Sterling
Chemicals who:
(1) was a member of such Board of Directors on the Issue
Date; or
(2) was nominated for election or elected to such Board of
Directors by holders of Sterling Chemicals Series A
Convertible Preferred Stock or with the approval of a majority
of the Continuing Directors who were members of such Board at
the time of such nomination or election.
Credit Facilities means one or more debt
facilities (including, without limitation, pursuant to the ABL
Facility) or commercial paper facilities, in each case with
banks or other institutional lenders providing for revolving
credit loans, term loans, receivables financing (including
through the sale of receivables to such lenders or to special
purpose entities formed to borrow from such lenders against such
receivables), bankers acceptances or letters of credit,
including any related notes, guarantees, collateral documents,
instruments and agreements executed in connection therewith,
and, in each case, as amended, restated, modified, increased,
renewed, refunded, replaced (whether upon termination or
otherwise) or refinanced (including by means of sales of debt
securities to institutional investors) in whole or in part from
time to time; provided that the aggregate principal amount of
Indebtedness outstanding at any time under all such Credit
Facilities is permitted to be incurred under clause (2) or
(15) of the definition of the term Permitted
Debt.
Credit Facility Agent means, at any time, the
Person serving at such time as the Agent,
Administrative Agent or Collateral Agent
under the applicable Credit Facility or any other representative
of the lenders thereunder then most recently designated by the
terms of the Credit Facility, in a written notice delivered to
the administrative agent, as the Credit Facility Agent for the
purposes of the indenture.
Credit Facility Lien means, to the extent
securing Credit Facility Obligations, a Lien granted on assets
constituting Secondary Collateral to the Credit Facility Agent
or any holder, or other administrative agent, agent or
representative of holders, of Credit Facility Obligations as
security for Credit Facility Obligations.
Credit Facility Lien Documents means the
documentation relating to the Liens granted under any Credit
Facility including, without limitation, the ABL Facility, the
ABL Facility Lien Security Documents, any related loans,
guarantees, collateral documents, instruments and agreements
executed in connection therewith and all other agreements
governing, securing or relating to any Credit Facility
Obligations.
Credit Facility Obligations means
Indebtedness arising under any Credit Facility and all other
Obligations of Sterling Chemicals or any Guarantor under the
Credit Facility Lien Documents.
136
Default means any event that is, or with the
passage of time or the giving of notice or both would be, an
Event of Default.
Disqualified Stock means any Capital Stock
that, by its terms (or by the terms of any security into which
it is convertible, or for which it is exchangeable, in each case
at the option of the holder of the Capital Stock) or upon the
happening of any event, matures or is mandatorily redeemable,
pursuant to a sinking fund obligation or otherwise, or
redeemable at the option of the holder of the Capital Stock, in
whole or in part, on or prior to the date that is 91 days
after the date on which the notes mature. Notwithstanding the
preceding sentence, any Capital Stock that would constitute
Disqualified Stock solely because the holders of the Capital
Stock have the right to require Sterling Chemicals to repurchase
such Capital Stock upon the occurrence of a Change of Control or
an Asset Sale will not constitute Disqualified Stock if the
terms of such Capital Stock provide that Sterling Chemicals may
not repurchase or redeem any such Capital Stock pursuant to such
provisions unless such repurchase or redemption complies with
the covenant described above under Certain
Covenants Restricted Payments;
provided, further, that if the Capital Stock is
issued to any plan for the benefit of employees of Sterling
Chemicals or its Subsidiaries or by any such plan to those
employees, that Capital Stock shall not constitute Disqualified
Stock solely because it may be required to be repurchased by
Sterling Chemicals in order to satisfy applicable statutory or
regulatory obligations. The amount of Disqualified Stock deemed
to be outstanding at any time for purposes of the indenture will
be the maximum amount that Sterling Chemicals and its Restricted
Subsidiaries may become obligated to pay upon the maturity of,
or pursuant to any mandatory redemption provisions of, such
Disqualified Stock, exclusive of accrued dividends.
Notwithstanding the foregoing, Sterling Chemicals existing
Series A Convertible Preferred Stock shall not be deemed to
be Disqualified Stock unless the terms thereof are changed after
the Issue Date in a manner that causes such Series A
Convertible Preferred Stock to become Disqualified Stock.
Domestic Subsidiary means any Restricted
Subsidiary of Sterling Chemicals that was formed under the laws
of the United States or any state of the United States or the
District of Columbia.
Equity Interests means Capital Stock and all
warrants, options or other rights to acquire Capital Stock (but
excluding any debt security that is convertible into, or
exchangeable for, Capital Stock).
Equity Offerings means one or more public or
private offerings of Equity Interests (other than Disqualified
Stock) of Sterling Chemicals or cash capital contributions
received by Sterling Chemicals in respect of such Equity
Interests (other than Disqualified Stock).
Event of Loss means, with respect to any
property or asset (tangible or intangible, real or personal)
that constitute Note Collateral (including, without limitation,
any of the Facilities but, in any event, excluding Non-Facility
Assets), any of the following:
(1) any loss, destruction or damage of such property or
asset in an amount in excess of $5.0 million;
(2) any institution of any proceedings for the condemnation
or seizure of such property or asset or for the exercise of any
right of eminent domain;
(3) any actual condemnation, seizure or taking by exercise
of the power of eminent domain or otherwise of such property or
asset, or confiscation of such property or asset or the
requisition of the use of such property or asset; or
(4) any settlement in lieu of clauses (2) or
(3) above.
Existing Notes means Sterling Chemicals
existing 10% Senior Secured Notes due 2007.
Facilities means Sterling Chemicals
acetic acid manufacturing facility, styrene monomer
manufacturing facility, phthalic anhydride manufacturing
facility, plasticizers esters manufacturing facility and, in
each case, all improvements thereto.
Fair Market Value means the value that would
be paid by a willing buyer to an unaffiliated willing seller,
determined in good faith by the chief financial officer of the
Company in the case of any transaction valued at less than
$5.0 million and in all other cases by the Board of
Directors of Sterling Chemicals (unless otherwise provided in
the indenture).
137
Fixed Charge Coverage Ratio means, with
respect to any specified Person for any period, the ratio of the
Consolidated Cash Flow of such Person for such period to the
Fixed Charges of such Person for such period. In the event that
the specified Person or any of its Restricted Subsidiaries
incurs, assumes, Guarantees, repays, repurchases, redeems,
defeases or otherwise discharges any Indebtedness (other than
ordinary working capital borrowings) or issues, repurchases or
redeems preferred stock (other than perpetual PIK
preferred stock) subsequent to the commencement of the period
for which the Fixed Charge Coverage Ratio is being calculated
and on or prior to the date on which the event for which the
calculation of the Fixed Charge Coverage Ratio is made (the
Calculation Date), then the Fixed Charge
Coverage Ratio will be calculated giving pro forma effect
to such incurrence, assumption, Guarantee, repayment,
repurchase, redemption, defeasance or other discharge of
Indebtedness, or such issuance, repurchase or redemption of such
preferred stock, and the use of the proceeds therefrom, as if
the same had occurred at the beginning of the applicable
four-quarter reference period.
In addition, for purposes of calculating the Fixed Charge
Coverage Ratio:
(1) acquisitions that have been made by the specified
Person or any of its Restricted Subsidiaries, including through
mergers or consolidations, or any Person or any of its
Restricted Subsidiaries acquired by the specified Person or any
of its Restricted Subsidiaries, and including any related
financing transactions and including increases in ownership of
Restricted Subsidiaries, during the four-quarter reference
period or subsequent to such reference period and on or prior to
the Calculation Date will be given pro forma effect as if
they had occurred on the first day of the four-quarter reference
period;
(2) the Consolidated Cash Flow attributable to discontinued
operations, as determined in accordance with GAAP, and
operations or businesses (and ownership interests therein)
disposed of prior to the Calculation Date, will be excluded;
(3) the Fixed Charges attributable to discontinued
operations, as determined in accordance with GAAP, and
operations or businesses (and ownership interests therein)
disposed of prior to the Calculation Date, will be excluded, but
only to the extent that the obligations giving rise to such
Fixed Charges will not be obligations of the specified Person or
any of its Restricted Subsidiaries following the Calculation
Date;
(4) any Person that is a Restricted Subsidiary on the
Calculation Date will be deemed to have been a Restricted
Subsidiary at all times during such four-quarter period;
(5) any Person that is not a Restricted Subsidiary on the
Calculation Date will be deemed not to have been a Restricted
Subsidiary at any time during such four-quarter period; and
(6) if any Indebtedness bears a floating rate of interest,
the interest expense on such Indebtedness will be calculated as
if the rate in effect on the Calculation Date had been the
applicable rate for the entire period (taking into account any
Hedging Obligation applicable to such Indebtedness if such
Hedging Obligation has a remaining term until the earlier of the
maturity of such Indebtedness or as at the Calculation Date in
excess of 12 months).
For purposes of this definition and the first paragraph of the
provision under Incurrence of Indebtedness
and Issuance of Preferred Stock, whenever pro forma
effect is to be given to any calculation, the pro forma
calculations shall be determined in good faith by the chief
financial officer of Sterling Chemicals. Any such pro forma
calculations may include operating expense reductions (net of
associated expenses) for such period resulting from the
acquisition which is being given pro forma effect that
(a) would be permitted to be reflected on pro forma
financial statements pursuant to
Rule 11-02
of
Regulation S-X
under the Securities Act or (b) have been realized or for
which substantially all the steps necessary for realization have
been taken or, at the time of determination, are reasonably
expected to be taken with 90 days immediately following any
such acquisition, including, but not limited to, the execution,
termination, renegotiation or modification of any contracts, the
termination of any personnel or the closing of any facility, as
applicable, provided that, in any case, such adjustments
shall be calculated on an annualized basis and such adjustments
are set forth in an Officers Certificate signed by
Sterling Chemicals chief financial officer and another
Officer which states in detail (i) the amount of such
adjustment or adjustments, (ii) that such adjustment or
adjustments are based on the reasonable good faith beliefs of
the Officers executing such Officers Certificate at the
time of such execution and (iii) that such adjustment or
adjustments and the plan or plans related thereto have been
reviewed and approved by Sterling Chemicals Board of
Directors.
138
Fixed Charges means, with respect to any
specified Person for any period, the sum, without duplication,
of:
(1) the consolidated interest expense of such Person and
its Restricted Subsidiaries for such period, whether paid or
accrued, including, without limitation, amortization of debt
issuance costs and original issue discount, non-cash interest
payments, the interest component of any deferred payment
obligations, the interest component of all payments associated
with Capital Lease Obligations, imputed interest with respect to
Attributable Debt, commissions, discounts and other fees and
charges incurred in respect of letter of credit or bankers
acceptance financings, and net of the effect of all payments
made or received pursuant to Hedging Obligations in respect of
interest rates; plus
(2) the consolidated interest of such Person and its
Restricted Subsidiaries that was capitalized during such period
to the extent the net income of such Restricted Subsidiary is
included in the calculation of Net Income; plus
(3) any interest accruing on Indebtedness of another Person
that is Guaranteed by such Person or one of its Restricted
Subsidiaries or secured by a Lien on assets of such Person or
one of its Restricted Subsidiaries, whether or not such
Guarantee or Lien is called upon; plus
(4) the product of (a) all dividends, whether paid or
accrued and whether or not in cash, on any series of preferred
stock of such Person or any of its Restricted Subsidiaries,
other than dividends on Equity Interests payable solely in
Equity Interests of Sterling Chemicals (other than Disqualified
Stock) or to Sterling Chemicals or a Restricted Subsidiary of
Sterling Chemicals times (b) a fraction, the numerator of
which is one and the denominator of which is one minus the then
current combined federal, state and local statutory tax rate of
such Person, expressed as a decimal,
in each case, on a consolidated basis and in accordance with
GAAP.
Foreign Subsidiary means any Restricted
Subsidiary that is not a Domestic Subsidiary.
GAAP means generally accepted accounting
principles set forth in the opinions and pronouncements of the
Accounting Principles Board of the American Institute of
Certified Public Accountants and statements and pronouncements
of the Financial Accounting Standards Board or in such other
statements by such other entity as have been approved by a
significant segment of the accounting profession which are in
effect from time to time.
Guarantee means a guarantee other than by
endorsement of negotiable instruments for collection in the
ordinary course of business, direct or indirect, in any manner,
including, without limitation, by way of a pledge of assets or
through letters of credit or reimbursement agreements in respect
thereof, of all or any part of any Indebtedness (whether arising
by virtue of partnership arrangements, or by agreements to
keep-well, to purchase assets, goods, securities or services or
to maintain financial statement conditions).
Guarantors means:
(1) all of Sterling Chemicals existing Domestic
Subsidiaries; and
(2) any other Subsidiary of Sterling Chemicals that
executes a Note Guarantee in accordance with the provisions of
the indenture,
and their respective successors and assigns, in each case, until
the Note Guarantee of such Person has been released in
accordance with the provisions of the indenture.
Hedging Obligations means, with respect to
any specified Person, the obligations of such Person under:
(1) interest rate swap agreements (whether from fixed to
floating or from floating to fixed), interest rate cap
agreements and interest rate collar agreements;
(2) other agreements or arrangements designed to manage
interest rates or interest rate risk; and
(3) other agreements or arrangements designed to protect
such Person against fluctuations in currency exchange rates.
Holders means a Person in whose name a note
is registered.
139
Indebtedness means, with respect to any
specified Person,
(1) any indebtedness of such Person (excluding accrued
expenses and trade payables), whether or not contingent:
(a) in respect of borrowed money;
(b) evidenced by bonds, loans, debentures or similar
instruments or letters of credit (or reimbursement agreements in
respect thereof);
(c) in respect of bankers acceptances;
(d) representing Capital Lease Obligations; or
(e) representing any Hedging Obligations, and
(2) all Obligations of such Person issued or assumed as the
deferred purchase price of property, all conditional sale
obligations and all Obligations under any title retention
agreement (but excluding trade accounts payable and other
accrued liabilities arising in the ordinary course of business
that are not overdue by 90 days or more or are being
contested in good faith by appropriate proceedings promptly
instituted and diligently conducted and any deferred purchase
price represented by earn outs consistent with Sterling
Chemicals past practice),
if and to the extent any of the preceding items (other than
letters of credit, Attributable Debt and Hedging Obligations)
would appear as a liability upon a balance sheet of the
specified Person prepared in accordance with GAAP. In addition,
the term Indebtedness includes such portion of the
Indebtedness of others secured by a Lien on any asset of the
specified Person (whether or not such Indebtedness is assumed by
the specified Person) as shall equal the lesser of (x) the
Fair Market Value of such asset as of the date of determination
and (y) the amount of such Indebtedness and, to the extent
not otherwise included, the Guarantee by the specified Person of
any Indebtedness of any other Person, provided that
Indebtedness of Sterling Chemicals or any Restricted Subsidiary
shall not include the pledge by Sterling Chemicals or such
Restricted Subsidiary of, or a Guarantee thereof limited in
recourse to, the Capital Stock of an Unrestricted Subsidiary to
secure Non-Recourse Debt of such Unrestricted Subsidiary.
Indenture Documents means, collectively, the
indenture, the notes, the Note Guarantees and the Collateral
Documents.
Intercreditor Agreement means the
intercreditor agreement entered into between the collateral
agent, on behalf of the trustee and the Holders and each
applicable Credit Facility Agent, as the same may be amended,
restated, replaced, supplemented or otherwise modified from time
to time, as described under the caption
Intercreditor Agreement).
Investments means, with respect to any
Person, all direct or indirect investments by such Person in
other Persons (including Affiliates) in the forms of loans
(including Guarantees or other obligations), advances or capital
contributions (excluding accounts receivable, trade credit and
advances to customers and commission, travel and similar
advances to officers and employees made in the ordinary course
of business), and purchases or other acquisitions for
consideration of Indebtedness, Equity Interests or other
securities of such other Person together with all items that are
or would be classified as investments on a balance sheet
prepared in accordance with GAAP. If Sterling Chemicals or any
Restricted Subsidiary of Sterling Chemicals sells or otherwise
disposes of any Equity Interests of any direct or indirect
Restricted Subsidiary of Sterling Chemicals such that, after
giving effect to any such sale or disposition, such Person is no
longer a Restricted Subsidiary of Sterling Chemicals, Sterling
Chemicals will be deemed to have made an Investment on the date
of any such sale or disposition equal to the Fair Market Value
of Sterling Chemicals Investments in such Restricted
Subsidiary that were not sold or disposed of in an amount
determined as provided in the last paragraph of the covenant
described above under Certain
Covenants Restricted Payments. The
acquisition by Sterling Chemicals or any Restricted Subsidiary
of Sterling Chemicals of a Person that became a Restricted
Subsidiary and that holds an Investment in a third Person will
be deemed to be an Investment by Sterling Chemicals or such
Restricted Subsidiary in such third Person in an amount equal to
the Fair Market Value of the Investments held by the acquired
Person in such third Person in an amount determined as provided
in the last paragraph of the covenant described above under
Certain Covenants Restricted
140
Payments. Except as otherwise provided in the
indenture, the amount or Fair Market Value of an Investment will
be determined at the time the Investment is made and without
giving effect to subsequent changes in value but giving effect
to all subsequent reductions in the amount of such Investment as
a result of (x) the repayment or disposition thereof for
cash or (y) the redesignation of an Unrestricted Subsidiary
as a Restricted Subsidiary (valued proportionate to the equity
interest in such Subsidiary of Sterling Chemicals or the
Restricted Subsidiary thereof owing such Unrestricted Subsidiary
at the time of such redesignation) at the Fair Market Value of
the net assets of such Subsidiary at the time of such
redesignation, in the case of clause (x) and (y), not to
exceed the original amount, or Fair Market Value, of such
Investment.
Issue Date means March 29, 2007.
Lien means, with respect to any asset, any
mortgage, lien, pledge, charge, security interest or encumbrance
of any kind in respect of such asset, whether or not filed,
recorded or otherwise perfected under applicable law, including
any conditional sale or other title retention agreement, any
lease in the nature thereof or any option or other agreement to
sell give a security interest.
Moodys means Moodys Investors
Service, Inc. and its successors.
Mortgage means each mortgage, deed of trust,
deed to secure debt, amendment to mortgage or amendment to deed
of trust, substantially in the respective form included as an
exhibit in the indenture, between each Obligor party thereto, as
mortgagor or trustor, and the collateral agent, as mortgagee or
beneficiary, entered into as of the Issue Date and relating to
the Obligors facilities in the locations listed in a
schedule to the indenture, and any mortgage, deed of trust, deed
to secure debt, amendment to mortgage or amendment to deed of
trust entered into pursuant to the indenture after the Issue
Date, in each case as amended from time to time.
Net Income means, with respect to any
specified Person, the net income (loss) of such Person,
determined in accordance with GAAP and before any reduction in
respect of preferred stock dividends, excluding, however:
(1) any gain (but not loss), together with any related
provision for taxes on such gain (but not loss), realized in
connection with: (a) any Asset Sale; or (b) the
disposition of any securities by such Person or any of its
Restricted Subsidiaries or the extinguishment of any
Indebtedness of such Person or any of its Restricted
Subsidiaries; and
(2) any extraordinary or nonrecurring gain (or loss),
together with any related provision for taxes on such
extraordinary or nonrecurring gain (or loss).
Net Loss Proceeds means the aggregate cash
proceeds received by Sterling Chemicals or any Guarantor in
respect of any Event of Loss, including, without limitation,
insurance proceeds, condemnation awards or damages awarded by
any judgment, net of the direct costs in recovery of such Net
Loss Proceeds (including, without limitation, legal, accounting,
appraisal and insurance adjuster fees and any relocation
expenses incurred as a result thereof), amounts required to be
applied to the repayment of Indebtedness, other than Credit
Facility Obligations, secured by a Lien on the asset or assets
that were the subject of such Event of Loss, and any taxes paid
or payable as a result thereof.
Net Proceeds means the aggregate cash
proceeds received by Sterling Chemicals or any of its Restricted
Subsidiaries in respect of any Asset Sale (including, without
limitation, any cash received upon the sale or other disposition
of any non-cash consideration received in any Asset Sale), net
of the direct costs relating to such Asset Sale, including,
without limitation, legal, accounting and investment banking
fees, and sales commissions, recording fees, title transfer fees
and appraiser fees and cost of preparation of assets for sale,,
and any relocation expenses incurred as a result of the Asset
Sale, taxes paid or payable as a result of the Asset Sale, in
each case, after taking into account any available tax credits
or deductions and any tax sharing arrangements, and amounts
required to be applied to the repayment of Indebtedness, other
than Credit Facility Obligations, secured by a Lien on the asset
or assets that were the subject of such Asset Sale and any
reserve for adjustment in respect of the sale price of such
asset or assets established in accordance with GAAP or amount
placed in an escrow account for purposes of such an adjustment.
Non-Facility Assets means (1) any
non-current assets of Sterling Chemicals or any of its
Restricted Subsidiaries, excluding (a) the Facilities and
(b) any asset (i) used primarily in connection with
the operation of any
141
of the Facilities or (ii) the loss of which would result in
the Company expending more than $1.0 million in the
aggregate to operate its acetic acid, styrene or plasticizers
businesses as currently conducted by Sterling Chemicals and its
Restricted Subsidiaries and (2) any other asset of Sterling
Chemicals or any of its Restricted Subsidiaries that is not
described in the exclusion to clause (1) and that primarily
relates to the construction, use, occupancy, possession,
operation or ownership of such other asset.
Non-Recourse Debt means Indebtedness:
(1) as to which neither Sterling Chemicals nor any of its
Restricted Subsidiaries (a) provides credit support of any
kind (including any undertaking, agreement or instrument that
would constitute Indebtedness) other than a pledge of the Equity
Interests of Unrestricted Subsidiaries, (b) is directly or
indirectly liable (as a guarantor or otherwise), other than by
virtue of a non-recourse pledge of the Equity Interests of
Unrestricted Subsidiaries or (c) constitutes the lender;
(2) no default with respect to which (including any rights
that the holders of the Indebtedness may have to take
enforcement action against an Unrestricted Subsidiary) would
permit upon notice, lapse of time or both any holder of any
other Indebtedness of Sterling Chemicals or any of its
Restricted Subsidiaries to Declare a Default on such other
Indebtedness or cause the payment of the Indebtedness to be
accelerated or payable prior to its Stated Maturity.
Note Collateral means, collectively, all the
property and assets (including, without limitation, Primary
Collateral and Secondary Collateral) that are from time to time
subject to the Lien of the Collateral Documents, including the
Liens, if any, required to be granted pursuant to the indenture.
Note Lien means, to the extent securing Note
Obligations, a Lien granted pursuant to a security document as
security for Note Obligations.
Note Obligations means the notes, the Note
Guarantees and all other Obligations of any Obligor under the
indenture, the Note Guarantees and the Collateral Documents.
Notes Guarantee means the Guarantee by each
Guarantor of Sterling Chemicals obligations under the
indenture and the other Indenture Documents, executed pursuant
to the provisions of the indenture.
Obligations means any principal, interest,
penalties, fees, indemnifications, reimbursements, damages and
other liabilities payable under the documentation governing any
Indebtedness.
Obligor means a Person obligated as an issuer
or Guarantor of the notes.
Officer means the Chief Executive Officer,
the President, the Chief Financial Officer or any Vice President
of Sterling Chemicals.
Officers Certificate means a
certificate signed by two Officers of Sterling Chemicals, at
least one of whom shall be the principal financial officer of
Sterling Chemicals, and delivered to the trustee.
Opinion of Counsel means a written opinion of
counsel who shall be reasonably acceptable to the trustee.
Permitted Business means (1) the
manufacturing and distributing of selected petrochemicals,
(2) any business or activity similar, ancillary or
reasonably related thereto, or a reasonable extension, expansion
or development of, such businesses or ancillary thereto and
(3) any business or activity carried out or performed
utilizing any of the Non-Facility Assets.
Permitted Holders means Resurgence Asset
Management, L.L.C. and its and its affiliates managed
funds and accounts and (1) entities controlled by any such
Persons, (2) trusts for the benefit of any such individual
Persons or the spouses, issue, parents or other relatives of
such individual Persons and (3) in the event of the death
of any such individual Person, heirs or testamentary legatees of
such Person. For purposes of this definition,
control, as used with respect to any Person, shall
mean the possession, directly or indirectly, of the power to
direct or cause the direction of the management and policies of
such Person, whether through the ownership of voting securities
or by contract or otherwise.
142
Permitted Investments means:
(1) any Investment by (a) Sterling Chemicals or a
Restricted Subsidiary of Sterling Chemicals in Sterling
Chemicals or a Guarantor, (b) Sterling Chemicals or a
Guarantor in a Restricted Subsidiary of Sterling Chemicals that
is not a Guarantor to the extent that the aggregate amount of
all such Investments does not exceed $5.0 million at any
time outstanding or (c) a Restricted Subsidiary of Sterling
Chemicals that is not a Guarantor in any other Restricted
Subsidiary;
(2) any Investment in Cash Equivalents;
(3) any Investment by Sterling Chemicals or any Restricted
Subsidiary of Sterling Chemicals in a Person, if as a result of
such Investment:
(a) such Person becomes a Restricted Subsidiary of Sterling
Chemicals; or
(b) such Person is merged, consolidated or amalgamated with
or into, or transfers or conveys substantially all of its assets
to, or is liquidated into, Sterling Chemicals or a Restricted
Subsidiary of Sterling Chemicals;
(4) any Investment made as a result of the receipt of
consideration from an Asset Sale that was made pursuant to and
in compliance with the covenant described above under
Certain Covenants Asset
Sales;
(5) any acquisition of assets or Capital Stock solely in
exchange for the issuance of Equity Interests (other than
Disqualified Stock) of Sterling Chemicals;
(6) any Investments received in compromise or resolution of
(A) obligations of any Person or customer that were
incurred in the ordinary course of business of Sterling
Chemicals or any of its Restricted Subsidiaries, including
pursuant to any plan of reorganization or similar arrangement
upon the bankruptcy or insolvency of such Person; or
(B) litigation, arbitration or other disputes with Persons
who are not Affiliates;
(7) investments represented by Hedging Obligations;
(8) other Investments having an aggregate Fair Market Value
(measured on the date each such Investment was made and without
giving effect to subsequent changes in value), when taken
together with all other Investments made pursuant to this
clause (8) that are at the time outstanding, not to exceed
$3.0 million;
(9) loans or advances to employees in the ordinary course
of business permitted by applicable law not to exceed $500,000
at any time outstanding;
(10) Investments in the notes;
(11) endorsements for collection or deposit in the ordinary
course of business by such Person of bank drafts and similar
negotiable instruments of any other Person received as payment
for ordinary course of business trade receivables;
(12) receivables and prepaid expenses, in each case arising
in the ordinary course of business; provided,
however, that such receivables and prepaid expenses would
be recorded as assets of such Person in accordance with GAAP;
(13) Investments owned by a Person if and when such Person
is acquired by Sterling Chemicals or a Restricted Subsidiary and
becomes a Restricted Subsidiary or if and when such Person
merges into, consolidates with or transfers substantially all of
such Persons assets to, Sterling Chemicals or a Restricted
Subsidiary; provided, however, that such
Investments are not made in contemplation of such acquisition or
transfer;
(14) reclassification of any Investment initially made in
(or reclassified as) one form into another form (such as from
equity to loan or vice versa); provided in each case that
the amount of such Investment is not increased thereby;
143
(15) any Investment existing on the date of the indenture
and any Investment that extends, renews, defeases, discharges,
replaces, refinances or refunds an existing Investment;
provided, that the new Investment is in an amount that
does not exceed the amount replaced, refinanced or refunded, and
is made in the same Person as the Investment replaced,
refinanced or refunded;
(16) Investments in Unrestricted Subsidiaries and other
Persons to the extent such Investments consist of
(a) Non-Facility Assets or (b) other assets having an
aggregate Fair Market Value (measured on the date each such
Investment was made and without giving effect to subsequent
changes in value), when taken together with all other
Investments made pursuant to this clause (16)(b) that are at the
time outstanding, not to exceed $2.0 million; and
(17) prepaid expenses, lease, utilities, workers
compensation, performance and similar deposits made in the
ordinary course of business,
provided, however, that with respect to any Investment,
Sterling Chemicals may, in its sole discretion, allocate all or
any portion of any Investment to one or more of the above
clauses (1) through (17) so that all or a portion of
the Investment would be a Permitted Investment.
Permitted Liens means:
(1) Liens created for the benefit of (or to secure) the
notes (or the Note Guarantees);
(2) Credit Facility Liens on assets constituting Secondary
Collateral;
(3) Liens in favor of Sterling Chemicals or the Guarantors
(not securing Credit Facility Obligations);
(4) Liens on property of a Person existing at the time such
Person is merged with or into or consolidated with Sterling
Chemicals or any Restricted Subsidiary of Sterling Chemicals;
provided that such Liens were in existence prior to the
contemplation of such merger or consolidation and do not extend
to any assets other than those of the Person merged into or
consolidated with Sterling Chemicals or such Restricted
Subsidiary;
(5) Liens on property (including Capital Stock) existing at
the time of acquisition of the property, including by way of
merger, consolidation or otherwise, by Sterling Chemicals or any
Restricted Subsidiary of Sterling Chemicals; provided
that such Liens were in existence prior to, such
acquisition, and not incurred in contemplation of, such
acquisition and do not extend to any assets other than those of
the Person merged into or consolidated with Sterling Chemicals
or such Restricted Subsidiary;
(6) Liens to secure the performance of statutory
obligations (including obligations under workers
compensation, unemployment insurance or similar legislation),
surety or appeal bonds, performance bonds or other obligations
of a like nature incurred in the ordinary course of business;
(7) Liens existing on the Issue Date (other than pursuant
to clause (2), (3) or (28) of this definition);
(8) Liens for taxes, assessments or governmental charges or
claims that are not yet delinquent or that are being contested
in good faith by appropriate proceedings promptly instituted and
diligently concluded; provided that any reserve or other
appropriate provision as is required in conformity with GAAP has
been made therefor;
(9) Liens imposed by law, such as carriers,
warehousemens, landlords and mechanics Liens,
in each case, incurred in the ordinary course of business, or to
secure the performance of tenders, statutory obligations,
surety, environmental liability or appeal bonds, bids, leases,
government contracts, performance or return-of-money bonds or
other similar obligations (exclusive of obligations for the
payment of borrowed money) incurred in the ordinary course of
business;
(10) survey exceptions, easements or reservations of, or
rights of others for, licenses, rights-of-way, sewers, electric
lines, telegraph and telephone lines and other similar purposes,
or zoning or other restrictions as to the use of real property
that were not incurred in connection with Indebtedness and that
do not in the aggregate materially adversely affect the value of
said properties or materially impair their use in the operation
of the business of such Person;
144
(11) minor irregularities in title, boundaries, or other
survey defects, easements, rights-of-way, restrictions,
servitudes, permits, reservations, exceptions, zoning
regulations, conditions, covenants, mineral or royalty rights or
reservations or oil, gas and mineral leases and rights of others
in any property of Sterling Chemicals or any Restricted
Subsidiary for streets, roads, bridges, pipes, pipe lines,
railroads, electric transmission and distribution lines,
electronic communication lines, the removal of oil, gas or other
minerals or other similar purposes, flood control, water rights,
rights of others with respect to navigable waters, sewage and
drainage rights and other similar charges or encumbrances
existing as of the Issue Date (or granted by Sterling Chemicals
or any Restricted Subsidiary in the ordinary course of business)
that do not, in the aggregate, materially impair the value of
the property of Sterling Chemicals or any Restricted Subsidiary
or the occupation, use and enjoyment by Sterling Chemicals or
any Restricted Subsidiaries of any of their respective
properties in the normal course of business;
(12) Liens securing an obligation of a third party neither
created, assumed nor guaranteed by Sterling Chemicals or any
Restricted Subsidiary upon lands over which easements or similar
rights are acquired by Sterling Chemicals or any Restricted
Subsidiary in the ordinary course of business;
(13) terminable or short term leases or permits for
occupancy, which leases or permits expressly grant to Sterling
Chemicals or any Restricted Subsidiary the right to terminate
them at any time on not more than one years notice and
which occupancy does not interfere with the operation of the
business of Sterling Chemicals and the Restricted Subsidiaries;
(14) Liens to secure any Permitted Refinancing Indebtedness
permitted to be incurred under the indenture; provided,
however, that:
(A) the new Lien shall be limited to all or part of the
same property and assets that secured or, under the written
agreements pursuant to which the original Lien arose, could
secure the original Lien (plus improvements and accessions to
such property or proceeds or distributions thereof); and
(B) the Indebtedness secured by the new Lien is not
increased to any amount greater than the sum of (1) the
outstanding principal amount or, if greater, committed amount of
the Permitted Referencing Indebtedness and (2) an amount
necessary to pay any fees and expenses, including premiums,
related to such refinancings, refunding, extension, renewal or
replacement;
(15) Liens arising pursuant to an order of attachment,
distraint or similar legal process arising in connection with
legal proceedings not giving rise to an Event of Default under
the indenture;
(16) any obligations or duties affecting any of the
property of Sterling Chemicals or any Restricted Subsidiary to
any municipality or public authority with respect to any
franchise, grant, license or permit that do not impair the use
of such property for the purposes for which it is held;
(17) Liens on property that is the subject of capital
projects between Sterling Chemicals or any Restricted Subsidiary
and a third party that has a production, operating or other
agreement with Sterling Chemicals; provided,
however, that such Liens are expressly limited to the
assets directly financed by such third party;
(18) [INTENTIONALLY OMITTED];
(19) Liens on any property in favor of domestic or foreign
governmental bodies to secure partial, progress, advance or
other payments pursuant to any contract or statute, not yet due
and payable;
(20) Liens (other than Liens securing the Credit
Facilities) securing Permitted Debt described in clause (5)
of the definition thereof that is incurred to finance the
construction, purchase or lease of, or repairs, improvements or
additions to, property of such Person used in the business of
Sterling Chemicals or any of its Restricted Subsidiaries;
(21) Liens with respect to the so called
greenbelt or buffer zone properties;
(22) leases and ground leases of underutilized or vacant
properties of Sterling Chemicals or any Subsidiary to third
parties with which Sterling Chemicals has a production,
co-production, co-generation, operating or other arrangement or
to third party providers of energy or raw materials in the
ordinary course of
145
business, provided such leases do not materially
interfere with the operation of the business of Sterling
Chemicals or any Subsidiary or materially diminish the value of
the Facility Assets;
(23) easements, rights-of-way, restrictions and other
similar charges or encumbrances granted to others, in each case
incidental to, and not interfering with, the ordinary conduct of
the business of Sterling Chemicals or any of its Subsidiaries,
provided that such Liens are not violated by the existing
Facility Assets and do not, in the aggregate, materially
diminish the value of the Facility Assets;
(24) the burdens of any law or governmental regulation or
permit requiring Sterling Chemicals to maintain certain
facilities or perform certain acts as a condition of its
occupancy of or interference with any public lands or any river
or stream or navigable waters;
(25) Liens on any of the Non-Facility Assets;
(26) Liens incurred in the ordinary course of business of
Sterling Chemicals or any Subsidiary of Sterling Chemicals with
respect to obligations that do not exceed $1.0 million at
any one time outstanding;
(27) Liens incurred in the ordinary course of business of
Sterling Chemicals or any Subsidiary of Sterling Chemicals with
respect to obligations that do not secure Indebtedness and that
do not exceed $5.0 million at any one time outstanding;
(28) Liens on the Primary Collateral that secure the
Existing Notes so long as the Indebtedness secured by such Liens
is paid in full no later than the 31st day following the
Issue Date; and
(29) extensions, renewals, modifications or replacements of
any Lien referred to in clauses (4), (5), (7), (18), (20), (22),
(23) and (25) of this definition; provided that
such Lien is not otherwise prohibited by the terms hereof and,
with respect to Liens securing Indebtedness, no extension or
renewal Lien shall (A) secure more than the amount of the
Indebtedness or other obligations secured by the Lien being so
extended or renewed or (B) extend to any property or assets
not subject to the Lien being so extended or renewed.
Permitted Refinancing Indebtedness means any
Indebtedness of Sterling Chemicals or any of its Restricted
Subsidiaries issued in exchange for, or the net proceeds of
which are used to refund, refinance, replace, defease or
discharge, other Indebtedness of Sterling Chemicals or any of
its Restricted Subsidiaries (other than intercompany
Indebtedness); provided that:
(1) the principal amount (or accreted value, if applicable)
of such Permitted Refinancing Indebtedness does not exceed the
principal amount (or accreted value, if applicable) of the
Indebtedness extended, refinanced, renewed, replaced, defeased
or refunded (plus all accrued interest on the Indebtedness and
the amount of all expenses and premiums incurred in connection
therewith);
(2) such Permitted Refinancing Indebtedness has a final
maturity date later than the final maturity date of, and has a
Weighted Average Life to Maturity equal to or greater than the
Weighted Average Life to Maturity of, the Indebtedness being
extended, refinanced, renewed, replaced, defeased or refunded,
taken as a whole;
(3) if the Indebtedness being extended, refinanced,
renewed, replaced, defeased or refunded is subordinated in right
of payment to the notes, such Permitted Refinancing Indebtedness
has a final maturity date later than the final maturity date of,
and is subordinated in right of payment to, the notes on terms
at least as favorable to the Holders as those contained in the
documentation governing the Indebtedness being extended,
refinanced, renewed, replaced, defeased or refunded, taken as a
whole; and
(4) such Indebtedness is incurred either by Sterling
Chemicals or by the Restricted Subsidiary that is the obligor on
the Indebtedness being extended, refinanced, renewed, replaced,
defeased or refunded or any other Restricted Subsidiary.
Person means any individual, corporation,
partnership, joint venture, association, joint-stock company,
trust, unincorporated organization, limited liability company or
government or other entity.
Restricted Investment means an Investment
other than a Permitted Investment.
146
Restricted Subsidiary of a Person means any
Subsidiary of such Person that is not an Unrestricted Subsidiary.
S&P means Standard &
Poors Ratings Group and its successors.
SEC means the U.S. Securities and
Exchange Commission.
Significant Subsidiary means any Subsidiary
that would be a significant subsidiary as defined in
Article 1,
Rule 1-02
of
Regulation S-X,
promulgated pursuant to the Securities Act, as such Regulation
is in effect on the Issue Date.
Stated Maturity means, with respect to any
installment of interest or principal on any series of
Indebtedness, the date on which the payment of interest or
principal was scheduled to be paid in the documentation
governing such Indebtedness as of the date such documentation
was entered into, and will not include any contingent
obligations to repay, redeem or repurchase any such interest or
principal prior to the date originally scheduled for the payment
thereof.
Subsidiary means, with respect to any
specified Person:
(1) any corporation, association or other business entity
of which more than 50% of the total voting power of shares of
Capital Stock entitled (without regard to the occurrence of any
contingency and after giving effect to any voting agreement or
stockholders agreement that effectively transfers voting
power) to vote in the election of directors, managers or
trustees of the corporation, association or other business
entity is at the time owned or controlled, directly or
indirectly, by that Person or one or more of the other
Subsidiaries of that Person (or a combination thereof); and
(2) any partnership (a) the sole general partner or
the managing general partner of which is such Person or a
Subsidiary of such Person or (b) the only general partners
of which are such Person or one or more Subsidiaries of such
Person (or any combination thereof).
Treasury Rate means the yield to maturity at
the time of computation of United States Treasury securities
with a constant maturity (as compiled and published in the most
recent Federal Reserve Statistical Release H.15 (519) which
has become publicly available at least two Business Days prior
to the redemption date (or, if such Statistical Release is no
longer published, any publicly available source of similar
market data)) most nearly equal to the period from the
redemption date to April 1, 2011; provided, however,
that if the period from the redemption date to April 1,
2011 is not equal to the constant maturity of a United States
Treasury security for which a weekly average yield is given, the
Treasury Rate shall be obtained by linear interpolation
(calculated to the nearest one-twelfth of a year) from the
weekly average yields of United States Treasury securities for
which such yields are given, except that if the period from the
redemption date to April 1, 2011 is less than one year, the
weekly average yield on actually traded United States Treasury
securities adjusted to a constant maturity of one year shall be
used.
Unrestricted Subsidiary means any Subsidiary
of Sterling Chemicals that is designated by the Board of
Directors of Sterling Chemicals as an Unrestricted Subsidiary
pursuant to a resolution of the Board of Directors, but only to
the extent that such Subsidiary:
(1) has no Indebtedness other than Non-Recourse Debt;
(2) except as permitted by the covenant described above
under Certain Covenants
Transactions With Affiliates, is not party to any
agreement, contract, arrangement or understanding with Sterling
Chemicals or any Restricted Subsidiary of Sterling Chemicals
unless the terms of any such agreement, contract, arrangement or
understanding are, in the good faith judgment of Sterling
Chemicals Board of Directors no less favorable to Sterling
Chemicals or such Restricted Subsidiary than those that might be
obtained at the time from Persons who are not Affiliates of
Sterling Chemicals;
(3) is a Person with respect to which neither Sterling
Chemicals nor any of its Restricted Subsidiaries has any direct
or indirect obligation (a) to subscribe for additional
Equity Interests or (b) to maintain or preserve such
Persons financial condition; and
(4) has not guaranteed or otherwise directly or indirectly
provided credit support for the notes.
147
Any designation of a Subsidiary of Sterling Chemicals as an
Unrestricted Subsidiary will be evidenced to the trustee by
filing with the trustee a certified copy of the resolution of
the Board of Directors giving effect to such designation and an
Officers Certificate certifying that such designation
complied with the preceding conditions and was permitted by the
covenant described above under Certain
Covenants Restricted Payments. If, at any
time, any Unrestricted Subsidiary would fail to meet the
preceding requirements as an Unrestricted Subsidiary, it will
thereafter cease to be an Unrestricted Subsidiary for purposes
of the indenture and any Indebtedness of such Subsidiary will be
deemed to be incurred by a Restricted Subsidiary of Sterling
Chemicals as of such date and, if such Indebtedness is not
permitted to be incurred as of such date under the covenant
described under Certain
Covenants Incurrence of Indebtedness and Issuance of
Preferred Stock, Sterling Chemicals will be in default
of such covenant. The Board of Directors of Sterling Chemicals
may at any time designate any Unrestricted Subsidiary to be a
Restricted Subsidiary; provided that such designation
will be deemed to be an incurrence by a Restricted Subsidiary of
Sterling Chemicals of any outstanding Indebtedness of such
Unrestricted Subsidiary and such designation will only be
permitted if (1) such Indebtedness is permitted under the
covenant described under Certain
Covenants Incurrence of Indebtedness and Issuance of
Preferred Stock, calculated on a pro forma
basis as if such designation had occurred at the beginning
of the four-quarter reference period; and (2) no Default or
Event of Default would be in existence following such
designation.
Voting Stock of any Person as of any date
means the Capital Stock of such Person that is at the time
entitled to vote in the election of the Board of Directors of
such Person.
Weighted Average Life to Maturity means, when
applied to any Indebtedness at any date, the number of years
obtained by dividing:
(1) the sum of the products obtained by multiplying
(a) the amount of each then remaining installment, sinking
fund, serial maturity or other required payment of principal,
including payment at final maturity, in respect of the
Indebtedness, by (b) the number of years (calculated to the
nearest one-twelfth) that will elapse between such date and the
making of such payment; by
(2) the then outstanding principal amount of such
Indebtedness.
Wholly-Owned Restricted Subsidiary of any
specified Person means a Restricted Subsidiary of such Person
all of the outstanding Capital Stock or other ownership
interests of which (other than directors qualifying
shares) will at the time be owned by such Person or by one or
more Wholly-Owned Restricted Subsidiaries of such Person or by
such Person and one or more Wholly-Owned Restricted Subsidiaries
of such Person.
148
MATERIAL
U.S. FEDERAL INCOME TAX CONSEQUENCES
General
The following is a summary of material U.S. federal income
tax consequences of the exchange of unregistered notes for
registered notes pursuant to this exchange offer, but does not
address any other aspects of U.S. federal income tax
consequences to holders of unregistered notes or registered
notes. This summary is based upon the Internal Revenue Code of
1986, as amended, or the Code, the Treasury Regulations
promulgated or proposed thereunder, and administrative and
judicial interpretations thereof, all as of the date hereof and
all of which are subject to change, possibly on a retroactive
basis. This summary is not binding on the Internal Revenue
Service, which we refer to as the Service, or on the
courts, and no ruling will be sought from the Service with
respect to the statements made and the conclusions reached in
this summary. There can be no assurance that the Service will
agree with such statements and conclusions.
This summary is limited to the U.S. federal income tax
consequences of those persons who are the original beneficial
owners of the notes, who exchange unregistered notes for
registered notes in this exchange offer and who hold the
unregistered notes as capital assets within the meaning of
Section 1221 of the Code, which we refer to as
Holders. This summary does not address specific tax
consequences that may be relevant to particular persons,
including banks, financial institutions, broker-dealers,
insurance companies, real estate investment trusts, regulated
investment companies, partnerships or other pass-through
entities, expatriates, tax-exempt organizations and persons that
have a functional currency other than the U.S. dollar or
persons in special situations, such as those who have elected to
mark securities to market or those who hold the notes as part of
a straddle, hedge, conversion transaction or other integrated
investment. In addition, this summary does not address
U.S. federal alternative minimum tax consequences, estate
and gift tax consequences, consequences under the tax laws of
any state, local or foreign jurisdiction, or consequences under
any U.S. federal tax laws other than income tax law.
If a partnership or other entity taxable as a partnership holds
notes, the tax treatment of a partner in the partnership
generally will depend upon the status of the partner and the
activities of the partnership. If you are a partner of a
partnership holding the notes, you should consult your tax
advisor regarding the tax consequences of the exchange of
unregistered notes for registered notes pursuant to this
exchange offer.
This summary is for general information only. Persons
considering the exchange of unregistered notes for registered
notes are urged to consult their own tax advisors concerning the
U.S. federal income tax consequences to them of exchanging
the notes, as well as the application of state, local and
foreign tax laws and U.S. federal tax laws other than
income tax law.
Exchange of an Unregistered Note for a Registered Note
Pursuant to the Exchange Offer
The exchange of an unregistered note for a registered note in
the exchange offer described herein will not constitute a
significant modification of the terms of the unregistered notes
and thus will not constitute a taxable exchange for
U.S. federal income tax purposes. Rather, the registered
notes will be treated as a continuation of the unregistered
notes. Consequently, a Holder will not recognize gain or loss,
the Holders basis in the registered notes will be the same
as its basis in the unregistered notes immediately before the
exchange, and the Holders holding period in the registered
notes will include its holding period in the unregistered notes.
149
PLAN OF
DISTRIBUTION
Each broker-dealer that receives registered notes for its own
account pursuant to the exchange offer must acknowledge that it
will deliver a prospectus in connection with any resale of such
registered notes. This prospectus, as it may be amended or
supplemented from time to time, may be used by a broker-dealer
in connection with resales of registered notes received in
exchange for unregistered notes only where such unregistered
notes were acquired as a result of market-making activities or
other trading activities. We have agreed that, for such period
of time as such broker-dealers subject to the prospectus
delivery requirements of the Securities Act must comply with
such requirements, from the date on which the exchange offer is
consummated, we will make this prospectus, as amended or
supplemented, available to any broker-dealer for use in
connection with any such resale. In addition, all dealers
effecting transactions in the registered notes may be required
to deliver a prospectus.
We will not receive any proceeds from any sale of registered
notes by broker-dealers. Registered notes received by
broker-dealers for their own account pursuant to the exchange
offer may be sold from time to time in one or more transactions
in the over-the-counter market, in negotiated transactions,
through the writing of options on the registered notes or a
combination of such methods of resale, at prices related to such
prevailing market prices or at negotiated prices. Any such
resale may be made directly to purchasers or to or through
brokers or dealers who may receive compensation in the form of
commissions or concessions from any such broker-dealer or the
purchasers of any registered notes. Any broker-dealer that
resells registered notes that were received by it for its own
account pursuant to the exchange offer and any broker or dealer
that participates in a distribution of such registered notes may
be deemed to be an underwriter within the meaning of
the Securities Act and any profit on any such resale of
registered notes and any commissions or concessions received by
any such persons may be deemed to be underwriting compensation
under the Securities Act. The letter of transmittal states that
by acknowledging that it will deliver and by delivering a
prospectus, a broker-dealer will not be deemed to admit that it
is an underwriter within the meaning of the
Securities Act. The letter of transmittal also states that any
holder participating in this exchange offer will have no
arrangements or understanding with any person to participate
with the distribution of the unregistered notes or the
registered notes within the meaning of the Securities Act.
For such period of time as such broker-dealers subject to the
prospectus delivery requirements of the Securities Act must
comply with such requirements, from the date on which the
exchange offer is consummated, we will promptly send additional
copies of this prospectus and any amendment or supplement to
this prospectus to any broker-dealer that requests such
documents in the letter of transmittal. We have agreed to pay
all expenses incident to the exchange offer, other than
commissions or concessions of any broker-dealers and will
indemnify the holders of the registered notes, including any
broker-dealers, against certain liabilities, including
liabilities under the Securities Act.
150
LEGAL
MATTERS
The validity of the registered notes and the related guarantees
will be passed upon for us by Akin Gump Strauss
Hauer & Feld LLP.
EXPERTS
The consolidated financial statements as of and for the three
months ended March 31, 2008, included in this prospectus
have been so included in reliance on the report of Grant
Thornton LLP, an independent registered public accounting firm,
given on the authority of said firm as experts in auditing and
accounting.
The consolidated financial statements (before retrospective
adjustments as of December 31, 2007 and 2006 and for each
of the three years in the period ended December 31, 2007
(not presented herein)) have been audited by
Deloitte & Touche LLP, an independent registered
public accounting firm, as stated in their report appearing
herein (which report expresses an unqualified opinion on the
financial statements and includes explanatory paragraphs
referring to 1) a change in the method of accounting for
defined benefit pension and other postretirement plans as of
December 31, 2006, and 2) the restatement of the
consolidated financial statements). Such consolidated financial
statements have been so included in reliance upon the reports of
such firm given upon their authority as experts in accounting
and auditing.
The retrospective adjustments to give effect to presentation of
the Companys styrene operations as discontinued operations
as of December 31, 2007 and 2006 and for each of the three
years in the period ended December 31, 2007 have been
audited by Grant Thornton LLP, an independent registered public
accounting firm. Such retrospective adjustments have been so
included in reliance on the report of said firm given on their
authority as experts in auditing and accounting.
AVAILABLE
INFORMATION
We have filed with the SEC a registration statement on
Form S-4
under the Securities Act relating to the exchange offer. This
prospectus, which is part of the registration statement, does
not contain all of the information set forth in the registration
statement and the exhibits to the registration statement. For
further information with respect to us and the notes, you should
refer to the registration statement and the exhibits filed as a
part of the registration statement. If we have made references
in this prospectus to any contracts, agreements or other
documents and also filed any of those contracts, agreements or
other documents as exhibits to the registration statement, you
should read the relevant exhibit for a more complete
understanding of the document or the matter involved.
To obtain timely delivery of any of our filings, agreements or
other documents, you must make your request to us no later than
September 5, 2008. See Where You Can Find More
Information. In the event that we extend the exchange
offer, you must submit your request at least five business days
before the expiration date of the exchange offer, as extended.
We may extend the exchange offer in our sole discretion. See
Exchange Offer for more detailed information.
151
INDEX TO
HISTORICAL CONSOLIDATED FINANCIAL STATEMENTS
INDEX TO
FINANCIAL STATEMENTS
Sterling
Chemicals, Inc.
|
|
|
|
|
Audited Financial Statements
|
|
|
|
|
|
|
|
F-2
|
|
|
|
|
F-3
|
|
|
|
|
F-4
|
|
|
|
|
F-5
|
|
|
|
|
F-6
|
|
|
|
|
F-7
|
|
|
|
|
F-42
|
|
|
|
|
F-43
|
|
|
|
|
F-44
|
|
|
|
|
F-45
|
|
|
|
|
F-46
|
|
|
|
|
F-47
|
|
Unaudited Financial Statements
|
|
|
|
|
|
|
|
F-43
|
|
|
|
|
F-44
|
|
|
|
|
F-46
|
|
F-1
REPORT OF
INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
To the Board of Directors and Stockholders of Sterling
Chemicals, Inc.
Houston, TX:
We have audited, before the effects of the retrospective
adjustments for the discontinued operations discussed in
Note 3 to the consolidated financial statements, the
consolidated balance sheets of Sterling Chemicals, Inc. and
subsidiaries (the Company) as of December 31,
2007 and 2006, and the related consolidated statements of
operations, changes in stockholders equity (deficiency in
assets), and cash flows for each of the three years in the
period ended December 31, 2007 (the 2007, 2006 and 2005
consolidated financial statements before the effects of the
retrospective adjustments discussed in Note 3 to the
consolidated financial statements are not presented herein).
These financial statements are the responsibility of the
Companys management. Our responsibility is to express an
opinion on these consolidated financial statements based on our
audits.
We conducted our audits in accordance with the standards of the
Public Company Accounting Oversight Board (United States). Those
standards require that we plan and perform the audit to obtain
reasonable assurance about whether the financial statements are
free of material misstatement. The Company is not required to
have, nor were we engaged to perform, an audit of its internal
control over financial reporting. Our audits included
consideration of internal control over financial reporting as a
basis for designing audit procedures that are appropriate in the
circumstances but not for the purpose of expressing an opinion
on the effectiveness of the Companys internal control over
financial reporting. Accordingly, we express no such opinion. An
audit includes examining, on a test basis, evidence supporting
the amounts and disclosures in the financial statements,
assessing the accounting principles used and significant
estimates made by management, as well as evaluating the overall
financial statement presentation. We believe that our audits
provide a reasonable basis for our opinion.
In our opinion, such 2007, 2006 and 2005 consolidated financial
statements, before the effects of the retrospective adjustments
for the discontinued operations discussed in Note 3 to the
consolidated financial statements, present fairly, in all
material respects, the financial position of the Sterling
Chemicals, Inc. and subsidiaries as of December 31, 2007
and 2006, and the results of their operations and their cash
flows for each of the three years in the period ended
December 31, 2007, in conformity with accounting principles
generally accepted in the United States of America.
We were not engaged to audit, review, or apply any procedures to
the retrospective adjustments for the discontinued operations
discussed in Note 3 to the consolidated financial
statements and, accordingly, we do not express an opinion or any
other form of assurance about whether such retrospective
adjustments are appropriate and have been properly applied.
Those retrospective adjustments were audited by other auditors.
As discussed in Note 16 to the consolidated financial
statements, the accompanying consolidated financial statements
have been restated.
As discussed in Note 8 to the consolidated financial
statements, the Company changed its method of accounting for
defined benefit pension and other postretirement plans as of
December 31, 2006.
/s/ DELOITTE & TOUCHE LLP
Houston, Texas
April 10, 2008
F-2
STERLING
CHEMICALS, INC. AND SUBSIDIARIES
(Dollars
in Thousands, Except Share Data)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Year Ended December 31,
|
|
|
|
|
|
|
2006 (As Restated
|
|
|
2005 (As Restated
|
|
|
|
2007 (As Adjusted,
|
|
|
and Adjusted,
|
|
|
and Adjusted,
|
|
|
|
See Note 3)
|
|
|
See Note 16 and Note 3)
|
|
|
See Note 16 and Note 3)
|
|
|
Revenues
|
|
$
|
129,813
|
|
|
$
|
141,259
|
|
|
$
|
128,098
|
|
Cost of goods sold
|
|
|
116,431
|
|
|
|
127,413
|
|
|
|
120,254
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Gross profit
|
|
|
13,382
|
|
|
|
13,846
|
|
|
|
7,844
|
|
Selling, general and administrative expenses
|
|
|
8,679
|
|
|
|
7,073
|
|
|
|
6,548
|
|
Other expense (income)
|
|
|
839
|
|
|
|
(724
|
)
|
|
|
|
|
Interest and debt related expenses (net of interest income of
$1,607, $601 and $679, respectively)
|
|
|
15,706
|
|
|
|
10,079
|
|
|
|
10,090
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Loss from continuing operations before income tax
|
|
|
(11,842
|
)
|
|
|
(2,582
|
)
|
|
|
(8,794
|
)
|
Benefit for income taxes
|
|
|
(4,129
|
)
|
|
|
(388
|
)
|
|
|
(2,938
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Loss from continuing operations
|
|
|
(7,713
|
)
|
|
|
(2,194
|
)
|
|
|
(5,856
|
)
|
Loss from discontinued operations, net of tax
|
|
|
(11,215
|
)
|
|
|
(103,465
|
)
|
|
|
(23,712
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net loss
|
|
|
(18,928
|
)
|
|
|
(105,659
|
)
|
|
|
(29,568
|
)
|
Preferred stock dividends
|
|
|
17,550
|
|
|
|
11,774
|
|
|
|
16,984
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net loss attributable to common stockholders
|
|
$
|
(36,478
|
)
|
|
$
|
(117,433
|
)
|
|
$
|
(46,552
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Loss per share of common stock attributable to common
stockholders, basic and diluted:
|
|
|
|
|
|
|
|
|
|
|
|
|
Loss from continuing operations
|
|
$
|
(8.93
|
)
|
|
$
|
(4.94
|
)
|
|
$
|
(8.08
|
)
|
Loss from discontinued operations
|
|
|
(3.97
|
)
|
|
|
(36.58
|
)
|
|
|
(8.38
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net loss per share, basic and diluted
|
|
$
|
(12.90
|
)
|
|
$
|
(41.52
|
)
|
|
$
|
(16.46
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Weighted average shares outstanding:
|
|
|
|
|
|
|
|
|
|
|
|
|
Basic and diluted
|
|
|
2,828,460
|
|
|
|
2,828,460
|
|
|
|
2,827,795
|
|
The accompanying notes are an integral part of the consolidated
financial statements.
F-3
STERLING
CHEMICALS, INC. AND SUBSIDIARIES
(Dollars
in Thousands, Except Share Data)
|
|
|
|
|
|
|
|
|
|
|
December 31,
|
|
|
|
|
|
|
2006 (As
|
|
|
|
2007 (As
|
|
|
Restated,
|
|
|
|
Adjusted,
|
|
|
See Note 16
|
|
|
|
See Note 3)
|
|
|
and Note 3)
|
|
|
ASSETS
|
Current assets:
|
|
|
|
|
|
|
|
|
Cash and cash equivalents
|
|
$
|
100,183
|
|
|
$
|
20,690
|
|
Accounts receivable, net of allowance of $39 and $0, respectively
|
|
|
29,157
|
|
|
|
11,637
|
|
Inventories, net
|
|
|
5,044
|
|
|
|
5,615
|
|
Prepaid expenses and other current assets
|
|
|
3,129
|
|
|
|
3,215
|
|
Deferred tax asset
|
|
|
5,029
|
|
|
|
3,044
|
|
Assets of discontinued operations
|
|
|
71,754
|
|
|
|
110,565
|
|
|
|
|
|
|
|
|
|
|
Total current assets
|
|
|
214,296
|
|
|
|
154,766
|
|
Property, plant and equipment, net
|
|
|
77,677
|
|
|
|
83,833
|
|
Other assets, net
|
|
|
14,471
|
|
|
|
7,224
|
|
|
|
|
|
|
|
|
|
|
Total assets
|
|
$
|
306,444
|
|
|
$
|
245,823
|
|
|
|
|
|
|
|
|
|
|
|
LIABILITIES AND STOCKHOLDERS DEFICIENCY IN ASSETS
|
Current liabilities:
|
|
|
|
|
|
|
|
|
Accounts payable
|
|
$
|
13,715
|
|
|
$
|
17,189
|
|
Accrued liabilities
|
|
|
22,789
|
|
|
|
16,247
|
|
Liabilities of discontinued operations
|
|
|
11,528
|
|
|
|
22,220
|
|
|
|
|
|
|
|
|
|
|
Total current liabilities
|
|
|
48,032
|
|
|
|
55,656
|
|
Long-term debt
|
|
|
150,000
|
|
|
|
100,579
|
|
Deferred income tax liability
|
|
|
5,029
|
|
|
|
|
|
Deferred credits and other liabilities
|
|
|
26,168
|
|
|
|
55,847
|
|
Long-term liabilities of discontinued operations
|
|
|
51,436
|
|
|
|
|
|
Commitments and contingencies (Note 9)
|
|
|
|
|
|
|
|
|
Redeemable preferred stock
|
|
|
99,866
|
|
|
|
82,316
|
|
Stockholders equity:
|
|
|
|
|
|
|
|
|
Common stock, $.01 par value (shares authorized 20,000,000;
shares issued and outstanding 2,828,460)
|
|
|
28
|
|
|
|
28
|
|
Additional paid-in capital
|
|
|
141,174
|
|
|
|
158,691
|
|
Accumulated deficit
|
|
|
(232,542
|
)
|
|
|
(213,614
|
)
|
Accumulated other comprehensive income
|
|
|
17,253
|
|
|
|
6,320
|
|
|
|
|
|
|
|
|
|
|
Total stockholders deficiency in assets
|
|
|
(74,087
|
)
|
|
|
(48,575
|
)
|
|
|
|
|
|
|
|
|
|
Total liabilities and stockholders deficiency in assets
|
|
$
|
306,444
|
|
|
$
|
245,823
|
|
|
|
|
|
|
|
|
|
|
The accompanying notes are an integral part of the consolidated
financial statements.
F-4
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Accumulated
|
|
|
|
|
|
|
|
|
|
|
|
|
Additional
|
|
|
|
|
|
Other
|
|
|
|
|
|
|
Common Stock
|
|
|
Paid-In
|
|
|
Accumulated
|
|
|
Comprehensive
|
|
|
|
|
|
|
Shares
|
|
|
Amount
|
|
|
Capital
|
|
|
Deficit
|
|
|
Income (Loss)
|
|
|
Total
|
|
|
Balance, December 31, 2004 (As reported)
|
|
|
2,825
|
|
|
$
|
28
|
|
|
$
|
199,408
|
|
|
$
|
(78,387
|
)
|
|
$
|
(966
|
)
|
|
$
|
120,083
|
|
Prior period adjustment (see Note 16)
|
|
|
|
|
|
|
|
|
|
|
(12,270
|
)
|
|
|
|
|
|
|
|
|
|
|
(12,270
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Balance, January 1, 2005 (As restated, see Note 16)
|
|
|
2,825
|
|
|
$
|
28
|
|
|
$
|
187,138
|
|
|
$
|
(78,387
|
)
|
|
$
|
(966
|
)
|
|
$
|
107,813
|
|
Comprehensive loss:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net loss
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(29,568
|
)
|
|
|
|
|
|
|
|
|
Other comprehensive loss:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Pension adjustment, net of tax of $(1,846)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(3,373
|
)
|
|
|
|
|
Comprehensive loss
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(32,941
|
)
|
Preferred stock dividends (as restated, see Note 16)
|
|
|
|
|
|
|
|
|
|
|
(16,984
|
)
|
|
|
|
|
|
|
|
|
|
|
(16,984
|
)
|
Exercised stock options
|
|
|
3
|
|
|
|
|
|
|
|
157
|
|
|
|
|
|
|
|
|
|
|
|
157
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Balance, December 31, 2005 (As restated, see Note 16)
|
|
|
2,828
|
|
|
$
|
28
|
|
|
$
|
170,311
|
|
|
$
|
(107,955
|
)
|
|
$
|
(4,339
|
)
|
|
$
|
58,045
|
|
Comprehensive loss:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net loss
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(105,659
|
)
|
|
|
|
|
|
|
|
|
Other comprehensive loss:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Benefit adjustment, net of tax of $2,249
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
3,903
|
|
|
|
|
|
Comprehensive loss
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(101,756
|
)
|
SFAS 158 adoption, net of tax of $3,719
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
6,756
|
|
|
|
6,756
|
|
Preferred stock dividends (as restated, see Note 16)
|
|
|
|
|
|
|
|
|
|
|
(11,774
|
)
|
|
|
|
|
|
|
|
|
|
|
(11,774
|
)
|
Stock-based compensation
|
|
|
|
|
|
|
|
|
|
|
154
|
|
|
|
|
|
|
|
|
|
|
|
154
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Balance, December 31, 2006 (As restated, see Note 16)
|
|
|
2,828
|
|
|
$
|
28
|
|
|
$
|
158,691
|
|
|
$
|
(213,614
|
)
|
|
$
|
6,320
|
|
|
$
|
(48,575
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Comprehensive loss:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net loss
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(18,928
|
)
|
|
|
|
|
|
|
|
|
Other comprehensive loss:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Benefit adjustment, net of tax of $5,887
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
10,933
|
|
|
|
|
|
Comprehensive loss
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(7,995
|
)
|
Preferred stock dividends
|
|
|
|
|
|
|
|
|
|
|
(17,550
|
)
|
|
|
|
|
|
|
|
|
|
|
(17,550
|
)
|
Stock-based compensation
|
|
|
|
|
|
|
|
|
|
|
33
|
|
|
|
|
|
|
|
|
|
|
|
33
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Balance, December 31, 2007
|
|
|
2,828
|
|
|
$
|
28
|
|
|
$
|
141,174
|
|
|
$
|
(232,542
|
)
|
|
$
|
17,253
|
|
|
$
|
(74,087
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
The accompanying notes are an integral part of the consolidated
financial statements.
F-5
STERLING
CHEMICALS, INC. AND SUBSIDIARIES
(Dollars
in Thousands)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Year Ended December 31,
|
|
|
|
2007
|
|
|
2006
|
|
|
2005
|
|
|
Cash flows from operating activities:
|
|
|
|
|
|
|
|
|
|
|
|
|
Net loss
|
|
$
|
(18,928
|
)
|
|
$
|
(105,659
|
)
|
|
$
|
(29,568
|
)
|
Adjustments to reconcile net loss to net cash provided by (used
in) operating activities:
|
|
|
|
|
|
|
|
|
|
|
|
|
Bad debt benefit
|
|
|
(213
|
)
|
|
|
(571
|
)
|
|
|
(2,133
|
)
|
Depreciation and amortization
|
|
|
10,908
|
|
|
|
30,476
|
|
|
|
33,342
|
|
Interest amortization
|
|
|
933
|
|
|
|
400
|
|
|
|
400
|
|
Unearned income amortization
|
|
|
(1,064
|
)
|
|
|
|
|
|
|
|
|
Impairment of long-lived assets
|
|
|
4,288
|
|
|
|
127,653
|
|
|
|
|
|
Lower-of-cost-or-market adjustment
|
|
|
1,363
|
|
|
|
|
|
|
|
2,738
|
|
Deferred tax benefit
|
|
|
|
|
|
|
(8,438
|
)
|
|
|
(18,905
|
)
|
Gain on disposal of property, plant and equipment
|
|
|
(182
|
)
|
|
|
(4,917
|
)
|
|
|
|
|
Other
|
|
|
1,066
|
|
|
|
154
|
|
|
|
156
|
|
Change in assets/liabilities:
|
|
|
|
|
|
|
|
|
|
|
|
|
Accounts receivable
|
|
|
(21,630
|
)
|
|
|
(4,514
|
)
|
|
|
56,983
|
|
Inventories
|
|
|
39,933
|
|
|
|
(22,608
|
)
|
|
|
45,772
|
|
Prepaid expenses
|
|
|
86
|
|
|
|
1,673
|
|
|
|
(690
|
)
|
Other assets
|
|
|
(2,160
|
)
|
|
|
(2,105
|
)
|
|
|
(1,003
|
)
|
Accounts payable
|
|
|
(21,933
|
)
|
|
|
(4,140
|
)
|
|
|
(23,348
|
)
|
Accrued liabilities
|
|
|
18,106
|
|
|
|
(10,314
|
)
|
|
|
4,396
|
|
Other liabilities
|
|
|
33,754
|
|
|
|
(11,298
|
)
|
|
|
(33
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net cash provided by (used in) operating activities
|
|
|
44,327
|
|
|
|
(14,208
|
)
|
|
|
68,107
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Cash flows used in investing activities:
|
|
|
|
|
|
|
|
|
|
|
|
|
Capital expenditures for property, plant and equipment
|
|
|
(6,411
|
)
|
|
|
(11,547
|
)
|
|
|
(9,460
|
)
|
Insurance proceeds relating to property, plant and equipment
|
|
|
|
|
|
|
1,960
|
|
|
|
|
|
Cash used for dismantling
|
|
|
|
|
|
|
(669
|
)
|
|
|
(667
|
)
|
Net proceeds from the sale of property, plant and equipment
|
|
|
182
|
|
|
|
2,957
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net cash used in investing activities
|
|
|
(6,229
|
)
|
|
|
(7,299
|
)
|
|
|
(10,127
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Cash flows provided by (used in) financing activities:
|
|
|
|
|
|
|
|
|
|
|
|
|
Repayment of Old Secured Notes
|
|
|
(100,579
|
)
|
|
|
|
|
|
|
|
|
Proceeds from the issuance of Secured Notes
|
|
|
150,000
|
|
|
|
|
|
|
|
|
|
Debt issuance costs
|
|
|
(8,026
|
)
|
|
|
|
|
|
|
|
|
Net repayments under the revolving credit facility
|
|
|
|
|
|
|
|
|
|
|
(17,684
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net cash provided by (used in) financing activities
|
|
|
41,395
|
|
|
|
|
|
|
|
(17,684
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net increase (decrease) in cash and cash equivalents
|
|
|
79,493
|
|
|
|
(21,507
|
)
|
|
|
40,296
|
|
Cash and cash equivalents beginning of year
|
|
|
20,690
|
|
|
|
42,197
|
|
|
|
1,901
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Cash and cash equivalents end of year
|
|
$
|
100,183
|
|
|
$
|
20,690
|
|
|
$
|
42,197
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Supplemental disclosures of cash flow information:
|
|
|
|
|
|
|
|
|
|
|
|
|
Interest paid, net of interest income received
|
|
$
|
11,438
|
|
|
$
|
10,508
|
|
|
$
|
10,726
|
|
Cash paid for income taxes
|
|
|
299
|
|
|
|
60
|
|
|
|
59
|
|
The accompanying notes are an integral part of the consolidated
financial statements.
F-6
STERLING
CHEMICALS, INC. AND SUBSIDIARIES
NOTES TO
CONSOLIDATED FINANCIAL STATEMENTS
|
|
1.
|
Basis of
Presentation and Summary of Significant Accounting
Policies
|
Unless otherwise indicated, references to we,
us, our and ours refer
collectively to Sterling Chemicals, Inc. and its wholly-owned
subsidiaries. We own or operate facilities at our petrochemicals
complex located in Texas City, Texas, approximately
45 miles south of Houston, on a
290-acre
site on Galveston Bay near many other chemical manufacturing
complexes and refineries. Currently, we produce acetic acid and
plasticizers and prior to the shutdown of our styrene operations
in December 2007, we also produced styrene. We own all of the
real property which comprises our Texas City facility and we own
the acetic acid, styrene and plasticizers manufacturing units
located at the site. Our Texas City site offers approximately
135 acres for future expansion by us or by other companies
that could benefit from our existing infrastructure and
facilities, and includes a greenbelt around the northern edge of
the plant site. We also lease a portion of our Texas City site
to Praxair Hydrogen Supply, Inc., or Praxair, who constructed a
partial oxidation unit on that land, and lease a portion of our
Texas City site to S&L Cogeneration Company, a 50/50 joint
venture between us and Praxair Energy Resources, Inc., who
constructed a cogeneration facility on that land. We generally
sell our petrochemicals products to customers for use in the
manufacture of other chemicals and products, which in turn are
used in the production of a wide array of consumer goods and
industrial products. As of December 31, 2007, we reported
our operations in two segments: acetic acid and plasticizers.
Principles
of Consolidation
The consolidated financial statements include the accounts of
our wholly-owned subsidiaries, with all significant intercompany
accounts and transactions having been eliminated. Our 50% equity
investment in a cogeneration joint venture, which is accounted
for under the equity method, is not material to our financial
position or results of operations.
Cash
and Cash Equivalents
We consider all investments having an initial maturity of three
months or less to be cash equivalents.
Allowance
for Doubtful Accounts
Accounts receivable is presented net of allowance for doubtful
accounts. We regularly review our accounts receivable balances
and, based on estimated collectibility, adjust the allowance
account accordingly. As of December 31, 2007 and 2006, the
allowance for doubtful accounts was less than $0.1 million
and zero, for continuing operations and zero and
$0.4 million for discontinued operations, respectively. Bad
debt expense for continuing operations was less than
$0.1 million for 2007 and 2006 and a credit of less than
$0.1 million for 2005. Bad debt expense for discontinued
operations was a credit of $0.3 million, $0.6 million
and $2.1 million for 2007, 2006 and 2005, respectively.
Inventories
Inventories are stated at the lower-of-cost-or-market. Cost is
primarily determined on a
first-in,
first-out basis, except for stores and supplies, which are
valued at average cost. The comparison of cost to market value
involves estimation of the market value of our products. For the
years ended December 31, 2007, 2006 and 2005, a
lower-of-cost-or-market adjustment was recorded in discontinued
operations for $1.4 million, zero and $2.7 million,
respectively. The adjustments in 2007 and 2005 were due to
decreasing benzene and styrene prices from December to January
during each period. Previously while our styrene unit was
running, we would enter into agreements with other companies to
exchange chemical inventories in order to minimize working
capital requirements and to facilitate distribution logistics.
Balances related to quantities due to or payable by us are
included in inventory; however, we do not expect to have any
significant exchange balances or activity subsequent to 2007.
F-7
STERLING
CHEMICALS, INC. AND SUBSIDIARIES
NOTES TO
CONSOLIDATED FINANCIAL
STATEMENTS (Continued)
Property,
Plant and Equipment
Property, plant and equipment are recorded at cost. Major
renewals and improvements, which extend the useful lives of
equipment, are capitalized. For certain capital projects, our
customers reimburse us for a portion of the project cost. For
such capital expenditures reimbursed by our customers, we treat
the reimbursements as a reduction of our cost basis. Disposals
are removed at carrying cost less accumulated depreciation with
any resulting gain or loss reflected in operations. Depreciation
is provided using the straight-line method over estimated useful
lives ranging from five to 25 years, with the predominant
life of plant and equipment being 15 years. We capitalize
interest costs, which are incurred as part of the cost of
constructing major facilities and equipment. The amount of
interest capitalized in continuing operations for 2007, 2006 and
2005 was $0.1 million, $0.3 million and
$0.6 million, respectively, and for discontinued operations
was $0.1 million, $0.5 million and $0.4 million for 2007, 2006
and 2005, respectively.
Plant
Turnaround Costs
As a part of normal recurring operations, each of our
manufacturing units is completely shut down from time to time,
for a period typically lasting two to four weeks, to replace
catalysts and perform major maintenance work required to sustain
long-term production. These periods are commonly referred to as
turnarounds or shutdowns. Costs of
turnarounds are expensed as incurred. As expenses for
turnarounds can be significant, the impact of expensing the
costs of turnarounds can be material for financial reporting
periods during which the turnarounds actually occur. Turnaround
costs expensed during 2007, 2006 and 2005 for continuing
operations were less than $0.1 million, $ 1.4 million
and $2.9 million, respectively, and for discontinued
operations were zero, $8.5 million and $1.1 million during 2007,
2006 and 2005, respectively.
Long-Lived
Assets
We assess our long-lived assets for impairment whenever facts
and circumstances indicate that the carrying amount may not be
fully recoverable. To analyze recoverability, we project
undiscounted net future cash flows over the remaining life of
the assets. If the projected cash flows from the assets are less
than the carrying amount, an impairment would be recognized. Any
impairment loss would be measured based upon the difference
between the carrying amount and the fair value of the relevant
assets. For these impairment analyses, impairment is determined
by comparing the estimated fair value of these assets, utilizing
the present value of expected net cash flows, to the carrying
value of these assets. In determining the present value of
expected net cash flows, we estimate future net cash flows from
these assets and the timing of those cash flows, and then apply
a discount rate to reflect the time value of money and the
inherent uncertainty of those future cash flows. The discount
rate we use is based on our estimated cost of capital. The
assumptions we use in estimating future cash flows are
consistent with our internal planning.
During the fourth quarter of 2006, we performed an asset
impairment analysis on our styrene production unit. This
analysis was performed due to contemporaneous industry
forecasts, forecasted negative cash flow generated by our
styrene business over the next few years and the uncertainty
surrounding the ability of the North American styrene industry
to successfully restructure. Our management determined that a
triggering event, as defined in Statement of Financial
Accounting Standards No. 144, Accounting for the
Impairment or Disposal of Long Lived Assets, had occurred
and an asset impairment analysis was performed. We analyzed the
undiscounted cash flow stream from our styrene business over the
next seven years, which represented the remaining book life of
our styrene assets, and compared it to the $128 million net
book carrying value of our styrene unit and related assets. This
analysis showed that the undiscounted projected cash flow stream
from our styrene business was less than the net book carrying
value of our styrene unit and related assets. As a result, we
performed a discounted cash flow analysis and subsequently
concluded that our styrene unit and related assets were impaired
and should be written down to zero. This write-down caused us to
record an impairment of $128 million in discontinued
operations in December 2006.
F-8
STERLING
CHEMICALS, INC. AND SUBSIDIARIES
NOTES TO
CONSOLIDATED FINANCIAL
STATEMENTS (Continued)
During the fourth quarter of 2007 in anticipation of the
shutdown of our styrene unit, we wrote down all construction in
progress that had been capitalized in 2007 pertaining to that
unit and the catalyst which we were using in production. This
write-down resulted in an impairment expense of
$4.3 million which was included in discontinued operations.
Debt
Issue Costs
Debt issue costs relating to long-term debt are amortized over
the term of the related debt instrument using the straight-line
method, which is materially consistent with the effective
interest method, and are included in other assets. Debt issue
cost amortization, which is included in interest and
debt-related expenses, was $0.9 million, $0.4 million
and $0.4 million for the years ended December 31,
2007, 2006 and 2005, respectively.
Income
Taxes
Deferred income taxes are provided for revenue and expenses
which are recognized in different periods for income tax and
financial statement purposes. Deferred tax assets are regularly
assessed for recoverability based on both historical and
anticipated earnings levels, and a valuation allowance is
recorded when it is more likely than not that these amounts will
not be recovered. As a result of our analysis, we concluded that
a valuation allowance was needed against our deferred tax
assets. As of December 31, 2007, our valuation allowance
was $36.2 million, an increase of $6.6 million from
December 31, 2006, which resulted in an overall net
deferred tax asset/liability balance of zero as of
December 31, 2007.
Environmental
Costs
Environmental costs are expensed as incurred, unless the
expenditures extend the economic useful life of the related
assets. Costs that extend the economic useful life of assets are
capitalized and depreciated over the remaining book life of
those assets. Liabilities are recorded when environmental
assessments or remedial efforts are probable and the cost can be
reasonably estimated.
Revenue
Recognition
We generate revenues through a profit sharing arrangement with
respect to our acetic acid operations and these revenues are
estimated and accrued monthly. We generate revenues from our
plasticizers operations through a tolling agreement. Deferred
credits are amortized over the life of the contracts which gave
rise to them. As of December 31, 2007 and 2006, we had a
balance in deferred income of approximately $11 million and
$10 million, respectively, related to continuing
operations, which primarily represents certain payments received
for our oxo-alcohol operations, which were part of our
plasticizers business, that are being amortized using the
straight-line method over the remaining life of the contract of
six years. As of December 31, 2007, in discontinued
operations, we had a balance in deferred income of approximately
$59 million of deferred income pertaining to the NOVA
supply agreement discussed in Note 3 that is being
amortized using the straight-line method over the contractual
non-compete period of five years and is reflected in
discontinued operations in other income. Styrene revenue was
recognized from sales in the open market, raw materials
conversion agreements and long-term supply contracts at the time
the products were shipped and title passed, the price was fixed
and determinable and collectibility was reasonably assured.
Styrene revenue (and corresponding cost of sales) from raw
materials conversion agreements was recognized on a gross basis
and does not include raw material components supplied by our
customers.
Preferred
Stock Dividends
We record preferred stock dividends on our Series A
Convertible Preferred Stock, or our Series A Preferred
Stock, in our consolidated statements of operations based on the
estimated fair value of dividends at each dividend accrual date.
Our Series A Preferred Stock has a dividend rate of 4% per
quarter of the liquidation value of the outstanding shares of
our Series A Preferred Stock, and is payable in arrears in
additional shares of our Series A
F-9
STERLING
CHEMICALS, INC. AND SUBSIDIARIES
NOTES TO
CONSOLIDATED FINANCIAL
STATEMENTS (Continued)
Preferred Stock on the first business day of each calendar
quarter. The liquidation value of each share of our
Series A Preferred Stock is $13,793.11 per share, and each
share of Series A Preferred Stock is convertible into
shares of our common stock (on a one to 1,000 share basis,
subject to adjustment). The carrying value of our redeemable
preferred stock in our consolidated balance sheets represents
the cumulative balance of the initial fair value at original
issuance in 2002 plus the fair value of each of the quarterly
dividends paid since issuance. The fair value of our preferred
stock dividends is determined each quarter using valuation
techniques that include a component representing the intrinsic
value of the dividends (which represents the greater of the
liquidation value of the preferred shares being issued or the
fair value of the common stock into which the shares could be
converted) and an option component (which is determined using a
Black-Scholes Option Pricing Model). These dividends are
recorded in our consolidated statements of operations, with an
offset to redeemable preferred stock in our consolidated balance
sheets. As we are in an accumulated deficit position, these
dividends are treated as a reduction to additional paid-in
capital.
Earnings
(Loss) Per Share
Basic earnings per share, or EPS, is computed using the
weighted-average number of shares outstanding during the year.
Diluted EPS includes common stock equivalents, which are
dilutive to earnings per share. For the years ending
December 31, 2007, 2006 and 2005, we had no dilutive
securities outstanding due to all common stock equivalents
having an anti-dilutive effect during these periods.
Disclosures
about Fair Value of Financial Instruments
In preparing disclosures about the fair value of financial
instruments, we have concluded that the carrying amount
approximates fair value for cash and cash equivalents, accounts
receivable, accounts payable and certain accrued liabilities due
to the short maturities of these instruments. The fair values of
long-term debt instruments are estimated based upon broker
quotes for private transactions or on the current interest rates
available to us for debt with similar terms and remaining
maturities.
Accounting
Estimates
The preparation of financial statements in conformity with
accounting principles generally accepted in the United States of
America requires management to make estimates and assumptions
that affect the reported amounts of assets and liabilities and
disclosure of contingent assets and liabilities at the date of
the financial statements and the reported amounts of revenues
and expenses during the reported periods. Significant estimates
include impairment considerations, allowance for doubtful
accounts, inventory valuation, preferred stock dividend
valuation, revenue recognition related to profit sharing
accruals, environmental and litigation reserves and provision
for income taxes.
Reclassifications
Certain amounts reported in the consolidated financial
statements for the prior periods have been reclassified to
conform with the current consolidated financial statement
presentation with no effect on net loss or stockholders
equity (deficiency in assets). For the years ended
December 31, 2006 and 2005, we have reclassed amounts
between bad debt benefit and accounts receivable and for the
year ended December 31, 2006, we have reclassed amounts
between accrued liabilities and other liabilities on the
statement of cash flows. For the years ended December 31,
2007, 2006 and 2005, we have reclassified certain amounts on the
consolidated statements of operations and the consolidated
balance sheets to reflect the discontinued operations of styrene.
|
|
2.
|
Stock-Based
Compensation Plan
|
On December 19, 2002, we adopted our 2002 Stock Plan and
reserved 363,914 shares of our common stock for issuance
under the plan (subject to adjustment). Under our 2002 Stock
Plan, officers and key employees, as
F-10
STERLING
CHEMICALS, INC. AND SUBSIDIARIES
NOTES TO
CONSOLIDATED FINANCIAL
STATEMENTS (Continued)
designated by our Board of Directors, may be issued stock
options, stock awards, stock appreciation rights or stock units.
There are currently options to purchase a total of
245,500 shares of our common stock outstanding under our
2002 Stock Plan, all at an exercise price of $31.60, and an
additional 118,414 shares of common stock available for
issuance under our 2002 Stock Plan.
On January 1, 2006, we adopted Statement of Financial
Accounting Standards, or
SFAS No. 123-Revised
2004, Share-Based Payments, or
SFAS No. 123(R), using the modified prospective
method. SFAS No. 123(R) is a revision of
SFAS No. 123, Accounting for Stock-Based
Compensation, or SFAS No. 123, and
superseded Accounting Principles Board No. 25,
Accounting for Stock Issued to Employees, or APB
No. 25. Under SFAS No. 123(R), the cost of
employee services received in exchange for a stock-based award
is determined based on the grant-date fair value (with
exceptions). That cost is then recognized over the period during
which the employee is required to provide services in exchange
for the award (usually the vesting period).
On January 1, 2006, using the modified prospective method
under SFAS No. 123(R), we began recognizing expense on
any unvested awards under our 2002 Stock Plan that were granted
prior to that time. Any awards granted under our 2002 Stock Plan
after December 31, 2005 will be expensed over the vesting
period of the award. Stock based compensation expense was
$32,970 and $153,809 for the years ended December 31, 2007
and 2006, respectively.
Prior to January 1, 2006, we had adopted the
disclosure-only provisions of SFAS No. 123
and accounted for substantially all of our stock-based
compensation using the intrinsic value method prescribed in APB
No. 25. Under APB No. 25, no compensation expense was
recognized for any of our stock option grants because all of the
stock options issued under our 2002 Stock Plan were granted with
exercise prices at or above fair value at the time of grant.
A summary of our stock option activity for the years ended
December 31, 2007, 2006 and 2005 is presented below:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
December 31, 2007
|
|
|
December 31, 2006
|
|
|
December 31, 2005
|
|
|
|
|
|
|
Weighted-Average
|
|
|
|
|
|
Weighted-Average
|
|
|
|
|
|
Weighted-Average
|
|
|
|
Shares
|
|
|
Exercise Price
|
|
|
Shares
|
|
|
Exercise Price
|
|
|
Shares
|
|
|
Exercise Price
|
|
|
Outstanding at beginning of year
|
|
|
278,500
|
|
|
$
|
31.60
|
|
|
|
278,500
|
|
|
$
|
31.60
|
|
|
|
294,334
|
|
|
$
|
31.60
|
|
Forfeited
|
|
|
(33,000
|
)
|
|
|
31.60
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Exercised
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(15,834
|
)
|
|
|
31.60
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Outstanding at end of year
|
|
|
245,500
|
|
|
$
|
31.60
|
|
|
|
278,500
|
|
|
$
|
31.60
|
|
|
|
278,500
|
|
|
$
|
31.60
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Options exercisable at end of year
|
|
|
245,500
|
|
|
|
|
|
|
|
269,333
|
|
|
|
|
|
|
|
176,500
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
As noted above, no options were granted in 2007, 2006 or 2005
and as of December 31, 2007 all options were vested.
F-11
STERLING
CHEMICALS, INC. AND SUBSIDIARIES
NOTES TO
CONSOLIDATED FINANCIAL
STATEMENTS (Continued)
The following table illustrates the effect on our net loss and
loss per share attributable to common stockholders for the year
ended December 31, 2005 if compensation costs for stock
options had been recorded pursuant to SFAS No. 123(R),
for the years prior to adoption: (Dollars in Thousands, Except
Share Data)
|
|
|
|
|
Net loss attributable to common stockholders
|
|
$
|
(46,552
|
)
|
Add: Stock-based employee compensation expense included in
reported net loss, net of related tax effects
|
|
|
157
|
|
Deduct: Total stock-based employee compensation expense
determined under fair value based method for all awards, net of
related tax effects
|
|
|
(606
|
)
|
|
|
|
|
|
Pro forma net loss
|
|
$
|
(47,001
|
)
|
|
|
|
|
|
Loss per share attributable to common stockholders:
|
|
|
|
|
As reported
|
|
$
|
(16.46
|
)
|
Pro forma
|
|
|
(16.62
|
)
|
|
|
3.
|
Discontinued
Operations
|
On September 17, 2007, we entered into a long-term
exclusive styrene supply agreement and a related railcar
purchase and sale agreement with NOVA Chemicals Inc., or NOVA.
Under this supply agreement, NOVA had the exclusive right to
purchase 100% of our styrene production (subject to existing
contractual commitments), the amount of styrene supplied in any
particular period being at NOVAs option. In November 2007,
this supply agreement, which was subsequently assigned by NOVA
to INEOS NOVA, LLC, or INEOS NOVA, obtained clearance under the
Hart-Scott-Rodino
Act. This clearance caused the supply agreement and the railcar
agreement to become effective and triggered a $60 million
payment to us in November 2007. In addition, in accordance with
the terms of the supply agreement, INEOS NOVA assumed
substantially all of our contractual obligations for future
styrene deliveries. After the supply agreement became effective,
INEOS NOVA nominated zero pounds of styrene under the supply
agreement for the balance of 2007 and, in response, we exercised
our right to terminate the supply agreement and permanently shut
down our styrene facility. Under the supply agreement, we are
responsible for the closure costs of our styrene facility and
are also subject to a long-term commitment to not reenter the
styrene business for a period of time. We operated our styrene
facility through early December 2007, as we completed our
production of inventory and exhausted our raw materials and
purchase requirements and sold substantially all our inventory
during the first quarter of 2008. During 2007 and the first
quarter of 2008, we incurred closure costs to decommission our
styrene facility of approximately $1 million and
$9 million, respectively. We expect to incur up to
$5 million in additional decommissioning costs related to
the closure of our styrene facility. Our styrene-related
personnel continue to work on the decommissioning and
decontamination of our styrene facility and some related tanks
and storage areas. We have not developed plans for a reduction
in workforce at this time as we hope to transition these
employees to new business ventures after their work in
decommissioning our styrene facility is complete.
On September 16, 2005, we announced that we were exiting
the acrylonitrile business and related derivative operations,
which included sodium cyanide and disodium iminodiacetic acid,
or DSIDA. These production facilities had been shut down since
February 2005 and, after our announcement, we dismantled these
facilities. Our decision was based on a history of operating
losses incurred by our acrylonitrile and derivatives businesses,
and was made after a full review and analysis of our strategic
alternatives.
In accordance with Statement of Financial Accounting Standards,
or SFAS, No. 144, Accounting for the Impairment and
Disposal of Long Lived Assets, we have reported the
operating results of these businesses as
F-12
STERLING
CHEMICALS, INC. AND SUBSIDIARIES
NOTES TO
CONSOLIDATED FINANCIAL
STATEMENTS (Continued)
discontinued operations in our consolidated financial
statements. The carrying amounts of assets and liabilities
related to discontinued operations as of December 31, 2007
and 2006 were as follows:
|
|
|
|
|
|
|
|
|
|
|
December 31,
|
|
|
December 31,
|
|
|
|
2007
|
|
|
2006
|
|
|
|
(Dollars in thousands)
|
|
|
Assets of discontinued operations:
|
|
|
|
|
|
|
|
|
Accounts receivable, net
|
|
$
|
55,995
|
|
|
$
|
51,672
|
|
Inventories
|
|
|
15,709
|
|
|
|
56,463
|
|
Other assets
|
|
|
50
|
|
|
|
2,430
|
|
|
|
|
|
|
|
|
|
|
Total
|
|
$
|
71,754
|
|
|
$
|
110,565
|
|
|
|
|
|
|
|
|
|
|
Liabilities of discontinued operations:
|
|
|
|
|
|
|
|
|
Accounts payable
|
|
$
|
3,363
|
|
|
$
|
21,934
|
|
Accrued liabilities
|
|
|
8,165
|
|
|
|
286
|
|
Deferred credits and other liabilities
|
|
|
51,436
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total
|
|
$
|
62,964
|
|
|
$
|
22,220
|
|
|
|
|
|
|
|
|
|
|
Revenues and pre-tax loss from discontinued operations for the
years ended December 31, 2007, 2006 and 2005 are presented
below (in thousands):
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Year Ended December 31,
|
|
|
2007
|
|
2006
|
|
2005
|
|
Revenues
|
|
$
|
681,513
|
|
|
$
|
524,922
|
|
|
$
|
557,162
|
|
Loss before income taxes
|
|
|
(12,589
|
)
|
|
|
(117,703
|
)
|
|
|
(37,775
|
)
|
Current severance obligations related to the exit from our
acrylonitrile operations are detailed below (in thousands):
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Accrued as of
|
|
|
|
|
|
|
|
|
Accrued as of
|
|
|
|
|
|
Accrued as of
|
|
|
|
December 31,
|
|
|
|
|
|
|
|
|
December 31,
|
|
|
Accrued in
|
|
|
December 31,
|
|
|
|
2005
|
|
|
Accrued in 2006
|
|
|
Cash Payments
|
|
|
2006
|
|
|
2007
|
|
|
2007
|
|
|
Severance accrual
|
|
$
|
477
|
|
|
$
|
386
|
|
|
$
|
(646
|
)
|
|
$
|
217
|
|
|
$
|
108
|
|
|
$
|
325
|
|
DSIDA contractual obligation
|
|
|
2,853
|
|
|
|
147
|
|
|
|
(3,000
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
DSIDA dismantling costs
|
|
|
496
|
|
|
|
62
|
|
|
|
(558
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Totals
|
|
$
|
3,826
|
|
|
$
|
595
|
|
|
$
|
(4,204
|
)
|
|
$
|
217
|
|
|
$
|
108
|
|
|
$
|
325
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
F-13
STERLING
CHEMICALS, INC. AND SUBSIDIARIES
NOTES TO
CONSOLIDATED FINANCIAL
STATEMENTS (Continued)
|
|
4.
|
Detail of
Certain Balance Sheet Accounts
|
|
|
|
|
|
|
|
|
|
|
|
December 31,
|
|
|
|
2007
|
|
|
2006
|
|
|
|
(Dollars in Thousands)
|
|
|
Inventories:
|
|
|
|
|
|
|
|
|
Raw materials
|
|
$
|
1,048
|
|
|
$
|
1,681
|
|
Stores and supplies (net of obsolescence reserve of $1,472 and
$2,149, respectively)
|
|
|
3,996
|
|
|
|
3,934
|
|
|
|
|
|
|
|
|
|
|
|
|
$
|
5,044
|
|
|
$
|
5,615
|
|
|
|
|
|
|
|
|
|
|
Property, plant and equipment, net:
|
|
|
|
|
|
|
|
|
Land
|
|
$
|
7,149
|
|
|
$
|
7,149
|
|
Buildings
|
|
|
4,809
|
|
|
|
4,506
|
|
Plant and equipment
|
|
|
121,900
|
|
|
|
116,966
|
|
Construction in progress
|
|
|
2,470
|
|
|
|
1,761
|
|
Less: accumulated depreciation
|
|
|
(58,651
|
)
|
|
|
(46,549
|
)
|
|
|
|
|
|
|
|
|
|
|
|
$
|
77,677
|
|
|
$
|
83,833
|
|
|
|
|
|
|
|
|
|
|
Other assets, net:
|
|
|
|
|
|
|
|
|
S&L Cogen joint venture
|
|
$
|
5,483
|
|
|
$
|
4,733
|
|
Debt issuance costs
|
|
|
7,673
|
|
|
|
283
|
|
Long-term deferred tax asset
|
|
|
|
|
|
|
641
|
|
Other
|
|
|
1,315
|
|
|
|
1,567
|
|
|
|
|
|
|
|
|
|
|
|
|
$
|
14,471
|
|
|
$
|
7,224
|
|
|
|
|
|
|
|
|
|
|
Accrued liabilities:
|
|
|
|
|
|
|
|
|
Employee compensation and benefits
|
|
|
6,425
|
|
|
$
|
6,878
|
|
Deferred income
|
|
|
3,719
|
|
|
|
3,009
|
|
Interest payable
|
|
|
4,036
|
|
|
|
470
|
|
Property taxes
|
|
|
3,089
|
|
|
|
4,301
|
|
Advances from customers
|
|
|
3,726
|
|
|
|
|
|
Other
|
|
|
1,794
|
|
|
|
1,589
|
|
|
|
|
|
|
|
|
|
|
|
|
$
|
22,789
|
|
|
$
|
16,247
|
|
|
|
|
|
|
|
|
|
|
Deferred credits and other liabilities:
|
|
|
|
|
|
|
|
|
Accrued postretirement, pension and post employment benefits
|
|
$
|
16,067
|
|
|
$
|
42,152
|
|
Deferred income
|
|
|
7,653
|
|
|
|
7,000
|
|
Advances from customers
|
|
|
1,000
|
|
|
|
1,000
|
|
Other
|
|
|
1,448
|
|
|
|
5,695
|
|
|
|
|
|
|
|
|
|
|
|
|
$
|
26,168
|
|
|
$
|
55,847
|
|
|
|
|
|
|
|
|
|
|
F-14
STERLING
CHEMICALS, INC. AND SUBSIDIARIES
NOTES TO
CONSOLIDATED FINANCIAL
STATEMENTS (Continued)
|
|
5.
|
Valuation
and Qualifying Accounts
|
Below is a summary of valuation and qualifying accounts for the
years ended December 31, 2007, 2006 and 2005:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
December 31,
|
|
|
|
2007
|
|
|
2006
|
|
|
2005
|
|
|
Continuing Operations
|
|
|
|
|
|
|
|
|
|
|
|
|
Allowance for doubtful accounts:
|
|
|
|
|
|
|
|
|
|
|
|
|
Balance at beginning of year
|
|
$
|
|
|
|
$
|
(2
|
)
|
|
$
|
(34
|
)
|
Add: bad debt benefit
|
|
|
(39
|
)
|
|
|
(13
|
)
|
|
|
26
|
|
Deduct: written-off accounts
|
|
|
|
|
|
|
15
|
|
|
|
6
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Balance at end of year
|
|
$
|
(39
|
)
|
|
$
|
|
|
|
$
|
(2
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Reserve for inventory obsolescence:
|
|
|
|
|
|
|
|
|
|
|
|
|
Balance at beginning of year
|
|
$
|
2,149
|
|
|
$
|
2,573
|
|
|
$
|
1,938
|
|
Add: obsolescence accrual
|
|
|
163
|
|
|
|
81
|
|
|
|
1,492
|
|
Deduct: disposal of inventory
|
|
|
(840
|
)
|
|
|
(505
|
)
|
|
|
(857
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Balance at end of year
|
|
$
|
1,472
|
|
|
$
|
2,149
|
|
|
$
|
2,573
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Discontinued Operations
|
|
|
|
|
|
|
|
|
|
|
|
|
Allowance for doubtful accounts:
|
|
|
|
|
|
|
|
|
|
|
|
|
Balance at beginning of year
|
|
$
|
(367
|
)
|
|
$
|
(951
|
)
|
|
$
|
(3,058
|
)
|
Add: bad debt (expense) benefit
|
|
|
252
|
|
|
|
584
|
|
|
|
2,107
|
|
Deduct: written-off accounts
|
|
|
115
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Balance at end of year
|
|
$
|
|
|
|
$
|
(367
|
)
|
|
$
|
(951
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
On March 1, 2007, we commenced an offer, or our tender
offer, to repurchase all $100.6 million of our outstanding
10% Senior Secured Notes due 2007, or our Old Secured
Notes. Concurrently with our tender offer, we solicited consents
from the holders of our Old Secured Notes to, among other
things, eliminate certain covenants contained in the indenture
governing our Old Secured Notes and related security documents.
On March 15, 2007, after receiving enough consents from the
holders of our Old Secured Notes, we and Sterling Chemicals
Energy, Inc., or Sterling Energy, one of our wholly-owned
subsidiaries, and the trustee entered into a supplemental
indenture amending the indenture and the related security
documents to eliminate most of the restrictive covenants
contained therein, as well as certain events of default and
repurchase rights. These amendments became effective when we
accepted for purchase the Old Secured Notes held by the
consenting holders pursuant to our tender offer and paid those
holders an aggregate of $0.1 million in consent fees. Our
tender offer expired at 12:00 midnight, New York City time, on
March 28, 2007. We accepted for repurchase $58 million
in aggregate principal amount of Old Secured Notes which were
validly tendered prior to the expiration of our tender offer,
and we repurchased those Old Secured Notes and paid the accrued
interest thereon together with the consent fee, on
March 30, 2007. On March 27, 2007, we issued a notice
of redemption for all of our Old Secured Notes that were not
tendered pursuant to our tender offer and, on April 27,
2007, we purchased those remaining Old Secured Notes for an
aggregate amount equal to $44 million, which included
$1.5 million in accrued interest.
On March 26, 2007, we entered into a purchase agreement, or
the Purchase Agreement, with respect to the sale of
$150 million aggregate principal amount of unregistered
101/4% Senior
Secured Notes due 2015, or our Secured Notes, to
Jefferies & Company, Inc. and CIBC World Markets
Corp., as initial purchasers. Sterling Energy was also
F-15
STERLING
CHEMICALS, INC. AND SUBSIDIARIES
NOTES TO
CONSOLIDATED FINANCIAL
STATEMENTS (Continued)
a party to the Purchase Agreement as a guarantor. On
March 29, 2007, we completed a private offering of the
unregistered Secured Notes pursuant to the Purchase Agreement.
In connection with that offering, we entered into an indenture,
dated March 29, 2007, among us, Sterling Energy, as
guarantor, and U.S. Bank National Association, as trustee
and collateral agent. On August 30, 2007, we made an
initial filing of an exchange offer registration statement to
exchange our unregistered Secured Notes for a new issue of
substantially identical debt securities registered under the
Securities Act. Pursuant to a registration rights agreement
among us, Sterling Energy and the initial purchasers, we agreed
to use commercially reasonable efforts to cause the registration
statement to become effective by December 24, 2007, and
complete the exchange offer within 50 days of the effective
date of the registration statement. However, as the registration
statement was not declared effective by December 24, 2007,
the interest rate on our Secured Notes increased by 0.25% per
annum on December 25, 2007 and on March 24, 2008, and
unless and until the registration statement is declared
effective, will increase by an additional 0.25% per annum at the
beginning of each subsequent
90-day
period if such failure continues, subject to a maximum increase
of 1.0% per annum. As such, penalty interest is expected to be
between $0.1 million and $0.2 million depending upon
the effectiveness date of the registration statement, of which
$0.1 was accrued as of December 31, 2007. All of this
additional interest will cease to accrue when the registration
statement is declared effective.
Our indenture contains affirmative and negative covenants and
customary events of default, including payment defaults,
breaches of covenants and certain events of bankruptcy,
insolvency and reorganization. If an event of default, other
than an event of default triggered upon certain bankruptcy
events, occurs and is continuing, the trustee under our
indenture or the holders of at least 25% in principal amount of
the outstanding Secured Notes may declare our Secured Notes to
be due and payable immediately. Upon an event of default, the
trustee may also take actions to foreclose on the collateral
securing our outstanding Secured Notes, subject to the terms of
an intercreditor agreement dated March 29, 2007, among us,
Sterling Energy, the trustee and The CIT Group/Business Credit,
Inc. Our indenture does not require us to maintain any financial
ratios or satisfy any financial maintenance tests. We are in
compliance with all of the covenants contained in our indenture.
Interest is due on our outstanding Secured Notes on April 1 and
October 1 of each year, with our first interest payment having
been made on October 1, 2007. Additional interest of 0.25%
per annum is currently accruing on our outstanding Secured Notes
as a result of our failure to have the registration statement
declared effective by December 24, 2007, as discussed
above. Our outstanding Secured Notes, which mature on
April 1, 2015, are senior secured obligations and rank
equally in right of payment with all of our existing and future
senior indebtedness. Subject to specified permitted liens, our
outstanding Secured Notes are secured (i) on a first
priority basis by all of our and Sterling Energys fixed
assets and certain related assets, including, without
limitation, all property, plant and equipment, and (ii) on
a second priority basis by all of our and Sterling Energys
other assets, including, without limitation, accounts
receivable, inventory, capital stock of our domestic restricted
subsidiaries (including Sterling Energy), intellectual property,
deposit accounts and investment property.
On December 19, 2002, we entered into a Revolving Credit
Agreement, or our revolving credit facility, with The CIT
Group/Business Credit, Inc., as administrative agent and a
lender, and certain other lenders. Our revolving credit facility
had an initial term ending on September 19, 2007. Under our
revolving credit facility, we and Sterling Energy are
co-borrowers and are jointly and severally liable for any
indebtedness thereunder. Our revolving credit facility is
secured by first priority liens on all of our accounts
receivable, inventory and other specified assets, as well as all
of the issued and outstanding capital stock of Sterling Energy.
On March 29, 2007, we amended and restated our revolving
credit facility to, among other things, extend the term of our
revolving credit facility until March 29, 2012, reduce the
maximum commitment thereunder to $50 million, make certain
changes to the calculation of the borrowing base and lower the
interest rates and fees charged thereunder. Borrowings under our
revolving credit facility now bear interest, at our option, at
an annual rate of either a base rate plus 0.0% to 0.50% or the
LIBOR rate plus 1.50% to 2.25%, depending on our borrowing
availability at the time. We are also required to pay an
aggregate commitment fee of 0.375% per year (payable monthly) on
any unused portion. Available credit under our revolving credit
facility is subject to a monthly borrowing base of 85% of
eligible accounts receivable plus 65% of eligible inventory. As
of December 31, 2007, our borrowing base exceeded the
maximum commitment
F-16
STERLING
CHEMICALS, INC. AND SUBSIDIARIES
NOTES TO
CONSOLIDATED FINANCIAL
STATEMENTS (Continued)
under our revolving credit facility, making the total credit
available under our revolving credit facility $50 million.
However, the monetization of accounts receivable and inventory
associated with our exit from the styrene business is expected
to significantly decrease the borrowing base under our revolving
credit facility with the total credit available expected to be
between $10 million and $20 million (after giving
effect to our outstanding letters of credit) after the
collection of outstanding styrene receivables. As of
December 31, 2007, there were no loans outstanding under
our revolving credit facility, and we had $12 million in
letters of credit outstanding, resulting in borrowing
availability of $38 million. Pursuant to Emerging Issues
Task Force Issue
No. 95-22,
Balance Sheet Classification of Borrowings under Revolving
Credit Agreements That Include both a Subjective Acceleration
Clause and a Lock-Box Arrangement, any balances
outstanding under our revolving credit facility are classified
as a current portion of long-term debt.
Our revolving credit facility contains numerous covenants and
conditions, including, but not limited to, restrictions on our
ability to incur indebtedness, create liens, sell assets, make
investments, make capital expenditures, engage in mergers and
acquisitions and pay dividends. Our revolving credit facility
also includes various circumstances and conditions that would,
upon their occurrence and subject in certain cases to notice and
grace periods, create an event of default thereunder. Our
revolving credit facility does not require us to maintain any
financial ratios or satisfy any financial maintenance tests. We
are in compliance with all of the covenants contained in our
revolving credit facility.
Debt
Maturities
Our Secured Notes, which had an aggregate principal balance of
$150 million outstanding as of December 31, 2007, are
due on April 1, 2015.
A reconciliation of federal statutory income taxes to our
effective tax benefit is as follows:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Year Ended December 31,
|
|
|
|
2007
|
|
|
2006
|
|
|
2005
|
|
|
|
(Dollars in Thousands)
|
|
|
Benefit for income taxes at statutory rates
|
|
$
|
(8,551
|
)
|
|
$
|
(42,100
|
)
|
|
$
|
(16,299
|
)
|
Non-deductible expenses
|
|
|
23
|
|
|
|
19
|
|
|
|
19
|
|
State income taxes
|
|
|
13
|
|
|
|
(1,262
|
)
|
|
|
(956
|
)
|
Change in valuation allowance
|
|
|
3,021
|
|
|
|
27,621
|
|
|
|
|
|
Other
|
|
|
(9
|
)
|
|
|
1,096
|
|
|
|
235
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Effective tax benefit
|
|
$
|
(5,503
|
)
|
|
$
|
(14,626
|
)
|
|
$
|
(17,001
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
The income tax benefit for continuing operations and
discontinued operations is shown below:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Year Ended December 31,
|
|
|
|
2007
|
|
|
2006
|
|
|
2005
|
|
|
|
(Dollars in Thousands)
|
|
|
Tax benefit continuing operations
|
|
$
|
(4,129
|
)
|
|
$
|
(388
|
)
|
|
$
|
(2,938
|
)
|
Tax benefit discontinued operations
|
|
|
(1,374
|
)
|
|
|
(14,238
|
)
|
|
|
(14,063
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total tax benefit
|
|
$
|
(5,503
|
)
|
|
$
|
(14,626
|
)
|
|
$
|
(17,001
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
F-17
STERLING
CHEMICALS, INC. AND SUBSIDIARIES
NOTES TO
CONSOLIDATED FINANCIAL
STATEMENTS (Continued)
The income tax benefit is composed of the following:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Year Ended December 31,
|
|
|
|
2007
|
|
|
2006
|
|
|
2005
|
|
|
|
(Dollars in Thousands)
|
|
|
Current federal
|
|
$
|
364
|
|
|
$
|
299
|
|
|
$
|
|
|
Deferred federal
|
|
|
(5,887
|
)
|
|
|
(13,685
|
)
|
|
|
(16,066
|
)
|
Current and deferred state
|
|
|
20
|
|
|
|
(1,240
|
)
|
|
|
(935
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total tax benefit
|
|
$
|
(5,503
|
)
|
|
$
|
(14,626
|
)
|
|
$
|
(17,001
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
The components of our deferred income tax assets and liabilities
are summarized below:
|
|
|
|
|
|
|
|
|
|
|
December 31,
|
|
|
|
2007
|
|
|
2006
|
|
|
|
(Dollars in Thousands)
|
|
|
Deferred tax assets:
|
|
|
|
|
|
|
|
|
Accrued liabilities
|
|
$
|
1,496
|
|
|
$
|
1,292
|
|
Accrued postretirement cost
|
|
|
2,236
|
|
|
|
7,518
|
|
Accrued pension cost
|
|
|
|
|
|
|
4,537
|
|
Tax loss and credit carry forwards
|
|
|
26,846
|
|
|
|
32,506
|
|
State deferred taxes
|
|
|
98
|
|
|
|
77
|
|
Unearned revenue
|
|
|
23,656
|
|
|
|
2,450
|
|
Other
|
|
|
719
|
|
|
|
1,347
|
|
|
|
|
|
|
|
|
|
|
Total deferred tax assets
|
|
$
|
55,051
|
|
|
$
|
49,727
|
|
|
|
|
|
|
|
|
|
|
Deferred tax liabilities:
|
|
|
|
|
|
|
|
|
Property, plant and equipment
|
|
$
|
(17,609
|
)
|
|
$
|
(16,458
|
)
|
Accrued pension cost
|
|
|
(1,277
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Subtotal
|
|
|
(18,886
|
)
|
|
|
(16,458
|
)
|
Less: valuation allowance
|
|
|
(36,165
|
)
|
|
|
(29,584
|
)
|
|
|
|
|
|
|
|
|
|
Total deferred tax liabilities
|
|
|
(55,051
|
)
|
|
|
(46,042
|
)
|
|
|
|
|
|
|
|
|
|
Net deferred tax assets
|
|
$
|
|
|
|
$
|
3,685
|
|
|
|
|
|
|
|
|
|
|
As of December 31, 2007, we had an available
U.S. federal income tax NOL of approximately
$67.7 million, which expires during the years 2023 through
2025. In 2006, the State of Texas enacted a new Texas Margins
Tax effective January 1, 2008. Under the 2006 provisions of
the Texas Margins Tax, our existing State of Texas net operating
loss carry-forwards, or State NOLs, were converted into state
tax credits of $3 million which resulted in an increase to
the valuation allowance of $2 million. In June 2007, the
State of Texas revised the provisions of the Texas Margins Tax
resulting in a recalculation of the conversion of our existing
State NOLs into state tax credits. Under the revised provisions,
the conversion our existing State NOLs resulted in additional
state tax credits of $2 million and an additional valuation
allowance of $2 million. We also have carryforward state
investment and R&D state tax credits of $0.8 million.
Deferred tax assets are regularly assessed for recoverability
based on both historical and anticipated earnings levels, and a
valuation allowance is recorded when it is more likely than not
that these amounts will not be recovered. As a result of our
analysis, we concluded that a valuation allowance was needed
against our deferred tax assets for $36.2 million resulting
in an overall net deferred tax asset/liability balance of zero
as of December 31, 2007.
F-18
STERLING
CHEMICALS, INC. AND SUBSIDIARIES
NOTES TO
CONSOLIDATED FINANCIAL
STATEMENTS (Continued)
In July 2006, the Financial Accounting Standards Board, or the
FASB, issued FASB Interpretation No. 48, Accounting
for Uncertainty in Income Taxes an
interpretation of FASB Statement No. 109, or
FIN 48, to clarify the accounting for uncertain tax
positions accounted for in accordance with FASB Statement
No. 109, Accounting for Income Taxes. This
interpretation prescribes a two-step approach for recognizing
and measuring tax benefits and requires explicit disclosure of
any uncertain tax position. We adopted the provisions of
FIN 48 as of January 1, 2007.
At December 31, 2006, we had a $3.7 million contingent
tax liability relating to certain tax deductions taken in
previous tax returns. Under FIN 48, we concluded that these
deductions do not meet the more likely than not recognition
threshold. As such, the deferred tax asset was not recognized
and the related contingent tax liability was eliminated at the
date of adoption. This had no net impact on our financial
statements and there was no cumulative impact on retained
earnings. Our accounting policy is to recognize any accrued
interest or penalties associated with unrecognized tax benefits
as a component of income tax expense. Due to significant net
operating losses incurred during the tax periods associated with
our uncertain tax positions, no amount for penalties or interest
has been recorded in our financial statements. We do not believe
the total amount of unrecognized tax benefits will change
significantly within the next twelve months. In addition, future
changes in the unrecognized tax benefit will have no impact on
the effective tax rate due to the existence of the valuation
allowance. As of December 31, 2007, there were no changes
to our uncertain tax positions.
A reconciliation of the beginning and ending amount of
unrecognized tax benefits is as follows:
|
|
|
|
|
Balance, January 1, 2007
|
|
$
|
3,685
|
|
Additions for tax positions of the current year
|
|
|
|
|
Additions for tax positions of prior years
|
|
|
|
|
Reductions for tax positions of prior years for
|
|
|
|
|
Changes in judgment
|
|
|
|
|
Settlements during the period
|
|
|
|
|
Lapses of applicable statute of limitation
|
|
|
|
|
|
|
|
|
|
Balance, December 31, 2007
|
|
$
|
3,685
|
|
|
|
|
|
|
We and one of our subsidiaries, Sterling Energy, file income tax
returns in the United States federal jurisdiction and file
income and franchise tax returns in the State of Texas. We
remain subject to federal examination for tax years ended
December 31, 2002 and subsequent years, and we remain
subject to examination by the State of Texas for tax years ended
December 31, 2004 and subsequent years.
We have established the following benefit plans:
Retirement
Benefit Plans
We have non-contributory pension plans which cover our salaried
employees who were employed by us on or before January 1,
2005 and our hourly wage employees who were employed by us on or
before July 1, 2007. Under our hourly plan, the benefits
are based primarily on years of service and an employees
pay as of the earlier of the employees retirement or
July 1, 2007. Under our salaried plan, the benefits are
based primarily on years of service and an employees pay
as of the earlier of the employees retirement or
January 1, 2005. Our funding policy is consistent with the
funding requirements of federal law and regulations.
F-19
STERLING
CHEMICALS, INC. AND SUBSIDIARIES
NOTES TO
CONSOLIDATED FINANCIAL
STATEMENTS (Continued)
Pension plan assets are invested in a balanced portfolio managed
by an outside investment manager. Our investment policy is to
generate a total return that, over the long term, provides
sufficient assets to fund its liabilities, reduces risk through
diversification of investments within asset classes and complies
with the Employee Retirement Income Security Act of 1974, or
ERISA, by investing in a manner consistent with ERISAs
fiduciary standards. Within this balanced fund, assets are
invested as follows:
|
|
|
|
|
|
|
|
|
|
|
As of December 31,
|
|
|
|
2007
|
|
|
2006
|
|
|
Equities
|
|
|
63
|
%
|
|
|
64
|
%
|
Bonds
|
|
|
26
|
%
|
|
|
23
|
%
|
Other
|
|
|
11
|
%
|
|
|
13
|
%
|
|
|
|
|
|
|
|
|
|
Total
|
|
|
100
|
%
|
|
|
100
|
%
|
|
|
|
|
|
|
|
|
|
Information concerning the pension obligation, plan assets,
amounts recognized in our financial statements and underlying
actuarial assumptions is stated below:
|
|
|
|
|
|
|
|
|
|
|
December 31,
|
|
|
|
2007
|
|
|
2006
|
|
|
|
(Dollars in Thousands)
|
|
|
Change in projected benefit obligation:
|
|
|
|
|
|
|
|
|
Benefit obligation at beginning of year
|
|
$
|
126,135
|
|
|
$
|
125,694
|
|
Service cost
|
|
|
228
|
|
|
|
593
|
|
Interest cost
|
|
|
7,096
|
|
|
|
7,610
|
|
Actuarial (gain) loss
|
|
|
(2,196
|
)
|
|
|
820
|
|
Curtailment gain
|
|
|
(19
|
)
|
|
|
|
|
Benefits paid
|
|
|
(8,079
|
)
|
|
|
(8,582
|
)
|
|
|
|
|
|
|
|
|
|
Benefit obligation at end of year
|
|
$
|
123,165
|
|
|
$
|
126,135
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
December 31,
|
|
|
|
2007
|
|
|
2006
|
|
|
|
(Dollars in Thousands)
|
|
|
Change in plan assets:
|
|
|
|
|
|
|
|
|
Fair value at beginning of year
|
|
$
|
109,654
|
|
|
$
|
95,690
|
|
Actual return on plan assets
|
|
|
10,695
|
|
|
|
14,684
|
|
Employer contributions
|
|
|
6,113
|
|
|
|
7,862
|
|
Benefits paid
|
|
|
(8,079
|
)
|
|
|
(8,582
|
)
|
|
|
|
|
|
|
|
|
|
Fair value at end of year
|
|
$
|
118,383
|
|
|
$
|
109,654
|
|
|
|
|
|
|
|
|
|
|
Funded status
|
|
$
|
(4,782
|
)
|
|
$
|
(16,481
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
December 31,
|
|
|
|
2007
|
|
|
2006
|
|
|
Amounts recognized in the balance sheet consist of:
|
|
|
|
|
|
|
|
|
Current liabilities
|
|
$
|
(163
|
)
|
|
$
|
(201
|
)
|
Non-current liabilities
|
|
|
(4,619
|
)
|
|
|
(16,280
|
)
|
|
|
|
|
|
|
|
|
|
Net amount recognized in financial position
|
|
$
|
(4,782
|
)
|
|
$
|
(16,481
|
)
|
|
|
|
|
|
|
|
|
|
F-20
STERLING
CHEMICALS, INC. AND SUBSIDIARIES
NOTES TO
CONSOLIDATED FINANCIAL
STATEMENTS (Continued)
|
|
|
|
|
|
|
|
|
|
|
December 31,
|
|
|
|
2007
|
|
|
2006
|
|
|
Amount recognized in accumulated other comprehensive income
(loss)
consists of (pre-tax):
|
|
|
|
|
|
|
|
|
Net gain (loss)
|
|
$
|
3,895
|
|
|
$
|
(764
|
)
|
|
|
|
|
|
|
|
|
|
Net amount recognized in accumulated other comprehensive income
(loss)
|
|
$
|
3,895
|
|
|
$
|
(764
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
December 31,
|
|
|
|
2007
|
|
|
2006
|
|
|
Weighted-average assumptions to determine benefit obligations:
|
|
|
|
|
|
|
|
|
Discount Rate
|
|
|
6.00
|
%
|
|
|
5.75
|
%
|
Rates of increase in salary compensation level
|
|
|
|
|
|
|
3.50
|
%
|
All plans have projected benefit obligations and accumulated
benefit obligation in excess of plan assets as of
December 31, 2007. The total accumulated benefit obligation
was $123 million and $126 million as of
December 31, 2007 and 2006, respectively. Estimated
contributions for 2008 are expected to be approximately
$3 million, a portion of which are above the minimum
funding requirements. The expected amortization of the actuarial
loss for 2008 is $7,000.
Effective July 1, 2007, we froze all accruals under our
defined benefit pension plan for our hourly employees, which
resulted in a plan curtailment under SFAS No. 88
Employers Accounting for Settlement and Curtailments
of Defined Benefit Pension Plans and for Termination
Benefits. As a result, we recorded a pre-tax curtailment
gain of less than $0.1 million in 2007.
Net periodic pension costs consist of the following components:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Year Ended December 31,
|
|
|
|
2007
|
|
|
2006
|
|
|
2005
|
|
|
|
(Dollars in Thousands)
|
|
|
Components of net pension costs:
|
|
|
|
|
|
|
|
|
|
|
|
|
Service cost-benefits earned during the year
|
|
$
|
228
|
|
|
$
|
593
|
|
|
$
|
622
|
|
Interest on prior years projected benefit obligation
|
|
|
7,096
|
|
|
|
7,610
|
|
|
|
6,993
|
|
Expected return on plan assets
|
|
|
(8,246
|
)
|
|
|
(7,767
|
)
|
|
|
(6,641
|
)
|
Net amortization of actuarial loss
|
|
|
13
|
|
|
|
13
|
|
|
|
8
|
|
Curtailment gain
|
|
|
(19
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net pension (benefit) costs
|
|
$
|
(928
|
)
|
|
$
|
449
|
|
|
$
|
982
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
December 31,
|
|
|
|
2007
|
|
|
2006
|
|
|
Changes in plan assets and benefit obligations recognized in
accumulated other comprehensive income (pre-tax):
|
|
|
|
|
|
|
|
|
Net gain
|
|
$
|
4,645
|
|
|
$
|
6,153
|
|
Amortization of loss
|
|
|
13
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total
|
|
$
|
4,658
|
|
|
$
|
6,153
|
|
|
|
|
|
|
|
|
|
|
F-21
STERLING
CHEMICALS, INC. AND SUBSIDIARIES
NOTES TO
CONSOLIDATED FINANCIAL
STATEMENTS (Continued)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
December 31,
|
|
|
|
2007
|
|
|
2006
|
|
|
2005
|
|
|
Weighted-average assumptions to determine net periodic benefit
cost:
|
|
|
|
|
|
|
|
|
|
|
|
|
Discount Rate
|
|
|
5.50
|
%
|
|
|
5.75
|
%
|
|
|
5.75
|
%
|
Rates of increase in salary compensation level
|
|
|
|
|
|
|
|
|
|
|
|
|
Expected long-term rate of return on plan assets
|
|
|
7.50
|
%
|
|
|
7.50
|
%
|
|
|
7.50
|
%
|
Postretirement
Benefits Other than Pensions
We provide certain health care benefits and life insurance
benefits for retired employees. Substantially all of our
employees become eligible for these benefits at early retirement
age. We accrue the cost of these benefits during the period in
which the employee renders the necessary service.
Health care benefits are currently provided to employees hired
prior to June 7, 2004, who retire from us with ten or more
years of credited service. Some of our employees are eligible
for postretirement life insurance, depending on their hire date.
Postretirement health care benefit plans are contributory.
Benefit provisions for most hourly employees are subject to
collective bargaining. In general, retiree health care benefits
are paid as covered expenses are incurred.
During the third quarter of 2007, we approved an amendment
(effective December 31, 2007) to our postretirement
medical plan which will end Medicare-supplemental medical and
prescription drug coverage for retirees who are Medicare
eligible. This amendment affects the majority of participants
currently enrolled in the Sterling Retiree Medical Plan who are
either enrolled in Medicare due to disability or because they
are 65 or over and was communicated to the participants during
the third quarter of 2007. This plan amendment reduced our other
postretirement benefit plan liability by $13 million with a
corresponding increase to accumulated other comprehensive income.
On December 8, 2003, the Medicare Prescription Drug
Improvement and Modernization Act of 2003, or the Act, was
passed. The Act introduces a prescription drug benefit under
Medicare (Medicare Part D), as well as a federal subsidy to
sponsors of retiree health care benefit plans that provide a
benefit that is at least actuarially equivalent to Medicare
Part D. We measured the effects of the Act on our
accumulated postretirement benefit obligation and determined
that, based on the regulatory guidance currently available,
benefits provided by our postretirement plan are at least
actuarially equivalent to Medicare Part D, and accordingly,
we expect to be entitled to the federal subsidy through 2009. In
2007, we received a subsidy of $0.3 million under the Act.
F-22
STERLING
CHEMICALS, INC. AND SUBSIDIARIES
NOTES TO
CONSOLIDATED FINANCIAL
STATEMENTS (Continued)
Information concerning the plan obligation, the funded status,
amounts recognized in our financial statements and underlying
actuarial assumptions are stated below:
|
|
|
|
|
|
|
|
|
|
|
December 31,
|
|
|
|
2007
|
|
|
2006
|
|
|
|
(Dollars in Thousands)
|
|
|
Change in projected benefit obligation:
|
|
|
|
|
|
|
|
|
Benefit obligation at beginning of year
|
|
$
|
25,942
|
|
|
$
|
27,834
|
|
Service cost
|
|
|
119
|
|
|
|
174
|
|
Interest cost
|
|
|
1,198
|
|
|
|
1,463
|
|
Plan amendments
|
|
|
(13,291
|
)
|
|
|
|
|
Actuarial gain
|
|
|
(487
|
)
|
|
|
(1,728
|
)
|
Benefits paid
|
|
|
(2,462
|
)
|
|
|
(1,801
|
)
|
|
|
|
|
|
|
|
|
|
Benefit obligation at end of year
|
|
$
|
11,019
|
|
|
$
|
25,942
|
|
|
|
|
|
|
|
|
|
|
Plan assets
|
|
$
|
|
|
|
$
|
|
|
|
|
|
|
|
|
|
|
|
Funded status
|
|
$
|
(11,019
|
)
|
|
$
|
(25,942
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
December 31,
|
|
|
|
2007
|
|
|
2006
|
|
|
Amounts recognized in the balance sheet consist of:
|
|
|
|
|
|
|
|
|
Current liabilities
|
|
$
|
(1,294
|
)
|
|
$
|
(1,275
|
)
|
Non-current liabilities
|
|
|
(9,725
|
)
|
|
|
(24,667
|
)
|
|
|
|
|
|
|
|
|
|
Net amount recognized in financial position
|
|
$
|
(11,019
|
)
|
|
$
|
(25,942
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
December 31,
|
|
|
|
2007
|
|
|
2006
|
|
|
Amounts recognized in accumulated other comprehensive income
(loss) consist of (pre-tax):
|
|
|
|
|
|
|
|
|
Net loss
|
|
$
|
(2,128
|
)
|
|
$
|
(3,695
|
)
|
Plan amendment/prior service costs
|
|
|
24,852
|
|
|
|
14,257
|
|
|
|
|
|
|
|
|
|
|
Net amount recognized in accumulated other comprehensive income
|
|
$
|
22,724
|
|
|
$
|
10,562
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Year Ended December 31,
|
|
|
|
2007
|
|
|
2006
|
|
|
Discount rate used to determine benefit obligations
|
|
|
6.00
|
%
|
|
|
5.75
|
%
|
F-23
STERLING
CHEMICALS, INC. AND SUBSIDIARIES
NOTES TO
CONSOLIDATED FINANCIAL
STATEMENTS (Continued)
Net periodic plan costs consist of the following components:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Year Ended December 31,
|
|
|
|
2007
|
|
|
2006
|
|
|
2005
|
|
|
|
(Dollars in Thousands)
|
|
|
Components of net plan costs:
|
|
|
|
|
|
|
|
|
|
|
|
|
Service cost
|
|
$
|
119
|
|
|
$
|
174
|
|
|
$
|
208
|
|
Interest cost
|
|
|
1,198
|
|
|
|
1,463
|
|
|
|
1,558
|
|
Net amortization:
|
|
|
|
|
|
|
|
|
|
|
|
|
Actuarial loss
|
|
|
1
|
|
|
|
99
|
|
|
|
333
|
|
Plan amendment/prior service costs
|
|
|
(1,617
|
)
|
|
|
(1,434
|
)
|
|
|
(1,485
|
)
|
Curtailment and special termination benefits
|
|
|
|
|
|
|
|
|
|
|
(1,727
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net plan (benefit) costs
|
|
$
|
(299
|
)
|
|
$
|
302
|
|
|
$
|
(1,113
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Discount rate used to determine periodic cost
|
|
|
5.75
|
%
|
|
|
5.75
|
%
|
|
|
5.75
|
%
|
|
|
|
|
|
|
|
|
|
|
|
December 31,
|
|
|
|
2007
|
|
|
2006
|
|
|
Changes in benefit obligations recognized in accumulated other
comprehensive income (pre-tax):
|
|
|
|
|
|
|
|
|
Net gain
|
|
$
|
1,567
|
|
|
$
|
2,353
|
|
Amortization of prior service cost
|
|
|
(1,617
|
)
|
|
|
(1,434
|
)
|
Plan amendment
|
|
|
12,212
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total
|
|
$
|
12,162
|
|
|
$
|
919
|
|
|
|
|
|
|
|
|
|
|
The weighted-average annual assumed health care trend rate is
assumed to be 9% for 2008. The rate is assumed to decrease
gradually to 4.5% by 2015 and remain level thereafter. Estimated
contributions for 2008 are expected to be approximately
$1.3 million. The expected amortization for 2008 is
$2.2 million. Based on plan changes enacted, assumed health
care cost trend rates no longer have a significant effect on the
amounts reported for our health care plans. A one percentage
point change in assumed health care trend rates would have the
following effects:
|
|
|
|
|
|
|
|
|
|
|
1% Increase
|
|
|
1% Decrease
|
|
|
|
(Dollars in Thousands)
|
|
|
Effect on total of service and interest cost components
|
|
$
|
30
|
|
|
$
|
(27
|
)
|
Effect on post-retirement benefit obligation
|
|
|
501
|
|
|
|
(446
|
)
|
In September 2006, the Financial Accounting Standards Board, or
the FASB, issued SFAS No. 158, Employers
Accounting for Defined Benefit Pension and Other Postretirement
Plans, or SFAS No. 158. SFAS No. 158
requires the recognition of the funded status of pension and
other postretirement benefit plans on the balance sheet. The
overfunded or underfunded status are recognized as an asset or
liability on the balance sheet with changes occurring during the
current year reflected through the comprehensive income portion
of equity. SFAS No. 158 also requires the measurement
date of the funded status of our defined benefit postretirement
plans match the date of our fiscal year-end financial
statements, eliminating the use of earlier measurement dates
that were previously permissible. We recognized the funded
status of our defined benefit postretirement plans in our
balance sheet as of December 31, 2006. We also measured the
assets and benefit obligations of our defined benefit
postretirement
F-24
STERLING
CHEMICALS, INC. AND SUBSIDIARIES
NOTES TO
CONSOLIDATED FINANCIAL
STATEMENTS (Continued)
plans as of the date of our fiscal year-end statement of
financial position. The incremental effect of applying
SFAS No. 158 to our employee benefit plans as of
December 31, 2006 is summarized below (in thousands):
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Other
|
|
|
|
Pension
|
|
|
Postretirement
|
|
|
|
Plan
|
|
|
Benefits Plan
|
|
|
Increase (decrease) in liabilities
|
|
$
|
87
|
|
|
$
|
(10,562
|
)
|
Increase (decrease) in accumulated other comprehensive income
|
|
|
(56
|
)
|
|
|
6,812
|
|
Increase (decrease) in deferred income tax liabilities
|
|
|
(31
|
)
|
|
|
3,750
|
|
Estimated
Future Benefits Payable
We estimate that the future benefits payable under our pension
and other post-retirement benefits as of December 31, 2007
are as follows (in thousands):
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Other
|
|
|
|
|
|
|
Pensions-
|
|
|
Pensions-
|
|
|
Pensions-
|
|
|
Postretirement
|
|
|
|
|
|
|
hourly
|
|
|
salaried
|
|
|
other
|
|
|
Benefits
|
|
|
Total
|
|
|
2008
|
|
$
|
3,411
|
|
|
$
|
4,369
|
|
|
$
|
164
|
|
|
$
|
1,294
|
|
|
$
|
9,238
|
|
2009
|
|
|
3,298
|
|
|
|
4,498
|
|
|
|
195
|
|
|
|
1,208
|
|
|
|
9,199
|
|
2010
|
|
|
3,060
|
|
|
|
4,597
|
|
|
|
187
|
|
|
|
1,139
|
|
|
|
8,983
|
|
2011
|
|
|
2,982
|
|
|
|
4,724
|
|
|
|
180
|
|
|
|
1,171
|
|
|
|
9,057
|
|
2012
|
|
|
2,978
|
|
|
|
4,943
|
|
|
|
173
|
|
|
|
1,108
|
|
|
|
9,202
|
|
2013-2017
|
|
|
15,729
|
|
|
|
26,314
|
|
|
|
800
|
|
|
|
4,959
|
|
|
|
47,802
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total
|
|
$
|
31,458
|
|
|
$
|
49,445
|
|
|
$
|
1,699
|
|
|
$
|
10,879
|
|
|
$
|
93,481
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Savings
and Investment Plan
Our Seventh Amended and Restated Savings and Investment Plan
covers substantially all employees, including executive
officers. This Plan is qualified under Section 401(k) of
the Internal Revenue Code. Each participant has the option to
defer taxation of a portion of his or her earnings by directing
us to contribute a percentage of such earnings to the Plan. A
participant may direct up to a maximum of 100% of eligible
earnings to this Plan, subject to certain limitations set forth
in the Internal Revenue Code. A participants contributions
become distributable upon the termination of his or her
employment. We match 100% of salaried employees
contributions, to the extent such contributions do not exceed 6%
of such participants base compensation (excluding bonuses,
profit sharing and similar types of compensation). Our expense
under this plan was $1 million, $1 million and
$1.1 million for the years ended December 31, 2007,
2006 and 2005, respectively.
Bonus
Plan and Gain Sharing Plan
In February 2002, our Board of Directors, upon recommendation of
its Compensation Committee, approved the establishment of a
Bonus Plan and a Gain Sharing Plan. The Bonus Plan is designed
to benefit all qualified salaried employees, while the Gain
Sharing Plan is designed to benefit all qualified hourly
employees. Both plans provide our qualified employees the
opportunity to earn bonuses depending on, among other things,
our annual financial performance. In January 2006, our
Compensation Committee amended our Bonus Plan in a manner that
provides each of our salaried employees the ability to earn a
bonus each year based on their individual performance,
irrespective of our overall financial performance. However, if a
bonus is paid for any year based upon our financial performance,
no additional bonus is paid under the new individual performance
provision of our Bonus Plan. Our Chief Executive Officer and
each of our four Senior Vice Presidents are excluded from this
portion of our Bonus Plan. Whether a bonus will be paid to our
Chief Executive Officer or any of our Senior Vice Presidents in
any year when a bonus is not paid based on our financial
performance, and if so, the amount to be paid, will be
determined at
F-25
STERLING
CHEMICALS, INC. AND SUBSIDIARIES
NOTES TO
CONSOLIDATED FINANCIAL
STATEMENTS (Continued)
that time by our Compensation Committee. We expensed
$1.4 million, $1.4 million and $0.7 million for
the years ended December 31, 2007, 2006 and 2005,
respectively, in connection with payments under our Bonus Plan
and Gain Sharing Plan.
Key
Employee Protection Plan
On January 26, 2000, we instituted our Key Employee
Protection Plan, which has subsequently been amended several
times. We established this Plan to help us retain certain of our
employees and motivate them to continue to exert their best
efforts on our behalf during periods when we may be susceptible
to a change of control, and to assure their continued dedication
and objectivity during those periods. Our Compensation Committee
has designated a select group of management or highly
compensated employees as participants under our Key Employee
Protection Plan, and has established their respective applicable
multipliers and other variables for determining benefits. Our
Compensation Committee is also authorized to designate
additional management or highly compensated employees as
participants under our Key Employee Protection Plan and set
their applicable multipliers. Our Compensation Committee may
also terminate any participants participation under this
Plan with 60 days prior notice if it determines that the
participant is no longer one of our key employees.
Under our Key Employee Protection Plan, any participant under
the Plan that terminates his or her employment for Good
Reason or is terminated by us for any reason other than
Misconduct or Disability within his or
her Protection Period is entitled to benefits under
the Plan. A participants Protection Period commences
180 days prior to the date on which a specified change of
control occurs and ends either two years or 18 months after
the date of that change of control, depending on the size of the
participants applicable multiplier. A participant may also
be entitled to receive payments under this Plan in the absence
of a change of control if he or she terminates his or her
employment for Good Reason or is terminated by us
for any reason other than Misconduct or
Disability, but in these circumstances his or her
applicable multiplier is reduced by 50%. If a participant
becomes entitled to benefits under our Key Employee Protection
Plan, we are required to provide the participant with a lump sum
cash payment that is determined by multiplying the
participants applicable multiplier by (a) the sum of
the participants highest annual base compensation during
the last three years plus (b) the participants
targeted bonus for the year of termination, and then deducting
the sum of any other separation, severance or termination
payments made by us to the participant under any other plan or
agreement or pursuant to law.
In addition to the lump sum payment, the participant is entitled
to receive any accrued but unpaid compensation, compensation for
unused vacation time and any unpaid vested benefits earned or
accrued under any of our benefit plans (other than qualified
plans). Also, for a period of 24 months (including
18 months of COBRA coverage), the participant will continue
to be covered by all of our life, medical and dental insurance
plans and programs (other than disability), as long as the
participant makes a timely COBRA election and pays the regular
employee premiums required under our plans and programs and by
COBRA. In addition, our obligation to continue to provide
coverage under our plans and programs to any participant ends if
and when the participant becomes employed on a full-time basis
by a third party which provides the participant with
substantially similar benefits.
If any payment or distribution under our Key Employee Protection
Plan to any participant is subject to excise tax pursuant to
Section 4999 of the Internal Revenue Code, the participant
is entitled to receive a
gross-up
payment from us in an amount such that, after payment by the
participant of all taxes on the
gross-up
payment, the amount of the
gross-up
payment remaining is equal to the excise tax imposed under
Section 4999 of the Internal Revenue Code. However, the
maximum amount of any
gross-up
payment is 25% of (a) the sum of the participants
highest annual base compensation during the last three years
plus (b) the participants targeted bonus for the year
of payment.
We may terminate our Key Employee Protection Plan at any time
and for any reason but any termination does not become effective
as to any participant until 90 days after we give the
participant notice of the termination of the Plan. In addition,
we may amend our Key Employee Protection Plan at any time and
for any reason, but any amendment that reduces, alters,
suspends, impairs or prejudices the rights or benefits of any
participant in any
F-26
STERLING
CHEMICALS, INC. AND SUBSIDIARIES
NOTES TO
CONSOLIDATED FINANCIAL
STATEMENTS (Continued)
material respect does not become effective as to that
participant until 90 days after we give him or her notice
of the amendment of the Plan. No termination of our Key Employee
Protection Plan, or any of these types of amendments to the
Plan, can be effective with respect to any participant if the
termination or amendment is related to, in anticipation of or
during the pendency of a change of control, is for the purpose
of encouraging or facilitating a change of control or is made
within 180 days prior to any change of control. Finally, no
termination or amendment of our Key Employee Protection Plan can
affect the rights or benefits of any participant that are
accrued under the Plan at the time of termination or amendment
or that accrue thereafter on account of a change of control that
occurred prior to the termination or amendment or within
180 days after such termination or amendment. We expensed
$0.6 million, zero and $0.4 million in 2007, 2006 and
2005, respectively, pursuant to this Plan.
Severance
Pay Plan
On March 8, 2001, our Board of Directors approved our
Severance Pay Plan, which has subsequently been amended. This
Plan covers all of our non-unionized employees and was
established to help us retain these employees by assuring them
that they will receive some compensation in the event that their
employment is adversely affected in specified ways. Under our
Severance Pay Plan, any participant that terminates his or her
employment for Good Reason or is terminated by us
for any reason other than Misconduct or
Disability is entitled to benefits under our
Severance Pay Plan. If a participant becomes entitled to
benefits under our Severance Pay Plan, we are required to
provide the participant with a lump sum cash payment in an
amount equivalent to two weeks of such participants base
salary for each credited year of service, with a maximum payment
of one years base salary. The amount of this lump sum
payment is reduced, however, by the amount of any other
separation, severance or termination payments made by us to the
participant under any other plan or agreement, including our Key
Employee Protection Plan, or pursuant to law.
In addition to the lump sum payment, for a period of six months
after the participants termination date, the COBRA premium
required to be paid by such participant for coverage under our
medical and dental plans may not be increased beyond that
required to be paid by active employees for similar coverage
under those plans, as long as the participant makes a timely
COBRA election and pays the regular employee premiums required
under those plans and otherwise continues to be eligible for
coverage under those plans.
We may terminate or amend our Severance Pay Plan at any time and
for any reason but no termination or amendment of our Severance
Pay Plan can affect the rights or benefits of any participant
that are accrued under the plan at the time of termination or
amendment. With respect to continued operations, we recorded
zero expense in 2007 and 2006, and less than $0.1 million
in 2005.
Due to our exit from the acrylonitrile and derivatives
businesses and subsequent workforce reduction, we expensed
$0.1 million in 2007, $0.4 million in 2006 and
$0.5 million in 2005 pursuant to this Plan. These amounts
are included in the results from discontinued operations.
|
|
9.
|
Commitments
and Contingencies
|
Product
Contracts
We have certain long-term agreements, which provide for the
dedication of 100% of our production of acetic acid and
plasticizers, each to one customer. Prior to our exit from the
styrene business, we also had various sales and conversion
agreements, which dedicate significant portions of our
production of styrene to various customers. Some of these
agreements generally provide for cost recovery plus an agreed
margin or element of profit based upon market price.
Lease
Commitments
We have entered into various non-cancelable long-term operating
leases. Specifically, future minimum lease commitments for the
lease of our corporate offices at December 31, 2007 are as
follows: 2008 $0.3 million; 2009
F-27
STERLING
CHEMICALS, INC. AND SUBSIDIARIES
NOTES TO
CONSOLIDATED FINANCIAL
STATEMENTS (Continued)
$0.3 million; 2010 $0.3 million; 2011
$0.3 million; 2012 $0.3 million and thereafter
$0.2 million. Rent expense for our corporate offices was
$0.3 million for each of the years ended December 31,
2007, 2006 and 2005, respectively.
Environmental,
Health and Safety
Our operations involve the handling, production, transportation,
treatment and disposal of materials that are classified as
hazardous or toxic and that are extensively regulated by
environmental and health and safety laws, regulations and permit
requirements. Environmental permits required for our operations
are subject to periodic renewal and may be revoked or modified
for cause or when new or revised environmental requirements are
implemented. Changing and increasingly strict environmental
requirements can affect the manufacture, handling, processing,
distribution and use of our chemical products and, if so
affected, our business and operations may be materially and
adversely affected. In addition, changes in environmental
requirements may cause us to incur substantial costs in
upgrading or redesigning our facilities and processes, including
our waste treatment, storage, disposal and other waste handling
practices and equipment.
Our operating expenditures for environmental matters, mostly
waste management and compliance, for continuing operations were
approximately $11.2 million, $13.3 million and
$12.8 million in 2007, 2006 and 2005, respectively, and for
discontinued operations were approximately $6.6 million,
$7.1 million and $7.5 million, respectively. For
environmentally-related capital projects in continuing
operations, we spent approximately $0.5 million,
$2.0 million and $1.0 million in 2007, 2006 and 2005,
respectively, and zero for both 2007 and 2006 and
$0.7 million in 2005, for discontinued operations. In 2008,
we anticipate spending approximately $4 million for capital
projects related to waste management, incident prevention and
environmental compliance. We do not expect to make any capital
expenditures in 2008 related to remediation of environmental
conditions.
Air emissions from our Texas City facility are subject to
certain permit requirements and self-implementing emission
limitations and standards under state and federal laws. Our
Texas City facility is subject to the federal governments
June 1997 National Ambient Air Quality Standards, or NAAQS,
which lowered the ozone and particulate matter concentration
thresholds for attainment. Our Texas City facility is located in
an area that the Environmental Protection Agency, or EPA, has
classified as not having attained the NAAQS for ozone, either on
a 1-hour or
an 8-hour
basis. Ozone is typically controlled by reduction of volatile
organic compounds, or VOCs, and nitrogen oxide, or NOx,
emissions. The Texas Commission for Environmental Quality, or
TCEQ, has imposed strict requirements on regulated facilities,
including our Texas City facility, to ensure that the air
quality control region will achieve the ambient air quality
standards for ozone. Local authorities may also impose new ozone
and particulate matter standards. Compliance with these stricter
standards may substantially increase our future NOx, VOCs and
particulate matter emissions control costs, the amount and full
impact of which cannot be determined at this time.
In 2002, the TCEQ adopted a revised State Implementation Plan,
or SIP, in order to achieve compliance with the
1-hour
ozone standard of the Clean Air Act by 2007. The EPA approved
this
1-hour
SIP, which implemented an 80% reduction of NOx emissions, and
extensive monitoring of emissions of highly reactive volatile
organic carbons, or HRVOCs, such as ethylene, in the
Houston-Galveston-Brazoria, or HGB, area. We are in full
compliance with these regulations. However, the HGB area failed
to attain compliance with the
1-hour ozone
standard, and Section 185 of the Clean Air Act requires
implementation of a program of emissions-based fees until the
standard is attained. These Section 185 fees
will be due on all NOx and VOC emissions in 2008 and beyond in
the HGB area, which are in excess of 80% of the baseline year.
The method for calculating baseline emissions as well as other
details of the program have not yet been developed. At the
present time, our forecasted emissions for 2008 are small enough
that no fee payment is anticipated.
In April 2004, the HGB region was designated a
moderate non-attainment area with respect to the
8-hour
ozone standard of the Clean Air Act, and compliance with this
standard is required no later than June 15, 2010 for
moderate areas. However, on June 15, 2007, the
Governor of the State of Texas requested that the EPA reclassify
the HGB region as a severe non-attainment area,
which would require compliance with the
8-hour
standard by
F-28
STERLING
CHEMICALS, INC. AND SUBSIDIARIES
NOTES TO
CONSOLIDATED FINANCIAL
STATEMENTS (Continued)
June 15, 2019 and the EPA has begun the process of
reclassification. On May 23, 2007, the TCEQ formally
adopted revisions to the SIP designed to achieve compliance with
the
8-hour
ozone standard in the HGB area, as a moderate
non-attainment area. This
8-hour
SIP calls for relatively modest additional controls which
will require very little expense on our part. However, the SIP
will have to be revised again once the HGB area is reclassified
from moderate to severe. Timing and
content of this revised
8-hour
SIP have not yet been determined. Based on these
developments, it is difficult to predict our final cost of
compliance. However, given the permanent shutdown of our
phthalic anhydride, styrene and ethylbenzene facilities, we
estimate the additional cost of compliance will range from zero
to $4 million for capital expenditures and allowance
purchases, depending on the terms of the final
8-hour
SIP.
To reduce the risk of offsite consequences from unanticipated
events, we acquired a greenbelt buffer zone adjacent to our
Texas City facility in 1991. We also participate in a regional
air monitoring network to monitor ambient air quality in the
Texas City community.
Legal
Proceedings
On July 5, 2005, Patrick B. McCarthy, an employee of
Kinder-Morgan, was seriously injured at Kinder-Morgan,
Inc.s facilities near Cincinnati, Ohio while attempting to
offload a railcar containing one of our plasticizers products.
On October 28, 2005, Mr. McCarthy and his family filed
a suit in the Court of Common Pleas, Hamilton County, Ohio (Case
No. A0509 144) against us and six other defendants.
Since that time, the plaintiffs have added two additional
defendants to this lawsuit. In addition, we and some of the
other defendants have brought Mr. McCarthys employer,
Kinder-Morgan, into this lawsuit as a third-party defendant. The
plaintiffs are seeking in excess of $32 million in alleged
compensatory and punitive damages. Discovery is ongoing in this
case as to the underlying cause of the accident and the
parties respective liabilities, if any. At this time, it
is impossible to determine what, if any, liability we will have
for this incident and we will vigorously defend the suit. We
believe that all, or substantially all, of any liability imposed
upon us as a result of this suit and our related out-of-pocket
costs and expenses will be covered by our insurance policies,
subject to a $1 million deductible which was met in January
2008. We do not believe that this incident will have a material
adverse affect on our business, financial position, results of
operations or cash flows, although we cannot guarantee that a
material adverse effect will not occur.
On August 17, 2006, we initiated an arbitration proceeding
against BP Chemicals to resolve a dispute involving the
interpretation of provisions of our acetic acid production
agreement with BP Chemicals. Under the production agreement, BP
Chemicals reimburses our manufacturing expenses and pays us a
percentage of the profits derived from the sales of the acetic
acid we produce. Historically, the costs of manufacturing
charged to our acetic acid business, and reimbursed by BP
Chemicals, included the amounts we paid Praxair for carbon
monoxide, hydrogen and a blend of carbon monoxide and hydrogen
commonly referred to as blend gas. Our acetic acid
business has always used all of the carbon monoxide produced by
Praxair, other than the small amount of carbon monoxide included
in the blend gas. Until July 1, 2006, all of the blend gas
produced by Praxair was used by the oxo-alcohols plant included
in our plasticizers business. During the period when the
oxo-alcohols plant was operating, BP Chemicals was compensated
for the use of this blend gas by our oxo-alcohols plant through
a credit to the amount of our manufacturing expenses reimbursed
by BP Chemicals. Effective July 1, 2006, we permanently
closed our oxo-alcohols plant. BP Chemicals has taken the
position that it is entitled to continue to deduct a portion of
the blend gas credit from the reimbursement of our manufacturing
expenses, even though our oxo-alcohols plant has been closed and
is no longer taking any blend gas and the Praxair facilities
have been modified so that the carbon monoxide previously used
in blend gas can be used in our acetic acid operations.
Effective August 1, 2006, BP Chemicals began short paying
our invoices for manufacturing expenses by the portion of the
credit that BP Chemicals claims should continue through
July 31, 2016. The disputed portion of the credit averaged
approximately $0.3 million per month during 2006 and 2007,
before adjusting for the portion of the profits we receive from
BP Chemicals sale of the acetic acid we produce. We are
also seeking additional damages from BP Chemicals in the
arbitration based on what we believe are breaches of duty by BP
Chemicals. The parties have abated the arbitration
F-29
STERLING
CHEMICALS, INC. AND SUBSIDIARIES
NOTES TO
CONSOLIDATED FINANCIAL
STATEMENTS (Continued)
proceedings while they attempt to reach a negotiated settlement.
As part of the agreement to abate the arbitration proceedings,
BP Chemicals reimbursed us $0.8 million on February 5,
2007, which was 50% of the disputed credit through that date,
and has continued and will continue to pay 50% of the disputed
amount each month during the period of negotiation. As of
December 31, 2007, the disputed amount is $5.6 million
and we have received payments totaling $2.7 million. We are
not recording any revenue related to any portion of the disputed
amount until the matter is resolved. The parties have stipulated
that the payments are made without prejudice, in that BP
Chemicals is not admitting liability and continues to insist
that we remain liable for the disputed portion of the blend gas
credit. According to the agreement, either party may reinstate
the arbitration process at any time after August 1, 2007.
If the arbitration is reinstated and an award is made, the
amounts paid by BP Chemicals will be credited against any sums
awarded to us or refunded by us to BP Chemicals, depending on
the ruling of the arbitration panel. We believe that our acetic
acid production agreement does not contemplate the continuation
of any portion of the blend gas credit under these circumstances
and will vigorously pursue our position. Although we are in a
dispute with BP Chemicals over the interpretation of this
contractual provision, we believe that we continue to have a
constructive working relationship with BP Chemicals, as has been
the case since 1986. As part of the on-going settlement
negotiations over the blend gas issue, we are discussing an
extension of the term of the acetic acid production agreement.
On February 21, 2007, we received a summons naming us,
several benefit plans and the plan administrators for those
plans as defendants in a class action suit, Case
No. H-07-0625
filed in the United States District Court, Southern District of
Texas, Houston Division. The plaintiffs seek to represent a
proposed class of retired employees of Sterling Fibers, Inc.,
one of our former subsidiaries that we sold in connection with
our emergence from bankruptcy in 2002. The plaintiffs are
alleging that we were not permitted to increase their premiums
for retiree medical insurance based on a provision contained in
the asset purchase agreement between us and Cytec Industries
Inc. and certain of its affiliates governing our purchase of our
former acrylic fibers business in 1997. During our bankruptcy
case, we specifically rejected this asset purchase agreement and
the bankruptcy court approved that rejection. The plaintiffs are
claiming that we violated the terms of the benefit plans and
breached fiduciary duties governed by the Employee Retirement
Income Security Act and are seeking damages, declaratory relief,
punitive damages and attorneys fees. We moved to dismiss
the plaintiffs claims in their entirety on July 6,
2007, based on the rejection of the asset purchase agreement in
our bankruptcy case. However, the court denied our motion to
dismiss, motion for reconsideration and our request to allow us
to take an interlocutory appeal. Discovery in this matter is in
its beginning stages and we are vigorously defending this
action. We are unable to state at this time if a loss is
probable or remote and are unable to determine the possible
range of loss related to this matter, if any.
On March 4, 2008, Gulf Hydrogen and Energy, L.L.C., or Gulf
Hydrogen, filed suit against us in the 212th District Court
of Galveston County, Texas (Cause No. 08CV0220) to enforce
the provisions of a Memorandum of Understanding, or MOU, entered
into between us and Gulf Hydrogen involving the possible sale of
our outstanding equity interests to Gulf Hydrogen for
approximately $390 million. This lawsuit also names certain
of our officers, a director and our primary stockholder as
defendants. Gulf Hydrogen does not allege a specific amount of
money damages in the lawsuit but has asked the court to enforce
certain MOU provisions which expired on March 1, 2008. Gulf
Hydrogen alleges that the defendants breached the terms of the
MOU and made certain misrepresentations in connection therewith.
We are vigorously defending this lawsuit, which we believe is
completely without merit. We also intend to file counterclaims
against Gulf Hydrogen and its principals for damages resulting
from their conduct.
We are subject to various other claims and legal actions that
arise in the ordinary course of our business. We do not believe
that any of these claims and actions, separately or in the
aggregate, will have a material adverse effect on our business,
financial position, results of operation or cash flows, although
we cannot guarantee that a material adverse effect will not
occur.
F-30
STERLING
CHEMICALS, INC. AND SUBSIDIARIES
NOTES TO
CONSOLIDATED FINANCIAL
STATEMENTS (Continued)
|
|
10.
|
Operating
Segment and Sales Information
|
As of December 31, 2007, after considering the effects of
discontinued operations, we have reported our operations through
two segments: acetic acid and plasticizers. The accounting
policies are the same as those described in Note 1. We use
gross profit for reporting the results of our operating segments
and this measure includes all operating items related to the
businesses. There are no sales between segments. The revenues
and gross profit (losses) for each of our reportable operating
segments are as follows:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Year Ended December 31
|
|
|
|
2007
|
|
|
2006
|
|
|
2005
|
|
|
|
(Dollars in Thousands)
|
|
|
Revenues:
|
|
|
|
|
|
|
|
|
|
|
|
|
Acetic acid
|
|
$
|
100,772
|
|
|
$
|
96,724
|
|
|
$
|
86,125
|
|
Plasticizers
|
|
|
28,133
|
|
|
|
44,535
|
|
|
|
41,973
|
|
Other
|
|
|
908
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total
|
|
$
|
129,813
|
|
|
$
|
141,259
|
|
|
$
|
128,098
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Segment gross profit (loss):
|
|
|
|
|
|
|
|
|
|
|
|
|
Acetic acid
|
|
$
|
23,441
|
|
|
$
|
25,976
|
|
|
$
|
20,930
|
|
Plasticizers
|
|
|
840
|
|
|
|
(847
|
)
|
|
|
(1,415
|
)
|
Other(1)
|
|
|
(10,899
|
)
|
|
|
(11,283
|
)
|
|
|
(11,671
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Gross profit (loss):
|
|
|
13,382
|
|
|
|
13,846
|
|
|
|
7,844
|
|
Selling, general and administrative expenses
|
|
|
8,679
|
|
|
|
7,073
|
|
|
|
6,548
|
|
Other expense (income)
|
|
|
839
|
|
|
|
(724
|
)
|
|
|
|
|
Interest and debt related expenses (net of interest income)
|
|
|
15,706
|
|
|
|
10,079
|
|
|
|
10,090
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Loss from continuing operations before income tax
|
|
|
(11,842
|
)
|
|
$
|
(2,582
|
)
|
|
$
|
(8,794
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Depreciation and amortization expenses:
|
|
|
|
|
|
|
|
|
|
|
|
|
Acetic acid
|
|
$
|
5,319
|
|
|
$
|
6,108
|
|
|
$
|
5,133
|
|
Plasticizers
|
|
|
1,990
|
|
|
|
4,328
|
|
|
|
2,535
|
|
Other(2)
|
|
|
3,599
|
|
|
|
20,040
|
|
|
|
25,674
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total
|
|
$
|
10,908
|
|
|
$
|
30,476
|
|
|
$
|
33,342
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Capital expenditures:
|
|
|
|
|
|
|
|
|
|
|
|
|
Acetic acid
|
|
$
|
1,220
|
|
|
$
|
771
|
|
|
$
|
498
|
|
Plasticizers
|
|
|
|
|
|
|
|
|
|
|
|
|
Other-plant
infrastructure(3)
|
|
|
5,191
|
|
|
|
10,776
|
|
|
|
8,962
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total
|
|
$
|
6,411
|
|
|
$
|
11,547
|
|
|
$
|
9,460
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Year Ended December 31
|
|
|
|
2007
|
|
|
2006
|
|
|
Total assets:
|
|
|
|
|
|
|
|
|
Acetic acid
|
|
$
|
53,769
|
|
|
$
|
44,243
|
|
Plasticizers
|
|
|
13,216
|
|
|
|
14,000
|
|
Other(4)
|
|
|
239,459
|
|
|
|
187,580
|
|
|
|
|
|
|
|
|
|
|
Total
|
|
$
|
306,444
|
|
|
$
|
245,823
|
|
|
|
|
|
|
|
|
|
|
F-31
STERLING
CHEMICALS, INC. AND SUBSIDIARIES
NOTES TO
CONSOLIDATED FINANCIAL
STATEMENTS (Continued)
|
|
|
(1)
|
|
Gross profit (loss) for Other
includes residual, unallocated costs from styrene operations and
various unallocated corporate charges and credits.
|
|
(2)
|
|
Includes depreciation and
amortization expense of $1.0 million, $18.1 million and
$23.8 million for discontinued operations in 2007, 2006 and
2005.
|
|
(3)
|
|
Includes capital expenditures of
$2.6 million, $6.6 million and $4.6 million for discontinued
operations in 2007, 2006 and 2005.
|
|
(4)
|
|
Components of Other are
presented in the table below:
|
|
|
|
|
|
|
|
|
|
|
|
Year Ended December 31
|
|
|
|
2007
|
|
|
2006
|
|
|
Total assets:
|
|
|
|
|
|
|
|
|
Corporate:
|
|
|
|
|
|
|
|
|
Cash
|
|
$
|
100,183
|
|
|
$
|
20,690
|
|
Other
|
|
|
27,998
|
|
|
|
16,301
|
|
Plant infrastructure:
|
|
|
|
|
|
|
|
|
Property, plant and equipment, net
|
|
|
39,524
|
|
|
|
40,024
|
|
Assets of discontinued operations
|
|
|
71,754
|
|
|
|
110,565
|
|
|
|
|
|
|
|
|
|
|
Total
|
|
$
|
239,459
|
|
|
$
|
187,580
|
|
|
|
|
|
|
|
|
|
|
Sales to major customers constituting 10% or more of total
revenues from continuing operations were as follows:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Year Ended December 31,
|
|
|
|
2007
|
|
|
2006
|
|
|
2005
|
|
|
|
(Dollars in thousands)
|
|
|
Major customers:
|
|
|
|
|
|
|
|
|
|
|
|
|
BP Chemicals
|
|
$
|
100,772
|
|
|
$
|
96,724
|
|
|
$
|
86,125
|
|
BASF
|
|
|
28,132
|
|
|
|
44,535
|
|
|
|
41,973
|
|
There were no export sales in continuing operations.
|
|
11.
|
Financial
Instruments
|
Concentrations
of Risk
We sell our products primarily to companies involved in the
petrochemicals industry. We perform ongoing credit evaluations
of our customers and generally do not require collateral for
accounts receivable. However, letters of credit are required by
us on many of our export sales. Historically, our credit losses
have been minimal.
We maintain cash deposits with major banks, which from time to
time may exceed federally insured limits. We periodically assess
the financial condition of these institutions and believe that
the likelihood of any possible loss is minimal.
Fair
Value of Financial Instruments
The carrying amounts reflected in the consolidated balance
sheets for cash and cash equivalents, accounts receivable,
accounts payable and certain accrued liabilities approximate
fair value due to the short maturities of these instruments. As
of December 31, 2007, the fair value of our Secured Notes
was $152 million based on broker quotes for private
transactions.
F-32
STERLING
CHEMICALS, INC. AND SUBSIDIARIES
NOTES TO
CONSOLIDATED FINANCIAL
STATEMENTS (Continued)
Under our Certificate of Incorporation, we are authorized to
issue 20,125,000 shares of capital stock, consisting of
20,000,000 shares of common stock, par value $0.01 per
share, and 125,000 shares of preferred stock, par value
$0.01 per share. In December 2002, we made our initial issuance
of 2,825,000 shares of common stock. Subject to applicable
law and the provisions of our Certificate of Incorporation, the
indenture governing our Secured Notes and our revolving credit
facility, dividends may be declared on our shares of capital
stock at the discretion of our Board of Directors and may be
paid in cash, in property or in shares of our capital stock.
Upon the effective date of our Plan of Reorganization, we also
issued warrants to purchase, in the aggregate,
949,367 shares of common stock. Each of these warrants,
none of which has been exercised, represents the right, at any
time on or before December 19, 2008, to purchase one share
of our common stock at an exercise price of $52 per share
(subject to adjustments).
|
|
13.
|
Series A
Convertible Preferred Stock
|
Under our Certificate of Incorporation, we are authorized to
issue 125,000 shares of preferred stock, par value $0.01
per share. In December 2002, we authorized 25,000 shares
and made an initial issuance of 2,175 shares of our
Series A Convertible Preferred Stock, or our Series A
Preferred Stock. Each share of Series A Preferred Stock is
convertible at the option of the holder thereof at any time into
1,000 shares of our common stock, subject to adjustments.
Our Series A Preferred Stock has a cumulative dividend rate
of 4% per quarter of the liquidation value of the outstanding
shares of our Series A Preferred Stock, payable in
additional shares of Series A Preferred Stock in arrears on
the first business day of each calendar quarter. As our shares
of Series A Preferred Stock are convertible into shares of
our common stock (currently on a one to 1,000 share basis),
each dividend paid in additional shares of our Series A
Preferred Stock has a dilutive effect on our shares of common
stock. Since the initial issuance of our Series A Preferred
Stock, we have issued an additional 2,617.635 shares of our
Series A Preferred Stock in dividends (convertible into
2,617,635 shares of our common stock).
Our Series A Preferred Stock carries a liquidation
preference of $13,793.11 per share, subject to adjustments. We
may redeem all or any number of our shares of Series A
Preferred Stock at any time after December 19, 2005, at a
redemption price determined in accordance with the Certificate
of Designations, Preferences, Rights and Limitations of our
Series A Preferred Stock, provided that the current equity
value of our capital stock issued in December 2002 exceeds
specified levels. The holders of our Series A Preferred
Stock may elect to have us redeem all or any of their shares of
our Series A Preferred Stock following a specified change
of control at a redemption price equal to the greater of:
|
|
|
|
|
the liquidation preference for such shares (plus accrued and
unpaid dividends);
|
|
|
|
in the event of a merger or consolidation, the fair market value
of the consideration that would have been received in such
merger or consolidation in respect of the shares of our common
stock into which such shares of our Series A Preferred
Stock were convertible immediately prior to such merger or
consolidation had such shares of our Series A Preferred
Stock been converted prior thereto; or
|
|
|
|
in the event of some other specified change of control, the
current market value of the shares of our common stock into
which such shares of our Series A Preferred Stock were
convertible immediately prior to such change of control had such
shares of our Series A Preferred Stock been converted prior
thereto (plus accrued and unpaid dividends).
|
Given that certain of the redemption features are outside of our
control, our Series A Convertible Preferred Stock has been
reflected in the consolidated balance sheet as temporary equity.
Our preferred stock dividends are recorded at their fair value,
at each dividend accrual date. The fair value of our preferred
stock dividends is determined each quarter using valuation
techniques that include a component representing the intrinsic
value of the dividends (which represents the greater of the
liquidation value of the
F-33
STERLING
CHEMICALS, INC. AND SUBSIDIARIES
NOTES TO
CONSOLIDATED FINANCIAL
STATEMENTS (Continued)
preferred shares being issued or the fair value of the common
stock into which the shares could be converted) and an option
component (which is determined using a Black-Scholes Option
Pricing Model). These dividends are recorded in our consolidated
statements of operations, with an offset to redeemable preferred
stock in our consolidated balance sheets. As we are in an
accumulated deficit position, these dividends are treated as a
reduction to additional paid-in capital. Assumptions utilized in
the Black-Scholes model include:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
2007
|
|
|
2006
|
|
|
2005
|
|
|
Risk-free interest rate
|
|
|
3.5
|
%
|
|
|
4.7
|
%
|
|
|
4.4
|
%
|
Volatility
|
|
|
55.5
|
%
|
|
|
46.2
|
%
|
|
|
50.3
|
%
|
Dividend yield
|
|
|
|
|
|
|
|
|
|
|
|
|
Expected term
|
|
|
5.0
|
|
|
|
5.0
|
|
|
|
5.0
|
|
Our Series A Preferred Stock is not currently redeemable or
probable of redemption. If the Series A Preferred Stock had
been redeemed as of December 31, 2007, the redemption
amount would have been approximately $83.9 million. The
liquidation amount of our Series A Preferred Stock as of
December 31, 2007 is $66.1 million.
|
|
14.
|
Related
Party Transactions
|
Resurgence Asset Management, L.L.C., or Resurgence, has
beneficial ownership of a substantial majority of the voting
power of our equity securities due to its investment and
disposition authority over securities owned by its and its
affiliates managed funds and accounts. Currently,
Resurgence has beneficial ownership of over 99% of our
Series A Preferred Stock and over 60% of our common stock,
representing ownership of over 84% of the total voting power of
our equity. Each share of our Series A Preferred Stock is
convertible at the option of the holder thereof at any time into
1,000 shares of our common stock, subject to adjustments.
The holders of our Series A Preferred Stock are entitled to
designate a number of our directors roughly proportionate to
their overall equity ownership, but in any event not less than a
majority of our directors as long as they hold in the aggregate
at least 35% of the total voting power of our equity. As a
result, these holders have the ability to control our
management, policies and financing decisions, elect a majority
of our Board and control the vote on most matters presented to a
vote of our stockholders. In addition, our shares of
Series A Preferred Stock, almost all of which are
beneficially owned by Resurgence, carry a cumulative dividend
rate of 4% per quarter, payable in additional shares of our
Series A Preferred Stock. Each dividend paid in additional
shares of our Series A Preferred Stock has a dilutive
effect on our shares of common stock and increases the
percentage of the total voting power of our equity beneficially
owned by Resurgence. Series A Preferred Stock dividends
were 695.874 shares, 594.832 shares and
508.465 shares during 2007, 2006 and 2005, respectively.
Four of our directors, Messrs. Steve Gidumal, Byron Haney,
Karl Schwarzfeld and Philip Sivin, are currently employed by
Resurgence. Pursuant to established policies of Resurgence, all
director compensation earned by employees of Resurgence is paid
directly to Resurgence. During 2007, 2006 and 2005, we paid
Resurgence an aggregate amount equal to $150,000, $115,000 and
$177,500, respectively, related to director compensation for
Messrs. Gidumal, Haney, Schwarzfeld and Sivin, along with
reimbursement of an immaterial amount of direct, out-of-pocket
expenses incurred in connection with services as directors.
|
|
15.
|
New
Accounting Standards
|
In September 2006, the FASB issued SFAS No. 157,
Fair Value Measurements, or SFAS No. 157.
This statement establishes a framework for measuring fair value
in generally accepted accounting principles and expands
disclosures about fair value measurements for financial assets
and liabilities, as well as for any other assets and liabilities
that are carried at fair value on a recurring basis in financial
statements. SFAS No. 157 is effective for financial
statements issued for fiscal years beginning after
November 15, 2007, and interim periods within those fiscal
years. There is a one year deferral for the implementation of
SFAS No. 157 for other non-financial assets and
liabilities. We will adopt SFAS No. 157 beginning
January 1, 2008. We are currently evaluating the impact on
our consolidated financial statements.
F-34
STERLING
CHEMICALS, INC. AND SUBSIDIARIES
NOTES TO
CONSOLIDATED FINANCIAL
STATEMENTS (Continued)
In February 2007, the FASB issued Statement of Financial
Accounting Standards No. 159, The Fair Value Option
for Financial Assets and Financial Liabilities, or
SFAS No. 159. SFAS No. 159, which amends
SFAS No. 115, Accounting for Certain Investments
in Debt and Equity Securities, allows certain financial
assets and liabilities to be recognized, at our election, at
fair market value, with any gains or losses for the period
recorded in the statement of operations. SFAS No. 159
is effective for fiscal years beginning after November 15,
2007, and we do not believe it will have a material impact on
our financial statements.
In December 2007, the FASB issued SFAS No. 141
(revised 2007), Business Combinations, or
SFAS 141R. SFAS 141R broadens the guidance of
SFAS 141, extending its applicability to all transactions
and other events in which one entity obtains control over one or
more other businesses. It broadens the fair value measurement
and recognition of assets acquired, liabilities assumed, and
interests transferred as a result of business combinations.
SFAS 141R expands on required disclosures to improve the
statement users abilities to evaluate the nature and
financial effects of business combinations. SFAS 141R is
effective for fiscal years beginning after December 15,
2008. We do not expect the adoption of SFAS 141R to have a
material impact on our financial statements.
In December 2007, the FASB issued SFAS No. 160,
Noncontrolling Interests in Consolidated Financial
Statements; an amendment of ARB No. 51, or
SFAS No. 160. This statement establishes the
accounting and reporting standards for a noncontrolling interest
in a subsidiary and for the deconsolidation of a subsidiary.
This statement clarifies that a noncontrolling interest in a
subsidiary is an ownership interest in the consolidated entity
that should be reported as equity in the consolidated financial
statements. SFAS No. 160 requires retroactive adoption
of the presentation and disclosure requirements for existing
minority interests and applies prospectively to business
combinations for fiscal years beginning after December 15,
2008 and will not have a material impact on our financial
statements.
In March 2008, the FASB issued SFAS No. 161,
Disclosures About Derivative Instruments and Hedging
Activities, or SFAS No. 161. This statement
requires enhanced disclosures about an entitys derivative
and hedging activities, with the intent to provide users of
financial statements with an enhanced understanding of
(a) how and why an entity uses derivative instruments,
(b) how derivative instruments and related hedged items are
accounted for under SFAS No. 133, Accounting for
Derivative Instruments and Hedging Activities and its
related interpretations and (c) how derivative instruments
and related hedged items affect an entitys financial
position, financial performance and cash flows.
SFAS No. 161 is effective for fiscal years beginning
after November 15, 2008. We are currently evaluating the
impact on our consolidated financial statements.
|
|
16.
|
Restatement
of Financial Information and Discontinued Operations
Adjustments
|
Subsequent to the issuance of our consolidated financial
statements for the quarter ended September 30, 2007, we
determined that accounting errors, as described below, were
included in our previously issued consolidated financial
statements. As a result, we have restated our consolidated
financial statements for the years ended December 31, 2006
and 2005 due to the following errors:.
|
|
|
|
|
Paid-in-kind
dividends on our Series A Preferred Stock were incorrectly
recorded as 4% of the Series A Preferred Stocks
liquidation value versus the fair value of the dividends. As a
result of this error, redeemable preferred stock was understated
and additional paid-in capital was overstated by approximately
$26 million and $22 million as of December 31,
2006 and 2005, respectively, and preferred stock dividends and
net loss attributable to common shareholders was understated by
$4 million, $10 million and $8 million for the
fiscal years ended December 31, 2006, 2005 and 2004,
respectively.
|
|
|
|
Disputed revenues were inappropriately recognized resulting in a
gross up of the consolidated statements of operations for the
fiscal year ended December 31, 2006. Revenues and selling,
general and administrative expenses were overstated by
$1.6 million for the fiscal year ended December 31,
2006. Accounts receivable and allowance for doubtful accounts
were both overstated by $1.6 million as of
December 31, 2006.
|
F-35
STERLING
CHEMICALS, INC. AND SUBSIDIARIES
NOTES TO
CONSOLIDATED FINANCIAL
STATEMENTS (Continued)
|
|
|
|
|
The current and non-current liabilities of our pension and
postretirement benefit plans were incorrectly recorded in the
consolidated balance sheet as of December 31, 2006. Current
liabilities were overstated and non-current liabilities were
understated by $6.6 million as of December 31, 2006.
|
|
|
|
Operating segments were not properly disclosed in accordance
with SFAS No. 131 Disclosure about Segments of an
Enterprise and Related Information. Historically we
believed our operations constituted one operating segment,
however, after further analysis we believe we have two operating
segments (after considering the effects of discontinued
operations) and have disclosed the required segment information
in Note 10.
|
As a result of our exit from the styrene business, as discussed
in Note 3 to the Consolidated Financial Statements for the
year ended December 31, 2007, we have reported the
operating results of this segment as discontinued operations in
our consolidated financial statements.
F-36
STERLING
CHEMICALS, INC. AND SUBSIDIARIES
NOTES TO
CONSOLIDATED FINANCIAL
STATEMENTS (Continued)
The following is a summary of the effect of the restatements and
the styrene-related discontinued operations adjustments on the
originally issued Consolidated Statements of Operations for the
years ended December 31, 2007, 2006 and 2005, Consolidated
Balance Sheet as of December 31, 2007 and 2006, and the
Consolidated Statements of Changes in Stockholders Equity
for the years ended December 31, 2006 and 2005:
CONSOLIDATED
STATEMENTS OF OPERATIONS
(Dollars in Thousands, Except Share Data)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Year Ended December 31,
|
|
|
|
2006
|
|
|
2005
|
|
|
|
|
|
|
|
|
|
Discontinued
|
|
|
|
|
|
|
|
|
|
|
|
Discontinued
|
|
|
|
|
|
|
Previously
|
|
|
Restatement
|
|
|
Operations
|
|
|
As Restated
|
|
|
Previously
|
|
|
Restatement
|
|
|
Operations
|
|
|
As Restated
|
|
|
|
Reported
|
|
|
Adjustment
|
|
|
Adjustment
|
|
|
and Adjusted
|
|
|
Reported
|
|
|
Adjustment
|
|
|
Adjustment
|
|
|
and Adjusted
|
|
|
Revenues
|
|
$
|
667,544
|
|
|
$
|
(1,621
|
)
|
|
$
|
(524,664
|
)
|
|
$
|
141,259
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Gross profit (loss)
|
|
|
12,826
|
|
|
|
(1,621
|
)
|
|
|
2,641
|
|
|
|
13,846
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Selling, general and administrative expenses
|
|
|
9,968
|
|
|
|
(1,621
|
)
|
|
|
(1,274
|
)
|
|
|
7,073
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Preferred stock dividends
|
|
|
8,205
|
|
|
|
3,569
|
|
|
|
|
|
|
|
11,774
|
|
|
|
7,014
|
|
|
|
9,970
|
|
|
|
|
|
|
|
16,984
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net loss attributable to common stockholders
|
|
|
(113,864
|
)
|
|
|
(3,569
|
)
|
|
|
|
|
|
|
(117,433
|
)
|
|
|
(36,582
|
)
|
|
|
(9,970
|
)
|
|
|
|
|
|
|
(46,552
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Per share:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Loss from continuing operations
|
|
|
(39.91
|
)
|
|
|
(1.26
|
)
|
|
|
36.23
|
|
|
|
(4.94
|
)
|
|
|
(9.03
|
)
|
|
|
(3.52
|
)
|
|
|
4.47
|
|
|
|
(8.08
|
)
|
Net loss per share attributable to common stockholders, basic
and diluted
|
|
|
(40.26
|
)
|
|
|
(1.26
|
)
|
|
|
|
|
|
|
(41.52
|
)
|
|
|
(12.94
|
)
|
|
|
(3.52
|
)
|
|
|
|
|
|
|
(16.46
|
)
|
F-37
STERLING
CHEMICALS, INC. AND SUBSIDIARIES
NOTES TO
CONSOLIDATED FINANCIAL
STATEMENTS (Continued)
CONSOLIDATED
BALANCE SHEETS
(Dollars in Thousands)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
As of December 31,
|
|
|
|
2006
|
|
|
|
|
|
|
|
|
|
Discontinued
|
|
|
|
|
|
|
Previously
|
|
|
Restatement
|
|
|
Operations
|
|
|
As Restated
|
|
|
|
Reported
|
|
|
Adjustment
|
|
|
Adjustment
|
|
|
and Adjusted
|
|
|
Accrued liabilities
|
|
|
22,872
|
|
|
|
(6,556
|
)
|
|
|
(69
|
)
|
|
|
16,247
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total current liabilities
|
|
|
62,212
|
|
|
|
(6,556
|
)
|
|
|
|
|
|
|
55,656
|
|
Deferred credits and other liabilities
|
|
|
49,291
|
|
|
|
6,556
|
|
|
|
|
|
|
|
55,847
|
|
Redeemable preferred stock
|
|
|
56,507
|
|
|
|
25,809
|
|
|
|
|
|
|
|
82,316
|
|
Stockholders equity:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Additional paid-in capital
|
|
|
184,500
|
|
|
|
(25,809
|
)
|
|
|
|
|
|
|
158,691
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total stockholders deficiency in assets
|
|
|
(22,766
|
)
|
|
|
(25,809
|
)
|
|
|
|
|
|
|
(48,575
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
F-38
STERLING
CHEMICALS, INC. AND SUBSIDIARIES
NOTES TO
CONSOLIDATED FINANCIAL
STATEMENTS (Continued)
CONSOLIDATED
STATEMENTS OF
CHANGES IN STOCKHOLDERS EQUITY (DEFICIENCY IN
ASSETS)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Year Ended December 31,
|
|
|
|
2006
|
|
|
2005
|
|
|
|
Previously
|
|
|
Restatement
|
|
|
|
|
|
Previously
|
|
|
Restatement
|
|
|
|
|
|
|
Reported
|
|
|
Adjustment
|
|
|
As Restated
|
|
|
Reported
|
|
|
Adjustment
|
|
|
As Restated
|
|
|
Stockholders deficiency in assets:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Preferred stock dividends
|
|
$
|
(8,205
|
)
|
|
$
|
(3,569
|
)
|
|
$
|
(11,774
|
)
|
|
$
|
(7,014
|
)
|
|
$
|
(9,970
|
)
|
|
$
|
(16,984
|
)
|
In addition, the prior period adjustment of $12.2 million
was comprised of $7.9 million and $4.3 million for
fiscal years ended December 31, 2004 and 2003, respectively.
F-39
STERLING
CHEMICALS, INC. AND SUBSIDIARIES
SUPPLEMENTAL
FINANCIAL INFORMATION (unaudited)
QUARTERLY
FINANCIAL DATA
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
First
|
|
|
Second
|
|
|
Third
|
|
|
Fourth
|
|
|
|
Year
|
|
|
Quarter
|
|
|
Quarter
|
|
|
Quarter
|
|
|
Quarter
|
|
|
|
|
|
|
(Dollars in thousands, except per share Data)
|
|
|
Revenues (as previously reported)
|
|
|
2007
|
|
|
$
|
197,120
|
|
|
$
|
253,484
|
|
|
$
|
208,830
|
|
|
$
|
154,896
|
|
Restatement adjustment
|
|
|
|
|
|
|
(1,006
|
)
|
|
|
(1,032
|
)
|
|
|
(966
|
)
|
|
|
|
|
Discontinued operations adjustment
|
|
|
|
|
|
|
(163,399
|
)
|
|
|
(218,319
|
)
|
|
|
(174,876
|
)
|
|
|
(124,919
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Revenues (as restated and adjusted)
|
|
|
2007
|
|
|
$
|
32,715
|
|
|
$
|
34,133
|
|
|
$
|
32,988
|
|
|
$
|
29,977
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Revenues (as previously reported)
|
|
|
2006
|
|
|
$
|
136,670
|
|
|
$
|
150,385
|
|
|
$
|
189,916
|
|
|
$
|
190,573
|
|
Restatement adjustment
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(646
|
)
|
|
|
(975
|
)
|
Discontinued operations adjustment
|
|
|
|
|
|
|
(99,826
|
)
|
|
|
(115,274
|
)
|
|
|
(150,414
|
)
|
|
|
(159,150
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Revenues (as restated and adjusted)
|
|
|
2006
|
|
|
$
|
36,844
|
|
|
$
|
35,111
|
|
|
$
|
38,856
|
|
|
$
|
30,448
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Gross profit (loss) (as previously reported)
|
|
|
2007
|
|
|
$
|
10,164
|
|
|
$
|
9,479
|
|
|
$
|
3,048
|
|
|
$
|
(10,113
|
)
|
Restatement adjustment
|
|
|
|
|
|
|
(1,006
|
)
|
|
|
(1,032
|
)
|
|
|
(966
|
)
|
|
|
|
|
Discontinued operations adjustment
|
|
|
|
|
|
|
(3,531
|
)
|
|
|
(5,643
|
)
|
|
|
3,833
|
|
|
|
9,150
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Gross Profit (loss) (as restated and adjusted)
|
|
|
2007
|
|
|
$
|
5,627
|
|
|
$
|
2,804
|
|
|
$
|
5,915
|
|
|
$
|
(963
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Gross profit (loss) (as previously reported)
|
|
|
2006
|
|
|
$
|
(11,853
|
)
|
|
$
|
5,482
|
|
|
$
|
13,334
|
|
|
$
|
5,863
|
|
Restatement adjustment
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(646
|
)
|
|
|
(975
|
)
|
Discontinued operations adjustment
|
|
|
|
|
|
|
12,641
|
|
|
|
(3,262
|
)
|
|
|
(6,425
|
)
|
|
|
(313
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Gross Profit (loss) (as restated and adjusted)
|
|
|
2006
|
|
|
$
|
788
|
|
|
$
|
2,220
|
|
|
$
|
6,263
|
|
|
$
|
4,575
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Income (loss) from continuing operations (as previously reported)
|
|
|
2007
|
|
|
|
3,223
|
|
|
|
441
|
|
|
|
(4,489
|
)
|
|
|
(21,584
|
)
|
Other comprehensive income adjustment
|
|
|
|
|
|
|
|
|
|
|
973
|
|
|
|
4,901
|
|
|
|
|
|
Discontinued operations adjustment
|
|
|
|
|
|
|
(3,279
|
)
|
|
|
(5,361
|
)
|
|
|
(442
|
)
|
|
|
17,904
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Income (loss) from continuing operations (as restated and
adjusted)
|
|
|
2007
|
|
|
$
|
(56
|
)
|
|
$
|
(3,947
|
)
|
|
$
|
(30
|
)
|
|
$
|
(3,680
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Income (loss) from continuing operations(1)
|
|
|
2006
|
|
|
|
(9,135
|
)
|
|
|
2,137
|
|
|
|
9,949
|
|
|
|
(107,613
|
)
|
Discontinued operations adjustment
|
|
|
|
|
|
|
8,140
|
|
|
|
(3,929
|
)
|
|
|
(9,933
|
)
|
|
|
108,190
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Income (loss) from continuing operations (as restated and
adjusted)
|
|
|
2006
|
|
|
$
|
(995
|
)
|
|
$
|
(1,792
|
)
|
|
$
|
16
|
|
|
$
|
577
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Income (loss) from discontinued operations, net of tax (as
previously reported)
|
|
|
2007
|
|
|
|
(554
|
)
|
|
|
(887
|
)
|
|
|
(395
|
)
|
|
|
(557
|
)
|
Discontinued operations adjustment
|
|
|
|
|
|
|
3,279
|
|
|
|
5,361
|
|
|
|
441
|
|
|
|
(17,905
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Income (loss) from discontinued operations, net of tax (as
adjusted)
|
|
|
2007
|
|
|
$
|
2,725
|
|
|
$
|
4,474
|
|
|
$
|
46
|
|
|
$
|
(18,462
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Income (loss) from discontinued operations, net of tax (as
previously reported)
|
|
|
2006
|
|
|
$
|
(1,254
|
)
|
|
$
|
(496
|
)
|
|
$
|
625
|
|
|
$
|
128
|
|
Discontinued operations adjustment
|
|
|
|
|
|
|
(8,140
|
)
|
|
|
3,929
|
|
|
|
9,933
|
|
|
|
(108,190
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Income (loss) from discontinued operations, net of tax (as
adjusted)
|
|
|
2006
|
|
|
$
|
(9,394
|
)
|
|
$
|
3,433
|
|
|
$
|
10,558
|
|
|
$
|
(108,062
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net income (loss) attributable to common stockholders (as
previously reported)
|
|
|
2007
|
|
|
$
|
409
|
|
|
$
|
(2,797
|
)
|
|
$
|
(7,329
|
)
|
|
$
|
(26,530
|
)
|
Restatement adjustments
|
|
|
|
|
|
|
(789
|
)
|
|
|
(1,653
|
)
|
|
|
2,211
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net income (loss) attributable to common stockholders (as
restated)
|
|
|
2007
|
|
|
$
|
(380
|
)
|
|
$
|
(4,450
|
)
|
|
$
|
(5,118
|
)
|
|
$
|
(26,530
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net income (loss) attributable to common stockholders (as
previously reported)
|
|
|
2006
|
|
|
$
|
(12,321
|
)
|
|
$
|
(368
|
)
|
|
$
|
8,484
|
|
|
$
|
(109,659
|
)
|
Restatement adjustments
|
|
|
|
|
|
|
(599
|
)
|
|
|
(1,146
|
)
|
|
|
(939
|
)
|
|
|
(885
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net income (loss) attributable to common stockholders (as
restated)
|
|
|
2006
|
|
|
$
|
(12,920
|
)
|
|
$
|
(1,514
|
)
|
|
$
|
7,545
|
|
|
$
|
(110,544
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net income (loss) per share of common stock:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Basic and diluted (as previously reported)
|
|
|
2007
|
|
|
$
|
0.14
|
|
|
$
|
(0.99
|
)
|
|
$
|
(2.59
|
)
|
|
$
|
(9.38
|
)
|
Restatement adjustments
|
|
|
|
|
|
|
(0.28
|
)
|
|
|
(0.58
|
)
|
|
|
0.78
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Basic and diluted (as restated)
|
|
|
2007
|
|
|
$
|
(0.14
|
)
|
|
$
|
(1.57
|
)
|
|
$
|
(1.81
|
)
|
|
$
|
(9.38
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Basic (as previously reported)
|
|
|
2006
|
|
|
$
|
(4.36
|
)
|
|
$
|
(0.13
|
)
|
|
$
|
3.00
|
|
|
$
|
(38.77
|
)
|
Restatement adjustments
|
|
|
|
|
|
|
(0.21
|
)
|
|
|
(0.41
|
)
|
|
|
(0.33
|
)
|
|
|
(0.31
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Basic (as restated)
|
|
|
2006
|
|
|
$
|
(4.57
|
)
|
|
$
|
(0.54
|
)
|
|
$
|
2.67
|
|
|
$
|
(39.08
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Diluted (as previously reported)
|
|
|
2006
|
|
|
$
|
(4.36
|
)
|
|
$
|
(0.13
|
)
|
|
$
|
1.60
|
|
|
$
|
(38.77
|
)
|
Restatement adjustments
|
|
|
|
|
|
|
(0.21
|
)
|
|
|
(0.41
|
)
|
|
|
|
|
|
|
(0.31
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Diluted (as restated)
|
|
|
2006
|
|
|
$
|
(4.57
|
)
|
|
$
|
(0.54
|
)
|
|
$
|
1.60
|
|
|
$
|
(39.08
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
F-40
As discussed in Note 16 to the consolidated financial
statements, subsequent to the issuance of our consolidated
financial statements for the quarter ended September 30,
2007, we determined that accounting errors, as described below,
were included in our previously issued consolidated financial
statements. As a result, we have restated our consolidated
financial statements for the quarters ended March 31, June
30 and September 30 in both 2007 and 2006 and December 31,
2006, due to the following errors:
|
|
|
|
|
Paid-in-kind
dividends on our Series A Preferred Stock were incorrectly
recorded as 4% of the Series A Preferred Stocks
liquidation value versus the fair value of the dividends. As a
result of this error, redeemable preferred stock was understated
and additional paid-in capital was overstated by approximately
$32 million, $29 million, $27 million,
$26 million, $25 million, $24 million and
$23 million as of September 30, 2007, June 30,
2007, March 31 2007, December 31, 2006, September 30,
2006, June 30, 2006 and March 31, 2006, respectively.
Preferred stock dividends and net loss attributable to common
shareholders was understated by approximately $3 million,
$2 million and $1 million for the three months ended
September 30, 2007, June 30, 2007 and March 31 2007,
respectively, and approximately $1 million for each of the
three months ended December 31, 2006, September 30,
2006, June 30, 2006 and March 31, 2006.
|
|
|
|
Disputed revenues were inappropriately recognized resulting in a
gross up of the consolidated statements of operations for
quarterly periods ended September 30, June 30, March
31 2007, December 31, 2006 and September 30, 2006.
Revenues and selling, general and administrative expenses were
overstated by $1.0 million, $1.0 million,
$1.0 million, $1.0 million and $0.6 million for
the three months ended September 30, 2007, June 30,
2007, March 31 2007, December 31, 2006, and
September 30, 2006, respectively.
|
|
|
|
Deferred taxes were not recognized on benefit adjustments to
other comprehensive income, or OCI, for the quarterly periods
ended September 30 and June 30, 2007. OCI was overstated
and benefit for income taxes was understated by
$4.9 million and $1.0 million as of September 30 and
June 30, 2007, respectively.
|
In addition, as discussed in Note 3 to the consolidated
financial statements, we have reported the operating results of
our styrene segment as discontinued operations in our
consolidated financial statements.
|
|
|
(1) |
|
In the fourth quarter of 2006, we recorded a $127.7 million
impairment charge to our styrene assets. |
* * *
F-41
Report of
Independent Registered Public Accounting Firm
To the Board of Directors and Stockholders of Sterling
Chemicals, Inc.
Houston, TX:
We have audited the accompanying consolidated balance sheet of
Sterling Chemicals, Inc. and its subsidiaries (the
Company) as of March 31, 2008, and the related
consolidated statements of operations, stockholders
equity, changes in stockholders equity (deficiency in
assets) and cash flows for the three month period ended
March 31, 2008. These financial statements are the
responsibility of the Companys management. Our
responsibility is to express an opinion on these financial
statements based on our audit.
We conducted our audit in accordance with the standards of the
Public Company Accounting Oversight Board (United States). Those
standards require that we plan and perform the audit to obtain
reasonable assurance about whether the financial statements are
free of material misstatement. The Company is not required to
have, nor were we engaged to perform an audit of its internal
control over financial reporting. Our audit included
consideration of internal control over financial reporting as a
basis for designing audit procedures that are appropriate in the
circumstances, but not for the purpose of expressing an opinion
on the effectiveness of the Companys internal control over
financial reporting. Accordingly, we express no such opinion. An
audit also includes examining, on a test basis, evidence
supporting the amounts and disclosures in the financial
statements, assessing the accounting principles used and
significant estimates made by management, as well as evaluating
the overall financial statement presentation. We believe that
our audit provides a reasonable basis for our opinion.
In our opinion, the financial statements referred to above
present fairly, in all material respects, the financial position
of Sterling Chemical, Inc. as of March 31, 2008, and the
results of its operations and its cash flows for the three month
period ended March 31, 2008 in conformity with accounting
principles generally accepted in the United States of America.
We also have audited the adjustments described in Notes 3
and 16 to the financial statements that were applied to revise
the December 31, 2007, 2006 and 2005 financial statements
to give effect to presentation of the Companys styrene
operations as discontinued operations. In our opinion, such
adjustments are appropriate and have been properly applied. We
were not engaged to audit, review, or apply any procedures to
the December 31, 2007, 2006 or 2005 financial statements of
the Company other than with respect to such adjustments and,
accordingly, we do not express an opinion or any other form of
assurance on the December 31, 2007, 2006 or 2005 financial
statements taken as a whole.
Houston, Texas
July 18, 2008
F-42
STERLING
CHEMICALS, INC.
CONSOLIDATED
STATEMENTS OF OPERATIONS
(Dollars in Thousands, Except Share Data)
|
|
|
|
|
|
|
|
|
|
|
Three Months Ended March 31,
|
|
|
|
|
|
|
2007
|
|
|
|
|
|
|
(Unaudited)
|
|
|
|
|
|
|
(As Restated,
|
|
|
|
2008
|
|
|
See Note 15)
|
|
|
Revenues
|
|
$
|
38,199
|
|
|
$
|
32,715
|
|
Cost of goods sold
|
|
|
33,799
|
|
|
|
27,088
|
|
|
|
|
|
|
|
|
|
|
Gross profit
|
|
|
4,400
|
|
|
|
5,627
|
|
Selling, general and administrative expenses
|
|
|
2,418
|
|
|
|
2,298
|
|
Interest and debt related expenses
|
|
|
4,213
|
|
|
|
3,461
|
|
Interest income
|
|
|
(1,326
|
)
|
|
|
(76
|
)
|
|
|
|
|
|
|
|
|
|
Loss from continuing operations before income tax
|
|
|
(905
|
)
|
|
|
(56
|
)
|
Provision for income taxes
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Loss from continuing operations
|
|
$
|
(905
|
)
|
|
$
|
(56
|
)
|
Income (loss) from discontinued operations, net of tax
|
|
|
(6,224
|
)
|
|
|
2,725
|
|
|
|
|
|
|
|
|
|
|
Net income (loss)
|
|
$
|
(7,129
|
)
|
|
$
|
2,669
|
|
Preferred stock dividends
|
|
|
4,271
|
|
|
|
3,049
|
|
|
|
|
|
|
|
|
|
|
Net loss attributable to common stockholders
|
|
$
|
(11,400
|
)
|
|
$
|
(380
|
)
|
|
|
|
|
|
|
|
|
|
Income (loss) per share of common stock attributable to common
stockholders, basic and diluted:
|
|
|
|
|
|
|
|
|
Loss from continuing operations
|
|
$
|
(1.83
|
)
|
|
$
|
(1.10
|
)
|
Income (loss) from discontinued operations, net of tax
|
|
|
(2.20
|
)
|
|
|
0.96
|
|
|
|
|
|
|
|
|
|
|
Basic and diluted loss per share
|
|
$
|
(4.03
|
)
|
|
$
|
(0.14
|
)
|
|
|
|
|
|
|
|
|
|
Weighted average shares outstanding:
|
|
|
|
|
|
|
|
|
Basic and diluted
|
|
|
2,828,460
|
|
|
|
2,828,460
|
|
The accompanying notes are an integral part of the consolidated
financial statements.
F-43
STERLING
CHEMICALS, INC.
CONSOLIDATED
BALANCE SHEETS
(Dollars in Thousands, Except Share Data)
|
|
|
|
|
|
|
|
|
|
|
March 31,
|
|
|
December 31,
|
|
|
|
2008
|
|
|
2007
|
|
|
|
|
|
|
(Unaudited)
|
|
|
|
ASSETS
|
Current assets:
|
|
|
|
|
|
|
|
|
Cash and cash equivalents
|
|
$
|
170,459
|
|
|
$
|
100,183
|
|
Accounts receivable, net of allowance of $49 and $39,
respectively
|
|
|
11,713
|
|
|
|
29,157
|
|
Inventories, net
|
|
|
5,211
|
|
|
|
5,044
|
|
Prepaid expenses
|
|
|
2,027
|
|
|
|
3,129
|
|
Deferred tax asset
|
|
|
5,029
|
|
|
|
5,029
|
|
Assets of discontinued operations
|
|
|
1,807
|
|
|
|
71,754
|
|
|
|
|
|
|
|
|
|
|
Total current assets
|
|
|
196,246
|
|
|
|
214,296
|
|
Property, plant and equipment, net
|
|
|
76,678
|
|
|
|
77,677
|
|
Other assets, net
|
|
|
14,301
|
|
|
|
14,471
|
|
|
|
|
|
|
|
|
|
|
Total assets
|
|
$
|
287,225
|
|
|
$
|
306,444
|
|
|
|
|
|
|
|
|
|
|
|
LIABILITIES AND STOCKHOLDERS DEFICIENCY IN ASSETS
|
Current liabilities:
|
|
|
|
|
|
|
|
|
Accounts payable
|
|
$
|
12,248
|
|
|
$
|
13,715
|
|
Accrued liabilities
|
|
|
18,538
|
|
|
|
22,789
|
|
Liabilities of discontinued operations
|
|
|
7,543
|
|
|
|
11,528
|
|
|
|
|
|
|
|
|
|
|
Total current liabilities
|
|
|
38,329
|
|
|
|
48,032
|
|
Long-term debt
|
|
|
150,000
|
|
|
|
150,000
|
|
Deferred tax liability
|
|
|
5,029
|
|
|
|
5,029
|
|
Deferred credits and other liabilities
|
|
|
25,656
|
|
|
|
26,168
|
|
Long-term liabilities of discontinued operations
|
|
|
49,561
|
|
|
|
51,436
|
|
Commitments and contingencies (Note 6)
|
|
|
|
|
|
|
|
|
Redeemable preferred stock
|
|
|
104,137
|
|
|
|
99,866
|
|
Stockholders equity:
|
|
|
|
|
|
|
|
|
Common stock, $.01 par value (shares authorized 20,000,000;
shares issued and outstanding 2,828,460)
|
|
|
28
|
|
|
|
28
|
|
Additional paid-in capital
|
|
|
136,903
|
|
|
|
141,174
|
|
Accumulated deficit
|
|
|
(239,671
|
)
|
|
|
(232,542
|
)
|
Accumulated other comprehensive income
|
|
|
17,253
|
|
|
|
17,253
|
|
|
|
|
|
|
|
|
|
|
Total stockholders deficiency in assets
|
|
|
(85,487
|
)
|
|
|
(74,087
|
)
|
|
|
|
|
|
|
|
|
|
Total liabilities and stockholders deficiency in assets
|
|
$
|
287,225
|
|
|
$
|
306,444
|
|
|
|
|
|
|
|
|
|
|
The accompanying notes are an integral part of the consolidated
financial statements.
F-44
STERLING
CHEMICALS, INC. AND SUBSIDIARIES
CONSOLIDATED
STATEMENT OF
CHANGES IN STOCKHOLDERS EQUITY (DEFICIENCY IN ASSETS)
(Amounts in Thousands)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Accumulated
|
|
|
|
|
|
|
|
|
|
|
|
|
Additional
|
|
|
|
|
|
Other
|
|
|
|
|
|
|
Common Stock
|
|
|
Paid-in
|
|
|
Accumulated
|
|
|
Comprehensive
|
|
|
|
|
|
|
Shares
|
|
|
Amount
|
|
|
Capital
|
|
|
Deficit
|
|
|
Income (Loss)
|
|
|
Total
|
|
|
Balance, December 31, 2007
|
|
|
2,828
|
|
|
$
|
28
|
|
|
$
|
141,174
|
|
|
$
|
(232,542
|
)
|
|
$
|
17,253
|
|
|
$
|
(74,087
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Comprehensive loss:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net loss
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(7,129
|
)
|
|
|
|
|
|
|
|
|
Comprehensive loss
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(7,129
|
)
|
Preferred stock dividends
|
|
|
|
|
|
|
|
|
|
|
(4,271
|
)
|
|
|
|
|
|
|
|
|
|
|
(4,271
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Balance, March 31, 2008
|
|
|
2,828
|
|
|
$
|
28
|
|
|
$
|
136,903
|
|
|
$
|
(239,671
|
)
|
|
$
|
17,253
|
|
|
$
|
(85,487
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
The
accompanying notes are an integral part of the consolidated
financial statements.
F-45
STERLING
CHEMICALS, INC.
CONSOLIDATED
STATEMENTS OF CASH FLOWS
(Dollars in Thousands)
|
|
|
|
|
|
|
|
|
|
|
Three Months Ended March 31,
|
|
|
|
|
|
|
2007
|
|
|
|
2008
|
|
|
(Unaudited)
|
|
|
Cash flows from operating activities:
|
|
|
|
|
|
|
|
|
Net income (loss)
|
|
$
|
(7,129
|
)
|
|
$
|
2,669
|
|
Adjustments to reconcile net income (loss) to net cash provided
by operating activities:
|
|
|
|
|
|
|
|
|
Bad debt expense
|
|
|
10
|
|
|
|
|
|
Depreciation and amortization
|
|
|
2,635
|
|
|
|
2,729
|
|
Interest amortization
|
|
|
279
|
|
|
|
100
|
|
Unearned income amortization
|
|
|
(2,125
|
)
|
|
|
|
|
Gain on disposal of property, plant and equipment
|
|
|
|
|
|
|
(182
|
)
|
Other
|
|
|
|
|
|
|
10
|
|
Change in assets/liabilities:
|
|
|
|
|
|
|
|
|
Accounts receivable
|
|
|
72,264
|
|
|
|
17,966
|
|
Inventories
|
|
|
14,900
|
|
|
|
4,255
|
|
Prepaid expenses
|
|
|
1,102
|
|
|
|
1,118
|
|
Other assets
|
|
|
(164
|
)
|
|
|
2,181
|
|
Accounts payable
|
|
|
(4,303
|
)
|
|
|
(13,405
|
)
|
Accrued liabilities
|
|
|
(4,905
|
)
|
|
|
(3,581
|
)
|
Other liabilities
|
|
|
(251
|
)
|
|
|
(5,224
|
)
|
|
|
|
|
|
|
|
|
|
Net cash provided by operating activities
|
|
|
72,313
|
|
|
|
8,636
|
|
|
|
|
|
|
|
|
|
|
Cash flows used in investing activities:
|
|
|
|
|
|
|
|
|
Capital expenditures for property, plant and equipment
|
|
|
(2,037
|
)
|
|
|
(2,248
|
)
|
Increase in restricted cash
|
|
|
|
|
|
|
(44,146
|
)
|
Net proceeds from the sale of property, plant and equipment
|
|
|
|
|
|
|
182
|
|
|
|
|
|
|
|
|
|
|
Net cash used in investing activities
|
|
|
(2,037
|
)
|
|
|
(46,212
|
)
|
|
|
|
|
|
|
|
|
|
Cash flows provided by financing activities:
|
|
|
|
|
|
|
|
|
Repayment of Old Secured Notes
|
|
|
|
|
|
|
(57,994
|
)
|
Proceeds from the issuance of Secured Notes
|
|
|
|
|
|
|
150,000
|
|
Debt issuance costs
|
|
|
|
|
|
|
(6,778
|
)
|
|
|
|
|
|
|
|
|
|
Net cash provided by financing activities
|
|
|
|
|
|
|
85,228
|
|
|
|
|
|
|
|
|
|
|
Net increase in cash and cash equivalents
|
|
|
70,276
|
|
|
|
47,652
|
|
Cash and cash equivalents beginning of year
|
|
|
100,183
|
|
|
|
20,690
|
|
|
|
|
|
|
|
|
|
|
Cash and cash equivalents end of period
|
|
$
|
170,459
|
|
|
$
|
68,342
|
|
|
|
|
|
|
|
|
|
|
Supplemental disclosures of cash flow information:
|
|
|
|
|
|
|
|
|
Interest paid
|
|
$
|
(128
|
)
|
|
$
|
(2,501
|
)
|
Interest received
|
|
|
1,326
|
|
|
|
76
|
|
Cash paid for income taxes
|
|
|
404
|
|
|
|
299
|
|
The accompanying notes are an integral part of the consolidated
financial statements.
F-46
STERLING
CHEMICALS, INC.
The accompanying interim consolidated financial statements were
prepared in accordance with accounting principles generally
accepted in the United States of America, or GAAP, and reflect
all adjustments (including normal recurring accruals) which, in
our opinion, are considered necessary for the fair presentation
of the results for the periods presented. The results of
operations and cash flows for the periods presented are not
necessarily indicative of the results to be expected for the
full year. These statements should be read in conjunction with
the audited consolidated financial statements and notes thereto
included in our Annual Report.
Principles
of Consolidation
The consolidated financial statements include the accounts of
our wholly-owned subsidiaries, with all significant intercompany
accounts and transactions having been eliminated. Our 50% equity
investment in a cogeneration joint venture, which is accounted
for under the equity method, is not material to our financial
position or results of operations.
Cash
and Cash Equivalents
We consider all investments having an initial maturity of three
months or less to be cash equivalents.
Allowance
for Doubtful Accounts
Accounts receivable is presented net of allowance for doubtful
accounts. We regularly review our accounts receivable balances
and, based on estimated collectibility, adjust the allowance
account accordingly. As of March 31, 2008, the allowance
for doubtful accounts was less than $0.1 million for
continuing operations and zero for discontinued operations. Bad
debt expense for continuing operations was less than
$0.1 million for the first quarter of 2008 and was zero for
discontinued operations.
Inventories
Inventories are stated at the lower-of-cost-or-market. Cost is
primarily determined on a
first-in,
first-out basis, except for stores and supplies, which are
valued at average cost. The comparison of cost to market value
involves estimation of the market value of our products.
Property,
Plant and Equipment
Property, plant and equipment are recorded at cost. Major
renewals and improvements, which extend the useful lives of
equipment, are capitalized. For certain capital projects, our
customers reimburse us for a portion of the project cost. For
such capital expenditures reimbursed by our customers, we treat
the reimbursements as a reduction of our cost basis. Disposals
are removed at carrying cost less accumulated depreciation with
any resulting gain or loss reflected in operations. Depreciation
is provided using the straight-line method over estimated useful
lives ranging from five to 25 years, with the predominant
life of plant and equipment being 15 years. We capitalize
interest costs, which are incurred as part of the cost of
constructing major facilities and equipment. The amount of
interest capitalized in continuing operations for the quarter
ended March 31, 2008 was less than $0.1 million.
Plant
Turnaround Costs
As a part of normal recurring operations, each of our
manufacturing units is completely shut down from time to time,
for a period typically lasting two to four weeks, to replace
catalysts and perform major maintenance work required to sustain
long-term production. These periods are commonly referred to as
turnarounds or shutdowns. Costs of
turnarounds are expensed as incurred. As expenses for
turnarounds can be significant, the impact of expensing the
costs of turnarounds can be material for financial reporting
periods during which the turnarounds actually occur. Turnaround
costs expensed during the first quarter of 2008 for continuing
operations were less than $0.1 million.
Long-Lived
Assets
We assess our long-lived assets for impairment whenever facts
and circumstances indicate that the carrying amount may not be
fully recoverable. To analyze recoverability, we project
undiscounted net future cash flows over
F-47
STERLING
CHEMICALS, INC.
NOTES TO
CONSOLIDATED FINANCIAL STATEMENTS
Continued
the remaining life of the assets. If the projected cash flows
from the assets are less than the carrying amount, an impairment
would be recognized. Any impairment loss would be measured based
upon the difference between the carrying amount and the fair
value of the relevant assets. For these impairment analyses,
impairment is determined by comparing the estimated fair value
of these assets, utilizing the present value of expected net
cash flows, to the carrying value of these assets. In
determining the present value of expected net cash flows, we
estimate future net cash flows from these assets and the timing
of those cash flows, and then apply a discount rate to reflect
the time value of money and the inherent uncertainty of those
future cash flows. The discount rate we use is based on our
estimated cost of capital. The assumptions we use in estimating
future cash flows are consistent with our internal planning.
There were no impairments in the quarter ended March 31,
2008.
Debt
Issue Costs
Debt issue costs relating to long-term debt are amortized over
the term of the related debt instrument using the straight-line
method, which is materially consistent with the effective
interest method, and are included in other assets. Debt issue
cost amortization, which is included in interest and
debt-related expenses, was $0.3 million for the quarter
ended March 31, 2008.
Income
Taxes
Deferred income taxes are provided for revenue and expenses
which are recognized in different periods for income tax and
financial statement purposes. Deferred tax assets are regularly
assessed for recoverability based on both historical and
anticipated earnings levels, and a valuation allowance is
recorded when it is more likely than not that these amounts will
not be recovered. As a result of our analysis, we concluded that
a valuation allowance was needed against our deferred tax
assets. As of March 31, 2008, our valuation allowance was
$36.2 million, which resulted in an overall net deferred
tax asset/liability balance of zero as of March 31, 2008.
Environmental
Costs
Environmental costs are expensed as incurred, unless the
expenditures extend the economic useful life of the related
assets. Costs that extend the economic useful life of assets are
capitalized and depreciated over the remaining book life of
those assets. Liabilities are recorded when environmental
assessments or remedial efforts are probable and the cost can be
reasonably estimated.
Revenue
Recognition
We produce acetic acid and plasticizers and recognize revenues
(and the related costs) when persuasive evidence of an
arrangement exists, delivery has occurred, the sales price is
fixed and determinable, and collectibility is reasonably assured.
Acetic Acid. Pursuant to a production
agreement, all acetic acid produced is sold to BP Chemicals, who
takes delivery, title and risk of loss at the time the acetic
acid is produced. BP Chemicals, in turn, markets and sells the
acetic acid and pays us a portion of the profits derived from
those sales. BP Chemicals reimburses us monthly for 100% of our
fixed and variable costs (excluding direct depreciation
associated with machinery and equipment used in the
manufacturing of acetic acid) of production and the revenue
associated with the reimbursement of these costs is matched
against our costs as they are incurred. We recognize revenue
related to the profit sharing component of the production
agreement based on quarterly estimates received from BP
Chemicals. These estimates are based on the profits from sales
of the acetic acid purchased from our acetic acid plant.
Plasticizers. We generate revenues from our
plasticizers operations through a tolling agreement with BASF.
BASF purchases all of our plasticizers and takes delivery,
title, and risk of loss at the time of production. We receive
fixed, level quarterly payments which are recognized on a
straight-line basis. In addition, BASF reimburses us monthly for
our actual fixed and variable production costs (excluding direct
depreciation associated with machinery and equipment used in the
manufacturing of plasticizers), and the revenue associated with
the reimbursement of these costs is matched against our costs as
they are incurred.
F-48
STERLING
CHEMICALS, INC.
NOTES TO
CONSOLIDATED FINANCIAL STATEMENTS
Continued
Deferred revenue. Deferred credits are
amortized over the life of the contracts which gave rise to
them. As of March 31, 2008, we had a balance in deferred
income of approximately $10 million which primarily
represents certain payments received for our oxo-alcohol
operations, which were part of our plasticizers business, that
are being amortized using the straight-line method over the
remaining life of the contract of six years. In discontinued
operations, as of March 31, 2008, we had a balance in
deferred income of approximately $57 million pertaining to
the NOVA supply agreement discussed in Managements
Discussion and Analysis of Financial Condition and Results of
Operations, that is being amortized using the
straight-line method over the contractual non-compete period of
five years, and is reflected in discontinued operations in other
income.
Preferred
Stock Dividends
We record preferred stock dividends on our Series A
Convertible Preferred Stock, or our Series A Preferred
Stock, in our consolidated statements of operations based on the
estimated fair value of dividends at each dividend accrual date.
Our Series A Preferred Stock has a dividend rate of 4% per
quarter of the liquidation value of the outstanding shares of
our Series A Preferred Stock, and is payable in arrears in
additional shares of our Series A Preferred Stock on the
first business day of each calendar quarter. The liquidation
value of each share of our Series A Preferred Stock is
$13,793.11 per share, and each share of Series A Preferred
Stock is convertible into shares of our common stock (on a one
to 1,000 share basis, subject to adjustment). The carrying
value of our redeemable preferred stock in our consolidated
balance sheets represents the cumulative balance of the initial
fair value at original issuance in 2002 plus the fair value of
each of the quarterly dividends paid since issuance. The fair
value of our preferred stock dividends is determined each
quarter using valuation techniques that include a component
representing the intrinsic value of the dividends (which
represents the greater of the liquidation value of the preferred
shares being issued or the fair value of the common stock into
which the shares could be converted) and an option component
(which is determined using a Black-Scholes Option Pricing
Model). These dividends are recorded in our consolidated
statements of operations, with an offset to redeemable preferred
stock in our consolidated balance sheets. As we are in an
accumulated deficit position, these dividends are treated as a
reduction to additional paid-in capital.
Earnings
(Loss) Per Share
Basic earnings per share, or EPS, is computed using the
weighted-average number of shares outstanding during the year.
Diluted EPS includes common stock equivalents, which are
dilutive to earnings per share. For the quarter ending
March 31, 2008, we had no dilutive securities outstanding
due to all common stock equivalents having an anti-dilutive
effect during these periods.
Disclosures
about Fair Value of Financial Instruments
In preparing disclosures about the fair value of financial
instruments, we have concluded that the carrying amount
approximates fair value for cash and cash equivalents, accounts
receivable, accounts payable and certain accrued liabilities due
to the short maturities of these instruments. The fair values of
long-term debt instruments are estimated based upon broker
quotes for private transactions or on the current interest rates
available to us for debt with similar terms and remaining
maturities.
Accounting
Estimates
The preparation of financial statements in conformity with
accounting principles generally accepted in the United States of
America requires management to make estimates and assumptions
that affect the reported amounts of assets and liabilities and
disclosure of contingent assets and liabilities at the date of
the financial statements and the reported amounts of revenues
and expenses during the reported periods. Significant estimates
include impairment considerations, allowance for doubtful
accounts, inventory valuation, preferred stock dividend
F-49
STERLING
CHEMICALS, INC.
NOTES TO
CONSOLIDATED FINANCIAL STATEMENTS
Continued
valuation, revenue recognition related to profit sharing
accruals, environmental and litigation reserves and provision
for income taxes.
Reclassifications
Certain amounts reported in the consolidated financial
statements for the prior periods have been reclassified to
conform with the current consolidated financial statement
presentation with no effect on net loss or stockholders
equity (deficiency in assets). For the three months ended
March 31, 2007, we have reclassed amounts between accrued
liabilities and other liabilities on the statement of cash
flows. For the three months ended March 31, 2008 and 2007, we
have reclassified certain amounts on the consolidated statements
of operations and the consolidated balance sheets to reflect the
discontinued operations of styrene.
|
|
2.
|
Stock-Based
Compensation
|
On December 19, 2002, we adopted our 2002 Stock Plan and
reserved 363,914 shares of our common stock for issuance
under the plan (subject to adjustment). Under our 2002 Stock
Plan, officers and key employees, as designated by our Board of
Directors, may be issued stock options, stock awards, stock
appreciation rights or stock units. There are currently options
to purchase a total of 222,500 shares of our common stock
outstanding under our 2002 Stock Plan, all at an exercise price
of $31.60, and an additional 141,414 shares of common stock
available for issuance under our 2002 Stock Plan.
On January 1, 2006, we adopted Statement of Financial
Accounting Standards, or
SFAS No. 123-Revised
2004, Share-Based Payments, or
SFAS No. 123(R), using the modified prospective
method. SFAS No. 123(R) is a revision of
SFAS No. 123, Accounting for Stock-Based
Compensation, or SFAS No. 123, and
superseded Accounting Principles Board No. 25,
Accounting for Stock Issued to Employees, or APB
No. 25. Under SFAS No. 123(R), the cost of
employee services received in exchange for a stock-based award
is determined based on the grant-date fair value (with
exceptions). That cost is then recognized over the period during
which the employee is required to provide services in exchange
for the award (usually the vesting period).
On January 1, 2006, using the modified prospective method
under SFAS No. 123(R), we began recognizing expense on
any unvested awards under our 2002 Stock Plan that were granted
prior to that time. Any awards granted under our 2002 Stock Plan
after December 31, 2005 will be expensed over the vesting
period of the award. Stock based compensation expense was zero
for the quarter ended March 31, 2008.
Prior to January 1, 2006, we had adopted the
disclosure-only provisions of SFAS No. 123
and accounted for substantially all of our stock-based
compensation using the intrinsic value method prescribed in APB
No. 25. Under APB No. 25, no compensation expense was
recognized for any of our stock option grants because all of the
stock options issued under our 2002 Stock Plan were granted with
exercise prices at or above fair value at the time of grant.
A summary of our stock option activity for the quarter ended
March 31, 2008 is presented below:
|
|
|
|
|
|
|
|
|
|
|
March 31, 2008
|
|
|
|
|
|
|
Weighted-Average
|
|
|
|
Shares
|
|
|
Exercise Price
|
|
|
Outstanding at beginning of period
|
|
|
278,500
|
|
|
$
|
31.60
|
|
Forfeited
|
|
|
(56,000
|
)
|
|
|
31.60
|
|
Exercised
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Outstanding at end of period
|
|
|
222,500
|
|
|
$
|
31.60
|
|
|
|
|
|
|
|
|
|
|
Options exercisable at end of period
|
|
|
222,500
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
As noted above, no options were granted in the first quarter of
2008 and as of March 31, 2008 all options were vested.
F-50
STERLING
CHEMICALS, INC.
NOTES TO
CONSOLIDATED FINANCIAL STATEMENTS
Continued
|
|
3.
|
Discontinued
Operations
|
On September 16, 2005, we announced that we were exiting
the acrylonitrile business and related derivative operations,
which included sodium cyanide and disodium iminodiacetic acid,
or DSIDA. These production facilities had been shut down since
February 2005 and, after our announcement, we dismantled these
facilities. Our decision was based on a history of operating
losses incurred by our acrylonitrile and derivatives businesses,
and was made after a full review and analysis of our strategic
alternatives.
On September 17, 2007, we entered into a long-term
exclusive styrene supply agreement and a related railcar
purchase and sale agreement with NOVA Chemicals Inc., or NOVA.
Under this supply agreement, NOVA had the exclusive right to
purchase 100% of our styrene production (subject to existing
contractual commitments), the amount of styrene supplied in any
particular period being at NOVAs option. In November 2007,
this supply agreement, which was subsequently assigned by NOVA
to INEOS NOVA, LLC, or INEOS NOVA, obtained clearance under the
Hart-Scott-Rodino
Act. This clearance caused the supply agreement and the railcar
agreement to become effective and triggered a $60 million
payment to us in November 2007. In addition, in accordance with
the terms of the supply agreement, INEOS NOVA assumed
substantially all of our contractual obligations for future
styrene deliveries. After the supply agreement became effective,
INEOS NOVA nominated zero pounds of styrene under the supply
agreement for the balance of 2007 and, in response, we exercised
our right to terminate the supply agreement and permanently shut
down our styrene facility. Under the supply agreement, we are
responsible for the closure costs of our styrene facility and
are also subject to a long-term commitment to not reenter the
styrene business for a period of time. We operated our styrene
facility through early December 2007, as we completed our
production of inventory and exhausted our raw materials and
purchase requirements and sold substantially all our inventory
during the first quarter of 2008. During 2007 and the first
quarter of 2008, we incurred closure costs to decommission our
styrene facility of approximately $1 million and
$9 million, respectively. We expect to incur up to
$5 million in additional decommissioning costs related to
the closure of our styrene facility. Our styrene-related
personnel continue to work on the decommissioning and
decontamination of our styrene facility and some related tanks
and storage areas. We have not developed plans for a reduction
in workforce at this time as we hope to transition these
employees to new business ventures after their work in
decommissioning our styrene facility is complete.
In accordance with Statement of Financial Accounting Standards,
or SFAS, No. 144, Accounting for the Impairment and
Disposal of Long Lived Assets, we have reported the
operating results of these businesses as discontinued operations
in our consolidated financial statements. The carrying amounts
of assets and liabilities related to discontinued operations as
of March 31, 2008 and December 31, 2007 were as
follows:
|
|
|
|
|
|
|
|
|
|
|
March 31,
|
|
|
December 31,
|
|
|
|
2008
|
|
|
2007
|
|
|
|
|
|
|
(Unaudited)
|
|
|
|
(Dollars in thousands)
|
|
|
Assets of discontinued operations:
|
|
|
|
|
|
|
|
|
Accounts receivable, net
|
|
$
|
1,165
|
|
|
$
|
55,995
|
|
Inventories
|
|
|
642
|
|
|
|
15,709
|
|
Other assets
|
|
|
|
|
|
|
50
|
|
|
|
|
|
|
|
|
|
|
Total
|
|
$
|
1,807
|
|
|
$
|
71,754
|
|
|
|
|
|
|
|
|
|
|
Liabilities of discontinued operations:
|
|
|
|
|
|
|
|
|
Accounts payable
|
|
$
|
21
|
|
|
$
|
3,363
|
|
Accrued
liabilities(1)
|
|
|
7,511
|
|
|
|
8,165
|
|
Deferred credits and other
liabilities(1)
|
|
|
49,572
|
|
|
|
51,436
|
|
|
|
|
|
|
|
|
|
|
Total
|
|
$
|
57,104
|
|
|
$
|
62,964
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(1)
|
|
Includes $57 million of deferred
income for the NOVA supply agreement that will be amortized over
the contractual non-compete period of five years using the
straight-line method. Accrued liabilities include the current
portion of $7.5 million and deferred credits and other
liabilities include the long-term portion of $49.5 million.
|
F-51
STERLING
CHEMICALS, INC.
NOTES TO
CONSOLIDATED FINANCIAL STATEMENTS
Continued
Revenues and pre-tax income (loss) from discontinued operations
for the three-month periods ended March 31, 2008 and 2007
are presented below (in thousands):
|
|
|
|
|
|
|
|
|
|
|
Three Months Ended March 31,
|
|
|
|
2008
|
|
|
2007
|
|
|
|
|
|
|
(Unaudited)
|
|
|
Revenues
|
|
$
|
14,597
|
|
|
$
|
163,400
|
|
Income (loss) before income taxes
|
|
|
(6,224
|
)
|
|
|
2,725
|
|
Current severance obligations related to the exit from our
acrylonitrile operations are detailed below (in thousands):
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Accrued as of
|
|
|
|
|
|
|
|
Accrued as of
|
|
|
December 31,
|
|
|
Additional
|
|
|
|
|
March 31,
|
|
|
2007
|
|
|
Accruals
|
|
Cash Payments
|
|
|
2008
|
|
|
(Unaudited)
|
|
|
|
|
|
|
|
|
|
Severance accrual
|
|
$
|
325
|
|
|
|
$
|
|
|
$
|
325
|
|
|
|
$
|
|
|
|
4.
|
Detail of
Certain Balance Sheet Accounts
|
|
|
|
|
|
|
|
March 31,
|
|
|
|
2008
|
|
|
|
(Dollars in Thousands)
|
|
|
Property, plant and equipment, net:
|
|
|
|
|
Land
|
|
$
|
7,149
|
|
Buildings
|
|
|
4,809
|
|
Plant and equipment
|
|
|
119,717
|
|
Construction in progress
|
|
|
3,808
|
|
Less: accumulated depreciation
|
|
|
(58,805
|
)
|
|
|
|
|
|
|
|
$
|
76,678
|
|
|
|
|
|
|
Other assets, net:
|
|
|
|
|
S&L Cogen joint venture
|
|
$
|
5,531
|
|
Debit issuance costs
|
|
|
7,394
|
|
Other
|
|
|
1,376
|
|
|
|
|
|
|
|
|
$
|
14,301
|
|
|
|
|
|
|
F-52
STERLING
CHEMICALS, INC.
NOTES TO
CONSOLIDATED FINANCIAL STATEMENTS
Continued
|
|
|
|
|
|
|
March 31,
|
|
|
|
2008
|
|
|
|
(Dollars in Thousands)
|
|
|
Accrued liabilities:
|
|
|
|
|
Employee compensation and benefits
|
|
$
|
5,168
|
|
Deferred income
|
|
|
1,800
|
|
Interest payable
|
|
|
7,858
|
|
Advances from customers
|
|
|
1,492
|
|
Property taxes
|
|
|
584
|
|
Legal fees
|
|
|
516
|
|
Other
|
|
|
1,120
|
|
|
|
|
|
|
|
|
$
|
18,538
|
|
|
|
|
|
|
Deferred credits and other liabilities:
|
|
|
|
|
Accrued postretirement, pension and post employment benefits
|
|
$
|
15,240
|
|
Deferred income
|
|
|
7,950
|
|
Advances from customers
|
|
|
1,000
|
|
Other
|
|
|
1,466
|
|
|
|
|
|
|
|
|
$
|
25,656
|
|
|
|
|
|
|
On March 1, 2007, we commenced an offer, or our tender
offer, to repurchase all $100.6 million of our outstanding
10% Senior Secured Notes due 2007, or our Old Secured
Notes, pursuant to a tender offer and a redemption. Concurrently
with our tender offer, we solicited consents from the holders of
our Old Secured Notes to, among other things, eliminate certain
covenants contained in the indenture governing our Old Secured
Notes and related security documents. On March 30, 2007, we
repurchased $58 million in aggregate principal amount of
Old Secured Notes which were validly tendered prior to the
expiration of our tender offer, and paid the accrued interest
thereon and $0.1 million in consent fees. On April 27,
2007, we redeemed all of our Old Secured Notes that were not
tendered pursuant to our tender offer for $44 million,
which included $1.5 million in accrued interest.
On March 29, 2007, we sold $150 million aggregate
principal amount of unregistered
101/4% Senior
Secured Notes due 2015, or our Secured Notes, to
Jefferies & Company, Inc. and CIBC World Markets
Corp., as initial purchasers. Sterling Chemicals Energy, Inc.,
or Sterling Energy, one of our wholly-owned subsidiaries, was
also a party to the Purchase Agreement as a guarantor. On
May 6, 2008, Sterling Energy was merged with and into
Sterling Chemicals, Inc. Upon consummation of the merger,
Sterling Energy no longer had independent existence and,
consequently, our Secured Notes are no longer guaranteed by
Sterling Energy. On March 29, 2007, we completed a private
offering of $150 million of unregistered Secured Notes
pursuant to the Purchase Agreement. In connection with that
offering, we entered into an indenture, dated March 29,
2007, among us, Sterling Energy, as guarantor, and
U.S. Bank National Association, as trustee and collateral
agent. On August 30, 2007, we made an initial filing of an
exchange offer registration statement to exchange our
unregistered Secured Notes for a new issue of substantially
identical debt securities registered under the Securities Act.
Pursuant to a registration rights agreement among us, Sterling
Energy and the initial purchasers, we agreed to use commercially
reasonable efforts to cause the registration statement to become
effective by December 24, 2007, and complete the exchange
offer within 50 days of the effective date of the
registration statement. However, the registration statement was
not declared effective by December 24, 2007 and, as a
result, the interest rate on our Secured Notes increased by
0.25% per annum on each of December 25, 2007,
March 24, 2008 and June 23, 2008. The interest on our
Secured Notes will increase by an additional 0.25% per
F-53
STERLING
CHEMICALS, INC.
NOTES TO
CONSOLIDATED FINANCIAL STATEMENTS
Continued
annum on August 21, 2008 if the registration statement is
not declared effective by that date. We expect this additional
interest to aggregate between $0.4 million and
$0.5 million depending upon when the registration statement
is declared effective by the SEC, of which $0.2 million was
accrued as of March 31, 2008, and we expect to accrue an
additional $0.2 million during the second quarter of 2008. Once
the registration statement is declared effective, the interest
rate on our Secured Notes will automatically decrease back to
the face amount of
101/4%
per annum.
Our indenture contains affirmative and negative covenants and
customary events of default, including payment defaults,
breaches of covenants and certain events of bankruptcy,
insolvency and reorganization. If an event of default occurs and
is continuing, other than an event of default triggered upon
certain bankruptcy events, the trustee under our indenture or
the holders of at least 25% in principal amount of our
outstanding Secured Notes may declare our Secured Notes to be
due and payable immediately. Upon an event of default, the
trustee may also take actions to foreclose on the collateral
securing our outstanding Secured Notes, subject to the terms of
an intercreditor agreement dated March 29, 2007, among us,
Sterling Energy, the trustee and The CIT Group/Business Credit,
Inc. Our indenture does not require us to maintain any financial
ratios or satisfy any financial maintenance tests. We are in
compliance with all of the covenants contained in our indenture.
Interest is due on our outstanding Secured Notes on April 1 and
October 1 of each year. Our outstanding Secured Notes, which
mature on April 1, 2015, are senior secured obligations and
rank equally in right of payment with all of our existing and
future senior indebtedness. Subject to specified permitted
liens, our outstanding Secured Notes are secured (i) on a
first priority basis by all of our and Sterling Energys
fixed assets and certain related assets, including, without
limitation, all property, plant and equipment, and (ii) on
a second priority basis by all of our and Sterling Energys
other assets, including, without limitation, accounts
receivable, inventory, capital stock of our domestic restricted
subsidiaries (including Sterling Energy), intellectual property,
deposit accounts and investment property.
On December 19, 2002, we entered into a Revolving Credit
Agreement, or our revolving credit facility, with The CIT
Group/Business Credit, Inc., as administrative agent and a
lender, and certain other lenders. Under our revolving credit
facility, we and Sterling Energy are co-borrowers and are
jointly and severally liable for any indebtedness thereunder.
Our revolving credit facility is secured by first priority liens
on all of our accounts receivable, inventory and other specified
assets, as well as all of the issued and outstanding capital
stock of Sterling Energy. On March 29, 2007, we amended and
restated our revolving credit facility to, among other things,
extend the term of our revolving credit facility until
March 29, 2012, reduce the maximum commitment thereunder to
$50 million, make certain changes to the calculation of the
borrowing base and lower the interest rates and fees charged
thereunder. Borrowings under our revolving credit facility now
bear interest, at our option, at an annual rate of either a base
rate plus 0.0% to 0.50% or the LIBOR rate plus 1.50% to 2.25%,
depending on our borrowing availability at the time. We are also
required to pay an aggregate commitment fee of 0.375% per year
(payable monthly) on any unused portion of our revolving credit
facility. Available credit under our revolving credit facility
is subject to a monthly borrowing base of 85% of eligible
accounts receivable plus 65% of eligible inventory. As of
December 31, 2007, our borrowing base exceeded the maximum
commitment under our revolving credit facility, making the total
credit available under our revolving credit facility
$50 million. However, the monetization of accounts
receivable and inventory associated with our exit from the
styrene business significantly decreased the borrowing base
under our revolving credit facility. As of March 31, 2008,
total credit available under our revolving credit facility was
limited to $9.5 million due to this reduced borrowing base.
As of March 31, 2008, there were no loans outstanding under
our revolving credit facility, and we had $4.1 million in
letters of credit outstanding, resulting in borrowing
availability of $5.4 million. Pursuant to Emerging Issues
Task Force Issue
No. 95-22,
Balance Sheet Classification of Borrowings under Revolving
Credit Agreements That Include both a Subjective Acceleration
Clause and a Lock-Box Arrangement, any balances
outstanding under our revolving credit facility would be
classified as a current portion of long-term debt.
Our revolving credit facility contains numerous covenants and
conditions, including, but not limited to, restrictions on our
ability to incur indebtedness, create liens, sell assets, make
investments, make capital
F-54
STERLING
CHEMICALS, INC.
NOTES TO
CONSOLIDATED FINANCIAL STATEMENTS
Continued
expenditures, engage in mergers and acquisitions and pay
dividends. Our revolving credit facility also includes various
circumstances and conditions that would, upon their occurrence
and subject in certain cases to notice and grace periods, create
an event of default thereunder. Our revolving credit facility
does not require us to maintain any financial ratios or satisfy
any financial maintenance tests. We are in compliance with all
of the covenants contained in our revolving credit facility.
Debt
Maturities
Our secured notes, which had an aggregate principal balance of
$150 million outstanding as of March 31, 2008, are due
on April 1, 2015.
|
|
6.
|
Commitments
and Contingencies
|
Product
Contracts:
We have long-term agreements, which provide for the dedication
of 100% of our production of acetic acid and plasticizers, each
to one customer.
Environmental
Regulations:
Our operations involve the handling, production, transportation,
treatment and disposal of materials that are classified as
hazardous or toxic and that are extensively regulated by
environmental and health and safety laws, regulations and permit
requirements. Environmental permits required for our operations
are subject to periodic renewal and may be revoked or modified
for cause or when new or revised environmental requirements are
implemented. Changing and increasingly strict environmental
requirements can affect the manufacture, handling, processing,
distribution and use of our chemical products and, if so
affected, our business and operations may be materially and
adversely affected. In addition, changes in environmental
requirements may cause us to incur substantial costs in
upgrading or redesigning our facilities and processes, including
our waste treatment, storage, disposal and other waste handling
practices and equipment.
A business risk inherent in chemical operations is the potential
for personal injury and property damage claims from employees,
contractors and their employees and nearby landowners and
occupants. While we believe our business operations and
facilities generally are operated in compliance with all
applicable environmental and health and safety requirements in
all material respects, we cannot be sure that past practices or
future operations will not result in material claims or
regulatory action, require material environmental expenditures
or result in exposure or injury claims by employees, contractors
or their employees or the public. Some risk of environmental
costs and liabilities is inherent in our operations and
products, as it is with other companies engaged in similar
businesses.
We have incurred, and may continue to incur, liability for
investigation and cleanup of waste or contamination at our own
facilities or at facilities operated by third parties where we
have disposed of waste. We continually review all estimates of
potential environmental liabilities, but we may not have
identified or fully assessed all potential liabilities arising
out of our past or present operations or the amount necessary to
investigate and remediate any conditions that may be significant
to us. Based on information available at this time and reviews
undertaken to identify potential exposure, we believe any amount
reserved for environmental matters is adequate to cover our
potential exposure for
clean-up
costs.
Air emissions from our manufacturing facility in Texas City,
Texas, or our Texas City facility, are subject to certain permit
requirements and self-implementing emission limitations and
standards under state and federal laws. Our Texas City facility
is subject to the federal governments June 1997 National
Ambient Air Quality Standards, or NAAQS, which lowered the ozone
and particulate matter concentration thresholds for attainment.
Our Texas City facility is located in an area that the
Environmental Protection Agency, or EPA, has classified as not
having achieved attainment under the NAAQS for ozone, either on
a 1-hour or
an 8-hour
basis. Ozone is typically controlled by reduction of emissions
of volatile organic compounds, or VOCs, and nitrogen oxide, or
NOx. The Texas
F-55
STERLING
CHEMICALS, INC.
NOTES TO
CONSOLIDATED FINANCIAL STATEMENTS
Continued
Commission for Environmental Quality, or TCEQ, has imposed
strict requirements on regulated facilities, including our Texas
City facility, to ensure that the air quality control region
will achieve attainment under the NAAQS for ozone. Local
authorities may also impose new ozone and particulate matter
standards. Compliance with these stricter standards may
substantially increase our future control costs for emissions of
NOx, VOCs and particulate matter, the amount and full impact of
which cannot be determined at this time.
In 2002, the TCEQ adopted a revised State Implementation Plan,
or SIP, in order to achieve compliance with the
1-hour
ozone standard under the Clean Air Act by 2007. The EPA approved
this
1-hour
SIP, which required an 80% reduction of NOx emissions, and
extensive monitoring of emissions of highly reactive VOCs, or
HRVOCs, such as ethylene, in the Houston-Galveston-Brazoria
area, or the HGB area. We are in full compliance with these
regulations. However, the HGB area failed to attain compliance
with the
1-hour ozone
standard, and Section 185 of the Clean Air Act requires
implementation of a program of emissions-based fees until the
standard is attained. These Section 185 fees
will be assessed on all NOx and VOC emissions in 2008 and beyond
in the HGB area which are in excess of 80% of the baseline year.
The method for calculating baseline emissions, as well as other
details of the program, has not yet been developed. At the
present time, we do not expect to be assessed any fee for our
emissions for 2008, primarily due to the reduction in emissions
from our Texas City facility following the closure of our
styrene facility.
In April 2004, the HGB area was designated a
moderate non-attainment area with respect to the
8-hour
ozone standard of the Clean Air Act, which would result in
mandated compliance with the
8-hour ozone
standard no later than June 15, 2010. However, on
June 15, 2007, the Governor of the State of Texas requested
that the EPA reclassify the HGB area as a severe
non-attainment area, which would result in mandated compliance
with the
8-hour ozone
standard by June 15, 2019, and the EPA has begun the
process of reclassification. On May 23, 2007, the TCEQ
formally adopted revisions to the SIP designed to achieve
compliance with the
8-hour ozone
standard in the HGB area, as a moderate
non-attainment area. This
8-hour
SIP calls for relatively modest additional controls which will
require very little expense on our part. However, the
8-hour SIP
will need to be revised if and when the HGB area is reclassified
from moderate to severe. The timing and
content of any revised
8-hour SIP
have not yet been determined. Based on these developments, it is
difficult to predict our final cost of compliance under these
regulations. However, given the permanent shutdown of our
phthalic anhydride, styrene and ethylbenzene facilities, we
estimate the additional cost of compliance will range from zero
to $4 million for capital expenditures and the purchase of
NOx emissions allowances, depending on the terms of the final
8-hour SIP.
Legal
Proceedings:
On July 5, 2005, Patrick B. McCarthy, an employee of
Kinder-Morgan, Inc., or Kinder-Morgan, was seriously injured at
Kinder-Morgans facilities near Cincinnati, Ohio while
attempting to offload a railcar containing one of our
plasticizers products. On October 28, 2005,
Mr. McCarthy and his family filed a suit in the Court of
Common Pleas, Hamilton County, Ohio (Case No. A0509
144) against us and six other defendants. Since that time,
the plaintiffs have added two additional defendants to this
lawsuit. In addition, we and some of the other defendants have
brought Kinder-Morgan into this lawsuit as a third-party
defendant. The plaintiffs are seeking in excess of
$32 million in alleged compensatory and punitive damages.
Discovery is ongoing in this case as to the underlying cause of
the accident and the parties respective liabilities, if
any. At this time, it is impossible to determine what, if any,
liability we will have for this incident and we will vigorously
defend the suit. We believe that all, or substantially all, of
any liability imposed upon us as a result of this suit and our
related out-of-pocket costs and expenses will be covered by our
insurance policies, subject to a $1 million deductible
which was met in January 2008, and we have set up a receivable
of $0.2 million as of March 31, 2008 for the
reimbursement of amounts exceeding the deductible. We do not
believe that this incident will have a material adverse affect
on our business, financial position, results of operations or
cash flows, although we cannot guarantee that a material adverse
effect will not occur.
F-56
STERLING
CHEMICALS, INC.
NOTES TO
CONSOLIDATED FINANCIAL STATEMENTS
Continued
On August 17, 2006, we initiated an arbitration proceeding
against BP Chemicals to resolve a dispute involving the
interpretation of provisions of our acetic acid Production
Agreement with BP Chemicals. Under the Production Agreement, BP
Chemicals reimburses our manufacturing expenses and pays us a
percentage of the profits derived from the sales of the acetic
acid we produce. Historically, the costs of manufacturing
charged to our acetic acid business, and reimbursed by BP
Chemicals, included the amounts we paid Praxair for carbon
monoxide, hydrogen and a blend of carbon monoxide and hydrogen
commonly referred to as blend gas. Our acetic acid
business has always used all of the carbon monoxide produced by
Praxair, other than the small amount of carbon monoxide included
in the blend gas. Until July 1, 2006, all of the blend gas
produced by Praxair was used by the oxo-alcohols plant included
in our plasticizers business. During the period when the
oxo-alcohols plant was operating, BP Chemicals was compensated
for the use of this blend gas by our oxo-alcohols plant through
a credit to the amount of our manufacturing expenses reimbursed
by BP Chemicals. Effective July 1, 2006, we permanently
closed our oxo-alcohols plant. BP Chemicals has taken the
position that it is entitled to continue to deduct a portion of
the blend gas credit from the reimbursement of our manufacturing
expenses, even though our oxo-alcohols plant has been closed and
is no longer taking any blend gas and the Praxair facilities
have been modified so that the carbon monoxide previously used
in blend gas can be used in our acetic acid operations.
Effective August 1, 2006, BP Chemicals began short paying
our invoices for manufacturing expenses by the portion of the
credit that BP Chemicals claims should continue through
July 31, 2016. The disputed portion of the credit averaged
approximately $0.3 million per month during 2006 and 2007,
before adjusting for the portion of the profits we receive from
BP Chemicals sale of the acetic acid we produce. We are
also seeking additional damages from BP Chemicals in the
arbitration based on what we believe are breaches of duty by BP
Chemicals. The parties have abated the arbitration proceedings
while they attempt to reach a negotiated settlement. As part of
the agreement to abate the arbitration proceedings, BP Chemicals
reimbursed us $0.8 million on February 5, 2007, which
was 50% of the disputed credit through that date, and has
continued and will continue to pay 50% of the disputed amount
each month during the period of negotiation. As of
March 31, 2008, the disputed amount is $6.8 million
and we have received payments totaling $3.2 million. The
parties have stipulated that the payments are made without
prejudice, in that BP Chemicals is not admitting liability and
continues to insist that we remain liable for the disputed
portion of the blend gas credit. According to the agreement,
either party may reinstate the arbitration process at any time
after August 1, 2007. If the arbitration is reinstated and
an award is made, the amounts paid by BP Chemicals will be
credited against any sums awarded to us or refunded by us to BP
Chemicals, depending on the ruling of the arbitration panel. We
believe that our acetic acid Production Agreement does not
contemplate the continuation of any portion of the blend gas
credit under these circumstances and will vigorously pursue our
position. Although we are in a dispute with BP Chemicals over
the interpretation of this contractual provision, we believe
that we continue to have a constructive working relationship
with BP Chemicals, as has been the case since 1986. As part of
the on-going settlement negotiations over the blend gas issue,
we are discussing an extension of the term of the acetic acid
Production Agreement.
On February 21, 2007, we received a summons naming us,
several benefit plans and the plan administrators for those
plans as defendants in a class action suit, Case
No. H-07-0625
filed in the United States District Court, Southern District of
Texas, Houston Division. The plaintiffs seek to represent a
proposed class of retired employees of Sterling Fibers, Inc.,
one of our former subsidiaries that we sold in connection with
our emergence from bankruptcy in 2002. The plaintiffs are
alleging that we were not permitted to increase their premiums
for retiree medical insurance based on a provision contained in
the asset purchase agreement between us and Cytec Industries
Inc. and certain of its affiliates governing our purchase of our
former acrylic fibers business in 1997. During our bankruptcy
case, we specifically rejected this asset purchase agreement and
the bankruptcy court approved that rejection. The plaintiffs are
claiming that we violated the terms of the benefit plans and
breached fiduciary duties governed by the Employee Retirement
Income Security Act and are seeking damages, declaratory relief,
punitive damages and attorneys fees. The parties have
taken minimal discovery to date. The plaintiffs have moved for
partial summary judgment and for class certification related to
their claims for denial of benefits under our retiree medical
plans. The parties have fully briefed the issues and the motions
are pending before the court. However, the court has stayed all
proceedings while the plaintiffs pursue administrative remedies
under the terms of our retiree
F-57
STERLING
CHEMICALS, INC.
NOTES TO
CONSOLIDATED FINANCIAL STATEMENTS
Continued
medical plans. On April 23, 2008, the plan administrator
denied the plaintiffs claims under the terms of our
retiree medical plans. We are vigorously defending this action
and are unable to state at this time if a loss is probable or
remote and are unable to determine the possible range of loss
related to this matter, if any.
On March 4, 2008, Gulf Hydrogen and Energy, L.L.C., or Gulf
Hydrogen, filed suit against us in the 212th District Court
of Galveston County, Texas (Cause No. 08CV0220) to enforce
the provisions of a Memorandum of Understanding, or MOU, entered
into between us and Gulf Hydrogen involving the possible sale of
our outstanding equity interests to Gulf Hydrogen for
approximately $390 million. This lawsuit also names certain
of our officers, a director and our primary stockholder as
defendants. Gulf Hydrogen does not allege a specific amount of
money damages in the lawsuit but has asked the court to enforce
certain MOU provisions which expired on March 1, 2008
including restrictions on our ability to engage in negotiations
related to transactions that would result in a change of control
or to enter into mergers, stock sales or other transactions
relating to a material part of our business or operations and
other insignificant restrictions customary for transactions of a
similar nature. Gulf Hydrogen alleges that the defendants
breached the terms of the MOU and made certain
misrepresentations in connection therewith. We are vigorously
defending this lawsuit, which we believe is completely without
merit. We do not believe that this incident will have a material
adverse affect on our business, financial position, results of
operations or cash flows, although we cannot guarantee that a
material adverse effect will not occur.
We are subject to various other claims and legal actions that
arise in the ordinary course of our business. We do not believe
that any of these claims and actions, separately or in the
aggregate, will have a material adverse effect on our business,
financial position, results of operation or cash flows, although
we cannot guarantee that a material adverse effect will not
occur.
7. Income
Taxes
During the first quarters of 2008 and 2007, we recorded net tax
expense of zero for income taxes from continuing operations.
Based on our net operating loss position and projections for the
year, we expect that any tax expense or benefit during 2008 will
be fully offset by a related change in the valuation allowance,
resulting in an effective tax rate of zero. For the first
quarter of 2008, this resulted in $0.1 million of tax
benefit being offset by an increase of $0.1 million to our
valuation allowance. This increase in our valuation allowance
brings our total valuation allowance to $36.2 million
As of March 31, 2008 there were no significant changes to
our uncertain tax positions.
A reconciliation of federal statutory income taxes to our
effective tax benefit in continuing operations is as follows:
|
|
|
|
|
|
|
Three Months Ended
|
|
|
|
March 31, 2008
|
|
|
Benefit for income taxes at statutory rate
|
|
$
|
(317
|
)
|
Non-deductible expenses
|
|
|
3
|
|
State income taxes
|
|
|
24
|
|
Adjustment to projected income limitation
|
|
|
276
|
|
Change in valuation allowance
|
|
|
14
|
|
|
|
|
|
|
Effective tax benefit
|
|
$
|
|
|
|
|
|
|
|
The income tax expense(benefit) for continuing operations and
discontinued operations is shown below:
|
|
|
|
|
|
|
Three Months Ended
|
|
|
|
March 31, 2008
|
|
|
Tax benefit-continuing operations
|
|
$
|
|
|
Tax benefit-discontinued operations
|
|
|
|
|
|
|
|
|
|
Total tax benefit
|
|
$
|
|
|
|
|
|
|
|
F-58
STERLING
CHEMICALS, INC.
NOTES TO
CONSOLIDATED FINANCIAL STATEMENTS
Continued
The income tax benefit is composed of the following:
|
|
|
|
|
|
|
Three Months Ended
|
|
|
|
March 31, 2008
|
|
|
Current federal
|
|
$
|
|
|
Deferred federal
|
|
|
|
|
Current and deferred state
|
|
|
|
|
|
|
|
|
|
Total tax benefit
|
|
$
|
|
|
|
|
|
|
|
The components of our deferred income tax assets and liabilities
are summarized below:
|
|
|
|
|
|
|
March 31,
|
|
|
|
2008
|
|
|
Deferred tax assets:
|
|
|
|
|
Accrued liabilities
|
|
$
|
1,507
|
|
Accrued postretirement cost
|
|
|
2,003
|
|
Tax loss and credit carry forwards
|
|
|
27,454
|
|
State deferred taxes
|
|
|
96
|
|
Unearned revenue
|
|
|
22,569
|
|
Other
|
|
|
719
|
|
|
|
|
|
|
Total deferred tax assets
|
|
$
|
55,348
|
|
|
|
|
|
|
|
|
|
|
|
Deferred tax liabilities
|
|
|
|
|
Property,plant and equipment
|
|
$
|
(17,504
|
)
|
Accrued pension cost
|
|
|
(1,665
|
)
|
|
|
|
|
|
Subtotal
|
|
|
(19,169
|
)
|
Less: valuation allowance
|
|
|
(36,179
|
)
|
|
|
|
|
|
Total deferred tax liabilities
|
|
|
(55,348
|
)
|
|
|
|
|
|
Net deferred tax assets
|
|
$
|
|
|
|
|
|
|
|
|
|
8.
|
Pension
Plans and Other Postretirement Benefits
|
We have non-contributory pension plans which cover our salaried
employees who were employed by us on or before January 1,
2005 and our hourly wage employees who were employed by us on or
before July 1, 2007. Under our hourly plan, the benefits
are based primarily on years of service and an employees
pay as of the earlier of the employees retirement or
July 1, 2007. Under our salaried plan, the benefits are
based primarily on years of service and an employees pay
as of the earlier of the employees retirement or
January 1, 2005. Our funding policy is consistent with the
funding requirements of federal law and regulations.
Net periodic pension costs consisted of the following components:
|
|
|
|
|
|
|
|
|
|
|
Three Months Ended March 31,
|
|
|
|
2008
|
|
|
2007
|
|
|
|
|
|
|
(Unaudited)
|
|
|
|
(Dollars in thousands)
|
|
|
Service cost
|
|
$
|
|
|
|
$
|
152
|
|
Interest cost
|
|
|
1,788
|
|
|
|
1,783
|
|
Expected return on plan assets
|
|
|
(2,148
|
)
|
|
|
(2,025
|
)
|
Amortization
|
|
|
2
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net pension benefit
|
|
$
|
(358
|
)
|
|
$
|
(90
|
)
|
|
|
|
|
|
|
|
|
|
F-59
STERLING
CHEMICALS, INC.
NOTES TO
CONSOLIDATED FINANCIAL STATEMENTS
Continued
We provide certain health care benefits and life insurance
benefits for retired employees. Substantially all of our
employees become eligible for these benefits at early retirement
age. We accrue the cost of these benefits during the period in
which the employee renders the necessary service.
Health care benefits are currently provided to employees hired
prior to June 7, 2004, who retire from us with ten or more
years of credited service. Some of our employees are eligible
for postretirement life insurance, depending on their hire date.
Postretirement health care benefit plans are contributory.
Benefit provisions for most hourly employees are subject to
collective bargaining. In general, retiree health care benefits
are paid as covered expenses are incurred.
Other postretirement benefits costs consisted of the following
components:
|
|
|
|
|
|
|
|
|
|
|
Three Months Ended March 31,
|
|
|
|
2008
|
|
|
2007
|
|
|
|
|
|
|
(Unaudited)
|
|
|
|
(Dollars in thousands)
|
|
|
Service cost
|
|
$
|
3
|
|
|
$
|
46
|
|
Interest cost
|
|
|
28
|
|
|
|
364
|
|
Amortization
|
|
|
(106
|
)
|
|
|
(342
|
)
|
|
|
|
|
|
|
|
|
|
Net plan costs (benefit)
|
|
$
|
(75
|
)
|
|
$
|
68
|
|
|
|
|
|
|
|
|
|
|
Refer to Note 8 Employee Benefits in the Annual
Report on
Form 10-K
for the year ended December 31, 2007 for more information
on the pension and postretirement benefit plans.
|
|
9.
|
Operating
Segment and Sales Information
|
As of March 31, 2008, we have reported our operations
through two segments: acetic acid and plasticizers. The critical
accounting policies for these operating segments are the same as
those disclosed in our Annual Report. We use gross profit for
reporting the results of our operating segments and this measure
includes all operating items
F-60
STERLING
CHEMICALS, INC.
NOTES TO
CONSOLIDATED FINANCIAL STATEMENTS
Continued
related to the businesses. There are no sales between segments.
The revenues and gross profit for each of our reportable
operating segments are as follows:
|
|
|
|
|
|
|
|
|
|
|
Three Months Ended March 31,
|
|
|
|
2008
|
|
|
2007
|
|
|
|
|
|
|
(Unaudited)
|
|
|
|
(Dollars in thousands)
|
|
Revenues:
|
|
|
|
|
|
|
|
|
Acetic acid
|
|
$
|
28,935
|
|
|
$
|
24,832
|
|
Plasticizers
|
|
|
8,994
|
|
|
|
7,516
|
|
Other
|
|
|
270
|
|
|
|
367
|
|
|
|
|
|
|
|
|
|
|
Total
|
|
$
|
38,199
|
|
|
$
|
32,715
|
|
|
|
|
|
|
|
|
|
|
Segment gross profit:
|
|
|
|
|
|
|
|
|
Acetic acid
|
|
$
|
3,987
|
|
|
$
|
5,833
|
|
Plasticizers
|
|
|
1,892
|
|
|
|
185
|
|
Other(1)
|
|
|
(1,479
|
)
|
|
|
(391
|
)
|
|
|
|
|
|
|
|
|
|
Gross profit
|
|
|
4,400
|
|
|
|
5,627
|
|
Selling, general and administrative expenses
|
|
|
2,418
|
|
|
|
2,298
|
|
Interest and debt related expenses
|
|
|
4,213
|
|
|
|
3,461
|
|
Interest income
|
|
|
(1,326
|
)
|
|
|
(76
|
)
|
|
|
|
|
|
|
|
|
|
Loss from continuing operations before income tax
|
|
$
|
(905
|
)
|
|
$
|
(56
|
)
|
|
|
|
|
|
|
|
|
|
Depreciation and amortization expenses:
|
|
|
|
|
|
|
|
|
Acetic acid
|
|
$
|
1,512
|
|
|
$
|
1,317
|
|
Plasticizers
|
|
|
532
|
|
|
|
486
|
|
Other(2)
|
|
|
591
|
|
|
|
926
|
|
|
|
|
|
|
|
|
|
|
Total
|
|
$
|
2,635
|
|
|
$
|
2,729
|
|
|
|
|
|
|
|
|
|
|
Capital expenditures:
|
|
|
|
|
|
|
|
|
Acetic acid
|
|
$
|
800
|
|
|
$
|
281
|
|
Plasticizers
|
|
|
|
|
|
|
|
|
Other plant
infrastructure(3)
|
|
|
1,237
|
|
|
|
1,967
|
|
|
|
|
|
|
|
|
|
|
Total
|
|
$
|
2,037
|
|
|
$
|
2,248
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
March 31,
|
|
|
December 31,
|
|
|
|
2008
|
|
|
2007
|
|
|
|
|
|
|
(Unaudited)
|
|
|
|
(Dollars in thousands)
|
|
Total assets:
|
|
|
|
|
|
|
|
|
Acetic acid
|
|
$
|
34,887
|
|
|
$
|
53,769
|
|
Plasticizers
|
|
|
12,999
|
|
|
|
13,216
|
|
Other(4)
|
|
|
239,339
|
|
|
|
239,459
|
|
|
|
|
|
|
|
|
|
|
Total
|
|
$
|
287,225
|
|
|
$
|
306,444
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(1) |
|
Gross profit (loss) for Other
includes various unallocated corporate charges and credits.
|
|
(2) |
|
Includes depreciation and
amortization expense of $0.3 million and $0.6 million
for discontinued operations for the three months ended
March 31, 2008 and 2007, respectively.
|
F-61
STERLING
CHEMICALS, INC.
NOTES TO
CONSOLIDATED FINANCIAL STATEMENTS
Continued
|
|
|
(3) |
|
Includes capital expenditures of
zero and $1.5 million for discontinued operations in the
quarters ended March 31, 2008 and 2007, respectively.
|
|
(4) |
|
Components of Other are presented
in the table below:
|
|
|
|
|
|
|
|
|
|
|
|
March 31,
|
|
|
December 31,
|
|
|
|
2008
|
|
|
2007
|
|
|
|
|
|
|
(Unaudited)
|
|
|
|
(Dollars in thousands)
|
|
Total assets:
|
|
|
|
|
|
|
|
|
Corporate:
|
|
|
|
|
|
|
|
|
Cash
|
|
$
|
170,459
|
|
|
$
|
100,183
|
|
Other
|
|
|
26,936
|
|
|
|
27,998
|
|
Plant infrastructure:
|
|
|
|
|
|
|
|
|
Property, plant and equipment, net
|
|
|
40,137
|
|
|
|
39,524
|
|
Assets of discontinued operations
|
|
|
1,807
|
|
|
|
71,754
|
|
|
|
|
|
|
|
|
|
|
Total
|
|
$
|
239,339
|
|
|
$
|
239,459
|
|
|
|
|
|
|
|
|
|
|
Sales to major customers constituting 10% or more of total
revenues were as follows:
|
|
|
|
|
|
|
|
|
|
|
Three Months Ended March 31,
|
|
|
|
2008
|
|
|
2007
|
|
|
|
|
|
|
(Unaudited)
|
|
|
|
(Dollars in thousands)
|
|
|
Major customers:
|
|
|
|
|
|
|
|
|
BP Chemicals
|
|
$
|
28,935
|
|
|
$
|
24,832
|
|
BASF Corporation
|
|
|
8,994
|
|
|
|
7,516
|
|
|
|
10.
|
Financial
Instruments
|
Concentrations
of Risk
We sell our products primarily to companies involved in the
petrochemicals industry. We perform ongoing credit evaluations
of our customers and generally do not require collateral for
accounts receivable. However, letters of credit are required by
us on many of our export sales. Historically, our credit losses
have been minimal.
We maintain cash deposits with major banks, which from time to
time may exceed federally insured limits. We periodically assess
the financial condition of these institutions and believe that
the likelihood of any possible loss is minimal.
Fair
Value of Financial Instruments
The carrying amounts reflected in the consolidated balance
sheets for cash and cash equivalents, accounts receivable,
accounts payable and certain accrued liabilities approximate
fair value due to the short maturities of these instruments. As
of March 31, 2008, the fair value of our Secured Notes was
$150 million based on broker quotes for private
transactions.
Under our Certificate of Incorporation, we are authorized to
issue 20,125,000 shares of capital stock, consisting of
20,000,000 shares of common stock, par value $0.01 per
share, and 125,000 shares of preferred stock, par value
$0.01 per share. In December 2002, we made our initial issuance
of 2,825,000 shares of common stock. Subject to applicable
law and the provisions of our Certificate of Incorporation, the
indenture governing our Secured Notes and our revolving credit
facility, dividends may be declared on our shares of capital
stock at the discretion of our Board of Directors and may be
paid in cash, in property or in shares of our capital stock.
Upon the effective date of our Plan of Reorganization, we also
issued warrants to purchase, in the aggregate,
949,367 shares
F-62
STERLING
CHEMICALS, INC.
NOTES TO
CONSOLIDATED FINANCIAL STATEMENTS
Continued
of common stock. Each of these warrants, none of which has been
exercised, represents the right, at any time on or before
December 19, 2008, to purchase one share of our common
stock at an exercise price of $52 per share (subject to
adjustments).
|
|
12.
|
Series A
Convertible Preferred Stock
|
Under our Certificate of Incorporation, we are authorized to
issue 125,000 shares of preferred stock, par value $0.01
per share. In December 2002, we authorized 25,000 shares
and made an initial issuance of 2,175 shares of our
Series A Convertible Preferred Stock, or our Series A
Preferred Stock. Each share of Series A Preferred Stock is
convertible at the option of the holder thereof at any time into
1,000 shares of our common stock, subject to adjustments.
Our Series A Preferred Stock has a cumulative dividend rate
of 4% per quarter of the liquidation value of the outstanding
shares of our Series A Preferred Stock, payable in
additional shares of Series A Preferred Stock in arrears on
the first business day of each calendar quarter. As our shares
of Series A Preferred Stock are convertible into shares of
our common stock (currently on a one to 1,000 share basis),
each dividend paid in additional shares of our Series A
Preferred Stock has a dilutive effect on our shares of common
stock. Since the initial issuance of our Series A Preferred
Stock, we have issued an additional 2,809.337 shares of our
Series A Preferred Stock in dividends (convertible into
2,809,337 shares of our common stock).
Our Series A Preferred Stock carries a liquidation
preference of $13,793.11 per share, subject to adjustments. We
may redeem all or any number of our shares of Series A
Preferred Stock at any time after December 19, 2005, at a
redemption price determined in accordance with the Certificate
of Designations, Preferences, Rights and Limitations of our
Series A Preferred Stock, provided that the current equity
value of our capital stock issued in December 2002 exceeds
specified levels. The holders of our Series A Preferred
Stock may elect to have us redeem all or any of their shares of
our Series A Preferred Stock following a specified change
of control at a redemption price equal to the greater of:
|
|
|
|
|
the liquidation preference for such shares (plus accrued and
unpaid dividends);
|
|
|
|
in the event of a merger or consolidation, the fair market value
of the consideration that would have been received in such
merger or consolidation in respect of the shares of our common
stock into which such shares of our Series A Preferred
Stock were convertible immediately prior to such merger or
consolidation had such shares of our Series A Preferred
Stock been converted prior thereto; or
|
|
|
|
in the event of some other specified change of control, the
current market value of the shares of our common stock into
which such shares of our Series A Preferred Stock were
convertible immediately prior to such change of control had such
shares of our Series A Preferred Stock been converted prior
thereto (plus accrued and unpaid dividends).
|
Given that certain of the redemption features are outside of our
control, our Series A Convertible Preferred Stock has been
reflected in the consolidated balance sheet as temporary equity.
Our preferred stock dividends are recorded at their fair value,
at each dividend accrual date. The fair value of our preferred
stock dividends is determined each quarter using valuation
techniques that include a component representing the intrinsic
value of the dividends (which represents the greater of the
liquidation value of the preferred shares being issued or the
fair value of the common stock into which the shares could be
converted) and an option component (which is determined using a
Black-Scholes Option Pricing Model). These dividends are
recorded in our consolidated statements of operations, with an
offset to redeemable preferred stock in our
F-63
STERLING
CHEMICALS, INC.
NOTES TO
CONSOLIDATED FINANCIAL STATEMENTS
Continued
consolidated balance sheets. As we are in an accumulated deficit
position, these dividends are treated as a reduction to
additional paid-in capital. Assumptions utilized in the
Black-Scholes model include:
|
|
|
|
|
|
|
2008
|
|
|
Risk-free interest rate
|
|
|
2.5
|
%
|
Volatility
|
|
|
54.5
|
%
|
Dividend yield
|
|
|
|
|
Expected term
|
|
|
5.0
|
|
Our Series A Preferred Stock is not currently redeemable or
probable of redemption. If the Series A Preferred Stock had
been redeemed as of March 31, 2008, the redemption amount
would have been approximately $79.7 million. The
liquidation amount of our Series A Preferred Stock as of
March 31, 2008 is $68.7 million.
|
|
13.
|
Related
Party Transactions
|
Resurgence Asset Management, L.L.C., or Resurgence, has
beneficial ownership of a substantial majority of the voting
power of our equity securities due to its investment and
disposition authority over securities owned by its and its
affiliates managed funds and accounts. Currently,
Resurgence has beneficial ownership of over 99% of our
Series A Preferred Stock and over 60% of our common stock,
representing ownership of over 84% of the total voting power of
our equity. Each share of our Series A Preferred Stock is
convertible at the option of the holder thereof at any time into
1,000 shares of our common stock, subject to adjustments.
The holders of our Series A Preferred Stock are entitled to
designate a number of our directors roughly proportionate to
their overall equity ownership, but in any event not less than a
majority of our directors as long as they hold in the aggregate
at least 35% of the total voting power of our equity. As a
result, these holders have the ability to control our
management, policies and financing decisions, elect a majority
of our Board and control the vote on most matters presented to a
vote of our stockholders. In addition, our shares of
Series A Preferred Stock, almost all of which are
beneficially owned by Resurgence, carry a cumulative dividend
rate of 4% per quarter, payable in additional shares of our
Series A Preferred Stock. Each dividend paid in additional
shares of our Series A Preferred Stock has a dilutive
effect on our shares of common stock and increases the
percentage of the total voting power of our equity beneficially
owned by Resurgence. Series A Preferred Stock dividends
were 191.705 shares during the first quarter of 2008. Four
of our directors, Messrs. Steve Gidumal, Byron Haney, Karl
Schwarzfeld and Philip Sivin, are currently employed by
Resurgence. Pursuant to established policies of Resurgence, all
director compensation earned by employees of Resurgence is paid
directly to Resurgence. During the first quarter of 2008, we
paid Resurgence an aggregate amount equal to $30,000 related to
director compensation for Messrs. Gidumal, Haney,
Schwarzfeld and Sivin, along with reimbursement of an immaterial
amount of direct, out-of-pocket expenses incurred in connection
with services as directors.
|
|
14.
|
New
Accounting Standards
|
In September 2006, the FASB issued SFAS No. 157,
Fair Value Measurements, or SFAS No. 157.
This statement establishes a framework for measuring fair value
in generally accepted accounting principles and expands
disclosures about fair value measurements for financial assets
and liabilities, as well as for any other assets and liabilities
that are carried at fair value on a recurring basis in financial
statements. SFAS No. 157 is effective for financial
statements issued for fiscal years beginning after
November 15, 2007, and interim periods within those fiscal
years. We adopted SFAS No. 157 in the first quarter of 2008 and
determined that it had no impact on our consolidated financial
statements.
FASB Staff Position
SFAS 157-2,
Effective Date of FASB Statement No. 157, or
SFAS No. 157-2,
defers the effective date of SFAS 157 to fiscal years
beginning after November 15, 2008, and interim periods
within those fiscal years, for all non-financial assets and
non-financial liabilities, except for items that are recognized
or disclosed at fair value in the financial statements on a
recurring basis (at least annually). An entity that has issued
interim or annual financial statements reflecting the
application of the measurement and disclosure provisions of
SFAS 157 prior to February 12, 2008, must continue to
apply all provisions of SFAS 157. We are currently
F-64
STERLING
CHEMICALS, INC.
NOTES TO
CONSOLIDATED FINANCIAL STATEMENTS
Continued
evaluating the impact of our adoption of the deferred portion of
SFAS No. 157, effective January 1, 2009, on our
consolidated financial statements.
In February 2007, the FASB issued SFAS No. 159,
The Fair Value Option for Financial Assets and Financial
Liabilities, or SFAS No. 159.
SFAS No. 159, which amends SFAS No. 115,
Accounting for Certain Investments in Debt and Equity
Securities, allows certain financial assets and
liabilities to be recognized, at our election, at fair market
value, with any gains or losses for the period recorded in the
statement of operations. SFAS No. 159 is effective for
fiscal years beginning after November 15, 2007, and did not
have a material impact on our consolidated financial statements.
In December 2007, the FASB issued SFAS No. 141
(revised 2007), Business Combinations, or
SFAS No. 141R. SFAS No. 141R broadens the
guidance of SFAS No. 141, extending its applicability
to all transactions and other events in which one entity obtains
control over one or more other businesses. It broadens the fair
value measurement and recognition of assets acquired,
liabilities assumed and interests transferred as a result of
business combinations. SFAS No. 141R expands on
required disclosures to improve the statement users
abilities to evaluate the nature and financial effects of
business combinations. SFAS No. 141R is effective for
fiscal years beginning after December 15, 2008. We do not
expect the adoption of SFAS No. 141R to have a
material impact on our consolidated financial statements.
In December 2007, the FASB issued SFAS No. 160,
Noncontrolling Interests in Consolidated Financial
Statements; an amendment of ARB No. 51, or
SFAS No. 160. This statement establishes the
accounting and reporting standards for a noncontrolling interest
in a subsidiary and for the deconsolidation of a subsidiary.
This statement clarifies that a noncontrolling interest in a
subsidiary is an ownership interest in the consolidated entity
that should be reported as equity in the consolidated financial
statements. SFAS No. 160 requires retroactive adoption
of the presentation and disclosure requirements for existing
minority interests and applies prospectively to business
combinations for fiscal years beginning after December 15,
2008. We do not expect the adoption of SFAS No. 160 to
have a material impact on our consolidated financial statements.
In March 2008, the FASB issued SFAS No. 161,
Disclosures About Derivative Instruments and Hedging
Activities, or SFAS No. 161. This statement
requires enhanced disclosures about an entitys derivative
and hedging activities, with the intent to provide users of
financial statements with an enhanced understanding of
(a) how and why an entity uses derivative instruments,
(b) how derivative instruments and related hedged items are
accounted for under SFAS No. 133, Accounting for
Derivative Instruments and Hedging Activities and its
related interpretations and (c) how derivative instruments
and related hedged items affect an entitys financial
position, financial performance and cash flows.
SFAS No. 161 is effective for fiscal years beginning
after November 15, 2008. We are currently evaluating the
impact of the adoption of SFAS No. 161 on our
consolidated financial statements.
|
|
15.
|
Restatement
of Financial Information
|
As discussed in Note 16 to the consolidated financial
statements for the year ended December 31, 2007, subsequent
to the issuance of our consolidated financial statements for the
quarter ended September 30, 2007, we determined that
accounting errors, as described below, were included in our
previously issued consolidated financial statements. As a
result, we have restated our consolidated financial statements
for the quarter ended March 31, 2007, due to the following
errors:
|
|
|
|
|
Paid-in-kind
dividends on our Series A Preferred Stock were incorrectly
recorded as 4% of the Series A Preferred Stocks
liquidation value versus the fair value of the dividends. As a
result of this error, redeemable preferred stock was understated
and additional paid-in capital was overstated by approximately
$27 million as of March 31 2007. Preferred stock dividends
and net loss attributable to common shareholders was understated
by approximately $1 million for the three months ended
March 31 2007.
|
F-65
STERLING
CHEMICALS, INC.
NOTES TO
CONSOLIDATED FINANCIAL STATEMENTS
Continued
|
|
|
|
|
Disputed revenues were inappropriately recognized resulting in a
gross up of the consolidated statements of operations for the
quarter ended March 31 2007. Revenues and selling, general and
administrative expenses were overstated by $1.0 million for
the three months ended March 31 2007.
|
CONSOLIDATED
STATEMENTS OF OPERATIONS
(Dollars
in Thousands, Except Share Data)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Three Months Ended March 31, 2007
|
|
|
|
|
|
|
(Unaudited)
|
|
|
|
|
|
|
|
|
|
|
|
|
Discontinued
|
|
|
As
|
|
|
|
Previously
|
|
|
Restatement
|
|
|
Operations
|
|
|
Restated
|
|
|
|
Reported
|
|
|
Adjustment
|
|
|
Adjustment
|
|
|
and Adjusted
|
|
|
Revenues
|
|
$
|
197,120
|
|
|
$
|
(1,005
|
)
|
|
$
|
(163,400
|
)
|
|
$
|
32,715
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Gross profit (loss)
|
|
|
10,164
|
|
|
|
(1,005
|
)
|
|
|
(3,532
|
)
|
|
|
5,627
|
|
Selling, general and administrative expenses
|
|
|
3,556
|
|
|
|
(1,005
|
)
|
|
|
(253
|
)
|
|
|
2,298
|
|
Preferred stock dividends
|
|
|
2,260
|
|
|
|
789
|
|
|
|
|
|
|
|
3,049
|
|
Net loss attributable to common stockholders
|
|
|
409
|
|
|
|
(789
|
)
|
|
|
|
|
|
|
(380
|
)
|
Per share:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Loss from continuing operations
|
|
|
0.34
|
|
|
|
(1.44
|
)
|
|
|
|
|
|
|
(1.10
|
)
|
Net loss attributable to common stockholders, basic and diluted
|
|
|
0.14
|
|
|
|
(0.28
|
)
|
|
|
|
|
|
|
(0.14
|
)
|
F-66
STERLING
CHEMICALS, INC.
NOTES TO
CONSOLIDATED FINANCIAL STATEMENTS
Continued
16. Discontinued
Operations Adjustments
The following is a summary of the effect of the styrene-related
discontinued operations adjustments on the Consolidated
Statements of Operations for the years ended December 31,
2007, 2006 and 2005 and the Consolidated Balance Sheet as of
December 31, 2007 and 2006:
CONSOLIDATED
STATEMENTS OF OPERATIONS
(Dollars in Thousands, Except Share Data)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Year Ended December 31,
|
|
|
|
2007
|
|
|
|
|
|
|
Discontinued
|
|
|
|
|
|
|
Previously
|
|
|
Operations
|
|
|
|
|
|
|
Reported
|
|
|
Adjustment
|
|
|
As Adjusted
|
|
|
|
(Unaudited)
|
|
|
|
|
|
(Unaudited)
|
|
|
Revenues
|
|
$
|
811,326
|
|
|
$
|
(681,513
|
)
|
|
$
|
129,813
|
|
Cost of goods sold
|
|
|
801,752
|
|
|
|
(685,321
|
)
|
|
$
|
116,431
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Gross profit
|
|
|
9,574
|
|
|
|
3,808
|
|
|
|
13,382
|
|
Selling, general and administrative expenses
|
|
|
11,843
|
|
|
|
(3,164
|
)
|
|
|
8,679
|
|
Impairment of long-lived assets
|
|
|
4,288
|
|
|
|
(4,288
|
)
|
|
|
|
|
Other expense (income)
|
|
|
(225
|
)
|
|
|
1,064
|
|
|
|
839
|
|
Interest and debt related expenses
|
|
|
15,706
|
|
|
|
|
|
|
|
15,706
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Loss from continuing operations before income tax
|
|
|
(22,038
|
)
|
|
|
10,196
|
|
|
|
(11,842
|
)
|
Benefit for income taxes
|
|
|
(5,503
|
)
|
|
|
1,374
|
|
|
|
(4,129
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Loss from continuing operations
|
|
|
(16,535
|
)
|
|
|
8,822
|
|
|
|
(7,713
|
)
|
Loss from discontinued operations, net of tax
|
|
|
(2,393
|
)
|
|
|
(8,822
|
)
|
|
|
(11,215
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net loss
|
|
|
(18,928
|
)
|
|
|
|
|
|
|
(18,928
|
)
|
Preferred stock dividends
|
|
|
17,550
|
|
|
|
|
|
|
|
17,550
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net loss attributable to common stockholders
|
|
|
(36,478
|
)
|
|
|
|
|
|
|
(36,478
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Per share:
|
|
|
|
|
|
|
|
|
|
|
|
|
Loss from continuing operations
|
|
|
(12.05
|
)
|
|
|
3.12
|
|
|
|
(8.93
|
)
|
Loss from discontinued operations
|
|
|
(0.85
|
)
|
|
|
(3.12
|
)
|
|
|
(3.97
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net loss per share attributable to common stockholders, basic
and diluted
|
|
|
(12.90
|
)
|
|
|
|
|
|
|
(12.90
|
)
|
F-67
STERLING
CHEMICALS, INC.
NOTES TO
CONSOLIDATED FINANCIAL STATEMENTS
Continued
CONSOLIDATED
STATEMENTS OF OPERATIONS (Continued)
(Dollars in Thousands, Except Share Data)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Year Ended December 31,
|
|
|
|
2006
|
|
|
|
|
|
|
Discontinued
|
|
|
|
|
|
|
Previously
|
|
|
Operations
|
|
|
|
|
|
|
Reported
|
|
|
Adjustment
|
|
|
As Adjusted
|
|
|
|
(Unaudited)
|
|
|
|
|
|
(Unaudited)
|
|
|
Revenues
|
|
$
|
665,923
|
|
|
$
|
(524,664
|
)
|
|
$
|
141,259
|
|
Cost of goods sold
|
|
|
654,718
|
|
|
|
(527,305
|
)
|
|
$
|
127,413
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Gross profit
|
|
|
11,205
|
|
|
|
2,641
|
|
|
|
13,846
|
|
Selling, general and administrative expenses
|
|
|
8,347
|
|
|
|
(1,274
|
)
|
|
|
7,073
|
|
Impairment of long-lived assets
|
|
|
127,653
|
|
|
|
(127,653
|
)
|
|
|
|
|
Other income
|
|
|
(15,724
|
)
|
|
|
15,000
|
|
|
|
(724
|
)
|
Interest and debt related expenses
|
|
|
10,079
|
|
|
|
|
|
|
|
10,079
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Loss from continuing operations before income tax
|
|
|
(119,150
|
)
|
|
|
116,568
|
|
|
|
(2,582
|
)
|
Benefit for income taxes
|
|
|
(14,488
|
)
|
|
|
14,100
|
|
|
|
(388
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Loss from continuing operations
|
|
|
(104,662
|
)
|
|
|
102,468
|
|
|
|
(2,194
|
)
|
Loss from discontinued operations, net of tax
|
|
|
(997
|
)
|
|
|
(102,468
|
)
|
|
|
(103,465
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net loss
|
|
|
(105,659
|
)
|
|
|
|
|
|
|
(105,659
|
)
|
Preferred stock dividends
|
|
|
11,774
|
|
|
|
|
|
|
|
11,774
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net loss attributable to common stockholders
|
|
|
(117,433
|
)
|
|
|
|
|
|
|
(117,433
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Per share:
|
|
|
|
|
|
|
|
|
|
|
|
|
Loss from continuing operations
|
|
|
(41.17
|
)
|
|
|
36.23
|
|
|
|
(4.94
|
)
|
Loss from discontinued operations
|
|
|
(0.35
|
)
|
|
|
(36.23
|
)
|
|
|
(36.58
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net loss per share attributable to common stockholders, basic
and diluted
|
|
|
(41.52
|
)
|
|
|
|
|
|
|
(41.52
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Year Ended December 31,
|
|
|
|
2005
|
|
|
|
|
|
|
Discontinued
|
|
|
|
|
|
|
Previously
|
|
|
Operations
|
|
|
|
|
|
|
Reported
|
|
|
Adjustment
|
|
|
As Adjusted
|
|
|
|
(Unaudited)
|
|
|
|
|
|
(Unaudited)
|
|
|
Revenues
|
|
$
|
641,886
|
|
|
$
|
(513,788
|
)
|
|
$
|
128,098
|
|
Cost of goods sold
|
|
|
653,134
|
|
|
|
(532,880
|
)
|
|
$
|
120,254
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Gross profit (loss)
|
|
|
(11,248
|
)
|
|
|
19,092
|
|
|
|
7,844
|
|
Selling, general and administrative expenses
|
|
|
7,811
|
|
|
|
(1,263
|
)
|
|
|
6,548
|
|
Impairment of long-lived assets
|
|
|
|
|
|
|
|
|
|
|
|
|
Other income
|
|
|
|
|
|
|
|
|
|
|
|
|
Interest and debt related expenses
|
|
|
10,090
|
|
|
|
|
|
|
|
10,090
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Loss from continuing operations before income tax
|
|
|
(29,149
|
)
|
|
|
20,355
|
|
|
|
(8,794
|
)
|
Benefit for income taxes
|
|
|
(10,641
|
)
|
|
|
7,703
|
|
|
|
(2,938
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Loss from continuing operations
|
|
|
(18,508
|
)
|
|
|
12,652
|
|
|
|
(5,856
|
)
|
Loss from discontinued operations, net of tax
|
|
|
(11,060
|
)
|
|
|
(12,652
|
)
|
|
|
(23,712
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net loss
|
|
|
(29,568
|
)
|
|
|
|
|
|
|
(29,568
|
)
|
Preferred stock dividends
|
|
|
16,984
|
|
|
|
|
|
|
|
16,984
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net loss attributable to common stockholders
|
|
|
(46,552
|
)
|
|
|
|
|
|
|
(46,552
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Per share:
|
|
|
|
|
|
|
|
|
|
|
|
|
Loss from continuing operations
|
|
|
(12.55
|
)
|
|
|
4.47
|
|
|
|
(8.08
|
)
|
Loss from discontinued operations
|
|
|
(3.91
|
)
|
|
|
(4.47
|
)
|
|
|
(8.38
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net loss per share attributable to common stockholders, basic
and diluted
|
|
|
(16.46
|
)
|
|
|
|
|
|
|
(16.46
|
)
|
F-68
STERLING
CHEMICALS, INC.
NOTES TO
CONSOLIDATED FINANCIAL STATEMENTS
Continued
CONSOLIDATED
BALANCE SHEETS
(Dollars in Thousands)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
As of December 31,
|
|
|
|
2007
|
|
|
2006
|
|
|
|
|
|
|
Discontinued
|
|
|
|
|
|
|
|
|
Discontinued
|
|
|
|
|
|
|
Previously
|
|
|
Operations
|
|
|
As
|
|
|
Previously
|
|
|
Operations
|
|
|
As
|
|
|
|
Reported
|
|
|
Adjustment
|
|
|
Adjusted
|
|
|
Reported
|
|
|
Adjustment
|
|
|
Adjusted
|
|
|
|
(Unaudited)
|
|
|
|
|
|
(Unaudited)
|
|
|
(Unaudited)
|
|
|
|
|
|
(Unaudited)
|
|
|
ASSETS
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Current assets:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Cash and cash equivalents
|
|
$
|
100,183
|
|
|
$
|
|
|
|
$
|
100,183
|
|
|
$
|
20,690
|
|
|
$
|
|
|
|
$
|
20,690
|
|
Accounts receivable, net of allowance
|
|
|
85,152
|
|
|
|
(55,995
|
)
|
|
|
29,157
|
|
|
|
63,289
|
|
|
|
(51,652
|
)
|
|
|
11,637
|
|
Inventories, net
|
|
|
20,753
|
|
|
|
(15,709
|
)
|
|
|
5,044
|
|
|
|
62,078
|
|
|
|
(56,463
|
)
|
|
|
5,615
|
|
Prepaid expenses and other current assets
|
|
|
3,129
|
|
|
|
|
|
|
|
3,129
|
|
|
|
3,215
|
|
|
|
|
|
|
|
3,215
|
|
Deferred tax asset
|
|
|
5,029
|
|
|
|
|
|
|
|
5,029
|
|
|
|
3,044
|
|
|
|
|
|
|
|
3,044
|
|
Assets of discontinued operations
|
|
|
|
|
|
|
71,754
|
|
|
|
71,754
|
|
|
|
20
|
|
|
|
110,545
|
|
|
|
110,565
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total current assets
|
|
|
214,246
|
|
|
|
50
|
|
|
|
214,296
|
|
|
|
152,336
|
|
|
|
2,430
|
|
|
|
154,766
|
|
Property, plant and equipment, net
|
|
|
77,677
|
|
|
|
|
|
|
|
77,677
|
|
|
|
83,833
|
|
|
|
|
|
|
|
83,833
|
|
Other assets, net
|
|
|
14,521
|
|
|
|
(50
|
)
|
|
|
14,471
|
|
|
|
9,654
|
|
|
|
(2,430
|
)
|
|
|
7,224
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total assets
|
|
$
|
306,444
|
|
|
$
|
|
|
|
$
|
306,444
|
|
|
$
|
245,823
|
|
|
$
|
|
|
|
$
|
245,823
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
LIABILITIES AND STOCKHOLDERS DEFICIENCY IN ASSETS
|
|
|
|
|
|
|
|
|
|
|
|
|
Current liabilities:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Accounts payable
|
|
$
|
17,078
|
|
|
$
|
(3,363
|
)
|
|
$
|
13,715
|
|
|
$
|
39,123
|
|
|
$
|
(21,934
|
)
|
|
$
|
17,189
|
|
Accrued liabilities
|
|
|
30,629
|
|
|
|
(7,840
|
)
|
|
|
22,789
|
|
|
|
16,316
|
|
|
|
(69
|
)
|
|
|
16,247
|
|
Liabilities of discontinued operations
|
|
|
325
|
|
|
|
11,203
|
|
|
|
11,528
|
|
|
|
217
|
|
|
|
22,003
|
|
|
|
22,220
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total current liabilities
|
|
|
48,032
|
|
|
|
|
|
|
|
48,032
|
|
|
|
55,656
|
|
|
|
|
|
|
|
55,656
|
|
Long-term debt
|
|
|
150,000
|
|
|
|
|
|
|
|
150,000
|
|
|
|
100,579
|
|
|
|
|
|
|
|
100,579
|
|
Deferred income tax liability
|
|
|
5,029
|
|
|
|
|
|
|
|
5,029
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Deferred credits and other liabilities
|
|
|
77,604
|
|
|
|
(51,436
|
)
|
|
|
26,168
|
|
|
|
55,847
|
|
|
|
|
|
|
|
55,847
|
|
Long-term liabilities of discontinued operations
|
|
|
|
|
|
|
51,436
|
|
|
|
51,436
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Commitments and contingencies Redeemable preferred stock
|
|
|
99,866
|
|
|
|
|
|
|
|
99,866
|
|
|
|
82,316
|
|
|
|
|
|
|
|
82,316
|
|
Stockholders equity:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Common stock, $.01 par value
|
|
|
28
|
|
|
|
|
|
|
|
28
|
|
|
|
28
|
|
|
|
|
|
|
|
28
|
|
Additional paid-in capital
|
|
|
141,174
|
|
|
|
|
|
|
|
141,174
|
|
|
|
158,691
|
|
|
|
|
|
|
|
158,691
|
|
Accumulated deficit
|
|
|
(232,542
|
)
|
|
|
|
|
|
|
(232,542
|
)
|
|
|
(213,614
|
)
|
|
|
|
|
|
|
(213,614
|
)
|
Accumulated other comprehensive income
|
|
|
17,253
|
|
|
|
|
|
|
|
17,253
|
|
|
|
6,320
|
|
|
|
|
|
|
|
6,320
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total stockholders deficiency in assets
|
|
|
(74,087
|
)
|
|
|
|
|
|
|
(74,087
|
)
|
|
|
(48,575
|
)
|
|
|
|
|
|
|
(48,575
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total liabilities and stockholders deficiency in assets
|
|
$
|
306,444
|
|
|
$
|
|
|
|
$
|
306,444
|
|
|
$
|
245,823
|
|
|
$
|
|
|
|
$
|
245,823
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
F-69
Sterling
Chemicals, Inc.
Offer to
Exchange
all outstanding
101/4% Senior
Secured Notes Due 2015
($150,000,000 aggregate amount outstanding)
for
101/4% Senior
Secured Notes Due 2015
which have been registered under the Securities Act
Prospectus
August 13, 2008
You should direct questions and requests for assistance,
requests for additional copies of this prospectus or of the
letter of transmittal and requests for the notice of guaranteed
delivery to the exchange agent addressed as follows:
|
|
|
|
|
By Mail:
|
|
By Facsimile:
|
|
By Hand:
|
U. S. Bank National Association
Westside Operations Center
60 Livingston Avenue
St. Paul, MN 55107
Attention: Specialized Finance
|
|
(651) 495-8158
Attention: Specialized Finance
|
|
U. S. Bank National Association
Westside Operations Center
60 Livingston Avenue
St. Paul, MN 55107
Attention: Specialized Finance
|
|
|
To Confirm by Telephone:
|
|
|
|
|
(800) 934-6802
|
|
|
|
|
Attention: Specialized Finance
|
|
|